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Aim. To investigate the association between Gaucher disease (GD) and 
gammopathy. Introduction. Gaucher disease is a disorder characterised by 
deficiency in lysosomal glucocerebrosidase, foamy macrophages, cytopenias, bony 
lesions, organomegaly and a high incidence of monoclonal/polyclonal gammopathy. 
Abnormalities in the bone marrow microenvironment, including pseudo-Gaucher 
cells, have been reported in non-GD patients with myeloma. Methods. Gaucher gene 
analysis, co-culture, drug assays, western blotting, enzymatic assays, flow cytometry, 
immunofluorescence and cytotoxic assays. Results. GD patients had a high 
incidence of gammopathy (polyclonal/monoclonal). Serum biomarkers of 
macrophage burden were predictive of gammopathy and the Zimran severity score 
was higher in those with monoclonal than polyclonal gammopathy. Enzyme 
replacement therapy ameliorated polyclonal gammopathy and stabilised paraprotein 
levels. Gaucher mutations were not prevalent in Jewish patients with 
paraproteinaemia (8/77 patients). Non-GD patients with paraproteinaemia had 
normal serum chitotriosidase and monocyte glucocerebrosidase activity. GD 
monolayers (osteoclasts/macrophages) did not confer a proliferative or survival 
advantage on co-cultured myeloma cell lines. GD monolayers, compared to control 
cultures, reduced sensitivity to melphalan and this was contact dependent. Western 
blotting identified differences in the levels of Bim and Bcl-xL between myeloma 
cells harvested from control and GD monolayers. When cultured alone, GD 
monolayers generated more osteoclasts and this was enhanced by plasma cell co-
culture (contact independent). GD monolayers did not preferentially rescue myeloma 
cells pre-treated with doxorubicin from cell death. Patients with GD have decreased 
lymphocyte glucocerebrosidase activity, abnormal lipid trafficking and low 
peripheral NK (natural-killer), invariant NK and CD4+ve T-cell numbers. Invariant 
NK cells, GD derived, displayed impaired proliferation to α-galactosylceramide. 
Cytotoxicity assays, derived from the GD peripheral blood mononuclear cells, 
displayed inferior killing compared to control assays. NK killing assays were 
equivalent between controls and GD patients. Conclusion. This thesis presents novel 
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1 CHAPTER 1 – INTRODUCTION 
1.1 LYSOSOMES – AN INTRODUCTION 
 
Christian de Duve, discovered lysosomes in 1955, using cell fractionation, work for 
which he subsequently was awarded the Nobel Prize1. These organelles, only 
constitute about 0.5% of the cell volume of fibroblasts, but are much more abundant 
in macrophages2. Lysosomes, membraned organelles, are found in all cells accept for 
red blood cells2. They have important regulatory roles in the digestion of cellular 
proteins, catabolism of abnormal proteins, digestion of pathogenic micro-organisms, 
apoptosis, antigen presentation, degradation of intra-cellular organelles and the re-
cycling of cell membrane constituents including receptors, sphingolipids and 
glycosaminoglycans (see Figure 1-1)1-5. In addition, packaged enzyme from the 
lysosome, can be transported by budded vesicles to the cell surface and undergo 
exocytosis, influencing a variety of disease processes, including the invasive 
properties of cancer cells6;7. Material is delivered to lysosomes for degradation via 
phagocytosis (phagosomes or autophagosomes), by clathrin-coated pits derived from 
the cell membrane (receptor mediated endocytosis) or ingested from the local 
microenvironment2;8. Intact lysosomal function is important for the degradation of 
bone and innate immunity in osteoclasts and neutrophils respectively2. Lysosomal 
related organelles include melanosomes and lytic granules in cytotoxic T-cells2;8.    
 
Lysosomes contain a cocktail of catabolic enzymes including lipases, proteases, 
glycosidases, phosphatases, sulfatases, and nucleases. Metabolised macromolecules, 
including amino acids, nucleotides, oligosaccharides and monosaccharides, are re-
cycled back to the cytosol2. Due to the high metabolic activity of these organelles, 
lysosomal hydrolases are constantly replenished by newly synthesised enzyme and 
packaged for delivery from the Golgi apparatus following post-translational 
modification9. Lysosomal delivery of vesicle-packaged enzyme from the Golgi 
apparatus to the lysosomal compartment is facilitated by the addition of Mannose-6-
phosphate (M6P) residues9. The lysosomal microenvironment is acidic, aiding 
dissociation of M6P residues from delivered hydrolases, provides an optimal pH for 
catalytic activity and denatures protein undergoing degradation2. Lysosomal 
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membranes consist of a heavily glycosylated glycolcalyx, lysosomal associated 





























Figure 1-1. Schematic diagram of lysosomal function in mammalian cells. 
Source:- www.utm.utoronto.ca/~w3bio315/lecture15.htm 
 
1.1.1 LYSOSOMAL STORAGE DISORDERS 
Currently, there have been described approximately 50 inherited deficiencies of 
metabolic enzymes or lysosomal-associated proteins that lead to clinical disease5;10. 
The lysosomal storage disorders (LSDs) are a heterogeneous group of diseases that 
most commonly occur from deficiency in a catabolic lysosomal enzyme. Hers and 
colleagues in the 1960s were the first to link deficiency in a lysosomal enzyme to the 
accumulation of substrate and lysosomal pathology (Pompe disease)11. Based on the 
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biochemical classification of the accumulated substrate the disorders could be 
subdivided into the sphingolipidoses (e.g. Gaucher disease and Fabry disease), 
mucopolysaccharidoses (e.g. Hurler’s or Hunter’s disease), glycoproteinoses (e.g. β-
mannosidosis disease) and glycogenosis (e.g. Pompe disease) 5. This classification is 
limited by the fact that many lysosomal enzymes are not specific for one substrate, 
such as in GM1 gangliosidosis, where accumulation of sphingolipids, keratin 
sulphate and oligosaccharides occurs due to low β-galactosidase activity5. In 
addition, due to the saturation of downstream enzymes, secondary substrates 
accumulate3. Enzyme deficiency compromises cells and organs where turnover of 
that specific substrate is high10;12. For example glycogen storage in the muscle of 
individuals with Pompe disease (α-maltase deficiency) or sphingolipid accumulation 
in macrophages involved in the digestion of apoptotic haematological cells in 
patients with Gaucher disease (glucocerebrosidase deficiency).  
 
Many degradative enzymes, especially those involved in sphingolipid metabolism, 
require the presence of activator proteins, such as the saposins, that act as detergents, 
for physiological activity5. Mutations in saposin C (prosaposin gene, PSAP; codes for 
saposin A, B, C and D) have been reported to lead to a phenotype of Gaucher disease 
(GD) with normal β-glucocerebrosidase activity13. Physiological glucosylceramide 
metabolism requires the interaction of saposin C with glucocerebrosidase. 
Furthermore, deficiency in prosaposin and saposin B, present with clinical features 
consistent with neurovisceral dystrophy or metachromatic leukodystrophy 
respectively, due to non-physiological sphingolipid accumulation14. In addition, 
genetic disorders leading to abnormalities in transmembrane transport within the 
lysosomal membrane, including the cystine and sialic acid transporter, result in 
human disease15. An example of a deficiency of LAMP expression causing human 
pathology is Danon disease, a glycogen storage disorder characterised by the triad of 
heart disease, skeletal myopathy and mental retardation2.    
 
Cellular pathology secondary to deficiency in an individual lysosomal enzyme has 
been postulated to occur via several different mechanisms. These include the 
deposition of accumulated substrate (lysosomal and non-lysosomal), generalised 
lysosomal dysfunction, increased cellular concentrations of downstream substrates, 
decreased cellular concentrations of upstream metabolites, impaired calcium 
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homeostasis, endoplasmic reticulum (ER) stress, oxidative stress, free radical 
production, an up-regulation of pro-inflammatory cytokines, abnormal lipid 
trafficking, non-physiological signal conduction, altered auto-immunity, abnormal 
sphingolipid signalling and disturbed autophagy3. Mutant alleles in Gaucher disease, 
due to abnormal protein folding, are retained in the endoplasmic reticulum, induce 
ER stress and disturb normal cell physiology (see section 1.2.6)16. Abnormal calcium 
haemostasis has been shown in mouse models of GD in response to 
glucosylceramide and in human tissue from those with neuronopathic GD17. Ong et 
al. (2010) demonstrated that a reduction in ER calcium was detrimental to residual 
glucocerebrosidase activity due to a microenvironment skewed to the abnormal 
folding and retention of mutant alleles in the ER. GD fibroblasts have been shown to 
be more susceptible to oxidative stress17. 
 
The majority of LSDs are autosomal recessive in inheritance although several 
disorders, including Fabry disease (α-galactosidase deficiency), are X-linked15. In a 
retrospective Australian study carried out over a period of 16 years, Gaucher disease 
(GD) was reported in approximately 1:60,000 individuals and is the commonest 
LSD18. GD is characterised by disordered sphingolipid metabolism and like several 
other LSDs may present with neuronopathic disease. Storage disorders associated 
with central nervous system manifestations, including metachromatic 
leukodystrophy, neuronopathic GD and neuronal ceroid lipofuscinosis, confer a poor 
prognosis typified by early-onset death.     
 
1.1.2 SPHINGOLIPIDOSIS 
These comprise a group of disorders that are involved in the catabolism of 
sphingomyelins and glycosphingolipids (the cerebrosides, sulfatides, globosides and 
gangliosides). GD, Niemann Pick, Fabry disease and Tay-Sachs disease (see Figure 
1-2) are examples of disorders secondary to sphingolipid accumulation5. 
Sphingolipids are composed of long-chain bases, fatty acids and a serine backbone19. 
They are an integral component of all cell membranes, regulate the activity of 
transmembrane receptors, manipulate immune response, including invariant natural 
killer T cell (NK-T) expansion, modulate host-pathogen interactions and are 




Figure 1-2. Sphingolipid metabolic pathway and inherited deficiencies leading to lysosomal 
dysfunction.   
Source:- Sphingolipid metabolism disorders. Kolter and Sandhoff (2006)22. 
 
1.2 GAUCHER DISEASE – INTRODUCTION 
Philippe Gaucher in 1882, whilst still a medical student, provided the first 
descriptions of this disorder in a young female with splenomegaly. Brady et al. 
(1965) described lysosomal β-glucocerebrosidase to be the deficient enzyme in GD23. 
Deficiency in this enzyme, an intermediate enzyme in sphingolipid metabolism, 
leads to accumulation of its substrate, glucosylceramide, within macrophages of the 
reticulo-endothelial system24. GD is an autosomal recessive disorder and is the 
commonest encountered LSD18. The gene coding for β-glucocerebrosidase (GBA1) 
was located to chromosome 1q2125 in the late 1980s and was subsequently 
sequenced by Horowitz et al. (1989)26. To date, approximately 300 mutations of the 
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GBA1 allele have been reported27. Meikle et al. (1999) reported the incidence of GD, 
based on screening data from an Australian population, to be 1:57,00018. However, 
the true incidence of GD is not known, with estimates of between 1:40,000 to 
1:100,000 being cited. Ethnicity data from an international Gaucher register in 1998 
(recorded for 514 patients of the available 1,698 patients) identified 68% as being of 
Jewish descent (Ashkenazi and Sephardic combined)28. GD is more common in 
Ashkenazi Jews where incidence has been cited as ~1:900-1:1225, with a carrier 
frequency of between ~1:10-1:17.529;30.   
 
1.2.1 GBA1 GENE AND PSEUDOGENE 
The GBA1 gene is located on chromosome 1q21, consisting of 11 exons and 10 
introns27. In 1989, Horowitz et al. sequenced the GBA1 locus (7.6 kilobases pairs, 
kb) together with the 5.7kb pseudogene. Glucocerebrosidase cDNA is about 2kb in 
length and is translated into a 497-residue protein27. The pseudogene (GBAP, 
glucocerebrosidase A pseudogene) is highly conserved, with 96% sequence 
homology to the 16kb upstream GBA1 locus26. In comparison to the GBA1 gene, the 
GBAP gene contains shorter sequences of intronic Alu repeats and a 55 base-pair 
(bp) deletion in exon 9. Additional genes in the vicinity of the GBA and GBAP genes 
include THBS3 (thrombospondin 3 gene), metaxin and the pseudogene of metaxin. 
Metaxin codes for a protein on the outer mitochondrial membrane27. 
Thrombospondin 3 has been shown in mouse models to regulate skeletal 
maturation31.   
 
1.2.2 GBA MUTATIONS  
There are over 300 reported GBA1 mutations and approximately 80% are missense 
mutations27. In addition, nonsense mutations, insertions, deletions, frameshift 
changes, splice site alterations, recombinant alleles together with mutations in cis 
have been described27. L444P, described in 1987, was the first reported mutation in 
GD and the N370S allele, was discovered the following year25;32. Genotype analysis, 
from interrogation of the International Collaborative Group Gaucher Registry 
(ICGG), demonstrated the presence of a N370S or L444P allele in 77% and 34% of 
patients respectively (n=635, type I GD, mixed ethnicity)33.  Alfonso et al. (2007) 
interrogated data from the Spanish Gaucher registry and reported that N370S and 
 31 
L444P were responsible for 50.2% and 18.4% of mutant alleles respectively34. 
Analysis of 766 patients (68% Ashkenazi or Sephardic Jews) from the Gaucher 
registry showed that 84% had one N370S allele, 30% had one L444P allele and that 
homozygosity for N370S was the most frequently identified genotype28. In contrast, 
a study from Brazil, reported that 65/139 patients had the N370S/L444P genotype 
(Ashkenazi-Jewish, 0.5%)35. In patients of Jewish ancestry, 8 mutations and 2 
recombinant alleles account for the genotype in 90% of cases (84GG, IVS2+1, 
N370S, V394L, D409H, L444P, R463C, R496H, RecNciI and RecTL)27;36. In one 
study, these mutations were reported to identify one or both mutant alleles in 63/64 
or 57/64 of patients respectively37. Analysis from an Italian group, all of non-Jewish 
descent, reported that these alleles were responsible for 92.4% of GBA1 mutations38. 
In an Hungarian cohort, 26/27 of whom were of non-Jewish ethnicity, screening for 
the mutations listed above would have failed to detect 11/54 disease causing alleles39.  
Horowitz et al. (1993) reported that these mutant alleles, excluding the V394L 
mutation (not checked for), would have detected in total 88% and 77% of mutant 
alleles in patients of Jewish and non-Jewish descent respectively40. Analysis of 766 
Gaucher Registry patients revealed the most common alleles to be N370S(53%), 
L444P(18%), 84GG(7%) and IVS2+1(2%)28. Amongst an Ashkenazi Jewish 
population, these four mutations have been reported to make up 93% of mutations37. 
Therefore, in summary, allele frequency varies with ethnicity and geographical 
location.  
 
Disease causing mutations have not been described in exon 1. The majority of GBA1 
mutations are in two exons blocks (exons 5-7 and 8-11). N370S, the commonest 
mutated allele results from a mutation in exon 9, whereas the L444P allele is derived 
from mutation or a recombinant allele in exon 10 (Figure 1-3)27. 
 
The X-ray structure of lysosomal glucocerebrosidase has been described41 and is 
composed of 3 domains with Domain III containing the catalytic site. Although, 
some mutations around the active site predict for a severe phenotype, generally the 
spatial location of the mutation does not correlate with disease severity17.    
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Figure 1-3. GBA1 gene, mutations and neighbouring loci. 
(A) Structure of the GBA1 gene and neighbouring loci on chromosome 1q. GBA1 
(glucocerebrosidase), MTXP (metaxin pseudogene), GBAP (glucocerebrosidase pseudogene), 
MTX1 (metaxin 1) and THBS3 (thrombospondin 3). (B) GBA1 gene contains 11 exons and 15 
common mutations are illustrated. (C) Number of reported mutations per exon including 
insertions, deletions, splice site mutations and substitutions. 
[Reproduced from Hruska et al. (2008)]27 
 
1.2.3 CLINICAL PRESENTATION 
Clinically GD is divided into non-neuronopathic (type 1) and neuronopathic (types 2, 
3) subtypes42. Charrow et al. (2000) reported type I, type II and type III disease in 
94%, <1% and 5% of 1,698 individuals in an international Gaucher registry 
respectively28. The clinical phenotype of type I disease includes hepato-
splenomegaly, bone marrow failure, cytopenias, skeletal disease, bleeding diathesis, 
liver fibrosis, fatigue, weight loss, growth retardation and gammopathy15;24;28;43-45. 
Observed skeletal disease includes osteoporosis, the Erlenmeyer flask deformity, 
osteopenia, avascular necrosis, bone marrow infiltration, lytic lesions, pathological 
fracture, osteonecrosis and osteosclerosis28;46. The Erlenmeyer flask deformity is the 
commonest skeletal anomaly (46%)28, has a classic appearance on X-ray examination 
and is secondary to impaired re-modelling of the tibial metaphyseal region46. Patients 
with GD (8%), not-uncommonly, require joint replacement28. Pulmonary 
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hypertension is not infrequent in type I GD and is more prominent in asplenic 
individuals47. Parkinson’s disease has been reported to be more common in 
individuals with type I GD48. 
 
Type 2 disease (early onset acute neuronopathic subtype) is characterised by 
oculomotor apraxia, corneal opacities, progressive neurological deficit and death at 
an early age (<5 years)15. Type 3 Gaucher disease, subacute neuronopathic subtype, 
presents with a mixed clinical phenotype incorporating features of both type 1 and 2 
disease with a life expectancy of early adulthood (<30 years)15. Genotype is 
predictive, on the whole, for whether a patient has neuronopathic or non-
neuronopathic disease. Data from the Gaucher registry reported that all patients who 
were carriers of a N370S mutation, homozygotic or heterozygotic (84% of 766 
patients), were labelled as having type 1 disease28. These findings mirror those of 
Koprivicia et al. (2000) who reported genotype-phenotype correlations in a smaller 
cohort of 152 patients (128 type I disease; 24 type III disease)37.  
 
The L444P allele is the most frequent mutation found in neuronopathic 
subtypes28;37;49. Gaucher register data from 52 patients with homozygous L444P 
mutations revealed 75% to have a phenotype compatible with type III disease with 
the other 25% having clinically type I disease28. However, neurological assessment 
of 31 patients with type 1 GD, revealed abnormalities in approximately 30% of 
patients, including peripheral neuropathy, dementia, features of parkinsonism, 
abnormal eye movements and psychomotor retardation50. Neurological 
complications associated with type I GD were reported to occur frequently in a 
Dutch cohort of patients51. These findings have challenged the subdivision of GD 
into neuronopathic and non-neuronopathic subtypes.  
 
Even for those with type I GD that carry the same genotype there can be marked 
variation in both disease severity and clinical phenotype34;39. Patients with 
homozygous N370S mutations, compared to other genotypes, have been suggested to 
have a higher rate of skeletal disease but less prominent visceral bulk52.  The 
N370S/N370S genotype is generally associated with milder disease and presents at a 
later mean age28. Although, many children with this genotype, present with severe 
disease at an early age33. 
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1.2.4 PATHO-PHYSIOLOGY IN TYPE I GAUCHER DISEASE 
Deficiency in glucocerebrosidase leads to the accumulation of glucosylceramide and 
its de-acetylated form glucosylsphingosine, which is undetectable in normal tissues42. 
In addition, intermediate metabolites of sphingolipid metabolism, including those 
derived from the enzymatic degradation of membrane gangliosides and globosides, 
accumulate in the organs of those with GD24. The accumulation of secondary 
substrates, such as glucosylsphingosine, may be as important pathologically, as 
glucosylceramide storage, in the cellular abnormalities seen in GD. 
Macrophages/monocytes are phagocytic cells and have significantly higher 
glucocerebrosidase activity compared to haematological cells derived from other 
lineages53. Blood glucosylceramide levels are increased in GD and have been 
reported to be higher in type III patients than those with type I disease54. Patients 
with GD have insufficient enzyme activity in their macrophages to catabolise 
membrane sphingolipids from the phagocytosis and degradation of senescent 
leucocytes and red blood cell membranes. This leads to intra-cellular lipid 
accumulation and the accumulation of Gaucher cells or foamy macrophages55. Cells 
derived from the monocytic lineage, including tissue macrophages in the liver 
(Kupffer cells), bone (osteoclasts), lung (alveolar macrophages), bone marrow, brain 
(microglial cells), spleen, lymph-nodes, gastro-intestinal tract, serous tissue, skin and 
urinary tract are all affected42. Patients with L444P/L444P, a genotype conferring 
neuronopathic disease, are associated with low residual glucocerebrosidase activity 
(<1%-13%)56. Speculatively, neuronopathic disease may require lower residual 
enzyme activity, as microglial cells are not exposed to the same substrate load as 
peripheral macrophages. The composition of glucosylceramide is also different. Post-
mortem analysis, in a type II GD patient, demonstrated a predominance of stearic 
acid containing glucosylceramide in the central nervous system, in contrast to 
palmitic acid complexed glucosylceramide in visceral organs57.  
 
Gaucher cells (20-100µm) accumulate in sheets within enzyme-deficient tissue and 
are associated with an inflammatory infiltrate, fibrotic reaction and the deposition of 
extra-cellular sphingolipid24;45. Gaucher cells are tartrate resistant acid phosphatase 
(TRAP) positive, express monocyte markers and have been shown to have a 
phenotype of alternatively activated macrophages58. They are round cells, exhibit an 
eccentrically placed nucleus, uni-nucleate or multi-nucleate and contain large 
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volumes of cytoplasm with the appearance of crumpled tissue paper59. X-ray 
crystallography demonstrates that Gaucher cells accumulate lipid in membrane-
bound tubular structures60.   
 
Hepatic pathology includes fibrosis, sheets of lipid laden Kupffer cells and extra-
medullary haematopoiesis61. Hepatomegaly is a clinical hallmark of GD, although 
hepatocytes are generally spared from glucosylceramide deposition, perhaps due to 
excretion in the bile62. The incidence of gallstones has been suggested to be 
increased in GD63. Cirrhosis, liver failure, portal hypertension, hepato-pulmonary 
syndrome and oesophageal varices, although rare, are seen in type I GD45;64. 
Successful long-term outcomes post liver transplantation in type I GD have been 
reported64. Pathological changes in the spleen include organomegaly, Gaucher cell 
infiltration, infarction, extra-medullary haematopoiesis, fibrotic change and nodules 
that are sometimes mistaken for cancerous infiltration on radiographical 
examination61. Glucosylceramide content, in grossly enlarged visceral organs, 
including the liver, has been shown at post-mortem to account for less that 2% of the 
total weight24. Lymphadenopathy, is secondary to the infiltration of Gaucher cells, 
but little inflammatory reaction, is not uncommon61.  
 
Bony pathology includes lytic lesions, an accumulation of osteoclasts, abnormalities 
of the microcirculation, fracture, sclerosis, demineralisation, deformity, fibrotic 
change, a dense infiltration by Gaucher cells, infarction, necrosis, loss of trabecular 
connectivity and porous trabeculated cortices24;42;61. Type I GD is associated with an 
increased incidence of clonal plasma cell disorders and non-Hodgkin lymphoma65;66. 
Bone marrow failure ensues, secondary to Gaucher cell infiltration, and cytopenias 
are compounded by concomitant sequestration secondary to organomely66.    
 
Pulmonary disease is rare but alveolar macrophages are affected as demonstrated 
morphologically by light and electron microscopy post broncho-pulmonary lavage in 
a young GD patient with respiratory symptoms67. Infiltrates of Gaucher cells have 
been reported to occur in the lung interstitium and alveolar air spaces, mimicking 
consolidation61.  Pulmonary involvement can lead to abnormal X-ray examination, 
impaired lung function tests, hypoxia and an interstitial infiltrate on high resolution 
computer tomography (CT) scanning68;69. Miller et al. (2003) reported that in a 
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cohort of 150 patients with GD, <5% had evidence of pulmonary disease70. In 
contrast, in a study reported by Kerem et al. (1996), approximately two thirds of 
individuals were shown to have abnormal lung function tests with 17% having an 
abnormal chest X-ray69. Pulmonary hypertension has been suggested to occur more 
commonly post-splenectomy71 and may complicate liver pathology64. 
Echocardiography demonstrated pulmonary hypertension in 7% of 134 analysed 
individuals with type I disease based on the assessment of tricuspid incompetence 
with a gradient of greater than 30mmHg71. It should be noted that clinically 
significant pulmonary hypertension is rarely encountered in practice and both 
echocardiography and pulmonary function tests are associated with significant 
technological limitations including reproducibility. Splenectomy is associated with 
an increased incidence of pulmonary hypertension in non-GD individuals adding 
further doubt to the aetiology of these abnormalities being related to lysosomal 
dysfunction. Cardiac, renal and gastro-intestinal disease has rarely been reported in 
GD61.  
 
Many studies have been published regarding the plasma levels of cytokines, growth 
factors and chemokines in patients and are summarised in Table 1-1 below. 
Conflicting data has been reported regarding serum levels of pro-inflammatory 
cytokines including Interleukin (IL)-1, IL-2, Tumour necrosis factor-alpha (TNF-α) 
and IL-672-77. GD is associated with an elevated incidence of gammopathy and serum 
levels of B-cell proliferating factors, including IL-6, IL-8 and IL-10, have been the 
subject of contrasting reports in the literature72;74;76;78. However, cytokines promoting 
monocyte maturation, leading to osteoclast differentiation, that are the product of 
activated macrophages have most consistently been reported to be elevated in the 
serum of those with GD. These include macrophage colony stimulating factor (M-
CSF), macrophage inflammatory protein (MIP) 1α, MIP1-β and pulmonary and 
activation regulatory cytokine (PARC)72;78-80. Furthermore, there is an isolated report 
of raised serum levels of hepatocyte growth factor (HGF), a cytokine known to 
promote osteoclastogenesis81.      
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Acute Phase Response 




Yoshino et al. (2007) - 0/8 
De Fost et al. (2006) - ↑4/24  
Barak et al. (1999) – ↑levels*  
Hollak et al. (1997) – normal 
Lichtenstein et al. (1997) –  
↑3/19 (IL-6 mRNA) 
Allen et al. (1997) - ↑levels* 






Yoshino et al. (2007) - 0/8 
Barak et al. (1999) – normal  
Hollak et al. (1997) –  ↑93%* 
Lichtenstein et al. (1997) –  
↑3/19 (IL-8 mRNA) 






De Fost et al. (2006) - ↑17/24  
Allen et al. (1997) - ↑levels* 
TNF-α  Inflammation 
Acute phase response 






Yoshino et al. (2007) - 1/8 
Altarescu et al. (2005) - ↑1/12  
Barak et al. (1999) – ↑3/21  
Hollak et al. (1997) – normal 
Lichtenstein et al. (1997) - ↑ 2/19 
(TNF-α mRNA) 
Allen et al. (1997) - ↑levels 4/11  
















Yoshino et al. (2007) - ↑ 1/8 
De Fost et al. (2006) - ↑4/24  
Barak et al. (1999) – ↑levels IL-1 β*, 
IL-1 RA*  
Hollak et al. (1997) – normal 
Lichtenstein et al. (1997) –  
↑5/19 (IL-1 β mRNA) 
Allen et al. (1997) – IL-1β, not 
detectable 
PARC Chemotactic for activated T-





De Fost et al. (2006) - ↑24/24  
Boot et al. (1997) - ↑levels in 100%* 




T-Lymphocytes Barak et al. (1999) – ↑levels IL-2R*  
 
M-CSF Macrophage differentiation  Osteoblasts  
Bone marrow stromal 
cells 
Yoshino et al. (2007) - ↑ 1/8 
Hollak et al. (1997) – ↑86%* 
MIP-1α  Implicated in myeloma bone 
disease 
Macrophages Van Breeman et al. (2007) - ↑mean 
levels 
MIP-1β Implicated in myeloma bone 
disease 
Macrophages Van Breeman et al. (2007) - ↑mean 
levels 
Table 1-1. Summary of plasma cytokines, chemokines and growth factors elevated in GD. 
PARC (pulmonary and activation regulated cytokine), M-CSF (monocyte colony stimulating 
factor), RANK-L (receptor activator of nuclear kappa-B ligand) and MIP (macrophage 
inflammatory protein). *Statistically significant (p<0.05), compared to a control population 
 
 
1.2.5 CLINICAL BIOMARKERS AND DISEASE SEVERITY 
SCORES 
Plasma biomarkers used commonly for monitoring disease severity in GD include 
serum angiotensin converting enzyme (S-ACE)82, chitotriosidase acitvity83, ferritin84,  
CCL18 (Chemokine [C-C motif] ligand 18)/PARC80 and acid phosphatase85. As 
discussed below, these biomarkers are elevated in other macrophages diseases, in 
addition to GD. 
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TRAP, a specific acid phosphatase, expressed in osteoclasts and dendritic cells, is 
characterised by its lack of inhibition to tartrate. TRAP is elevated in GD24;86 but 
serum levels seem not to mirror the severity of skeletal disease. Chitotriosidase 
activity, a macrophage-derived enzyme, correlates with clinical burden and decreases 
with disease-modifying therapy83;87. Levels may rise greater than 200-fold in severe 
disease, whereas levels under 1000 units/litre (normal <150 units/litre) generally 
indicates stable disease15. In addition to GD, vastly elevated activity is seen in 
children with Niemann Pick A or B88. Milder elevations in chitotriosidase activity are 
seen in elderly individuals89 and in those with sarcoidosis90. Korolenko et al. (2000) 
argued that chitotriosidase activity is a surrogate marker of macrophage activation. 
The authors demonstrated an increase in enzyme production in macrophages 
challenged with zymosan or Triton WR-133991. Boven et al. (2004), using in-situ 
hybridisation, demonstrated chitotriosidase production specifically in Gaucher cells, 
but not in normal macrophages58. Approximately 6% of the population have 
undetectable chitotriosidase activity due to homozygous null mutations in 
chromosome 192. Furthermore a further third of individuals are heterozygous for a 
null mutation and are expected to have half the activity of those with functional 
genes92.  
 
PARC, a biomarker measurable in serum or urine, is produced by Gaucher cells58, 
correlates with visceral bulk93, parallels chitotriosidase activity80 and can be used to 
monitor disease severity in those with non-functional chitotriosidase genes94. 
Although, not to the same magnitude as seen in GD, PARC is elevated in the serum 
of those with beta thalassaemia95. Niemann Pick B, a LSD associated with the 
accumulation of foamy macrophages and sea blue histiocytes, is associated with 
elevated CCL18 levels96. Sarcoidosis is a disorder characterised by granuloma and 
macrophage pathology. Chitotriosidase activity and CCL18 levels reflect disease 
severity and predict for clinical relapse in sarcoidosis97. Ferritin, a protein complexed 
with iron, is stored in macrophages of the reticulo-endothelial system. Serum ferritin 
levels are raised in GD84 and thalassaemia95. In addition, high levels of serum ferritin 
are seen in haemophagocytic syndrome, a disorder characterised by cytopenia, fever, 
hepato-splenomegaly and the infiltration of organs by macrophages with enhanced 
phagocytic activity98. Stimulated or activated macrophages secrete storage ferritin in 
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many clinical states, including those associated with inflammation or infection. 
Furthermore, malignant states are associated with hyperferritinaemia and the storage 
of complexed ferritin in macrophages, secondary to hepcidin dysregulation and the 
production of pro-inflammatory cytokines99.  
 
S-ACE is a useful serum marker for monitoring disease severity and the response to 
disease-modifying therapy in GD100. However, S-ACE is elevated in several other 
disorders associated with macrophage pathology, including those of alveolar 
macrophages such as sarcoidosis101. S-ACE is expressed in many other tissues 
including vascular endothelium, heart, brain, adrenal cortex, leucocytes, kidney, 
monocytes, neurons and uterus102.  S-ACE converts angiotensin I to angiotensin II 
which controls blood pressure by stimulating the adrenals to produce aldosterone. 
Angiotensin II has been suggested to lead to increased free radical production, 
decreased nitric oxide generation and the secretion of pro-inflammatory cytokines, 
including TNF-α plus IL-1102. Although data are conflicting, ACE-inhibitors have 
been associated with a lower incidence of cancer, including oesophageal103. Whether 
elevated S-ACE levels and enhanced angiotensin II production contributes to an 
elevated risk of cancer in GD is unclear. 
 
Traditionally, the Zimran severity score (ZSS)104, described in the era prior to 
enzyme replacement therapy and before the discovery of serum biomarkers, has been 
used to document disease load in GD. This severity index contains scoring domains 
for bony disease, spleen status, age at presentation, liver function abnormalities, 
hepatomegaly, cytopenias, splenomegaly, clinical signs of liver disease and the 
involvement of organs not fore-mentioned. The Zimran score is insensitive for 
assessing the response to ERT as prior splenectomy and osteonecrosis are not 
reversible variables105. Proposed severity scoring indexes, including the Gau-SSI106, 
that address these issues and incorporate biomarker data, may prove more sensitive 
in monitoring clinical response.   
 
Charrow et al. (2000) reported that genotype was predictive of disease severity and 
correlated with the mean age at presentation (N370S/N370S – 27.2yrs, N370S/? – 
18.1yrs, N370S/L444P – 16.2yrs, L444P/L444P – 2.3yrs, N370S/IVS(2+1) - 
6.4yrs)28. However, each genotype was associated with a wide range of presentation 
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ages. Analysis of a Spanish cohort demonstrated significant clinical heterogeneity in 
patients carrying a N370S allele. The authors reported that 6% of heterozygotes for a 
N370S allele had neurological disease with marked clinical variation in 
N370S/L444P patients34. Neither residual enzyme activity or genotype correlates 
well with disease severity107. N370S homozygotes may fail to present clinically in 
life whereas others have severe disease at an early age52. In addition, in a Canadian 
analysis of 24 siblings with GD, 10/24 were found to have non-concordant 
disease108.  
 
It is unclear at present which genetic and environmental factors modify disease 
severity in GD. Polymorphisms in the glucosylceramide synthase gene were not 
found to account for disease variation in individuals with homozygous N370S 
disease109. Low lysosomal glucocerebrosidase activity, due to homozygous GBA1 
mutations, leads to substrate accumulation predominantly in macrophages. In the last 
few decades, GBA2, a cell membrane associated β-glucosidase has been 
described110;111. In contrast to GBA1, GBA2 is an integral membrane protein and not 
located to the lysosomal compartment. Ceramide formed by lysosomal 
glucocerebrosidase activity (GBA1) is rapidly converted to sphingosine and fatty 
acids. However, ceramide generated by GBA2 glucocerebrosidase activity, leads to 
the accumulation of sphingomyelin111. Yildez et al. (2006) demonstrated the 
accumulation of glucosylceramide in the testes, liver and brain of GBA2 knockout 
mice, but this did not lead to the development of organomegaly, neuronopathic 
disease or reduced life span112. Speculatively, GBA2 activity may modulate GD 
phenotype, or prevent significant patho-physiology in cells not exposed to large 
amounts of substrate.     
 
1.2.6 TREATMENT 
The mainstay of GD therapy is ERT. A minority of patients are treated with substrate 
reduction therapy (SRT; e.g. Miglustat, N-butyl-deoxynojirimycin)113;114 or 
chaperone therapy as part of a clinical trial. Historically, in the pre-ERT era, patients 
with severe type I or type III disease were treated therapeutically with bone marrow 
transplantation (BMT)115;116. Transplantation, however, is associated with significant 
morbidity and mortality. Although performed rarely in the era of ERT, splenectomy 
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was previously employed for painful splenic infarcts, cytopenias, diagnostic purposes 
and for symptom control117. Splenectomy leads to worsening bony disease and the 
development of pulmonary hypertension118. Additional treatment modalities include 
joint-replacement, analgesics, calcium supplements and bisphosphonates.  
 
In the 1980s, glucocerebrosidase purified from human placentas, was infused into 
individuals with GD. Although, associated with a therapeutic effect, a large number 
of human placentas were required per dose and exposed the recipient to the 
possibility of transmittable diseases118.  Imiglucerase, recombinant 
glucocerebrosidase, modified for increased macrophage uptake by the addition of 
terminal mannose residuals, became commercially available in 1991 (Cerezyme®; 
Genzyme Cooperation)118;119. Analysis of 1028 Gaucher registry patients treated with 
imiglucerase, demonstrated its efficacy in ameliorating cytopenias, visceral bulk, 
bony pain and episodes of bony crisis120. Skeletal response to enzyme therapy may 
be slower to improve than the haematological and visceral manifestations121. ERT 
leads to a reduction in plasma chitotriosidase activity83. Human recombinant enzyme, 
Velaglucerase122, and a plant derived glucocerebrosidase123 has been reported to have 
therapeutic effect with tolerable side-effects in early phase clinical trials. However, 
ERT, due to its inability to cross the blood brain barrier, is not effective in 
neuronopathic GD. 
 
Miglustat (N-butyldeoxynojirimycin), an oral inhibitor of substrate synthesis in the 
sphingolipidoses, leads to an improvement in haematological parameters, a reduction 
in spleen and liver volumes, decreased chitotriosidase activity and improves bony 
disease in GD patients124-126.  
 
Mutant glucocerebrosidase, due to abnormal protein folding, is sensed by the ER 
where it is retained and subsequently degraded (ERAD, ER associated 
degradation)16. Mutated glucocerebrosidase leads to ER stress and is targeted to the 
proteasome for catabolism. Pharmacological chaperone therapy aims to stabilise or 
re-fold mutant enzyme, allowing trafficking from the ER to the lysosomal 
compartment127. Clinical trials are on going using chaperones, small molecules (e.g. 
isofagamine), which have the potential to cross the blood brain barrier. It is unclear 
at present whether chaperone therapy leads to a sufficient increase in residual 
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enzyme activity to ameliorate disease pathology in patients. In the future, as GD is a 
monogenetic disorder, gene therapy may become a therapeutic option127, pending 
advancements in vector delivery and safety. Viral safety and transfection rates limit 
this approach at present.  
 
1.2.7 PROGNOSIS 
An average a life expectancy of 68 years was found in registry patients with type I 
GD compared to 77 years in a reference population from the United States (US)128. 
Splenectomised patients were found to have an inferior life expectancy to those with 
an intact spleen (72 years versus 64 years). In total, there were 102 deaths, of which 
90% had received imiglucerase for a median of 5.4 years128. Malignancy was the 
cause of death in 17/63 patients with an identifiable aetiology, at a similar median 
age to the reference population. In the era of disease modifying therapy, where 
patients are treated at an early clinical stage, reducing the incidence of splenectomy 
and peak disease burden, life expectancy may be speculated to be higher. 
 
1.3 GAUCHER DISEASE AND CANCER RISK 
Patients with GD, compared to the general population, have been shown to have an 
elevated risk of both haematological and non-haematological cancer65;78;129;130. An 
early report by Lee et al. (1982), based on a cohort of 239 patients in the pre-ERT 
era, identified malignancy as the cause of death in approximately 50% of 
individuals131. Furthermore, Shiran et al. (1993) reported the development of cancer 
in 10/48 (20.8%) of their patients with GD, compared to in 35/511 (6.8%) 
individuals in a control population132. N370S homozygosity, in an American cohort, 
has been associated with a higher incidence of cancer (haematological and non-
haematological), compared to other genotypes52. Splenectomised GD patients have 
been suggested to have an elevated cancer risk133. In contrast, data from an 
international Gaucher registry, failed to show an increased risk of cancer per se130, 
but did conclude an increased incidence of multiple myeloma. Prior literature, 
reporting the development of malignancy in individuals with GD, is listed in Table 
1-2. Numerically, the number of case reports describing haematological cancer in 
GD far outweighs those describing malignancies of non-haematological origin.  
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Multiple myeloma has been shown to be more prevalent in several published cohorts 
of patients with GD78;130;132. In addition, based on the number of case reports, 
multiple myeloma is the commonest reported cancer in GD134-137. Rosenbloom et al. 
(2005) analysed 2,742 patients from the international Gaucher registry, and estimated 
a relative risk of 5.9 for the development of multiple myeloma in those with GD130. 
Zimran et al. (2005), in a cohort of 500 GD patients, reported the development of 
multiple myeloma in 2 individuals129. In a combined Dutch/German cohort of 131 
individuals with GD, a standardised rate ratio of 51.1 was estimated for the 
development of this haematological neoplasm78. The association of GD and multiple 
myeloma led to the subsequent development of consensus recommendations 
regarding the frequency of immunoglobulin analysis in those with GD66. 
 
Landgren et al. (2007) failed to find an increased risk of multiple myeloma, in the 
analysis of 1,525 adult male United States (US) veterans with GD65. However, 
criticisms of their study include its retrospective nature, the young median age of 
their cohort (~50yrs) and the use of non-specific coding systems to identify patients 
with GD. In addition, severely affected GD patients are unlikely to enrol for military 
service, skewing the affected population towards a milder phenotype. In the report, 
by Rosenbloom et al. (2005), 9/10 GD patients with myeloma were older than 60 
years of age130. Interestingly, the literature is devoid of reports describing 
myelomatous disease in individuals with type III GD, who would typically present 
with severe disease at an early age, suggesting additional aetiological factors.  
 
GD is associated with an elevated risk of polyclonal43;81 and benign monoclonal 
gammopathy138;139. The development of malignant gammopathy from either of these 
two conditions, as a continuum of disease, is discussed in more detail below. AL 
amyloidosis, a less common malignancy of plasma cells, has been reported to occur 
more frequently than expected in patients with GD, based on the number of case 
reports140-144. Primary AL amyloidosis is reported to have an age-adjusted incidence 
of approximately 5-13 per million patient-years in the US145. Non-Hodgkin 
Lymphoma (NHL), an umbrella term encompassing both ‘low’ and ‘high grade’ 
lymphoma, was found to be more common in a cohort of patients with GD, 
compared to that expected in the general population65. Excluding chronic 
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lymphocytic leukaemia (CLL), there are only isolated case reports of ‘low grade’ 
lymphoma, including mucosal associated lymphoid tissue lymphoma146 and splenic 
marginal zone lymphoma in individuals with GD147. Several case descriptions of 
common haematological malignancies including Hodgkin disease, chronic 
lymphocytic leukaemia and diffuse large B-cell lymphoma (DLBCL) exist in the GD 
literature (Table 1-2).  
 
Non-haematological cancer including melanoma, pancreatic cancer and hepato-
cellular carcinoma, have been suggested to be more common in those with GD65;78. 
Lo et al. (2010) reported that 9/403 of their patients, with type I GD, developed two 
or more malignancies, giving an incidence of 2.2%133. However, this was less than 
the reported incidence of sequential cancers (8%) in the general US population, 
quoted by the authors. Speculatively, these patients may have co-inherited additional 
cancer genes. Although, GD is a panethnic disorder, 68% of patients, based on 
registry data, are of Jewish descent28. GD is commoner in Ashkenazi Jews and this 
sect has a higher carriage rate than the general population of certain cancer genes, 
including BRCA1 and BRCA2 mutations. These mutations confer an elevated risk of 
breast and gynaecological cancer148. Despite this, these cancers have not been 
reported to be more prevalent in patients with GD. It could be hypothesised that the 
elevated risk of malignancy in GD may be due to gene-linkage and the co-inheritance 
of proto-oncogenes adjacent to the GBA1 locus at 1q2149. Abnormalities at 1q21-23 
are associated with early onset hepatocellular carcinoma 149. In addition, 
chromosome 1 abnormalities have been reported in the plasma cell clones of 
approximately 45% of patients with multiple myeloma. Several genes have been 
reported to be up-regulated in the region of chromosome 1q22-25 in myeloma 
patients who have acquired gains in chromosomal material within this region150.  
 
In support of disease burden not being causal for malignancy, several patients 
experienced an episode of cancer that pre-dated their diagnosis of type I GD136;151. 
This includes a 57-year-old female who was treated with chemotherapy and an 
autograft for multiple myeloma. She was diagnosed with GD on a 3 month staging 
marrow, post-transplant, for investigation of progressive thrombocytopenia. GD was 
confirmed by deoxyribonucleic acid (DNA) analysis136. There are no reports in the 
literature of monoclonal gammopathy of undetermined significance (MGUS), 
 45 
multiple myeloma or an increased incidence of other malignancies in paediatric 
patients, including those presenting with severe disease in the first few years of life. 
This suggests that additional factors, environmental or age-related, may be required 
in addition to homozygous GBA1 mutations to inflict an elevated risk of 
carcinogenesis. The length of exposure to GD related pathology including substrate 
accumulation may be important aetiologically. Fabry disease, an X-linked disorder 
resulting in to a deficiency in alpha-galactosidase-A activity, has only rarely been 
reported to be associated with malignancy, including renal cell carcinoma152;153 and 
leukaemia154. Therefore, lysosomal dysfunction per se, seems not to be sufficient to 
confer an elevated risk of cancer.         
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CANCER Literature - Case Reports Literature - Case Series 
Haematological Cancers   de Fost et al. 200678 
Shiran et al. 1993132 








Pinkhas et al. 1965155, Benjamin et 
al. 1979156, Ruestow et al. 1980157, 
Harder et al. 2000158, Cheung et al. 
2007136, Gal et al. 1988134, Garfinkel 
et al. 1982137, Brady et al. 1997159, 
Shvidel et al. 1995160, Machaczka et 
al. 2009161 
de Fost et al. 200678 
Rosenbloom et al 2005130 
Zimran et al .2005129 
Taddei et al. 200952 
Shiran et al. 1993132 
Lee et al. 1982131 
Shoenfeld et al. 1982162 





Cho et al. 1976164, Bruckstein et al. 
1980165, Sharer et al. 1976166, 





Mark et al. 1982168, Fox  et al. 
1984169, Kaufman et al. 1986170, 
Marsh et al. 1993171, Chang-Lo et al. 
1975172, Paulson et al. 1989173  
 
‘High Grade’ B-cell 
Lymphoma 
Carreiro et al. 2008174, Perales et al. 
1998175, Shvidel et al. 2007176, 
Brody et al. 2006177, Manz 2001178,  
 
Peripheral T-cell Lymphoma Sanchez et al. 2005179  
‘Low grade’ lymphoma:- 




Bertram et al. 2003147 
 
Taddei et al. 200952 
 
AL-Amyloidosis Dikman et al. 1978140, Elstein et al. 
2003141, Hanash et al. 1978142, 
Kaloterakis et al. 1999143, Hrebicek 




Krishnan et al. 2003180  
Acute leukaemia Castelli et al. 2006181 (ALL), Krause 
et al. 1979182 (AML), Burstein et al. 
1985183 (ALL), Corbett et al. 1987184 
(AML) 
 
Chronic Myeloid Leukaemia Shinar et al. 1982185, Petrides et al. 
1998186 
 
Hepatocellular Carcinoma Breiden-Langen et al. 1991187, 
Erjavec et al. 1999188, Xu et al. 
2005189 
de Fost 200678 
Primary bone cancer Kenan et al. 1996190 
(Osteoblastoma), Bohm et al. 2001 
(Leiomyosarcoma) 
 
Prostate Cancer Lo et al. 2010133  
Pancreatic Cancer  Landgren et al. 200765 
Lung Cancer Tsung et al. 1977191, Leone et al. 
2008192 
 
Melanoma  Landgren et al. 200765 
Breast Cancer Gal et al. 1988134  
Malignant Epitheloid 
Haemangioendothelioma 
Pins et al. 1995193  
Glioblastoma Multiforme Lyons et al. 1982194  
Dysgerminoma Kojiro et al. 1983195  
 
Table 1-2. Publications describing episodes of cancer in patients with Gaucher disease.
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1.3.1 PLASMA CELL NEOPLASMS 
Plasma cells, first described by Waldeyer in 1875196, are terminally differentiated B-
lymphocytes that have class switched and secrete immunoglobulin of a specific 
isotype. Plasma cells have undergone clonal re-arrangement of their immunoglobulin 
genes together with somatic hyper-mutation in their variable regions. Plasma cells 
are absent from the peripheral blood in health, comprise 1-5% of all nucleated bone 
marrow cells and are present in lymphoid tissue197. Morphological features on light 
microscopy (Giemsa staining) include cytoplasmic basophilia, an eccentrically 
placed nucleus, clumped chromatin and a prominent peri-nuclear golgi zone197. 
Plasma cells are typically uni-nucleate although multi-nucleate forms may be seen in 
normal individuals. Typically plasma cells have a diameter of between 15-20µm and 
form small clusters, either in the interstium or around capillaries, in normal bone 
marrow197. Characteristic electron microscopic appearances include a double 
membraned nucleus, an abundant Golgi system and cytoplasm packed with ER and 
scattered mitochondria196. Non-malignant plasma cells express cell surface 
CD[cluster of differentiation]19, CD38 and CD138 but lack CD56 together with light 
chain restriction on immuno-phenotyping198.   
 
MGUS is a clonal disorder of plasma cells that is associated with either a serum or 
urinary paraprotein in the absence of end organ impairment. MGUS is associated 
with a plasma cell infiltrate of less than 10% and a paraprotein level of <30g/l199. 
Furthermore, deletions of 13q, hyperdiploidy and translocations involving the IgH 
[immunoglobulin-heavy chain] locus (14q32) are reported in about 50%, 40-50% and 
40% of patients with benign gammopathy respectively198. Clonal plasma cells are 
CD19-ve, CD38+ve, CD138+ve, light chain restricted with variable CD56 
expression on immunophenotyping198. The incidence of MGUS increases with age200 
and according to a Minnesota based study of 21,462 people, is 3.2% in those >50 
years old and 7.5% in those >85 years old201. The frequency of MGUS in other 
published cohorts is shown in Table 1-3 and illustrates geographical differences in 
incidence. Monoclonal gammopathy is commoner in blacks than whites202. The 
incidence of MGUS in Ashkenazi Jews has not been reported in the literature. 
Population studies have demonstrated that around 1% per year of patients with 
MGUS progress to a haematological malignancy203.  Kyle et al. (2002) showed that 
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pre-existing MGUS was most likely to transform to multiple myeloma (Relative risk 
[RR], 25.0) with lymphoma (RR 2.4), amyloidosis (RR 8.4), chronic lymphocytic 
leukaemia (RR 0.9) and solitary plasmacytoma (RR 8.5) being subsequently 
diagnosed in a minority of individuals203.   
 
Country Age Number of 
individuals 
Incidence Authorship 
America ≥70 816 3.6% Cohen et al.204 
Greece >50 1564 3.9% Anagnostopoulos et al.205  
France ≥50 17,968 1.7% Saleun et al.200 
Ghana ≥50 917 5.9% Landgren et al.206 
 
Table 1-3. Frequency of MGUS in different geographical populations. 
 
Approximately 84% of 1,384 individuals with MGUS in an American based cohort 
had a presenting paraprotein of under 20g/l203. In this study Ig(Immunoglobulin)G, 
IgA, IgM and bi-clonal paraproteins were found in 70%, 12%, 15% and 3% of 
individuals respecitively203.  These findings are in keeping with the isotype 
frequency reported in a Greek population205. Risk factors for progression from 
MGUS to multiple myeloma include immunoglobulin isotype (IgA>IgG)203, an 
abnormal serum light chain ratio207, a high paraprotein level199, increased bone 
marrow angiogenesis208 and the percent of infiltrating plasma cells on staging bone 
marrow examination209. Age, sex and specific cytogenetics are not thought to be risk 
factors for malignant transformation199. Cesana et al. (2002) suggested the Bence-
Jones proteinuria, a high erythrocyte sedimentation rate (ESR) and immunoparesis to 
confer a higher rate of malignant transformation209.  
 
Multiple Myeloma is a malignant haematological disorder secondary to the 
accumulation of clonal plasma cells with rearranged heavy and light chain 
immunoglobulin genes. Elevated plasma cell numbers, dysplastic morphology, 
abnormal clustering and multi-nuclearity are features found on bone marrow 
examination that are suggestive of malignant disease198. Additionally, the presence of 
plasmablasts (high nuclear: cytoplasmic ratio, increased cell size, dispersed 
chromatin and visible nucleoli), mitotic figures and plasma cells with flamed shaped 
eosinophilic cytoplasm (flame-cells), raise suspicion of neoplastic disease. Malignant 
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plasma cells may accumulate immunoglobulin in cytoplasmic vacuoles (Mott cells), 
the cisternae of distended ER (Russell bodies) or impinge on the nucleus, secondary 
to cytoplasmic accumulation, giving rise to Dutcher bodies196;198;210. 
Immunophenotyping normally reveals a population of malignant plasma cells that 
are CD19-ve, cytoplasmic Ig+ve, CD56+ve (67-79%), CD38+ve, CD138+ve with 
variable expression of cyclin D1, CD20, CD52, CD10 and CD117198.     
 
Data from the office of national statistics reported an incidence of multiple myeloma 
of 3.2 per 50,000 individuals with male predominance 
(http://info.cancerresearchuk.org/ cancerstats /types 
/multiplemyeloma/incidence). Diagnostic criteria for symptomatic myeloma, as 
stipulated by the international myeloma working group (IMWG), are a plasma cell 
infiltrate of >10% and the presence of related end organ impairment (ROTI) 
including renal failure, skeletal disease (lytic lesions, vertebral collapse or 
osteoporosis), hypercalcaemia, anaemia, amyloidosis, recurrent bacterial infection or 
hyperviscosity199;211. Based on a study from the Mayo clinic, 43% of patients had a 
paraprotein less than 30g/l at diagnosis, but 96% of patients had an infiltrate of >10% 
plasma cells on bone marrow examination212. Therefore, complete and careful 
interpretation of staging investigations is mandatory at presentation. Malignant 
plasma cells are capable of metastasis and can lead to end organ impairment by 
either direct infiltration or by paraneoplastic effect. Approximately 3% of individuals 
have non-secretory myeloma (no urine or serum M-band) with a further 20% being 
categorised as light chain myeloma212. Below describes the frequency of specific 
serum monoclonal bands from this study212:- 
[IgGκ (34%), IgGλ (18%), IgAκ (13%), IgAλ (8%), IgMκ (0.3%), IgMλ (0.2%), 
IgDκ (1%), IgDλ (1%), Free κ only (9%), Free λ only (7%), Bi-clonal (2%) and 
Negative (7%)] 
 
IgG Myeloma is commoner than those sub-typed as IgA with these two isotypes 
being expressed in 73% of cases212. IgD and IgE Myeloma are rare, suggested to 




Current first-line therapy in patients with symptomatic myeloma from the Royal Free 
Hospital involves a combination of an alkylating agent, steroid and an immuno-
modulatory agent. For younger patients eligible for high dose therapy with stem cell 
rescue, ‘CDT’ chemotherapy (cyclophosphamide, dexamathasone and thalidomide) 
is instigated. ‘CDT’ has been shown to be superior to ‘C-VAD’  (cyclophosphamide, 
vincristine, adriamycin and dexamethasone) as an induction regime (Morgan et al. 
2007; Myeloma IX trial; ASH abstract). MPT (melphalan, prednisolone and 
thalidomide) has been shown to induce superior remission rates and event-free 
survival, compared to MP chemotherapy in elderly patients unsuitable for bone 
marrow transplantation215.  Bortezomib, a proteasome inhibitor, has potent anti-
myeloma activity in clinical trials in both newly diagnosed patients and those with 
relapsed disease216;217. Lenalidomide, a second generation immuno-modulatory 
agent, in combination with dexamethasone leads to superior response rates and 
overall survival compared to dexamethasone therapy alone218. In addition, 
lenalidomide/dexamethasone, has been suggested an effective treatment strategy in 
relapse219.  In the UK, the National Institute of Clinical Excellence (NICE) has 
approved bortezomib in first relapse and a lenalidomide containing regimen as third-
line therapy.  In the era of novel therapies (lenalidomide, bortezomib etc.), phase III 
trials are being conducted to re-assess the role of autografting as a consolidative 
procedure post first-line therapy220. Bisphosphonates, inhibitors of 
osteoclastogenesis, are mandatory adjuvant therapy in the treatment of myeloma. 
Reported in abstract form, zoledronic acid has been shown to be superior to oral 
clodronate in the Myeloma IX trial and imparts a survival advantage (Morgan et al. 
2010; European Haematology Association, Abstract book).  
 
Prognosis may be predicted from several published scoring systems including the 
Durie-Salmon staging system, International Staging System (ISS) and from lists of 
adverse risk factors extrapolated from population studies, such as that reported by the 
Mayo clinic211;221. The ISS, based on presenting serum albumin and β2-microglobulin 
level, categorises three risk groups. Stage I disease is defined as a β2-microglobulin 
<3.5mg/l with an albumin ≥35g/l. Those with a β2-microglobulin≥5.5mg/l having 
stage III disease and stage II disease includes individuals that do not meet criteria for 
either of these two risk groups. Survival in a cohort of over 10,000 newly diagnosed 
myeloma patients using the ISS predicted survival (stage I 62 months, stage II 44 
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months and stage III 29 months)221 and is recommended by the IMWG for staging in 
the United Kingdom. In a cohort of patients >70 years old, stage I and II disease, 
predicted for a poorer survival than that seen in younger individuals, although, the 
prognosis in stage III disease was identical222. Based on Mayo clinic data, monosomy 
13, hypodiploidy, translocation (4;14), translocation (14;16), 17p- (p53) and a 
plasma cell labelling index ≥3% have been suggested as adverse predictors of 
outcome223. Additionally, other investigators, have reported, a raised lactate 
dehydrogenase (LDH), the percentage of bone marrow plasma cells, the degree of 
anaemia, the number of positive lesions by positron emission tomography (PET), 
elevated serum M-CSF, hypercalcaemia, progression to plasma cell leukaemia, 
plasmablastic morphology and a high C-reactive protein to predict for inferior 
survival222;224-226.   
 
Asymptomatic myeloma is defined by the IMWG as a paraprotein >30g/l and/or a 
plasma cell infiltrate on bone marrow staging of >10%, in the absence of ROTI211. 
Kyle et al. (2007) described the rate of progression to malignant disease in 276 
individuals as 10% per year for the first 5 years, 3% per year for the next 5 years and 
then 1% per year thereafter227. Risk factors, reviewed by Bladé et al. (2010), for 
progression to symptomatic myeloma include the percentage of infiltrating plasma 
cells, paraprotein level, the presence of circulating plasma cells, a high plasma cell 
labelling index, abnormal signal intensity on magnetic resonance imaging (MRI) 
examination, elevated serum light chains and an abnormal immunophenotype, 
including CD56 expression228. Patients with asymptomatic myeloma are carefully 
observed and not treated until the development of ROTI.    
 
Primary AL-amyloidosis is caused by a clonal population of plasma cells that secrete 
an amyloidogenic light chain, usually lambda, capable of forming beta-pleated sheets 
that stain positive with Congo red229. Organ dysfunction correlates with amyloid 
fibril deposition and is usually secondary to a small population of bone marrow 
plasma cells with similar cytogenetics and immunophenotyping to those with MGUS 
or symptomatic myeloma198. Deposited organ amyloid contains non-fibrillar 
macromolecules including serum-amyloid protein (SAP)230. Presentation is 
heterogeneous but includes renal failure, proteinuria, cardiac dysfunction, liver 
impairment, hepato-splenomegaly, neuropathy, low level paraproteinaemia, elevated 
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serum light chains, macroglossia, abnormal bleeding/bruising and gastrointestinal 
disturbance229. Disease bulk can be serially assessed by a combination of routine 
blood tests, serum light chain analysis, echocardiography and serum amyloid protein 
(SAP) scintigraphy229;231;232. Prognosis is inferior to those with multiple myeloma 
with an average life expectancy of 3.3 years230. Chemotherapy regimens are similar 
to those used in symptomatic myeloma. Treatment duration may be attenuated in 
some individuals as responses in many are obtained early due to the presence of low 
tumour burden230. The upfront role of autografting in AL-amyloidosis is currently 
being investigated.  
 
1.3.2 GAUCHER DISEASE AND GAMMOPATHY 
Polyclonal gammopathy is defined as an isolated or general increase in serum 
immunoglobulin levels without a detectable urinary or serum paraprotein by gel 
electrophoresis, densitometry and immunofixation199. This state is not associated 
with clonally arranged plasma cells or end-organ tissue impairment. For several 
decades the incidence of polyclonal gammopathy and paraproteinaemia has been 
known to be increased in patients with GD138;139;233. Publications pertaining to the 
incidence of gammopathy in GD are documented in Table 1-4 below. The incidence 
of polyclonal gammopathy, has been suggested to be higher in paediatric GD 
populations (81-91%)234;235 and this may reflect a cohort of patients presenting with 
severe early-onset disease. This supports disease severity being a risk factor for 
polyclonal gammopathy. In a report by Khalifa et al. (2010), which contained 12/16 
children with more aggressive type III disease, polyclonal increases in IgM were 
seen in approximately 80% of patients235. The incidence of polyclonal gammopathy 
in adult cohorts has been reported in up to 60% of individuals, with IgG being the 
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NR NR 
Table 1-4. Prior cases series relating to gammopathy in Gaucher disease.  
NR, not reported. 
 
Brautbar et al. (2004), demonstrated a reduction in polyclonal immunoglobulin 
levels (IgG, IgM and IgA), with the introduction of ERT43. In a paediatric 
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population, disease-modifying therapy was shown to decrease IgA and IgM levels234, 
suggesting disease severity as a contributing factor to the development of 
gammopathy. However, in an Israeli based study, polyclonal gammopathy was not 
associated with markers of severity, including the Zimran score, splenectomy status, 
genotype or the presence of bony disease43. However, no correlation was made with 
biomarkers, such as serum chitotriosidase activity83, that reflect disease bulk and 
mirror the clinical response to ERT. In a cohort of children with GD (type I/type III), 
age, platelet count, haemoglobin, gender and type III disease were not predictive of 
gammopathy235. Current literature is insufficient to answer whether spleen volume, 
liver volume, biomarker activity (S-ACE, acid-phosphatase, chitotriosidase activity) 
or bone marrow macrophage burden are risk factors for polyclonal gammopathy in 
GD.  
 
The incidence of paraproteinaemia (8-35%), reported in Table 1-4, as discussed 
above, is higher than expected in the general population200;201. Advanced age has 
been shown to be a risk factor for the development of monoclonal gammopathy in 
GD81;236. This may explain why Brautbar et al. (2004) reported a low incidence of 
paraproteinaemia (1%) in a comparatively younger cohort of ERT treated patients 
(mean age 42 years)43.  In an untreated cohort, reported by Marti et al. (1988), a 
monoclonal band was found in 35% of individuals of a similar mean age139. 
Exposure time (diagnosis to treatment), prior splenectomy, Zimran severity score and 
baseline chitotriosidase activity did not predict for the development of MGUS in one 
study81. Serum IL-6 levels were found to be higher in GD patients with a monoclonal 
band than those without74. IL-6 is a plasma cell proliferating cytokine. MGUS is not 
associated with ROTI, but IgMκ cryoglobinaemia, leading to neuropathy, has been 
previously described in an elderly patient with GD237.  
 
The incidence of GD is approximately 1:59,00018 and that of multiple myeloma, in a 
Minnesota based study, is 1:25,000238. In addition, many patients with GD, fail to 
present clinically in life, due to variable disease severity52. Therefore, the number of 
observed cases (Table 1-2) is greater than expected, based on probability alone. 
There are several case reports of AL-amyloidosis in patients with GD81;140-144 and has 
been suggested to have an incidence of approximately 1:100,000 in the US general 
population145. Furthermore the increased frequency of MGUS and polyclonal 
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gammopathy in GD supports an increased prevalence of plasma cell disorders in this 
disorder. 
 
IgG is the commonest isotype secreted in non-GD myeloma212. In patients with GD, 
reports include IgG81;132;158;161;236, IgA74;132;157;159;160, light chain136 and non-secretory 
IgD myeloma156. Homozygous N370S disease has been suggested, compared to other 
genotypes, to be an additional risk factor for the development of multiple myeloma52. 
Those with N370S/N370S disease, compared to the general population, were 
reported to have an 25-times higher life time risk of developing multiple myeloma52. 
The authors also reported that within their cohort of homozygous N370S individuals, 
prior splenectomy was a risk factor for the subsequent development of multiple 
myeloma. This genotype is associated with comparatively milder disease, although 
rarely individuals with N370S/NS70S, have severe disease52. Pratt et al. (1968) 
reported that hepato-splenomegaly was found in all GD patients with either 
monoclonal or polyclonal gammopathy138. However, Cheung et al. (2007), described 
the incidental diagnosis of GD in a 57 year old lady with multiple myeloma, post 
autograft136. Evidence is currently insufficient to conclude that disease severity is a 
risk factor for the subsequent development of a plasma cell neoplasm.  
 
In a report, by a French based group, 6/17 patients with a monoclonal band 
experienced either a reduction in the paraprotein level or its disappearance with 
ERT236. This is in keeping with the conclusions of some investigators239 but contrasts 
to those of Brautbar et al. (2004)43. Another report, by de Fost et al. (2008), 
suggested that ERT reduced or stabilised the level of paraproteinaemia in GD81. 
Currently, a diagnosis of MGUS is not a clinical indication for ERT66. In addition, it 
is unknown, whether ERT prevents progression to malignant gammopathy. 
Furthermore, is a diagnosis of multiple myeloma, in an otherwise asymptomatic 
Gaucher patient, an indication for ERT? Do patients with benign gammopathy and 
GD, progress to multiple myeloma, at the same rate as those without GD? 
Collaborative meta-analysis is required, via an international registry, to clarify these 
points.    
 
In addition, there is insufficient data to recommend specific chemotherapy regimens 
for GD patients with multiple myeloma. Prior reports of treatment with MP have led 
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to the development of severe cytopenia81;136;161. Concomitant high-dose ERT may 
reduce Gaucher cell burden, improve the severity of cytopenia and improve 
haematological recovery post chemotherapy. In one GD patient with myeloma, 
myelodysplasia followed by leukaemia transformation developed post-treatment with 
MP chemotherapy161. Immunomodulatory agents, including thalidomide and 
lenalidomide, can lead to profound cytopenias240;241 and may be poorly tolerated in 
GD. In addition, Machaczka et al. (2009), postulated that bortezomib, may also lead 
to unacceptable side effects in GD patients161. GD causes proteasomal dysfunction16 
and the use of bortezomib may compound GD cellular pathology further. Although, 
there are reports in the literature, of both favourable81 and unfavourable outcomes161 
to chemotherapy, no firm conclusion can be drawn on treatment outcome due to the 
low number of reported cases.   
 
1.3.3 GAUCHER DISEASE - AETIOLOGY OF PLASMA CELL 
DISORDERS  
Multiple myeloma and GD have overlap in their clinical presentation including bone 
marrow infiltration, cytopenias, and skeletal disease (lytic lesions, pathological 
fracture and osteoporosis)24;242;243. Non-GD and GD individuals with MGUS 
progress to malignant disease81;244. Patients with GD, as discussed above, have a 
higher incidence of polyclonal gammopathy, MGUS and multiple myeloma43;78;81. 
Gammopathy in GD therefore represents a spectrum of disease and pathological 
disturbances within the bone marrow microenvironment, as suggested in non-GD 
patients with MGUS, maybe fundamental to malignant transformation. In addition, 
there are several biological features common to both disorders, which may be 
speculated to contribute to the development of clonal plasma cell disorders. GD is 
predominantly a disorder of the monocytic lineage, including macrophages and 
osteoclasts. An accumulation of lipid laden macrophages within the bone 
marrow131;245;246, elevated serum biomarkers of macrophage activity79;247, 
radiological evidence of osteoclast over-activity242;248,  elevated serum biomarkers of 
bone resorption249;250 and raised blood levels of cytokines promoting 
osteoclastogenesis72;251 have been described in both GD and multiple myeloma. Both 
macrophages and osteoclasts, based on in vitro co-culture models, have been shown 
to promote plasma cell survival245;252.  Furthermore elevation in the serum levels of 
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plasma cell proliferating cytokines including IL-6, a macrophage manufactured 
cytokine, have been reported as elevated in individuals with either myeloma or 
GD74;253.  
 
Numerical and functional abnormalities in lymphoid subsets4;139;254;255 have been 
reported in individuals with either GD or multiple myeloma. Patients with GD, as 
discussed above, have an elevated risk of several non-haematological malignancies, 
including hepatocellular carcinoma65;78;133. These observations suggest a more global 
defect, extending beyond the bone marrow microenvironment, that renders an 
elevated cancer risk in those with GD. Impaired tumour surveillance, a concept 
described in patients with Human immunodeficiency syndrome (HIV) infection256 
due to depressed cellular immunity, has not been fully explored in GD.   
 
The following theories for the development of multiple myeloma in GD are explored 
below, although not mutually exclusive:- 
1. Disturbances of the bone marrow microenvironment  
2. Chronic inflammation 
3. Chronic antigen presentation  
4. Impaired tumour surveillance 
5. GBA1 mutations  
 
1.3.4 BONE MARROW MICROENVIRONMENT 
The bone marrow microenvironment encompasses stromal cells, osteoblasts, 
osteoclasts, plasma cells, macrophages, haematopoietic cells/progenitors, the 
microcirculation and connective tissue including bone257. Over the last 2 decades 
many abnormalities of the bone marrow microenvironment have been described 
favouring plasma cell growth, expansion, malignant transformation and chemo-
resistance245;252;258-261. Furthermore many of these abnormalities are also seen in 
individuals with GD, including elevated macrophage and osteoclasts numbers, 
suggesting potential common aetiology for the development of a plasma cell 




Macrophages are derived from the monocytic lineage263 and these phagocytic cells 
have important roles in innate immunity, antigen presentation, inflammation, 
angiogenesis, coagulation, the breakdown of apoptotic cells, the destruction of 
microbes, tumour surveillance and many metabolic pathways including iron 
recycling263;264. In normal bone marrow, macrophages are large cells with 
voluminous cytoplasm, small nuclei and are often surrounded by plasma cells, 
lymphocytes or maturing erythroid cells. Their cytoplasm may be vacuolated, ruffled 
and may contain phagocytosed debris197. Monocytic precursors are driven into 
macrophage differentiation by colony stimulating factor-1 (CSF-1), IL-3, M-CSF and 
GM-CSF265. 
 
Tissue macrophages harbour a cocktail of signalling membrane molecules including 
Ig Fc receptors (FcRγR1 [CD64], FcRγRIII [CD16]), CD4, complement receptors 
(CR1, CR3 [CD11b/CD18]), the mannose receptor (CD206), toll like receptors 
(TLR), scavenger receptors, hormone receptors, chemokine receptors, lipoprotein 
receptors, growth hormone receptors (M-CSF, GM-CSF), fibronectin receptors and 
HLA proteins (class I and II)263. Scavenger receptors recognise low-density 
lipoproteins, lipopolysaccharide (LPS), dead cells and microbes264. LPS, 
peptidoglycan, bacterial DNA, RNA and several other microbial components 
comprise the ligands recognised by TLRs263. Opsonised molecules including those 
derived from tumour cells or microbes activate macrophages via their Fc receptors. 
This can lead to a host of responses including antibody mediated cell death, 
engulfment, enzyme secretion and the production of toxic nitrogen and oxygen 
species. Complement receptors mediate macrophage chemotaxis (e.g.C5a) and the 
recognition of non-self by the binding of complement components (e.g. C3b)263. The 
addition of mannose residues to ERT has facilitated its uptake by macrophages in 
GD118.  
 
Macrophages secrete a rheostat of cytokines, chemokines and growth factors which 
modulate tumour cell growth, chemoresistance, neoangiogenesis, chemotaxis and the 
recruitment of T-cells266. Macrophages can be differentiated via external stimuli into 
either classically activated type I macrophages (M1) or alternatively activated type II 
macrophages (M2)267. Type I macrophages are pro-inflammatory, anti-microbial, 
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tumourcidal and are characterised by the secretion of INFγ and TNF-α. In contrast, 
M2 macrophages, promote carcinogenesis267;268, regulate tolerance, mediate an anti-
inflammatory response, facilitate angiogenesis, express low levels of HLA-class II 
molecules and secrete IL-1RA, IL-4 and IL10267;269. A higher burden of macrophage 
infiltration has been associated with a poorer prognosis in those with glioblastoma270.  
M1 and M2 macrophages differ in their expression of membrane receptors (e.g. 
scavenger, Fcγ-R, CD14/64), cytokines, cytokine receptors, chemokines, chemokine 
receptors and effector molecules267. Tumour cells produce a cocktail of inflammatory 
cytokines including extracellular matrix components, IL-10, chemokines (CCL2, 4, 
17 and 22) and CSF-1 that can recruit and polarise macrophages into a M2 
phenotype269.   
 
Macrophages are more abundant in the bone marrow trephines of patients with 
myeloma than in healthy controls245. Zheng et al. (2009), using cell culture models, 
demonstrated that macrophages in a contact-dependent manner, up-regulated anti-
apoptotic proteins, and prevented chemotherapy-induced death in co-cultured plasma 
cells. Furthermore, macrophages which were conditioned with the culture medium of 
myeloma cells afforded greater protection than unconditioned macrophages245. 
Higher numbers of infiltrating tumour-associated macrophages (TAMs) are 
associated with tumour invasion, lymph node metastasis and advanced disease in 
colorectal cancer271. Poor prognosis is conferred by the presence of large infiltrates 
of TAMs in other cancers, including sino-nasal melanoma,272 and predicts for an 
inferior outcome to hormonal therapy in prostate cancer273. Macrophages are an 
important component of the malignant microenvironment and investigators are 
currently exploring the use of antibodies against CCL2 (promotes M2 polarisation 
and the recruitment of TAMs) in early phase clinical trials267. In addition, 
macrophages secrete a cocktail of cytokines promoting osteoclastogenesis (see 
below). Osteoclasts have been shown in vitro to support myeloma cell growth and 
survival274.  
 
GD, as discussed above, is a disorder characterised by the accumulation of foamy 
macrophages or Gaucher cells. Boven et al. (2004) demonstrated that Gaucher cells 
expressed common macrophage markers including CD68, CD14, HLA (Human 
leucocyte antigen)-class II and have a phenotype of M2 macrophages (CD163, IL-
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1RA and CCL-18)58. Based on the evidence presented here, the accumulation of M2 
macrophages in GD speculatively leads to a microenvironment permissive of 
carcinogenesis. Hepato-cellular carcinoma, NHL and multiple myeloma have been 
reported to be more common in GD65;78;130. These cancers affect the liver and bone 
marrow, major organs infiltrated by foamy macrophages in GD.  
 
1.3.4.2 GAUCHER AND PSEUDO-GAUCHER CELLS 
Macrophages, with identical appearances to Gaucher cells by light microscopy 
(pseudo-Gaucher cells), have been demonstrated in the bone marrow trephines of 
non-GD patients with MGUS275 and multiple myeloma246. Lipid laden macrophages, 
therefore, may have a crucial role in supporting plasma cell expansion. Gaucher cells 
and pseudo-Gaucher cells have been suggested to acquire their morphological 
appearance from phagocytosed cells and the subsequent saturation of residual 
glucocerebrosidase activity276;277. The accumulation of pseudo-Gaucher cells, in GD-
individuals, has been reported in the staging bone marrow trephines of individuals 
with other haematological cancers including Hodgkin lymphoma278, NHL279, chronic 
myeloid leukaemia (CML)280, myelodysplasia281 and common B-ALL282.  The 
accumulation of pseudo-Gaucher cells, in one report, pre-dated the diagnosis of 
NHL, adding further speculation to their role in carcinogenesis279.  
 
The presence of pseudo-Gaucher cells, have been reported in other non-malignant 
haematological conditions that are associated with haemolysis and decreased red 
blood cell survival including thalassaemia283 and sickle cell disease284. 
Glucosylceramide is a major component of cell membranes and macrophage 
glucocerebrosidase activity may become saturated in disorders associated with high 
cellular turnover. An association between myeloma and sickle cell disease has not 
been established, perhaps due to decreased life expectancy. There is one case series 
describing 6 Greek patients with sickle cell related haemoglobinopathies (ages 56-
65) and myeloma in the literature285. A high incidence of paraproteinaemia was noted 
in a family of patients with congenital dyserythropoietic anaemia (3/20 MGUS; 1/20 
Myeloma) but not in their relatives (n=10)286. However, co-inheritance of a cancer-
gene, in individuals reported in this study, cannot be excluded.  
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Florena et al. (1996), using immuno-cytochemistry, demonstrated equivalent staining 
intensity for CD68 and MHC class II expression on Gaucher and pseudo-Gaucher 
cells. In addition, they found, that HLA-DR expression was expressed on all Gaucher 
cells, but on only 50% of pseudo-Gaucher cells276.  Ultrastructural studies, using 
electron microscopy (EM), have demonstrated differences in structure between 
Gaucher cells and pseudo-Gaucher cells278. Furthermore, Gaucher cells have been 
suggested to express a different cytokine profile polarised towards a M2 phenotype58. 
Currently, it is unclear whether Gaucher cells, contribute to the elevated risk of 
multiple myeloma in GD. The liver contains the largest bulk of tissue macrophages 
in the human body. Therefore, as individuals with GD have been suggested to have 
an increased risk of hepatocellular carcinoma287, the accumulation of Gaucher cells 
may be pathologically important. Those with homozygous N370S disease, associated 
with predominantly skeletal disease rather than organomegaly, have been suggested 
to be a subgroup of GD patients with a high risk of myeloma, perhaps due to an 
increased bone marrow burden of Gaucher cells52. Biological models are required to 
explore the contribution of Gaucher cells and pseudo-Gaucher cells in the 
development of carcinogenesis and plasma cell expansion.  
 
1.3.4.3 OSTEOCLASTOGENESIS 
Three cell types, osteoclasts, osteoblasts and osteocytes, contribute to bone 
remodelling288. Osteoblasts and osteocytes, derived from bone marrow mesenchymal 
cells, are involved in bone formation whereas osteoclasts digest mineralised bone via 
a ruffled cytoplasmic border288. Osteoclasts are highly specialised cells that originate 
either from the monocyte-macrophage lineage or are formed directly from 
granulocyte-macrophage colony forming units (CFU-GM)289;290. Morphologically, 
osteoclasts are large multi-nucleate cells found in Howship’s lacunae with a diameter 
of 30-100µM, have abundant cytoplasm, contain azurophilic granules and stain 
positive for TRAP197. They express specific surface markers and are characterised by 
the presence of an F-actin ring plus the vitronectin and calcitonin receptors289;291;292.  
 
M-CSF stimulates the expansion and survival of osteoclast progenitors289. 
Osteoblasts, stromal cells and tumour cells secrete cytokines including M-CSF that 
facilitate the recruitment, commitment, differentiation and activation of osteoclast 
precursors289. The final common effector system mediating osteoclast differentiation 
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is the OPG (osteoprotegerin)-RANK (receptor activator of nuclear factor κB)-
RANK-L (RANK-ligand) system. RANK-L, a member of the TNF-superfamily, 
binds to its receptor, RANK, on the surface of osteoclast progenitors. This leads to 
the up-regulation of several intracellular messengers, including Erk (extracellular 
signal-regulated kinases), p38, matrix metalloproteinase, PKC (protein kinase C), 
Akt, cfos and C-Jun, that mediate osteoclast differentiation and maturation288;289. 
RANK-L expression is inducible by parathyroid hormone and vitamin-D. RANK-L 
is expressed on the cell surface of stromal cells including osteoblasts and is secreted 
as a soluble factor by activated lymphocytes274.  Genetically modified mice deficient 
in M-CSF or RANK-L develop osteopetrosis due to impaired 
osteoclastogenesis293;294. OPG, a dummy receptor secreted by stromal cells and 
osteoblasts, chelates free RANK-L leading to a microenvironment favourable to bone 
formation288;295. Knockout mice for OPG develop osteoporosis in adulthood296.   
 
Patients with multiple myeloma, Paget’s disease and psoriatic arthropathy, conditions 
associated with abnormal bone resorption, are associated with elevated numbers of 
osteoclast progenitor cells within the peripheral blood290. Bone marrow osteoclasts, 
based on experimental and clinical data, have been found to promote plasma cell 
growth and survival252;258. Osteoclast numbers are increased in non-GD patients with 
monoclonal gammopathy with significantly more being present in the bone marrow 
of those with malignant disease262. Serum TRAP levels and hydroxyproline excretion 
(markers of bone turnover) have been shown to be elevated in individuals with 
multiple myeloma297, confirming elevated osteoclast activity. Experimental models 
using conditioned medium from cultured plasma cells lines on rabbit osteoclasts have 
led to increased osteoclast activity and decreased osteoclast apoptosis298. This was 
found to be dependent on the production of M-CSF by immortalised plasma cells298. 
Patients with multiple myeloma have raised serum or tissue levels (in vitro or in 
vivo) of several cytokines capable of promoting osteoclastogenesis including RANK-
L, IL-3, IL-6, stromal-derived factor 1α, TNF-α, MIP-1α258;274;299. The RANK-
L/OPG ratio has shown to be comparatively higher in myeloma patients with severe 
bone disease or advanced stage251. Myeloma cells have been shown to induce 
RANK-L expression and to reduce OPG production in stromal cells plus 
osteoblasts300. Myeloma cells lead to a RANK-L/OPG ratio favourable to bony 
resorption by shredding CD138 (syndecan-1), which binds extra-cellular OPG301. 
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Histological analysis has shown that osteolytic lesions occur adjacent to plasma cell 
infiltrates in the bone marrow specimens of patients with myeloma274. Abe et al. 
(2004), in a landmark paper, demonstrated the beneficial reciprocal interactions 
between osteoclasts and plasma cells252. They used a co-culture system consisting of 
osteoclasts derived from rabbit bone or generated post differentiation of human 
peripheral blood mononuclear cells (PBMCs) with RANK-L and M-CSF. 
Osteoclasts were shown in vitro to support myeloma cell survival (primary and cell 
line), rescue plasma cells grown in serum-depleted culture medium and to induce 
chemo-resistance in immortalised plasma cells to doxorubicin252. In addition, the 
authors demonstrated that the co-culture of plasma cells was sufficient for 
osteoclastogenesis, despite the absence of osteoclast differentiating cytokines252. 
Several other investigators have confirmed these findings with plasma cell expansion 
and osteoclastogenesis being enhanced in co-culture models259;302. Osteoclasts 
support myeloma cell survival and expansion by up-regulating the activity of 
intracellular signalling pathways (p44/42, STAT3 [Signal transducer and activator of 
transcription 3], MAPK [Mitogen-activated protein kinases]) and by the secretion of 
soluble factors including IL-6, osteopontin, BAFF (B-cell activating factor) and 
APRIL (a proliferation-inducing ligand)252;258. Yaccoby et al. (2005) showed that 
plasma cells become left shifted with plasmablastic morphology and a more 
immature immunophenotype post osteoclast co-culture. Furthermore, the authors 
demonstrated the development of dexamethasone chemoresistance in these de-
differentiated cells303.  
 
Myeloma cells adhere to stromal cells or osteoclasts by the interaction of VLA (Very 
late antigen)-4 with VCAM (vascular cell adhesion molecule)-1. These interactions 
has been shown to lead to the production of MIP-1α and MIP-1β, potent osteoclast 
stimulating cytokines, from myeloma cells304. MIP-1α levels correlate with disease 
stage in patients (stage III>stages I, II)305 and high levels of this chemokine have 
been associated with a poor prognosis306. Osteoclasts have been shown to support 
angiogenesis, which is enhanced further by the co-culture of human multiple 
myeloma cell lines261.  
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Zoledronic acid, a potent inhibitor of osteoclastogenesis, has been shown to prolong 
survival in patients with multiple myeloma (Morgan et al, European Haematology 
Association abstract book, Barcelona, 2010), compared to a less potent oral 
bisphosphonate (clodronate).  The addition of bisphosphonates to co-culture models 
(osteoclasts plus myeloma cells) has been shown to retard plasma cell expansion252. 
Therapies employed successfully in the treatment of multiple myeloma, including 
immuno-modulatory agents and proteasome inhibitors, have been shown to inhibit 
osteoclastogenesis in in vitro models307-309.  
 
The prolonged culture of circulating B-lymphocytes from myeloma patients in the 
presence of RANK-L has been shown to lead to osteoclastic differentiation. 
However, this was not seen in the peripheral cultures derived from controls. In 
addition, the prolonged culture of immortalised myeloma cell lines with RANK-L, 
has been reported by the same group to lead to osteoclastogenesis310. Furthermore, 
based on cytogenetic examination, myeloma cells have been suggested to fuse with 
osteoclasts to form hybrid cells311.  Roato et al. (2005) demonstrated spontaneous 
osteoclast differentiation in cultured peripheral blood mononuclear cells from cancer 
patients with bony lesions, including those with multiple myeloma. In comparison to 
normal controls, the presence of osteoclast differentiating cytokines was not 
required290.  
 
Based on the data presented here, the OPG-RANK-RANK-L axis is a candidate 
pathway for the development of anti-myeloma drugs. Denosumab, a monoclonal 
antibody to RANK-L, failed to reduce the paraprotein level in relapsed or plateau 
phase patients with myeloma in a phase II trial312. However, it is currently unclear 
whether it will prove beneficial in combination with traditional chemotherapeutic 
regimes or solely as an agent for the treatment of myeloma bone disease. The 
therapeutic use of OPG analogues is also being explored313.  
 
Patients with GD have increased osteoclast numbers61, in keeping with the high 
incidence of lytic lesions and osteoporosis28. TRAP, an acid phosphatase specific to 
osteoclasts, has been shown to be elevated in the serum of patients with GD86. 
However, many studies in GD, measuring markers of osteoclastic activity including 
deoxypyrindinoline and collagen C-terminal telopeptide, have failed to confirm 
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increased bone resorption314;315. As described above, elevated serum levels of 
osteoclast promoting factors, including M-CSF, IL-6, IL-8, HGF, MIP-1α and MIP-
1β, have been reported in the literature of patients with GD81. Serum OPG levels 
have not been found to be decreased in patients with GD316. Prior results from our 
laboratory have suggested that monocytic precursors in vitro, derived from GD 
patients, are more sensitive to osteoclast differentiation and are capable of resorbing 
large areas of bone (personal communication, Dr Derralynn Hughes and Matthew 
Reed). GD patients have a large reservoir of accumulated macrophages within the 
bone marrow microenvironment61. Speculatively, these may lead to a pool of 
progenitor cells that are primed for osteoclastic differentiation. Literature is sparse 
regarding osteoclast pathology in GD. Osteoclastogenesis therefore seems a common 
feature to both multiple myeloma and GD. Further studies are required to assess 
whether GD patients generate a higher number of osteoclasts and whether these are 
supportive of the development and propagation of plasma cell clones. In addition, 
osteoclast function maybe disturbed in GD, given the macrophage origin of these 
cells. It is unclear at present whether GD patients with severe skeletal disease and 




Evidence detailing abnormalities of osteoblastogenesis in the bone marrow 
microenvironment of myeloma patients has multiplied in recent years317. Yaccoby et 
al. (2006), utilising a co-culture system, showed that the proliferative and survival 
benefits conferred by osteoclasts on co-cultured primary plasma cells were 
attenuated by the addition of osteoblasts318. In addition, the authors demonstrated a 
reduction in myeloma tumour growth in SCID-hu mice injected with mesenchymal 
stem cells (MSCs). Engrafted MSCs led to osteoblastic differentiation and increased 
bone marrow density318. Co-culture studies have shown that osteoblast expansion, 
differentiation and function are inhibited by either the co-culture of myeloma cells or 
addition of their conditioned medium260;300;319. Dickkopf-1 (DKK-1), a soluble factor 
secreted by myeloma cells, inhibits osteoblast maturation, suppresses OPG 
production and increases RANK-L expression in osteoblasts260. DKK-1 inhibits the 
canonical Wnt pathway crucial to osteoblastogensis300. Serum DKK-1 levels are 
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higher in individuals with lytic bone disease, advanced myeloma and in those with 
malignant rather then benign gammopathy320.  Li et al. (2008) elegantly showed that 
osteoblasts secrete decorin, a small leucine-rich proteoglycan that reduces myeloma 
cell survival, attenuates the stimulatory effects of osteoclasts on myeloma cell 
growth and retards the ability of plasma cells to induce osteoclastogenesis and the 
formation of vascular elements319. Secreted frizzled-related proteins, Sfrp-2 and sfrp-
3, inhibitors of the Wnt pathway like DKK-1, impair osteoblast function and are 
manufactured by primary or immortalised plasma cells300. Furthermore the co-culture 
of myeloma cells leads to the down-regulation of the transcription factor 
RUNX2/CBFA-1 and OPG secretion in osteoblasts321;322. Giuliani et al. (2005) 
showed that the number of RUNX2/CBFA-1 cells in the bone marrow trephines of 
myeloma patients with lytic disease was greater than those without skeletal 
pathology321. 
 
As for osteoclasts, there is sparse literature regarding osteoblast pathology in GD. 
Speculatively, osteoporosis, may be secondary to impaired osteoid formation rather 
than enhanced osteoclastogenesis. Bone density has been shown to be decreased in 
the spine and hips of type I GD patients323. Serum biomarkers of osteoblastogenesis 
including type I procollagen and osteocalcin have been reported as elevated by some 
investigators250;314 but normal by others315;324. It is unknown at present, if any, the 
degree of osteoblast pathology in GD or if present its contribution to the 
development of malignant gammopathy. A recent report, by Mistry et al. 2010, 
demonstrated severe osteoporosis, impaired osteoblastogenesis and decreased 
osteoblast differentiation in a GD mouse model325. They failed to show in their 
mouse model evidence of enhanced osteoclastogenesis.    
 
1.3.4.5 CHRONIC INFLAMMATION 
Chronic inflammation and immune stimulation are clearly important in the aetiology 
of carcinogenesis. Chronic bronchitis, inflammatory bowel disease, gastritis, 
hepatitis and chronic cholecystitis confer an elevated risk of lung, GI, liver and gall-
bladder cancer respectively266. Osteoarthritis, ankylosing spondylitis and 
inflammatory arthropathies are associated with an elevated risk of 
paraproteinaemia326. Furthermore, Bacille Calmette-Guérin administration treats 
localised bladder malignancy by inducing an inflammatory response266. 
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Inflammation is mediated by many different mediators, including prostaglandins, 
which are generated post degradation of arachidonic acid by cyclooxygenase (COX). 
Elevated COX-2 activity predicts for a worse prognosis in patients with GI-cancer. 
The use of non-steroid anti-inflammatory drugs (NSAIDs) and selective inhibitors of 
COX-2 are being explored in the treatment of bowel cancer327. Patients with 
rheumatoid arthritis, another chronic inflammatory disorder, have been reported to 
have a higher incidence of polyclonal gammopathy328, MGUS and multiple 
myeloma329. In GD, deposited substrate is responsible for only 2% of visceral organ 
weight with large infiltrates of lipid-laden macrophages and inflammatory cells 
predominating24. As described above, pro-inflammatory cytokines including TNF-α, 
IL-6, IL-8 and IL-1 have been reported in the serum of patients with GD73;74;76. IL-6 
is a major plasma cell proliferating cytokine196. Interestingly, a mouse model of GD 
demonstrated multi-system inflammation and evidence of B-cell expansion330. 
Speculatively, if inflammatory infiltrates are associated with gammopathy, then 
patients with high visceral load, or severe disease, may be at an elevated risk of 
developing plasma cell tumours.  
 
Individuals with GD have a higher incidence of polyclonal gammopathy, MGUS and 
multiple myeloma suggesting that these conditions represent a continuum of disease. 
Shoenfeld et al. 1982 hypothesised that chronic immune stimulation was one 
plausible mechanism and that polyclonal stimulation pre-disposed activated plasma 
cells to clonal expansion162.  However, follow-up in a cohort of non-GD patients 
failed to demonstrate that polyclonal gammopathy was a risk factor for developing a 
blood paraprotein328. 
1.3.4.6 CHRONIC ANTIGEN PRESENTATION 
GD is a metabolic disorder that leads to disturbed sphingolipid metabolism resulting 
in the non-physiological accumulation and depletion of intermediate breakdown 
products. Sphingolipids are involved in cell signalling, cell membrane integrity, 
influence trans-membrane receptor activity and regulate apoptosis 19. Ceramides, 
downstream products of glucosylceramide metabolism, facilitate apoptosis in cells 
exposed to chemotherapy or radiotherapy19. Glucosylsphingosine accumulates in 
enzymatic disorders of sphingolipid metabolism including GD24. One hypothesis 
pertaining to the development of gammopathy in GD is that of chronic antigenic 
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stimulation66. Here imbalances in sphingolipid metabolism lead to their non-
physiological presentation on antigen presenting cells (APCs), facilitating an 
immune response favouring plasma cell expansion. Furthermore organ compromise 
may lead to the enhanced presentation of non-sphingolipid inflammatory antigens 
associated with tissue damage, leading to a microenvironment more favourable to B-
cell proliferation. CD1d and MHC II class molecules, antigen presenting molecules, 
have been shown to have increased expression on the cell surface of GD monocytes4. 
However myeloid and plasmacytic derived dendritic cells (APCs) have been 
demonstrated to be decreased in the peripheral blood of patients with GD331.   
  
Glycolipids are the naturally occurring ligands for CD1d, a highly conserved 
molecule present on antigen presenting cells, including those derived from the 
monocytic lineage332. Processed sphingolipid, presented by CD1d tetramers on 
APCs, can expand and polarise invariant NK-T (iNKT) cells into either a Th1 or Th2 
immune response21. CD1d complexed sphingolipid is presented to iNKT cells via 
their T-cell receptor that consists of an invariant alpha chain (Vα24Jα18) with 
preferential β chain pairings21. 
 
Alpha-galactosylceramide (αGalCer), derived from the marine sponge Agelas 
Mauritianus, is the first known ligand to expand iNK-T cells and has also been 
reported to be the most potent332. Endogenous glycolipids include 
isoglobotrihexosylceramide (iGB3)333. Knockout mice devoid of type I NK-cells 
(iNK-T cells) develop fibrosarcomas more readily when exposed to 
methylcholanthrene and the authors attributed this finding to impaired tumour 
survelliance334. Early phase trials in human patients with cancer have demonstrated 
only a transient benefit of αGalCer injections.  However, the infusion of pre-loaded 
DCs with αGalCer has been suggested to result in an enhanced ability to expand 
iNK-T cells in vitro333. Many groups are exploring the potential of DCs, primed in 
vitro by tumour specific antigens, to regress human cancer via the stimulation of type 
I NK cells.        
 
It is currently unclear whether glucosylceramide is a natural ligand for CD1d 
molecules. In addition, Ilan et al. (2009) argued, based on experimental data, that 
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glucosylceramide administration polarises iNKT cells towards a Th2 response. They 
cited the beneficial effects of glucosylceramide administration in animal models of 
auto-immunity, malignancy and inflammatory disorders20. Failings in their argument 
include that the chronic antigenic stimulation of plasma cells in GD maybe mediated 
by the accumulation of secondary substrates. Furthermore it is currently unknown 
whether pathological quantities of glucosylceramide confer the same biological 
effect as those seen at lower levels. Other investigators have speculated that 
glucosylceramide may out-compete natural ligands such as iGB3 or that CD1d 
molecules are ineffectively loaded with lysosomal sphingolipids335. The 
accumulation of secondary substrates, including glucosylsphingosine, may be more 
important mechanistically in the development of gammopathy in GD. 
 
Speculatively, pathological quantities of glucosylceramide, could promote Th2 
polarisation of type I NK cells, resulting in a cytokine profile favourable to the 
development of a plasma cell clone.  
 
1.3.4.7 IMPAIRED TUMOUR SURVELLIANCE 
The discriminating features of cancer cells are that they undergo autonomous 
proliferation, ignore inhibitory growth signals, invade adjacent tissues, promote 
angiogenesis and escape cell death due to dysregulation of apoptotic mechanisms336.  
In addition, the concept of impaired tumour-surveillance as a facilitator of tumour 
growth and chemo-resistance has gained increasing support in recent years337-339. 
This is highlighted by the fact that patients with human immunodeficiency virus 
(HIV) have an elevated risk of malignancy, including haematological cancer and 
multiple myeloma340. Furthermore, the level of paraproteinaemia has been suggested 
to decline with anti-retroviral therapy in HIV341. Reduced B-cells, CD4+ve T-cells 
and cytotoxic T-cells have been reported to confer a poor prognosis in multiple 
myeloma, perhaps due to the immune escape of tumour cells339. A retrospective 
study of US veterans case-notes, based on ICD (international classification of 
disease) codes, demonstrated that a prior history of autoimmune disease (including 
pernicious anaemia and haemolytic anaemia) was a risk factor for developing MGUS 
or multiple myeloma326.  Chediak-Higashi syndrome is caused by mutations within 
the lysosomal trafficking regulator gene (CHS1/LYST). Patients with this syndrome 
have dysfunctional cytotoxic T-cells, abnormal NK cells, recurrent infections and an 
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increased incidence of malignancy336. Imai et al. (2000) demonstrated in a 
prospective trial of 3,625 individuals that low peripheral lymphocyte cytotoxic 
activity was associated with a higher risk of developing cancer342. In addition, it has 
been shown that individuals with breast cancer have lower peripheral NK activity on 
calcein-AM release assays. Furthermore the same authors showed that individuals 
with HER2+ve  (Human Epidermal Growth Factor Receptor 2) breast cancer 
(confers a poor prognosis) had lower NK activity than that seen in HER2-ve 
individuals343. Patients with myeloma have been shown to have impaired NK cell 
activity344. 
 
It is unknown at present whether lysosomal dysfunction pre-disposes to an elevated 
risk of malignancy. The literature is devoid of case series describing an elevated risk 
of cancer in LSDs other than GD.  
 
Early evidence supporting the idea that GD lymphocytes may be functionally 
abnormal is derived from transmission electron microscopy (TEM) studies 
describing storage deposition345. EBV-transformed lymphoid cells from patients with 
GD have been shown to have reduced glucocerebrosidase activity (15-30% of 
normal) and to accumulate sphingolipid346. Marti et al. (1988) found the absolute 
lymphocyte count (ALC) to be marginally elevated in 6/7 untreated patients with 
type I GD together with an increase in the number of peripheral CD20+ve (B-cells), 
CD4+ve and CD8+ve lymphoid cells139.  The authors also described a stastically 
non-significant decrease in the percentage of CD57+ve and CD16+ve NK cells. 
Although, the percentage of NK cells was reported to be reduced, a higher absolute 
number of NK cells was noted139. There have been several other reports, many 
contradictory, detailing CD4, CD8 and NK-T cell subsets in patients with GD 
4;347;348. In contrast to Marti et al. (1988), some investigators have shown a decrease 
in the absolute number of CD4+ve and CD8+ve T-cells, whereas others have 
reported normal percentages in treatment-naïve patients4;347. Early reports of T-cell 
dysfunction include impaired E rosetting349 and abnormal responses to lectin 
stimulation348.  However, for the past two decades the literature is devoid of reports 
detailing functional T-cell anomalies.  
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Macrophages play a critical role in tumour surveillance, including the stimulation of 
cytotoxic γδ T-cell and NK-cells. In addition, they mediate antibody-dependent 
cytotoxicity and present tumour antigens on MHC and CD1d molecules. Lipid-laden 
Gaucher cells have been demonstrated to have a Th2 or M2 phenotype which has 
been reported in histological specimens of non-GD patients to be associated with 
tumour progession268. 
 
Dendritic cells (DCs), potent antigen presenting cells, present cancer-derived 
antigens on MHC-I, MHC-II and CD1d molecules. It has been demonstrated that 
patients with GD have a reduction in the number of myeloid and plasmacytoid-
derived peripheral blood DCs. In addition, the authors showed that patients with GD 
were unable to expand monocyte-derived DCs in culture331. The frequency of 
peripheral blood DCs is also decreased in patients with Fabry disease, suggesting 
lysosomal dysfunction as a common aetiology350. Abnormalities of DCs may confer 
impaired tumour surveillance. 
 
Currently, our understanding of lymphocyte anomalies in GD is insufficient to 
ascertain whether they could contribute to a microenvironment more conducive to 
cancerous expansion. Patients with GD have an elevated risk of malignancy287 and 
further studies are required to delineate whether glucocerebrosidase-deficient cells 
undergo oncogenic transformation more readily or whether their expansion is 
favoured by impaired elimination, secondary to defects in innate and adaptive 
immunity.  
 
1.3.5 GBA1 MUTATION STATUS – GAMMOPATHY 
It is currently unclear why patients with GD have a higher incidence of myeloma130. 
Interestingly, in recent years, individuals who are heterozygotes for a GBA1 mutation 
have been shown to have a higher incidence of Parkinson’s disease351. Misfolded 
mutant GBA1 alleles are associated with the induction of endoplasmic reticulum 
stress plus cellular dysfunction16 and this has been suggested to result in toxicity to 
substantia nigra cells352. Speculatively, heterozygotes for Gaucher gene mutations, 
may have an elevated incidence of plasma cell dyscrasias. However, if an association 
were proven then co-inheritance of a closely located cancer gene to GBA1 on 
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chromosome 1 would require exclusion. Speculatively, hypotheses relating to 
chronic inflammation, substrate deposition, macrophage accumulation, immune 
abnormalities and a permissive bone marrow microenvironment would become less 
credible if carrier status was linked to gammopathy. However, methodology 
depending, GBA1 heterozygotes, have been reported to have residual 
glucocerebrosidase activity that overlaps with both homozygotes and normal 
controls353. Carriers may have “intermittent lipid status” and it is unknown at present 
whether cellular dysfunction or disturbed sphingolipid metabolism in these 
individuals is sufficient to confer gammopathy.   
 
In a study of 95 patients with myeloma (18/95 Ashkenazi Jews), 2 Jewish patients 
were found to be carriers of a N370S allele354. However, this study was of 
insufficient power to assess for an association between GBA1 mutation status and a 
malignant plasma cell disorder. As discussed above, N370S homozygotes have been 
reported to have a higher incidence of multiple myeloma compared to patients who 
are heterozygous for a N370S allele52.  These findings, if confirmed in other cohorts, 
raise questions on a cellular level regarding the pathophysiological disturbances 
imparted on cells by different mutations.
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1.3.6 PROJECT AIMS AND HYPOTHESIS  
Despite several clinical papers detailing immunoglobulin abnormalities in GD 
patients, few have investigated potential aetiologies. In addition, over the past 2 
decades, novel disturbances within the bone marrow microenvironment and immune 
system have been described in non-GD patients with multiple myeloma. These 
abnormalities have yet to be explored in GD and may be similar. The aims of this 
thesis are:- 
(1) To identify whether carriers for a GBA1 mutation, as GD patients, have a 
higher than expected incidence of gammopathy. 
(2) To identify severity markers in patients with GD that predict for 
gammopathy. 
(3) To identify abnormalities within the GD microenvironment that pre-dispose 
to gammopathy.  
 
These aims are explored in the chapter hypotheses stated below:-  
 
Chapter 3 
Hypothesis 1:- Disease severity predicts for monoclonal and polyclonal 
gammopathy in GD 
Rationale:- Several cohorts of GD patients have been shown to have an increased 
incidence of gammopathy. Prior literature has been inconclusive and not sufficient to 
answer whether markers of disease severity including biomarkers predict for 
immunoglobulin abnormalities.  
Methods:- Analysis of clinical data pertaining to local patients with GD at the Royal 
Free Hospital.  
 
Hypothesis 2:- GBA1 is a cancer gene or B-cell promoter and carrier status 
leads to an elevated risk of paraproteinaemia.  
Rationale:- Patients with GBA1 mutations, homozygotic or heterozygotic, have an 
elevated risk of Parkinson’s disease. It is currently unknown whether carrier status 
confers an increased risk of monoclonal gammopathy.  
Methods:- GBA1 gene analysis of non-GD patients who have an established 
paraprotein from Jewish descent.  
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Hypothesis 3:- Patients with myeloma acquire pathology in the monocytic 
lineage similar to that seen in GD.  
Rationale:- Non-GD individuals with haematological malignancies including 
multiple myeloma have infiltrates of foamy macrophages by light microscopy on 
bone marrow examination (pseudo-Gaucher cells). It is unclear whether these cells or 
their precursors acquire similar biochemical disturbances to monocytic cells derived 
from patients with GD. 
Methods:- Monocyte glucocerebrosidase activity and plasma chitotriosidase activity.  
 
Chapter 4 
Hypothesis 1:- GD compared to non-GD derived monocytic cells preferentially 
support plasma cell expansion and survival.  
Rationale:- Co-culture experiments in non-GD patients have demonstrated that 
osteoclasts and macrophages promote plasma cell survival. Osteoclast cultures have 
been shown to expand plasma cells. 
Methods:-  Plasma cell co-culture experiments utilising adherent monolayers 
derived from controls and GD patients. 
 
Hypothesis 2:- GD compared to non-GD derived macrophages/osteoclasts 
protects myeloma cells from chemotherapy-induced apoptosis. 
Rationale:- Co-culture experiments of non-GD patients have shown that 
macrophages and osteoclasts reduce the sensitivity of plasma cells to 
chemotherapeutic drugs. Furthermore there are anecdotal reports of poor responses to 
chemotherapy in GD patients with myeloma. 
Methods:- Plasma cell co-culture experiments utilising adherent monolayers derived 
from controls and GD patients.
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Hypothesis 3:- GD macrophages precursors are primed for osteoclastic 
differentiation which is potentiated by plasma cell co-culture 
Rationale:- Plasma cell co-culture promotes osteoclast formation in macrophage 
cultures derived from non-GD patients. Osteoclasts and plasma cells co-localise in 
the bone marrow specimens of non-GD patients and have been suggested to 
reciprocally facilitate the growth and survival of each other. 
Methods:- Plasma cell co-culture experiments utilising adherent monolayers derived 
from controls and GD patients.  
 
Hypothesis 4:- Compared to control cultures GD derived 
macrophages/osteoclasts are more efficient at rescuing myeloma cells pre-
treated with chemotherapy. 
Rationale:- Co-culture experiments in non-GD patients have shown that 
macrophages and osteoclasts rescue plasma cells pre-treated with chemotherapy.  
Methods:- Plasma cell co-culture experiments utilising adherent monolayers derived 
from controls and GD patients.  
 
Chapter 5 
Hypothesis 1:- GD lymphocytes have low glucocerebrosidase activity, accumulate 
substrate and have abnormalities within their lymphoid repertoire that contribute to a 
microenvironment favourable to carcinogenesis.   
Rationale:- Non-GD patients with abnormalities in their lymphocyte count or 
subsets including NK cells have an increased incidence of malignancy.   
Methods:- Local patient data, immunophenotyping and electron microscopy.   
 
 
Hypothesis 2:- GD patients due to disturbances in sphingolipid metabolism and 
glycolipid presentation have abnormalities in iNK-T cell expansion. This contributes 
to a microenvironment conducive to malignancy.  
Rationale:- Numerical low numbers of invariant NK-T cells are seen in individuals 
with malignancy.  




Hypothesis 3:- GD patients due to impaired NK-function have impaired tumour 
surveillance.   
Rationale:- Decreased peripheral NK-cell lytic activity is associated with impaired 
tumour surveillance in non-GD individuals. 
Methods:- NK killing assays.  
 
 
Hypothesis 4:- Patients with GD have numerical and function abnormalities within 
their peripheral blood cells that lead to impaired tumour surveillance.  
Rationale:- Non-GD patients with impaired peripheral blood killing assays have an 
elevated risk of malignancy.  
Methods:- Peripheral blood killing assays.
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2 GENERAL METHODS 
2.1 PATIENT AND HEALTHY CONTROL 
RECRUITMENT 
This study was approved by the Royal Free Hospital Multi-Centre Research Ethics 
Committee (MREC) to recruit healthy controls or individuals with either Gaucher 
disease or a blood paraprotein (myeloma, MGUS or non-specified). In addition, site-
specific approval was obtained from the Local Research Ethics Committee (LREC) 
and Research and Development (R&D) departments in the following NHS hospital 
trusts:- 
o Royal Free Hampstead NHS Trust 
o Barnet and Chase Farm Hospitals NHS Trust 
o North West London Hospitals NHS Trust 
o Barking, Havering and Redbridge University Hospitals NHS Trust 
 
All patients received an information sheet 14 days prior to providing signed informed 
consent (See Appendix A; example information sheet/consent form). Recruited 
individuals were assigned a unique identification code. Individual patient data were 
stored within a secure location, on a password protected system and access was 
limited to study investigators. Tissue specimens (DNA and bone marrow) were 
acquired and stored in accordance with the Human Tissue Act.  
 
2.2 GENERAL CELL CULTURE METHODS 
2.2.1 CELL CULTURE 
Primary cells and cell lines (K562, NCI-H929, U266 and JJN3) were maintained in 
R10 growth medium, which contained RPMI 1640 (Sigma-Aldrich, Poole, UK), 10% 
heat-inactivated foetal calf serum (Invitrogen™, Paisley, UK), 10mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer (Invitrogen, Paisley, 
UK), 2mM L-glutamine (Sigma Aldrich) and penicillin/streptomycin (>10,000U/ml 
penicillin, >10mg/ml streptomycin; Sigma Aldrich). Cells were incubated in a 
humidified atmosphere at 37°C and 5% CO2 (Haraeus Instruments, Michigan, US). 
Growth medium was changed in all cell lines the day before use to ensure that cells 
were in the exponential phase of growth. Osteoclast medium refers to R10 
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supplemented with the osteoclast differentiating cytokines Receptor Activator for 
Nuclear Factor κ B Ligand (RANK-L; 30ng/ml; Peprotech EC, London, UK) and 
macrophage colony stimulating factor (M-CSF; 25ng/ml; Genscript Co-operation, 
NJ, USA).     
 
2.2.2 IMMORTALISED CELL LINES 
(a) U266 – Generously donated by Dr Popat, Institute of Cancer, Barts Cancer 
Centre, UK (St Bartholomew’s Hospital). This is a non-adherent, IgE lambda human 
multiple myeloma cell line with a doubling time of approximately 55 hours. Cell 
density was maintained between 0.2x105-1.5x106 cells/ml. Cells were grown in R10 
with twice weekly cell passage. Immuno-phenotyping confirmed CD138 positivity 
but the absence of CD38, another plasma cell marker (Figure 2-1).  
 
(b) NCI-H929 – Generously donated by Dr Ellie Necheva, Academic Haematology, 
Royal Free Hospital, UK. This is a non-adherent human multiple myeloma cell line 
and is IgA secreting. Doubling time is approximately 70 hours and subcultures were 
performed twice weekly in order to maintain a cell density of approximately 1x106 
cells/ml. In this NCI cell line CD38 was expressed by only a minority of cells 
(Figure 2-1).  
 
(C) JJN3 – Generously donated by Dr Ellie Necheva, Academic Haematology, Royal 
Free Hospital, UK. This is a sub-clone of the cell line JJN-1 that originated from a 
patient with IgA1κ plasma cell leukaemia. JJN-3 is a non-adherent cell line 
composed of mainly uni-nucleate oval shaped cells. Doubling time is 20-35 hours 
and cell densities were maintained between 0.2-2x106cells/ml. CD138 positivity 
confirmed the cell line to be of plasma cell origin.   
 
(D) K562 - Generously donated by Janet North, Academic Haematology, Royal Free 
Hospital, UK. This cell line was derived from a patient with chronic myeloid 
leukaemia in blast crisis and harbours the BCR-ABL fusion gene (Philadelphia 
chromosome). K562 cells are non-adherent and were maintained with a density of 






Figure 2-1. CD138/CD38 expression of the (A) U266 and (B) NCI-H929 cell lines.  
2.2.3 CELL COUNTS AND VIABILITY 
Cells were counted by light microscopy using a haemocytometer with an etched grid 
system. 10µl of cell suspension was added to 10µl of 0.2% trypan blue (diluted in 
filtered phosphate buffered saline, PBS; Sigma Aldrich) for 1 minute in a micro-
centrifuge tube. Live cells are colourless and dead cells stain blue, as they are unable 
to exclude dye due to impaired membrane integrity. A minimum of 200 cells was 
analysed. The viability of all cell lines was maintained at greater than 90%. 
 
2.3 THAWING AND FREEZING OF CELL LINES 
2.3.1 LIQUID NITROGEN STORAGE OF CELL LINES 
The prolonged culture of immortalised cell lines can lead to baseline changes in their 
growth characteristics, morphological appearance and chemosensitivity secondary to 
genotypic drift. Therefore, stocks of cryopreserved cells, frozen on the same date, 
were used for each cohort of experiments. Growth medium (R10) was changed the 
day before cryopreservation. Cells were spun (300g, 10 minutes) and re-suspended in 
freezing medium consisting of 90% Foetal Calf Serum (FCS) and 10% dimethyl 
sulfoxide (DMSO; Sigma Aldrich) at a concentration of 5x106cells/ml. Vials were 
immediately transferred to a freezing container containing iso-2-propanolol (Sigma-
Aldrich), to allow slow cooling (1°C per minute), and placed in a -80°C freezer. The 
following day, cryovials (Jencons, East Grinstead, UK [division of VWR]) were 
stored in liquid nitrogen until required. 
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2.3.2 THAWING CELLS FROM LIQUID NITROGEN 
Cryovials containing 5x106cells/ml were recovered from liquid nitrogen and thawed 
in a pre-warmed water bath. Cells were transferred carefully into 14mls of warmed 
growth medium (R10, 37°C) before gentle centrifugation at 250g for 5 minutes. Cells 
were re-suspended in 3mls growth medium and placed in a cell incubator for 4 days 
prior to splitting. 
 
2.4 SAMPLE PREPERATION 
2.4.1 SEPERATION OF PERIPHERAL BLOOD MONO-
NUCLEAR CELLS (PBMCS) 
Blood (20mls) was collected into a sterile universal container with 200µl of 
preservative free heparin (5,000U/ml, CP pharmaceuticals Ltd, Wrexham, UK) 
before being inverted several times to ensure adequate mixing. Heparinised blood 
was mixed with 10mls of 3% Dextran-500 (Fisher Scientific, Loughborough, UK) 
and incubated for 45 minutes in a pre-heated waterbath at 37ºC. PEG was made up 
with 1L PBS supplemented with 1mM ethylenediaminetetraacetic acid (EDTA; 
Sigma Aldrich) and 10mM glucose (Sigma Aldrich). Isolated fractions (supernatant 
and non-supernatant) were supplemented with PEG to a total volume of 20mls before 
being carefully pipetted onto a layer of 12mls Ficoll-Pague™-Plus (GE Healthcare, 
Chalfont St Giles, UK). Samples were centrifuged at 650g at 4ºC for 25 minutes 
(brake off). Following gradient centrifugation, the white cell layer was removed 
using a sterile pipette and recovered cells were washed twice in 50mls of PEG 
(centrifuged for 10 minutes at 4ºC, at 400g). Cells were re-suspended in 5mls of R10 
medium.   
 
2.4.2 PREPERATION OF CELL SUSPENSIONS FOR 
TRANSMISSION ELECTON MICROSCOPY 
PBMCs were isolated as described above before being re-suspended in 1ml of 
refrigerated fixative solution (20mls of 20% paraformaldehyde [Sigma Aldrich], 
16mls of 25% glutaldehyde [Sigma Aldrich] and 59mls of PBS). Cells were stored 
for a minimum of 2 hours at 4°C before being centrifuged in a microcentrifuge tube 
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to form a pellet. Cells were washed twice in PBS and incubated for 10 minutes in 
staining solution (1% osmium tetroxide [TAAB Laboratories Equipment, 
Aldermaston, UK], 1.5% potassium ferricyanide [TAAB Laboratories Equipment], 
PBS). Cells were washed 5 times in distilled water and dehydrated with increasing 
concentrations of ethanol (30%, 50%, 70%, 90% and 100%). Samples were left in a 
mixture of 50% alcohol/50% Lemix epoxy resin (TAAB Laboratories Equipment) on 
a mixer overnight. 
 
The following day, resin infiltrated samples were placed in 100% Lemix resin for at 
least 4 hours before being embedded in 100% Lemix Resin overnight. Semi-thin 
(1µm) sections were cut using glass knives on a Reichert-Jung Ultracut microtome 
before being stained with 1% Toluidine Blue overnight (TAAB Laboratories 
Equipment).  Ultra-thin sections were cut using a diamond knife (Diatome; TAAB 
Laboratories Equipment) and collected on 300HS 3.05mm copper grids (Gilder 
Grids, Grantham, UK). Sections were stained with saturated alcoholic uranyl acetate 
(TAAB Laboratories Equipment) for 5 minutes and transferred into Reynold’s lead 
citrate (TAAB Laboratories Equipment) for a further 5 minutes. Specimens were 
viewed and photographed using a Phillips CM120 transmission electron microscope 
(Philips, Eindhoven, Netherlands). Specimens were prepared by Royal Free Hospital, 
Electron Microscopy Department.  
 
2.4.3 PREPERATION OF PLASMA SAMPLES 
Blood, collected into tubes containing EDTA, were centrifuged at 3500rpm for 5 
minutes at 4°C. Aspirated supernatant was stored in microcentrifuge tubes (Fisher 
scientific) at -80°C until further use.  
 
2.5 FLOW CYTOMETRY ANTIBODIES 
2.5.1 GENERAL FLOW CYTOMETRY 
Throughout this project, monoclonal antibodies were used as direct conjugates with 
fluorescein isothiocyanate (FITC), R-Phycoerythrin (PE) plus peridinin-chlorophyll-
protein complex (PerCP) and following fluorochrome excitation, emitted light was 
detected in the FL1, FL2 and FL3 channels respectively (Table 2-1). Generally, 0.1-
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1x106/100µl cells were incubated in the dark with an antibody cocktail for 15-30 
minutes before washing twice in PBS. Cells were re-suspended in PBS (accept for 
AnnexinV, see below) or FACSflow fluid (Becton Dickinson, BD, Oxford, UK) 
prior to analysis.   
 
Table 2-1. Antibodies utilised in flow cytometry.  
BD, Becton Dickinson.  
 
Stained samples were kept on ice if there was a delay in analysis. Samples were 
acquired on a FACScan (BD) and analysed with CellQuestTM (BD) or FlowJo 7.6.1 
software (©Tree Star, Inc., Oregon, USA). Typically 5,000-10,000 gated events were 
collected for analysis. 
 




COMPANY CLONE CONJUGATE DILUTION/ 
INCUBATION 
TIME 
Human CD3 Mouse IgG1k 345766 BD SK7 PerCP 1:20 
15-30 minutes 
Human CD4 Mouse IgG1k 345768 BD SK3 FITC 1:10 
15 minutes 










Human CD56 Mouse IgG2b,k 345812 BD NCAM16.2 PE 1:5 
15 minutes 
Human CD56 Mouse IgG1k 345810 BD MY31 PE 1:5 
15 minutes 
Invariant NK-
T Cell (6B11) 
Mouse IgG1k 558371 BD 6B11 FITC 1:5 
30 minutes 




Mouse IgG1k 552026 BD Mi15 PE 1:10 
10 minutes 
Human CD1d Mouse IgG1k 550254 BD CD1d42 PE 1:5 
30 minutes 
Human CD19 Mouse IgG1k 345777 BD 4G7 PE 1:5 
30 minutes 
BrdU Mouse IgG1k 347583 BD B44 FITC 1:5 
30 minutes 




- FITC 1:10 
15 minutes 
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2.5.2 ANNEXIN V/PROPIDIUM IODIDE FLOW CYTOMETRY 
ASSAY 
In healthy cells, phosphatidylserine (PS), a negatively charged membrane 
phospholipid, is located to the cytoplasmic side of the lipid bi-layer. PS is 
translocated to the extracellular surface of the cell membrane during early apoptosis 
and the additional uptake of the nucleic acid stain propidium iodide (PI) signifies late 
apoptotic cells that are unable to exclude PI due to breakdown in their cellular and 
nuclear membranes. AnnexinV has high affinity to PS in the presence of binding 
buffer rich in calcium ions. This assay therefore is able to identify both an early 
apoptotic population (annexinV+ve, PI-ve) and a necrotic/dead subpopulation 
(annexinV+ve, PI+ve).  
 
Cell concentration varied between 0.25-1x106 per ml depending on the number 
recovered from individual experiments. Cells were washed twice in annexin binding 
buffer (10mM HEPES, 150mM NaCl [Sigma Aldrich], 5mM KCl [Sigma Aldrich], 
1mM MgCl2 [Sigma Aldrich] and 1.8mM CaCl2 [Sigma Aldrich] buffered at pH 7.2) 
and centrifuged at 400g for 5 minutes before being re-suspended in 100µl of binding 
buffer. 10µl of FITC-labelled annexinV was added to samples before incubation in 
the dark at room temperature for 15 minutes. Samples were washed twice in 
annexinV binding buffer before being re-suspended in a final volume of 500µl. 
Immediately prior to analysis, 5µl of PI solution (100µg/ml ddH20; Fluka, Sigma 
Aldrich) was added. PI stock solution, 1mg/ml in distilled water, remained stable for 
6 months at 4°C. On excitation, PI, emits fluorescent light with a wavelength 
(617nm) detectable in FL2.   
 
2.5.3 BRDU ASSAY – U266 CELLS – FLOW CYTOMETRIC 
ASSAY 
Bromodeoxyuridine (BrdU) is a uridine analogue that is incorporated into DNA 
instead of thymidine during the S-phase of cell replication. Culture cells are pulsed 
with BrdU for a pre-designated time period prior to being fixed, permeabilised and 
stained with mouse anti-BrdU IgG1 FITC (BD Biosciences). Combined staining with 
the nucleic acid stain PI allows the percentage of cells in G0/G1, S and G2/M phases 











Figure 2-2. Representative cell cycle obtained from U266 cells pulsed with BrdU for 4 hours. 
Live cells were gated on (A, B) prior to quantifying the % of S, GO/G1 and G2/M phase cells.    
 
BrdU (Sigma Aldrich) was added to experimental wells to achieve a final 
concentration of 20-30µM before being placed in the cell incubator for 1-4 hours 
(specific time detailed for each experiment). Recovered cells were washed twice 
(centrifuged at 500g, room temperature, for 15 minutes) in 1% BSA (bovine serum 
albumin, Sigma Aldrich)/PBS. Cells were then re-suspended in 200µl of ice cooled 
PBS and added slowly to a vortex of 70% ethanol (pre-chilled to -20ºC). Samples 
were placed on ice for 30 minutes and then centrifuged for 10 minutes at 400g 
(10ºC). The supernatant was carefully removed to leave a pellet of fixed cells. The 
pellet was loosened by vortexing before being re-suspended in 1ml of 2N 




The denatured fixed cells were centrifuged at room temperature (400g for 10 
minutes) before being washed in 0.1M sodium borate solution, pH 8.5 (Sigma 
Aldrich). Cells were centrifuged again at 400g for 10 minutes at room temperature 
before suspension in 100µl of 0.5% Tween 20 (Sigma Aldrich)/1%BSA/PBS 
solution. 10µl of anti-BrdU FITC was added and cells were incubated in the dark for 
30 minutes at room temperature.  
 
After washing once in 0.5%Tween/1%BSA/PBS, cells were re-suspended in 1ml of 
PBS containing 5µg/ml of PI and left in the dark for a further 15 minutes. Cell cycle 
analysis was then performed by flow cytometry.   
 
2.5.4 FLOW CYTOMETRY BETA-GLUCOCEREBROSIDASE 
ASSAY 
Lysosomal β-glucocerebrosidase was determined as described previously (Rudensky 
et al 2003355; Havenga et al. 1998356). The biochemical basis of this assay is the 
cellular uptake and enzymatic degradation of the substrate fluorescein di-β-D-
glucopyranoside (FDGlu; Invitrogen) by β-glucocerebrosidase and results in the 
production of a cellular fluorochrome that is detectable in the FL1 channel. This 
assay was made specific for lysosomal glucocerebrosidase by comparison to a paired 
sample pre-treated with conduritol-B-epoxide (CBE; Sigma Aldrich), an inhibitor of 
lysosomal β-glucosidase activity. Aliquots of FDGlu (20mM, DMSO) and CBE 
(50mM, dH20) were stored at -20°C until required. Leucocytes, isolated from 
peripheral blood, were re-suspended at a concentration of 105-106 cells/ml in 
RPMI1640 with 2% FCS (R2). Two aliquots of 100µl cell suspension were placed in 
test tubes before one aliquot was incubated with 2µl of 50mM CBE (Sigma Aldrich) 
for 1 hour at room temperature. Following the addition of 100µl of R2, cells were 
incubated at 37°C with 10µl of 20mM FDGlu for 1 minute and diluted with an extra 
780µl of R2 before incubation for 45 minutes at room temperature.  
 
Glucocerebrosidase activity was determined by the median fluorescent intensity 
(MFI) of liberated fluorochrome from the carrier substrate FDGlu and was expressed 
as a ratio of the sample MFI to that obtained from a paired sample (from the same 
individual) treated with the lysosomal glucocerebrosidase inhibitor, CBE.  
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Monocytes and lymphocytes were identified based on their forward and side-scatter 
characteristics. Lymphocyte subsets were identified by CD3, CD56 and CD19 co-
immunostaining in the FL2 and FL3 channels.  
 
2.5.5 TO-PRO®-3 IODIDE NUCLEIC ACID STAINING 
TO-PRO®-3 iodide (1mM, DMSO, stored -20°C; Invitrogen) was thawed and 500µl 
was added to 50mls of Hank’s buffered salt solution (HBSS; Invitrogen, 10µM stock 
solution).  Stock solution was added to cells in a 1:10v/v ratio before analysis in the 
FL4 channel (excitation wavelength 642nm; emission wavelength 661nm; He-Ne 
laser).  
 
2.6 OSTEOCLAST CULTURE 
2.6.1 OSTEOCLAST ASSAY 
PBMCs were separated from whole blood (20-40mls) as described above and the 
number of cells isolated was determined. Between 0.5-1.0x106 PBMCs were stained 
with CD14/64 before undergoing FACs analysis to determine the monocyte 
percentage (Figure 2-3). 
 
Figure 2-3. Flow cytometry for CD16/64. The percentage of monocytes is indicated by the 




PBMCs were re-suspended in R10 medium to give a monocyte concentration of 
0.5x106/ml. Osteoclast cultures were grown in 24 well plates. In each experimental 
well, 3 ethanol-sterilised coverslips were inserted (6mm diameter, Richardsons of 
Leicester Ltd, UK). These were subsequent recovered, fixed and stained using a 
histo-chemical technique for osteoclasts (tartrate resistant acid phosphatase; TRAP). 
0.5mls of cell suspension was added before being placed in the cell incubator for 2 
hours. Following incubation, culture wells were washed twice in PBS and replaced 
with 1ml of osteoclast medium (25ng/ml M-CSF and 30ng/ml RANK-L). This step 
was performed to remove the majority of non-adherent cells and to leave adhered a 
relatively pure population of monocytes. Osteoclast growth medium was changed 
twice weekly between D1-14 with three medium changes in week 3 when cells were 
larger and more metabolic.  
 
2.7 HISTOCHEMICAL STAINING TECHNIQUES 
2.7.1 GIEMSA STAINING 
Cells recovered from co-culture experiments were analysed morphologically. To 
prepare a cytospin, funnels were assembled with glass slides and adsorbent filter 
paper (Thermo Electron Co-operation, East Grinstead, UK). 100µl of cell 
suspension, typically 0.22x106cells/ml, was pipetted into assembled funnels and 
centrifuged for 6 minutes at 400rpm (Shandon Cytospin© 2). Following this slides 
were air dried for a minimum of 2 hours before being fixed in pure methanol (Sigma 
Aldrich) for 10 minutes. Giemsa (Sigma Aldrich) was diluted 1:20 in distilled water 
and filtered. Samples were stained for 30 minutes in Giemsa solution prior to being 
rinsed and air-dried. This protocol was also used to stain recovered coverslips from 
co-culture experiments. 
 
2.7.2 TARTRATE RESISTANT ACID PHOSPHATASE 
STAINING 
A TRAP assay kit was obtained from Sigma Aldrich and performed in accordance to 
manufacturers’ instructions. Briefly, ethanol-sterilised forceps were used to extract 
cover-slips harbouring adherent cells from D21 culture wells. Recovered cover-slips 
were washed in PBS before being fixed for 30 seconds in a mixture of citrate, 
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acetone and distilled water. Specimens were washed once in distilled water and 
allowed to air dry for at least 30 minutes prior to TRAP staining. Processed cover 
slips were placed in 24 well plates before the addition of pre-warmed (37ºC) tartrate 
solution that consisted of fast garnet, dissolved tartrate, napthol bi-phosphoric acid 
solution and acetate. Plates were left at 37 ºC for 1 hour in the dark. After thorough 
washing some specimens were counter-stained for 5 minutes with acid haematoxylin. 
Cover-slips were then rinsed thoroughly in distilled water and allowed to dry 
overnight before being mounted cell-side up on microscopic slides with DPX (Sigma 
Aldrich). Osteoclasts were defined as cells with 3 or more nuclei and exhibiting 














Figure 2-4. TRAP staining revealing large numbers of osteoclasts from a GD patient. Scale bar 
50µm. 
 
2.8 CELL VIABILITY ASSAYS 
2.8.1 DRUG PREPARATION /STORAGE 
All drugs were acquired from the Royal Free Hospital pharmacy department:- 
(a) Melphalan (GlaxoSmithKline, Brentford, UK) was re-constituted in the supplied 
ethanol solvent to a stock concentration of 16.38mM. 200µl aliquots were stored at  
-20°C until required. Concentrations between 0-400µM were used in cytotoxic 
assays. 
 89 
(b) Doxorubicin (Teva, Harlow, UK) was re-constituted in sterile water to create a 
stock concentration of 2mg/ml (3.4mM) which was stored at 4°C until use. 
Concentrations between 0-16µM were used in drug assays.     
(c) Bortezomib (Jannsen-Cilag, Wycombe, UK) was dissolved and stored at -80°C in 
15µl vials of 2µM solution. Concentrations between 0-160nM were used.   
(d) Dexamethasone (Organon Labs Ltd, Cambridge, UK) is soluble in water and 
15µl vials of 46.47mM stock solution were stored at -20°C until required. Cytotoxic 
assays used drug concentrations up to 10mM.  
(e) U266 plasma cells were exposed to irradiation delivered by a GammaCell 3000 
irradiator (Nodrion International Inc., Ottawa, Canada).  
 
2.8.2 MTT DYE REDUCTION ASSAY 
Cell lines or primary cells were pre-exposed to co-culture, doubling dilutions of drug 
or irradiation dose prior to performing the MTT dye reduction assay. This is a 
colorimetric test which is based on the mitochondrial reduction by living cells of the 
yellow tetrazole 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium into an 
insoluble purple formazan that is quantifiable by spectrophotometry (reference 
wavelength 540nm, measurement wavelength 650nm).  The MTT assay is a measure 
of cell proliferation, viability or both. Typically, depending on experiment, 90µl of 
cell suspension (1x104-1x105 cells/well) was plated in triplicate in 96-well plates. 
10µl of MTT reagent (Sigma Aldrich; 5mg/ml in PBS) was then added to each well 
and the plate was placed in a cell incubator for 2-4 hours. Plates were centrifuged at 
1800rpm for 10 minutes and residual supernatant was carefully aspirated. Plates 
could be stored at -20°C at this stage prior to further analysis. DMSO, 100µL, was 
added to experimental wells followed by agitation for 15 minutes on a plate shaker 
set at 400rpm. Absorbance was quantified using a BMG FLUROstar Galaxy plate 
reader (MTX Lab Systems Inc., Virginia, US).  
 
2.8.3 MTS DYE REDUCTION ASSAY 
Cell lines or primary cells were pre-exposed to co-culture, doubling dilutions of drug 
or irradiation dose prior to MTS dye reduction assay. This is a colorimetric assay 
based on the same principle as the MTT assay. However the mitochondrial 
conversion of MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
 90 
sulfophenyl)-2H-tetrazolium] by respiring cells has the advantage of producing a 
formazen product that is soluble in tissue culture. Therefore, this assay is useful for 
experiments involving adherent cells. Aliquots of MTS reagent were made up from 
supplied stock solutions and stored at -20°C in accordance to manufacturers’ 
instructions (CellTiter 96® AQueous Non-Radioactive Proliferation Assay, 
Promega, Southampton, UK). Briefly, 20µl of MTS solution was added to each 
experimental well per 100µl of culture medium. Cells were placed in a cell incubator 
for between 1-4 hours before measuring absorbance at 490nm using a FLUROstar 
Galaxy plate reader (reference wavelength 650nm). 
 
2.8.4 CHITOTRIOSIDASE ASSAY 
The principle of the test is the release and fluorescent detection of 4-
methylumbelliferone (4MU) on degradation of the substrate 4MU-chitotrioside by 
the plasma enzyme chitotriosidase (macrophage derived). This assay was performed 
on plasma samples collected from healthy controls or patients with Gaucher disease, 







Figure 2-5. Principle of the chitotriosidase assay.  
Residual chitotriosidase activity in sample plasma cleaves 4MU from 4MU-chitrotrioside and 
this is detected on a fluorimeter (460nm). 
 
In duplicate sample wells, 5µl of patient plasma was added to 100µl of the substrate 
4MU-chitotrioside (1mg dissolved in 57.8mls of McIlvaine Buffer [see section 
2.8.5]; stored at -20ºC). Two wells, labelled Substrate Blank (SubB), were 
constructed in duplicate; these consisted of 5µl distilled water and 100µl of 4MU-
chitotrioside. The plate was incubated for 1 hour at 37ºC. To each sample and 
substrate blank well, 1ml of 1M glycine solution (pH10.4) was added as a ‘stopping-
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agent’ to terminate the enzymatic reaction. Two Standard Blank (StB) wells were 
created by adding 200µl of 4MU (176mg in 1 litre of distilled water) plus 0.9mls of 
1M glycine solution. Analysis was then performed on a BMG-labs fluorimeter 
(excitation 365nm, emission 450nm). Chitotriosidase activity was calculated based 
on the following formula:- 
(T-SubB)/(StaB-SubB)*(1000/5)*(1.105/1) = nmol/hr/ml plasma 
 
T = Average of patients fluorometric reading 
SubB =Average of Substrate Blank reading 
StaB =Average of Standard Blank reading  
 
Normal plasma activity is between 0-150nmol/hr/ml. Samples with chitotriosidase 
activity above maximal sensitivity of the fluorimeter were diluted or/and incubated 
for shorter incubation time. 
 
2.8.5 BETA GLUCOSIDASE ASSAY 
Recovered PBMCs were re-suspended in 2mls of Red blood cell (RBC) lysis 
solution (8.29g NH4Cl [Sigma Aldrich]; 1g KHCO3 [Sigma Aldrich]; 0.02g EDTA, 
di-sodium [Sigma Aldrich]; 1 litre distilled water) and left at room temperature for 5 
minutes. As contaminating RBCs lead to artificially high results, this step was 
repeated if lysis was incomplete. PBMCs were washed twice in PBS (5 minutes; 
300g), pelleted and stored at -80°C until analysis. 
 
Prior to analysis, the pellet was thawed at room temperature (10 minutes) and re-
suspended in 0.2-0.4mls of distilled water in order to create a cell lysate. The 
resulting suspension was vortexed and the supernatant was recovered after 
centrifugation at 1300rpm for 2 minutes. Total protein content was determined 
against a standard curve generated from dilutions of BSA between 0-1000 mg/ml. 
25µl of the diluted standard or cell lysate was transferred, in duplicate, to a 96-well 
plate. 200µl of a 1:10 mixture of bicinchoninic acid (Sigma Aldrich) to copper (II) 
sulfate pentahydrate solution (Sigma Aldrich) was then added to each well.  The 
immediate purple discoloration of sample wells indicated protein content above the 
top standard and the requirement for test sample dilution. The 96-well plate was 
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incubated for 30 minutes at 37°C before protein content was quantified by 
colorimetric measurement using a BMG FLUROstar Galaxy™ plate reader 
(absorbance wavelength 562nm; reference wavelength 650nm).   
 
The following solutions were prepared in order to determine the enzyme activity of 
β-glucocerebrosidase:- 
Buffer:- 
McIlvaine Citrate Phosphate Buffer 0.15M pH5.2 (100mls) was prepared by mixing 
46.9mls of 0.1M citric acid with 53.1mls of 0.2M Na2HPO4.2H2O solution.  
Standard:-  
A stock solution of 4MU was prepared by dissolving 176.9mg in 1L dH20 and 
solubilisation was encouraged by warming to 80ºC (MW=176.9mg; Sigma Aldrich). 
100µl of stock solution was added to 19.9mls of dH20 to give a standard working 
solution of 5nmol/ml. Stock and working solutions were stored at -20ºC until 
required. 
Stopping Reagent:-  
100mls of 1M glycine (pH 10.4) solution was created by mixing the following:- 
(1) 55.7mls of solution A (75g glycine [Sigma Aldrich] and 58g NaCl [Sigma 
Aldrich] in 1 litre of distilled water) 
(2) 44.3mls of solution B (1M sodium hydroxide solution; Sigma Aldrich)  
Stopping reagent was kept at room temperature until required.  
4MU-Substrate/Inhibitor:- 
0.2mmol/litre of 4MU-β-glucopyranoside (Sigma Aldrich) in McIlvaine buffer was 
mixed with 9.6g/l of the competitive enzyme inhibitor sodium taurocholate (Sigma 
Aldrich). The solution was stored at -20ºC until further use. 
 
The enzymatic assay was then performed in a 24-well plate as described below:- 
 








 “ “ “ S2 S2 
 “ “ “ S3 S3 
      
 
Table 2-2. Plate configuration of fluorometric based glucocerebrosidase assay.  
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15µl of sample supernatant was added to sample wells (S1, S2 etc.) and 150µl of 
4MU-substrate/inhibitor solution was then added to Substrate Blank and sample 
wells. The plate was incubated at 37°C for 1 hour before termination of the 
enzymatic reaction by adding 1ml of 1M glycine stopping solution to sample and 
Substrate Blank wells. Following this, 15µl of sample supernatant was added to 
Standard, Standard Blank and Substrate Blank wells. In addition, 200µl of distilled 
water was added to Standard blank wells followed by 200µl of 4MU Standard into 
the corresponding standard well for each sample. Glycine stopping solution, 950µl, 
was added to Standard and Standard Blank wells to make a total volume of 1.165mls 
per well. Fluorometric measurement was performed using a BMG FLUROstar 
Galaxy™ plate reader (excitation 365nm, emission 450nm) and enzyme activity was 
calculated using the formula below:- 
 
Enzyme activity = (Average of sample-Substrate Blank)/(Standard-Standard 
Blank)x(1000/protein mg/ml)*(1000/15) 
(normal range 5.4-16.8 nmol/hr/mg protein) 
 
2.9 WESTERN BLOT ANALYSIS 
2.9.1 LYSATE PREPARATION  
Harvested NCI-H929 plasma cells were centrifuged at 1000g for 5 minutes at 4°C 
before washing once in HBSS. Cells were re-suspended in 100µl of western blot 
lysis solution (containing protease and phosphatase inhibitors) before incubation on 
ice for 10 minutes. Following centrifugation at 14,000rpm for 15 minutes (4°C), the 
supernatant was recovered and stored at -80°C until analysis. 
 
Western Blot Lysis solution:-20mM HEPES-KOH, 50mM NaCl, 2% nonyl 
phenoxylpolyethoxylethanol, 0.5% sodium deoxycholate, 0.2% sodium dodecyl 
sulphate, 1mM sodium orthovanadate, 1mM Ethylene glycol-bis-(2-aminoethyl)-
N,N,N', N'-tetraacetic acid (EGTA) and10mM sodium fluoride. 10µl of protease 
inhibitor cocktail and10µl of 100mM phenylmethylsulfonyl fluoride was added to 
each 1ml of lysis solution. All reagents purchased from Sigma Aldrich. 
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2.9.2 PROTEIN QUANTIFICATION 
Protein content of cell lysates was quantified using the Bio-Rad Protein assay 
(Bradford method). Doubling dilutions of BSA were used to create a standard curve 
(0 to 12µg/ml). 200µl of Bio-Rad protein assay solution (Bio-Rad, Birmingham, UK) 
was added to 800µl of test sample (1-4µl of lysate made up to 800µl with distilled 
water) or BSA standard. Following 5 minutes incubation at room temperature, 
samples were analysed by spectrophotometry at 595nm (NovaSpec II, Pharmacia). 
Protein content was ascertained from a standard curve correcting for background 
absorbance (sample blank) and sample dilution. 
 
 




















Figure 2-6. Bio-Rad Protein Assay.  Standard Curve, absorbance versus protein content (µg/ml). 
 
2.9.3 PREPARATION OF SAMPLES FOR LOADING ONTO 
GEL 
Samples for analysis were diluted to give a total protein content of 30µg in 20µl lysis 
solution. Following this, 10µl of master mix (1:3 ratio dithiothreitol, Invitrogen: 
NuPage sample buffer, Invitrogen) was added to each sample. Samples were then 
centrifuged at 13,000rpm for 30 seconds, incubated at 80°C for 10 minutes and 
cooled for 5 minutes in tap water. A molecular weight ladder was created from a 
1:3:2 ratio of HMW rainbow marker (GE Healthcare):lysate buffer:master mix. All 
samples were centrifuged at 13,000rpm for 30 seconds prior to loading. 
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2.9.4 GEL ELECTROPHORESIS 
Gel tanks were filled with running buffer (50ml of NuPage running buffer, 
Invitrogen, to 950mls of distilled water). 12% tris-glycine gels (Invitrogen) were 
warmed to room temperature and rinsed in distilled water and running buffer. 
Samples were loaded using a Hamilton syringe. Anti-oxidant (Invitrogen, NP0005), 
0.5mls, was added to the centre of the gel tank. Gel electrophoresis proceeded for 90 
minutes using a Novex gel tank (200V, 50mA, 15W [Invitrogen]).   
 
2.9.5 GEL TRANSFER   
Transfer buffer consisting of 20mls of solution A (see below), 40ml methanol (Sigma 
Aldrich), 340ml distilled water and 400µl of anti-oxidant (Invitrogen, NP0005) was 
warmed to room temperature.  
 
Solution A :- 20.5mM EDTA (Sigma Aldrich) 
  500mM Bicine (Sigma Aldrich)  
500mM Bis(2-hydroxyethyl)-amino-tris(hydroxymethyl)-methane 
(Sigma Aldrich) 
     
Following electrophoresis, the gel was removed and placed on 3mm thick filter 
paper. After wetting with transfer buffer, an appropriately sized nitrocellulose 
transfer membrane (HYBOND, GE Healthcare) was placed directly onto the gel 
before sandwiching with an additional piece of filter paper.  Pads soaked in transfer 
buffer were added either side of the gel complex before being placed in a blotting 
cassette. Transfer proceeded for 90 minutes (25V, 125mA, 15.0W). 
 
2.9.6 PONCEAU S STAINING 
Following the transfer step, the membrane was stained for 2 minutes in Ponceau S 
stain (Sigma Aldrich) to confirm protein transfer. The membrane was then washed in 
1x tris buffer containing 1% FCS and placed on a shaker for 2 minutes. Two 
additional washes in tris buffer were performed. 
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Tris Buffer x20 stock:-20mM  tris(hydroxymethyl) aminomethane (Sigma Aldrich) 
   137mM NaCl 
    2g/l Tween-20 (Sigma Aldrich) 
   pH 7.4-7.8  
 
2.9.7 PRIMARY ANTIBODY STAINING 
FCS (0.5ml) and 100µl 10% azide (Sigma Aldrich) was added to 10mls of blocking 
solution (Tris Buffer containing 5% polyvinylpyrolidine; Sigma Aldrich). The 
relevant primary antibody was added before incubation of the membrane overnight at 

































Table 2-3. Western blot antibodies.  
Cell Signalling (New England Biolabs, Hitchin, Herts, UK). Santa Cruz Biotechnology 
(Heidelberg, Germany). DAKO ( Stockport, UK).  
 
 
Antibody Species Manufacturer kDa 
 
MCL-1 Rabbit Santa Cruz 
Biotechnology 
40 
Bim Rabbit Santa Cruz 
Biotechnology 
23, 15, 12 
Bcl-xL Rabbit Cell Signalling 30 
p53 Mouse Santa Cruz 
Biotechnology 
53 
PUMA Rabbit Cell Signalling 23 
Bcl-2 Mouse Dako 26 
BETA-
ACTIN 
Mouse Sigma 45 
ERK 1/2 Mouse Cell Signalling 42, 44 
p-ERK Rabbit Cell Signalling 140 
PARP Mouse BD 116, 89 
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2.9.8 SECONDARY ANTIBODY STAINING 
Following incubation with primary antibody the membrane was washed with tris 
buffer for 45 minutes. Horseradish peroxidise (HRP) labelled secondary antibody 
(3µl anti goat or anti rabbit HRP; Dako) was then added to 10mls of blocking 
solution and 0.5ml FCS before incubating the membrane for a further 2 hours at 
room temperature. Membranes were washed three times in tris buffer. 
 
2.9.9 VISUALISATION OF PROTEIN BANDS 
Western Blots were developed with ECL (enhanced chemiluminscent) reagent 
(Fisher Scientific) according to the manufacturers’ instruction and visualised on Fuji 
X-ray film.  
 
2.10 DNA BASED TECHNIQUES 
2.10.1 GAUCHER DNA ANALYSIS (STRIPTEST) 
Gaucher DNA strip test kits were obtained from ViennaLabs (Vienna, Austria) and 
performed in accordance with the manufacturers’ instructions. Briefly, blood was 
collected from consented individuals into EDTA tubes and aliquots of 500-1000µl 
were frozen at -80°C until required. Pre-prepared lysis and DNA binding solutions 
were used to isolate DNA from whole blood via several different centrifugation 
steps. Processed DNA was cooled on ice for immediate use. Alternatively, isolated 
DNA was stored refrigerated for up to 1 week at 4°C or frozen at -80°C until 
required.  
 
Processed DNA was amplified using Taq Polymerase (0.2µl; Applied Biosystems; 
Warrington, UK) in 2 different amplification mixtures covering the 10 wild type and 
mutated Gaucher alleles. PCR was performed in accordance with specifications 
provided on a Bio-Rad S1000™ thermal cycler (Pre-PCR 94°C/2minutes; PCR 35 
cycles; 94°C/15 seconds, 58°C/30 seconds, 72°C seconds; final extension 72°C/3 
minutes).  
 
Following amplification, products were washed, mixed with hybridisation solution 
and treated with denaturing solution. The products were then incubated with test 
 98 
strips in the dark at 45°C for 30 minutes. Test strips then were treated with conjugate 
solution and colour developer prior to reading. Test strips were impregnated with the 
oligonucleotides of the 10 common mutations found in Jewish patients with GD 





























Figure 2-7. Gaucher Strip Test (ViennaLabs). 
 
2.10.2 DNA ISOLATION 
DNA was extracted from either freshly collected peripheral blood (EDTA sample) or 
from stored whole blood samples (-80°C). Thawed samples were diluted with PBS 
(6mls total) and pipetted gently onto 5mls of Ficoll-Pague™-Plus before being 
centrifuged at 2100rpm for 15 minutes (brake off). The isolated buffy coat was 
washed in PBS before centrifugation at 400g for 5 minutes. From here on, the 
method of DNA extraction was identical for both freshly acquired and frozen 
samples. Samples were incubated at room temperature with RBC lysis solution 
(8.29g NH4Cl; 1g KHCO3; 0.02g EDTA, di-sodium; 1 litre distilled water) for 5 
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minutes, centrifuged, re-suspended and washed again in PBS. Cells were thoroughly 
re-suspended in 2mls of whole cell lysis solution (Qiagen, Crawley, UK). An 
appropriate volume of protein precipitation solution (Qiagen) was then added (whole 
cell lysis solution: protein precipitation solution 3:1 v/v). Samples were vortexed for 
30 seconds and centrifuged at 2500rpm for 10 minutes. Soluble DNA from the 
resulting supernatant was removed using a pastette and precipitated from solution by 
the addition of an equal volume of isopropanol.  
 
Figure 2-8. Nanodrop quantification.  
Processed sample was analysed for DNA quantity and evidence of RNA or protein 
contamination.    
 
Samples were centrifuged for 5 minutes at 3000rpm, the supernatant discarded, and 
the remaining DNA pellet was dried at room temperature for 2 hours before 
dissolving in 50-200µl of distilled water. DNA was rehydrated for a minimum of 24 
hours prior to determining DNA concentration and quality (Nanodrop 1000™, 
spectrophotometer, Thermo Scientific, Wilmington, USA). Protein/RNA 
contamination was assessed by the 260/280 ratio with a value of 1.8-2.1 being 
desirable.  
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2.10.3 POLYMERASE CHAIN REACTION (PCR)                                                                                   
SEQUENCING 
Exons 5-11 of the GBA1 gene were analysed by direct DNA sequencing. Exon 
blocks 5-7 and 8-11 were expanded in two separate PCR reactions using a pair of 
intronic primers specific for the GBA1 gene and not the pseudogene. Following 
initial amplification, the products were subjected to a second PCR reaction using an 
exon-specific pair of intronic primers. Primer sequences and PCR reaction conditions 
were performed as described by Stone et al. (2000)49. In addition, the direct 
amplification and sequencing of exon 6 was performed in a subset of samples. 
(A) Initial Amplification Reaction 
Each PCR reaction contained 5µl of diluted DNA (20ng/µl) and 20µl of a master mix  
Table 2-4) containing the appropriate dilution of primers (exons block 5-7, 8-11;  
Table 2-5). Master-mix (20µl) was aliquoted into 96-well plates (Appleton Woods, 
Birmingham, UK) using an automatic pipette (Anachem, Luton, UK) before the 
addition of diluted DNA. The PCR plate was sealed with an adhesive plate sealer 
(Platemax™, Axygen, California USA; Distributed VWR, Leicestershire, UK) before 
being centrifuged at 1000rpm to ensure adequate mixing and the eradication of air 
bubbles. PCR reactions were performed as detailed in Table 2-6 (PCR-blocks, 
C1000™ thermal cycler, Bio-Rad Laboratories, Hemel Hampstead, UK). All reagents 
were defrosted and placed on ice prior to use. 
Reagent µ l/Sample Company 
X10 PCR buffer II 2.5 Applied Biosytems Limited, Warrington, UK 
MgCl2 – 25mM 1.5 Applied Biosytems Limited, Warrington, UK 
dNTPs – 2mM 2.5 GE Healthcare, Chalfont St Giles, UK 
Forward Primer 10mM 1.0 Invitrogen, Paisley, UK 
Reverse Primer 10mM 1.0 Invitrogen, Paisley, UK 
AmpliTaq Gold DNA 
Polymerase 5u/ml 
0.25 Applied Biosytems Limited, Warrington, UK 
Distilled Water 11.25 - 
 
Table 2-4. Constituents of the PCR master mix solution. 
 
GBA Forward Sequence Reverse Sequence 




Exons 8-11 5’-TGTGTGCAAGGTCCAGGATCAG-3’ 5’-CCACCTAGAGGGGAAAGTG-3’ 
 
 
Table 2-5. Exon block primers for the initial PCR reaction. 
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PCR Reaction Conditions 
Exons 8-11 Amplification 95°C – 15 minutes 
34 cycles (95°C 1 minute, 61°C 1 minute, 72°C 1:30 
minutes) 
72°C – 5 minutes 
4°C – Indefinitely  
Exons 5-7 Amplification 95°C – 15 minutes 
34 cycles (95°C 1 minute, 58.5°C 1 minute, 72°C 2 
minutes) 
72°C – 5 minutes 
72°C – 5 minutes 
4°C – Indefinitely 
Sequence Reaction 24 cycles (96°C 1 minute, 50°C 5 seconds, 60°C 4:00 
minutes) 
4°C – Indefinitely 
ExoSap/Enzyme digest 37°C – 30 minutes 
80°C – 15 minutes 
4°C – Indefinitely 
 
Table 2-6. Thermal cycler programs for DNA expansion/sequencing.   
 
 
(B). Sequence Reaction 
Following initial amplification, DNA products were purified by adding 15µl of 
sample to 6µl ExoSap-ITTM (GE Healthcare; Stored -20°C) in 96-well plates. After 
sealing, the microplate was centrifuged briefly at 100rpm to eradicate air bubbles. 
ExoSap-ITTM contains two hydrolytic enzymes that degrade excess deoxynucleoside 
triphosphates (DNTPs) and residual single stranded primers. Plates were incubated at 
37°C for 30 minutes (Bio-Rad) before inactivating the ExoSap-ITTM by heating to 
80°C for 15 minutes. 
 
Sequencing was performed using the BigDyeTM v1.1 platform (Applied Biosystems 
Limited).  Details of the sequencing primers are given in Table 2-7. A master mix 
containing 0.5µl BigDyeTM, 2µl BigDyeTM x5 sequencing buffer and 5.5µl distilled 
water per sample was placed on ice. Each reaction well contained 8µl master mix, 
1µl PCR product and 1µl of 0.5mM primer (Forward or Reverse). Sequence primers 
were manufactured by Invitrogen and reactions were performed in duplicate in both 
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directions (forward and reverse). Prior to product amplification on the Bio-Rad, the 
microplate was centrifuged at 300g (Table 2-6). Following amplification, products 
were purified by centrifugation (1000g, 3 minutes) through a DyeExTM plate. The 
DyeExTM plate utilises gel-filtration technology to remove untagged dye terminators 
in order to obtain a ‘cleaner’ sequence. DyeExTM plates were used in accordance 
with the manufacturers’ instructions (Applied Biosytems). The microplate was 
incubated for 60 minutes at 72°C in order to evaporate excess fluid. Dried product 
was re-suspended in 10µl of HI-DI formamide (Applied Biosytems Limited) and 
briefly vortexed. Reactions were transferred to a sequencing micro-plate (MicroAmp, 
Applied Biosystems), analysed immediately or stored frozen until required at -20°C. 




Table 2-7. Forward and reverse sequencing primers for GBA exons 5-11. 
 
2.10.4 AMPLIFICATION/SEQUENCING OF EXON 6 
Following amplification of exon block 5-7, sequencing of exon 6 failed in a few 
samples due to sample degradation, despite using alternative primers. This occurred 
mainly in archived whole blood samples that were frozen at -80°C for up to 2 years 
in duration. This was overcome by using exon 6 primers for both the initial 
amplification and sequencing reactions. The reverse primer detailed in Table 2-7 was 
specific for the GBA1 gene and not the downstream GBAP pseudogene (compared to 
NCBI DNA Pseudogene Sequences AF032368.1, J03060.1 and AF267177).  
 
GBA Exon Forward Sequence Reverse Sequence 
5 5-GCAAGTGATAAGCAGAGTCC-3 5-AGCAGACCTACCCTACAGTTT-3 
6 5-CTCTGGGTGCTTCTCTCTTC-3 5-ACAGATCAGCATGGCTAAAT-3 
7 5-TTGGCCGGATCATTCATGAC-3 5-AGTTTGGGAGCCAGTCATTT-3 
8 5-TGTGTGCAAGGTCCAGGATCAG-3 5-TTTGCAGGAAGGGAGACTGG-3 
9 5-CACAGGGCTGACCTACCCAC-3 5-GCTCCCTCGTGGTGTAGAGT-3 
10 5-CAGGAGTTATGGGGTGGGTC-3 5-GAGGCACATCCTTAGAGGAG-3 
11 5-GTGGGCTGAAGACAGCGTTGG-3 5-ACCACCTAGAGGGGAAAGTG-3 
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Using 10mM dilutions of the forward and reverse primers (exon 6) samples were 
initially amplified using the same master mix described in Table 2-4. A temperature 
gradient was performed (Figure 2-9) to optimize the PCR gradient and products were 
subjected to gel electrophoresis (2% agarose; Sigma Aldrich). Based on these results, 
an annealing temperature of 60.9°C was used in the final PCR program which is 
described below:-  
 95°C 15 minutes, 
 34x (95°C 30 seconds, 60.9°C 40 seconds, 72°C 1 minute) 
 72°C 5 minutes  





Figure 2-9. Temperature gradient determination for Exon 6.  
Lane A (55.0°C), B (56.0°C), C (58.0°C), D (60.9°C), E (64.5°C), F (67.5°C), G (69.2°C) and H 
(70.0°C). 
 
The sequencing reaction was performed as described above using the same primer 
set as the initial amplification reaction. 
 
2.10.5 SEQUENCE ANALYSIS 
Analysis of acquired sequences was performed using Mutation Surveyor (BioGene 
Ltd, Cambridgeshire, UK). All mutations were confirmed on both forward and 
reverse sequences. A reference sample of the GBA1 gene was obtained from the 
NCBI DNA Sequence Database. 
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2.10.6 84GG/IVS2+1 MUTATIONS 
Exon 2 harbours the 84GG and the IVS2+1 mutations. Wild or mutant forward 
primers were used, together with a reverse primer specific for the GBA1 gene but not 
the pseudogene (Mistry et al. 1992). A master mix was created as detailed in Table 
2-8. 
 
Reagent µ l/sample Primer Sequences 
Distilled water 22.5  
MgCl2 25mM 3  
2mM DNTPS 5  
X10 PCR Buffer II 5  
Forward Primer 
(Wild or mutant) 
10mM 
2 WILD 
5 - GCATCATGGCTGGCAGCCTCACAGGACTGC - 3 
MUTANT 
5 – GCATCATGGCTGGCAGCCTCACAGGACTGG – 3 
Invitrogen, Paisley, UK 
Reverse Primer 2 5 – GCCCAGGCAACAGAGTAAGACTCTGTTTCA – 3 






Table 2-8. 84GG sequence reaction. 
 
To 40µl of master mix 10µl of diluted DNA was added (20ng/µl). DNA was 
amplified using the following PCR program: - 
   95°C 15 minutes 
   34x (95°C 45 seconds, 68°C 45 seconds, 72°C 45 seconds) 
   72°C 5 minutes 
   Cooling to 4.0°C  
Following amplification, products were subjected to gel electrophoresis on a 2% 
agarose gel and bands were visualised with Syber Safe® (Invitrogen) by trans-
illumination. The desired product was 255bp in length. Inclusion of a known 84GG 
heterozygote within the terminal lane acted as an internal control (Figure 2-10). The 
IVS2+1 mutation was identified by enzyme digest from the same 255bp product 
(wild forward primer) amplified for the detection of the 84GG allele. The IVS2+1 













product. Therefore 3 bands are visualised in those with unmutated GBA alleles 
(41bp, 72bp and 141bp), 4 in heterozygotes (41bp, 72bp, 141bp and 213bp) and 2 in 
homozygotes (213bp and 42bp). To 20µl of amplified product, 2µl of HphI enzyme 
(NEB, Hitchin, UK), 3µl NEB4 buffer (NEB) and 5µl of distilled water was added. 
Samples were incubated at 37°C for 2 hours on a Bio-Rad thermal cycler prior to gel 




















Figure 2-10. Gel electrophoresis, 84GG mutation.  
Amplified products were analysed on a 2% agarose gel with the terminal lane containing a 




















Figure 2-11. IVS2+1 Mutation. Amplified products were analysed on a 3% agarose gel.
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2.11  CELLULAR KILLING ASSAYS 
2.11.1 NK-T KILLING ASSAY 
NK-T cells were isolated by magnetic column technology from healthy controls or 
patients with GD (effector cells) before co-incubation in a cytotoxicity assay with 
various target cells (K562, NCI-H929 or JJN3 cell lines).  
 
Peripheral blood (40mls) was diluted 1:2 with PBS and layered over 20mls of Ficoll-
Pague™-Plus before centrifugation at 650g for 25 minutes (4°C; brake off). 
Recovered cells were washed twice in PBS (400g, 15 minutes) and re-suspended in 
10mls of Magnetic-Activated Cell Sorting buffer (MACS buffer; PBS, 0.5% BSA, 
2mM EDTA). MACs buffer was kept on ice until use. Prior to NK-sorting, flow 
cytometry was performed for CD3/56 quantification. The remaining cells were 
counted, centrifuged and re-suspended in 80µl MACS buffer/107 cells. 20µl of CD56 
micro-bead solution was added (Miltenyl-Biotec, Surrey, UK) per 107 mononuclear 
cells. Samples were incubated for 15 minutes at 4°C. 
 
The LS (large-size) separation column (Miltenyl Biotec) was placed in a VarioMACs 
magnet/stand and primed for use by flushing with 5mls MACs buffer. Following 
incubation, samples were diluted with 5mls of MACs buffer and gently pipetted into 
the separation column in order to minimise air bubbles. The LS column was flushed 
3 times with MACs buffer (3mls) in order to elute the CD56-ve fraction. CD56+ve 
cells were collected after removing the LS column from the magnet and flushed with 
5mls MACs buffer using the provided plunger. Recovered cells (+ve and –ve 
fraction) were centrifuged for 10 minutes at 400g before re-suspension in at 2x106 
cells/ml in R10 medium. Typically, high purities (>95%) of CD56+ve cells were 
isolated. Aliquots of CD56+ve and CD56-ve cells were incubated alone or 
supplemented with 200IU/ml (Miltenyl Biotec) of human IL-2 overnight 








Figure 2-12. Flow cytometry demonstrating (A) Pre-sorted cells, (B) CD56-ve cells (C) CD56+ve 
cells post magnetic sorting.  
 
All target cell lines (K562, NCI-H9292 and JJN3) underwent growth medium change 
together with viability testing (trypan blue) the day before co-culture. Cell line 
viability was maintained at greater than 90%. Target cells were stained with the red 
membrane dye PKH26 (Sigma Aldrich) according to the manufacturers’ instructions. 
Briefly, target cells were re-suspended in 500µl of diluent C (Sigma Aldrich) at 
1x106cells/ml after washing twice in PBS. Following re-suspension, 500µl of diluted 
dye (498µl Diluent C, 2µl PKH26 ethanolic dye solution) was added to target cells 
and samples were incubated at room temperature for 3 minutes. Staining was halted 
by the addition of 1ml FCS and to this, 5mls of R10 medium, was added 1 minute 
later. Cells were centrifuged and re-suspended in 2mls of growth medium. Successful 
membrane staining was confirmed by flow cytometry (PKH26 fluorescent in FL2 
channel). PKH26 staining is toxic to cells and background death was quantified by 
positivity for the nuclear stain TO-PRO®-3 iodide. 
 
Killing assays (CD56+ve and CD56-ve fractions) were performed at an 
effector:target ratio of 5:1 (2x105cells: 4x104 cells). After mixing, samples were 
placed in a cell incubator for 4 hours prior to analysis. Killed target cells were 
identified by dual positivity for PKH26 and TO-PRO®-3 iodide. Adjustment was 








Figure 2-13.  CD56+ve effector cell killing assays.   
Flow cytometry demonstrating (A, B) PHK26 stained target cells and background cell death as 
indicated by the % of apoptotic TO-PRO+ve cells in the right upper quadrant.  (C, D) NK 
killing assay of JJN3 cells.  
 
2.11.2 PBMC KILLING ASSAYS 
PBMC were isolated from peripheral blood as described above. PBMCs were 
incubated with 200IU/ml of IL-2 overnight. Killing assays were performed at 
different effector:target ratios (40:1, 20:1 and 10:1) as described in the section above 
with 4x104 K562, NCI-H929 or JJN3 PKH26 stained cells.  
 
2.12  FLUORESCENT MICROSCOPY  
2.12.1 BODIPY-LACTOSYLCERAMIDE/LYSOTRACKER 
STAINING   
Cytospins were made of isolated PBMCs (2x104 cells, 400rpm and 3 minutes). Using 
a water indelible pen, a circle was drawn around the cells. Approximately 200µl o
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5µM BODIPY-lactosylceramide (Molecular Probes; Supplied Invitrogen) was 
pipetted over the cells before incubating in the dark for 60 minutes. After washing 
three times for 1 minute in R10 medium, specimens were incubated in the dark for a 
further 170 minutes. R10 was then replaced with 200µl of 200nM lysotracker 
solution (Invitrogen) for an additional 30 minutes. Following this, specimens were 
washed twice in PBS before fixing with 4% paraformaldehyde in the dark for 20 
minutes. Specimens were washed twice in PBS (5 minutes) before mounting a glass 
coverslip (Prolong®Gold anti-fade reagent, Invitrogen). Specimens were allowed to 
dry overnight before analysis. Samples were analysed using a Zeiss LSM 510 Meta 
confocal microscope (Carl Zeiss Ltd., Welwyn Garden City, UK).  
 
2.13  STATISTICS 
All experimental data were analysed using GraphPad Prism 5.0™ (GraphPad 
Software Inc., California, USA) or Microsoft Excel 2003 (Microsoft Co-operation, 
California, USA). Standard deviation (SD), mean, median and inter-quartile range 
were used to summarise data. The D'Agostino & Pearson omnibus normality test was 
used to identify whether the data had a Gaussian distribution. A paired t-test and 
Wilcoxon signed rank test were used for paired parametric and non-parametric data 
respectively. An unpaired t-test was used to compare parametric data, whereas non-
parametric data were analysed using a Mann-Whitney test. One-way ANOVA 
(analysis of variance) was used to compare the means of 3 or more discrete 
populations. A p value <0.05 was considered to be statistical significant. Drug 
activity was summarised to an IC50, which was calculated using a sigmoidal 
concentration-response model with a variable slope. Data correlation was performed 





3 PATIENT DEMOGRAPHICS AND GBA 
MUTATIONS 
3.1 INTRODUCTION 
3.1.1 GAUCHER DISEASE AND GAMMOPATHY 
Patients with GD have an increased incidence of MGUS, polyclonal gammopathy and 
multiple myeloma81;130;139, as described in section 1.3.2. Polyclonal gammopathy is 
common in GD being more frequent in untreated patients43 and reported in 14-64% of 
untreated patients with type I GD43;74;138;162. In an untreated paediatric population with a 
mean age of 8.5 years, 21/23 (91%) had evidence of polyclonal gammopathy234. One of 
the first descriptions of monoclonal gammopathy in patients with GD came from Pratt et 
al., in 1968, in which 4/16 patients had an IgG M-band. Studies from America, Germany 
and the Netherlands have reported a 9-25% incidence of MGUS in patients with 
GD81;138;139. Data from a Gaucher Registry identified 10 out of the 2,742 patients to have 
multiple myeloma, conferring an estimated relative risk of approximately six times130. 
Data from an Israel based registry reported 2/500 patients with type I GD to have 
multiple myeloma, and concluded an increased risk129.  
 
In a small cohort of 63 patients (13/63 paraprotein), de Fost et al. (2008) failed to 
establish baseline disease severity as a risk factor for paraproteinaemia81. Although not 
statistically significant, GD patients with a paraprotein, in this study, were found to have 
a higher baseline Zimran severity score (ZSS) and chitotriosidase activity those without 
an M-band. Brautbar et al. (2004) failed to demonstrate an association between disease 
severity and the presence of polyclonal gammopathy43, but visceral disease was 
suggested to be risk factor for gammopathy in one study138.  
 
Although, there have been several studies detailing the incidence of gammopathy in GD 
patients, several questions remain unanswered. Based on the low number of published 
reports it is not possible at present to dismiss disease severity as a risk factor for 
gammopathy. Chitotriosidase activity is a sensitive marker of disease activity83 but due 
to the presence of null mutations (33% heterozygotic and 6% homozygotic)357 
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comparative analysis may fail to identify a true difference when comparing small 
cohorts of individuals. Macrophage derived biomarkers including S-ACE and acid-
phosphatase have yet to be compared between individuals with gammopathy and those 
with normal immunoglobulins. Such an association would add weight to hypotheses 
exploring the ability of lipid-laden macrophages to support plasma cell growth and 
survival. Furthermore, it is currently unknown, whether residual glucocerebrosidase 
activity, is predictive of gammopathy. In addition, no study has addressed, whether 
individuals with monoclonal gammopathy have more severe disease than those with 
polyclonal gammopathy and whether markers of disease severity predict for the presence 
of gammopathy in the era of ERT. These lines of investigation are addressed below. 
 
3.1.2 MACROPHAGE PATHOLOGY – COMMON TO MYELOMA 
AND GAUCHER DISEASE 
GD is caused by low glucocerebrosidase activity23 and is associated with the 
accumulation of lipid laden macrophages or Gaucher cells. Gaucher cells are larger than 
normal macrophages with a wrinkled ‘onion-skin’ appearance to their cytoplasm. Foamy 
macrophages (Pseudo-Gaucher cells), similar to Gaucher cells, are seen in the bone 
marrow of patients with haematological cancer including chronic myeloid leukaemia280 
and myeloma358. Macrophages are more abundant in the bone marrow of those with 
multiple myeloma than controls245. These histological findings have lead to the 
suggestion that macrophage abnormalities are common to both GD and non-GD patients 
with plasma cell disorders. Investigators have postulated that Gaucher and Pseudo-
gaucher cells, via similar pathological mechanisms, predispose to a cancerous 
microenvironment. The accumulation of Pseudo-Gaucher cells in those with 
haematological cancer may pre-date the development of malignancy. Alternatively, 
Pseudo-Gaucher cells may be innocent bystander cells, which develop as a secondary 
consequence of haematological cancer. Non-GD patients with malignancy have been 
hypothesised to acquire abnormalities in glucosylceramide metabolism. Zidar et al. 
(1987) reported the accumulation of pseudo-Gaucher cells in a patient with Hodgkin’s 
lymphoma278. The authors went on to confirm normal leucocyte glucocerebrosidase 
activity in Pseudo-Gaucher cells. However, this finding does not exclude saturated 
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glucocerebrosidase activity, secondary to excessive cell breakdown, leading to the 
development of a similar macrophage phenotype to that seen in GD278.  
 
Kampine et al. (1967) hypothesised that patients with haematological cancer have 
acquired abnormalities in sphingolipid metabolism within the cancerous clone, in 
comparison to the discussion above relating to tissue macrophages277. However, based 
on the hydrolysis of 14C-labelled substrates, enzyme activity, including that of 
glucocerebrosidase, was not reduced in leucocytes of patients with either acute or 
chronic leukaemia (myeloid or lymphoid)277. Glucocerebrosidase hydrolyses 
glucosylceramide into glucose and ceramide. Intracellular ceramide has a role in the 
regulation of cell cycling, the immune system and the induction of apoptosis within 
cells, normal or cancerous.20  
 
Boven et al. (2004), reporting spleen histology, showed that Gaucher cells have the 
phenotype of alternatively activated (M2) macrophages. Tumour infiltration by M2 
macrophages are linked to a poorer outcome in cancer patients268. Speculatively, 
acquired glucocerebrosidase deficiency, secondary to a neoplastic process, could lead to 
the accumulation of M2 macrophages in non-GD patients. Abnormalities within the 
bone marrow microenvironment contribute to the emergence, malignant transformation, 
growth characteristics and chemo-resistance of plasma cell clones359;360. The 
demonstration of low glucocerebrosidase activity in macrophage precursors of non-GD 
individuals with plasma cell dyscrasias would support chapter hypotheses suggesting 
common aetiology to that seen in GD.  
 
Chitotriosidase is a macrophage-derived enzyme detectable in plasma, which was 
initially described based on its ability to hydrolyse artificial chitotrioside substrates357. 
Chitotriosidase is synthesised by activated macrophages but its role in humans is 
unclear90. Macrophage storage is the hallmark of GD and Gaucher cells secrete large 
quantities of chitotriosidase. Plasma chitotriosidase activity correlates with both disease 
severity and the success of ERT in GD83;361. Chitotriosidase activity is elevated in the 
plasma of individuals with inflammation, sarcoidosis362, atherosclerosis363, 
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thalassaemia364, advanced prostate cancer365, malaria366 and other lysosomal storage 
disorders90;96;367;368 (fucosidosis, Niemann Pick disease, Fabry disease and 
galactosialidosis). However, in comparison, the level of increase in plasma enzyme 
activity in GD is pronounced. Normal chitotriosidase activity, determined by the method 
of Hollak et al. (1994)83, using a fluorometric enzyme assay with a 4-methyl 
umbelliferone (4-MU) substrate, is typically less than 200 nmol/mL/hr. However, 
chitotriosidase activity is usually greater than 10,000nmol/mL/hr in untreated patients 
with GD and can be >100,000nmol/mL/hr.369. It is not reported in the literature, whether 
non-GD individuals with plasma cell disorders, including multiple myeloma, have 
increased chitotriosidase activity, therefore sharing similar macrophage pathology to 
patients with GD.   
 
The chitotriosidase gene (CHIT1) is located on chromosome 1q31-32, is approximately 
20 kilobases in length and contains 12 exons. One third of the population are 
heterozygous for a 24bp duplication that inactivates the enzyme. Approximately 6% of 
the population have homozygous null mutations within the chitotriosidase gene. The 
frequency of null mutations, either homozygous or heterozygous, was found to be 
similar in a Dutch based study between the general population and Ashkenazi Jews357.  
GBA1, the gene coding β-glucocerebrosidase, has been mapped to chromosome 1q21 
and is approximately 50,000kb apart from the CHIT1 gene 
(http://www.ncbi.nlm.nih.gov/gene). Regarding the possibility of gene linkage, these 
loci are separated by a base pair distance equivalent to the size of the Y-chromosome370.    
 
3.1.3 GBA GENE AND PSEUDOGENE 
The GBA1 gene is located to chromosome 1q21 and codes for 11 exons and 10 introns 
(see chapter 1.2.1) 27. About 300 mutant alleles have been reported and 10 alleles 
complete the genotype in approximately 90% of Ashkenazi Jews with GD (84GG, 
IVS2+1, N370S, V394L, D409H, L444P, R463C, R496H, RecNciI and RecTL)27;36. The 
GBA1 pseudogene (GBAP) is closely located to the GBA1 gene and shares 96% 
sequence homology27. Therefore, the construct of primers, for the screening of GBA1 
mutations in GD is crucial, in order to avoid amplification of the GBAP locus. The 
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majority of reported mutations are found in exons 5-11 with no disease causing alleles 
being described in exon 127. As discussed in section 1.2.2, the N370S and L444P alleles 
are the commonest encountered mutations.    
 
3.1.3.1 PARKINSONS DISEASE – GBA1 MUTATIONS 
Patients with GD are more likely to develop Parkinson’s disease (PD). In a cohort of 57 
patients of mixed ethnicity with PD, GBA1 mutations were found in brain samples of 12 
patients (21%) at post mortem371. Four individuals were found to have polymorphisms, 
including E326K, 8 had disease-associated mutations with 10/12 patients being carriers 
for a GBA1 mutation. In addition, within the last decade, the frequency of GBA1 
mutations has been found to be increased in populations of PD patients, irrespective of 
ethnicity352. Aharon-Pertz et al. (2007) screened Ashkenazi Jews, including 1543 
healthy controls and 99 patients with PD, for 6 common GBA1 mutations (N370S, 
L444P, 84GG, IVS2+1, V394L and R496H). They found a higher frequency of GBA1 
mutations in the PD cohort (mostly heterozygotes, 3 homozygotes), compared to healthy 
controls (31.3%v6.2%)372. Geographical location dictates which GBA1 mutations are 
found in individuals with PD. In the UK, N370S and L444P were the commonest 
mutations373, whereas R120W and RecNciI were the most frequent in patients from 
Japan374. GBA1 polymorphisms, including E326K and T369M, are not uncommon in 
those with familial PD, being associated with a low age at onset375. 
 
Several theories have been postulated as to why carriers of GBA1 mutations have an 
elevated risk of PD. Historically, leucocyte glucocerebrosidase activity, depending on 
methodology, is unable to reliably distinguish between heterozygotes and those with 
GD353. Therefore, carriers may have some impairment in sphingolipid metabolism, 
which confers an elevated risk to PD, similar to that observed in those with GD.  
 
Under normal circumstances, α-synuclein, a soluble protein found in brain tissue, is 
complexed to lipids including within the cell membrane. However, in certain 
neurological diseases, including PD and Lewy Body disease, α-synuclein can aggregate 
to form β-pleated sheets consisting of insoluble amyloid fibrils. Decreased 
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glucocerebrosidase activity has been suggested to promote a cellular environment 
favourable to fibril deposition and neuro-degneration352. Using CBE to inhibit 
glucocerebrosidase, investigators have demonstrated the accumulation of α-synuclein in 
the midbrain of C57BL/6 mice and a cultured neuroblastoma cell line376. However, this 
does not explain the development of PD in individuals with non-enzyme depleting 
GBA1 polymorphisms, including E326K375. 
 
 Other proposed hypothesis leading to neuro-toxicity in PD patients with GBA1 
mutations include16;352:- 
1. Disturbed autophagy, a lysosomal dependent process, leading to the reduced 
catabolism of α-synuclein. 
2. Induction of endoplasmic reticulum stress and proteasomal dysfunction leading 
to the impaired degradation of α-synuclein. 
 
3.1.4 GBA1 MUTATIONS AND GAMMOPATHY 
Despite the association between GBA1 heterozygotes and PD, it is unclear from the 
literature, whether carriers for a Gaucher gene mutation have other features of GD 
including an elevated incidence of paraproteinaemia. Several hypotheses, including 
chronic immune stimulation, decreased tumour surveillance, the accumulation of lipid-
laden macrophages and the elevation of B-cell proliferating cytokines, have all been 
suggested to play a role in the development of gammopathy in GD66. If carrier status for 
a GBA1 mutation was found to confer an elevated risk of paraproteinaemia then 
hypotheses linked to disease burden would become less credible. Moreover if GBA1 
heterozygotes were demonstrated to have an elevated incidence of plasma cell 
neoplasms then gene linkage studies to exclude the co-inheritance of a cancer gene 
would require investigation.  
 
Rosenbloom et al. (2009) performed GBA1 mutational analysis on 95 patients with 
multiple myeloma including 18 Ashkenazi-Jews. In those of Ashkenazi-Jewish descent, 
2 had mutations, however, none were identified in those of non-Jewish ethnicity354. 
Their study was of insufficient sample size or power to disprove an association. 
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Potentially, an associated between carrier status and a monoclonal band could be 
approached either by screening for GBA1 mutations in patients with an M-band or by 
testing the parents of patients with GD i.e. obligate carriers, for a paraprotein. 
Additionally, siblings of patients with GD, that were found to be carriers of mutations, 
could be included. 
 
3.1.5 HYPOTHESIS 
The following hypotheses are tested in this chapter based on the introduction above:- 
 
Hypothesis 1:- Disease severity predicts for monoclonal and polyclonal 
gammopathy in GD 
Rationale:- Several cohorts of GD patients have been shown to have an increased 
incidence of gammopathy. Prior literature has been inconclusive and not sufficient to 
answer whether markers of disease severity including biomarkers predict for 
immunoglobulin abnormalities.  
Methods:- Analysis of clinical data pertaining to local patients with GD at the Royal 
Free Hospital.  
 
Hypothesis 2:- GBA1 is a cancer gene or B-cell promoter and carrier status leads to 
an elevated risk of paraproteinaemia.  
Rationale:- Patients with GBA1 mutations, homozygotic or heterozygotic, have an 
elevated risk of Parkinson’s disease. It is currently unknown whether carrier status 
confers an increased risk of monoclonal gammopathy.  
Methods:- GBA1 gene analysis of non-GD patients who have an established paraprotein 
from Jewish descent.  
 
Hypothesis 3:- Patients with myeloma acquire pathology in the monocytic lineage 
similar to that seen in GD.  
Rationale:- Non-GD individuals with haematological malignancies including multiple 
myeloma have infiltrates of foamy macrophages by light microscopy on bone marrow 
examination (pseudo-Gaucher cells). It is unclear whether these cells or their precursors 
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acquire similar biochemical disturbances to monocytic cells derived from patients with 
GD. 
Methods:- Monocyte glucocerebrosidase activity and plasma chitotriosidase activity.  
 
3.2 METHODS 
3.2.1 LOCAL GAUCHER DISEASE COHORT – ROYAL FREE 
HOSPITAL 
Clinical information was recorded on 75 patients with type I Gaucher disease who were 
treated at the Lysosomal Storage Disorders Unit, Royal Free Hospital.  Data was 
recovered from local pathology databases and the patients case notes. Analysis was 
performed on the same cohort of patients, depending on treatment status, at 2 different 
time points. Data was recorded on treated patients immediately prior to commencing 
ERT and from the most recent evaluation as of the 1/2/2009. Approximately 85% of 
patients had gone on to receive ERT for a minimum of 12 months. For untreated 
patients, clinical and pathological parameters were recorded as of 1/2/2009.  
 
Data capture included disease severity (Zimran severity score), immunoglobulin levels, 
serum electrophoresis, splenectomy status, platelet count, baseline glucocerebrosidase 
activity, GBA1 genotype, chitotriosidase activity, ferritin, acid phosphatase (ACP), 
serum-angiotensin converting enzyme (S-ACE) and treatment status.   
 
3.2.2 CHITOTRIOSIDASE ACTIVITY  
Plasma was collected from healthy controls and patients with GD, myeloma and MGUS. 
All samples were processed on the same day as collection and stored at -80°C until 
analysis. Chitotriosidase activity was determined by fluorometric assay in accordance 
with the method of Hollak et al. 1994 (see section 2.8.4). 
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3.2.3 GLUCOCEREBROSIDASE ACTIVITY 
PBMCs were isolated from peripheral blood and the glucocerebrosidase activity of 
monocytes was determined by a flow cytometry as described (section 2.8.5). Monocytes 
were identified based on forward and side scatter characteristics with a minimum of 
10,000 gated events being analysed. 
 
3.2.4 GBA1 MUTATION ANALYSIS 
3.2.4.1 STATITICAL CONSIDERATIONS 
Prior to commencing screening for GBA1 mutations, several statistical scenarios were 
modelled. Statistical analysis was provided by Richard Morris (Department of Primary 
Care and Population Sciences, Royal Free Hospital). This was performed using an 
available online application (http://www.swogstat.org).The following assumptions were 
made in the statistical models presented below:- 
(a) Gaucher Gene Carrier frequency in the Ashkenazi-Jewish population – 1/12 
(b) Incidence of a paraprotein in the non-GD Jewish population (>50 in age) – 
3% 
(c) Carriage of a Gaucher gene mutation in the general population 1:800 
 
Option (1):- 
How many Ashkenazi-Jews with a paraprotein are required to demonstrate an 
association with a mutated GBA1 allele? 
(i) Relative risk 2.0 with power of 80% together with p<0.05 = 118 people 
(ii) Relative risk 1.5 with power of 80% together with p<0.05 = 382 people 
[1 tailed statistical test, assuming a control population:sample population of 32:1]  
 
Option (2):  How many people from a general population, of unspecified ethnicity, are 
required to demonstrate an association between a paraprotein and a mutated GBA1 
allele? 
Assuming a relative risk of 2.0, power of 0.8, p<0.05 and carrier frequency of 1/800 in 
the general population, approximately 9,043 people are required for recruitment. 
[1 sided statistical test] 
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Option (3): How many relatives of patients with GD with a GBA1 mutation (>50 years 
in age) are required in order to demonstrate a casual association with a blood 
paraprotein? 
(i) Relative risk 2.0, power 0.8 with a p<0.05 = 353 people 
(ii) Relative risk 3.0, power 0.8 with a p<0.05 = 123 people 
(iii) Relative risk 3.0, power 0.9 with a p<0.05 = 150 people 
[1 tailed statistical test, 99:1 control population:sample population] 
  
Option 2, screening the general population, is unfeasible based on recruitment numbers, 
expense and manpower. Option 3, is also not plausible, as over 300 individuals are 
required to demonstrate a relative risk of 2.0. There are approximately 90 patients with 
GD under the care of the Royal Free Hospital with their relatives geographically 
distributed across the United Kingdom. Therefore, we opted for option 1, with the aim of 
recruiting approximately 120 patients.  
 
3.2.4.2 DEMOGRAPHICS OF THE JEWISH POPULATION IN LONDON 
Data collected from the 2001 census, for the first time, described the demographics of 
the Jewish population in London (Piggott and Lewis 2006; Greater London Authority). 
They reported a total of 149,789 people of Jewish ancestry in London, comprising 2.1% 
of all individuals, of which 59% were less than 50 years old. London is divided into 
boroughs with the borough of Barnet containing approximately one third of all London 
Jews and about 18% of all Jews nationally. Harrow, Brent, Redbridge and Camden are 
the next four London boroughs with the highest number of Jewish residents (Table 3-1). 
Hackney and Haringey contain a relatively young Jewish population. Criticisms of the 
2001 census include the absence of information detailing Jewish denomination. 
Ashkenazi Jews have the highest carriage rate of GBA1 mutations and therefore 
targeting these populations would require less numbers in order to gain sufficient 
















Table 3-1. Demographics of the Jewish population in the 10 London boroughs with the highest 
number of Jewish residents (2001 census).  
 
3.2.4.3 RECRUITMENT OF JEWISH PATIENTS WITH A PARAPROTEIN  
Approximately 90 patients of Jewish origin with a paraprotein were identified at the 
Royal Free Hospital. Individuals were identified based on recorded ethnicity and a 
detectable M-band. However, the majority of these patients had MGUS, and many were 
receiving yearly review. In order to address recruitment difficulties, amendments were 
made to the original local ethics and R&D submission. This allowed for multi-site 
involvement, an invitation to participate by post, telephone communication and 
phlebotomy in the patients’ home. Ethical and R&D approvals were obtained from each 
participating hospital trust. These trusts were identified as serving London boroughs of 
high Jewish ethnicity. These included:- 
 
1. Royal Free Hospital (RFH) Hampstead NHS Trust – Camden, Barnet 
2. Barnet and Chase Farm Hospitals NHS Trust – Barnet, Enfield 
3. Barking Havering and Redbridge NHS Trust – Redbridge 














Barnet 52 46,686 14.8 
Redbridge 46 14,796 6.2 
Harrow 47 13,112 6.3 
Camden 43 11,153 5.6 
Hackney 33 10,732 5.3 
Westminster 49 7,732 4.3 
Brent 52 6,464 2.5 
Haringey 38 5,724 2.6 
Enfield 48 5,336 2.0 
Kensington and 
Chelsea 
43 3,550 2.2 
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Signed informed consent was acquired from all participating patients. An example of a 
patient information and consent form is found in Appendix 1. All patients who were 
found to be homozygous or compound heterozygotes for GBA1 mutations were 
reviewed at the Lysosomal Storage Disorders centre, Royal Free Hospital. Those found 
to be carriers of a GBA1 mutation received counselling by telephone and their General 
Practitioner was asked to refer for genetic counselling, if appropriate.   
 
3.2.4.4 GBA1 MUTATION SCREENING – STRATEGY 
DNA was isolated from stored whole blood (thawed from -80°C) or immediately from 
freshly isolated PBMCs. As described by Hruska et al. (2008), 84.3% of all GBA1 
mutations, including 13 of the 15 commonest mutations, are contained within exons 5-
11 (Hruska et al. 2008). Amplification of these exons was performed using two initial 
PCRs encompassing blocks 5-7 and 8-11. Primers were designed to be specific for the 
GBA1 gene and not the GBAP pseudogene, as used by Stone et al. (2000).  Sequence 
primers were exon specific. In a minority of samples, due to degraded DNA, exon 6 was 
amplified and sequenced using the same set of exon specific primers. Two common 
mutations found in the Jewish population, 84GG and IVS2+1, are contained in a 255bp 
fragment in exon 2. An allele specific PCR was used to detect the 84GG mutation. The 
IVS2+1 allele was detected by performing an enzyme digest on the amplified 255bp 





Figure 3-1. GBA1 gene identifying the location of the 15 most commonly mutated alleles.  
Adapted from Hruska et al. (2008).
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3.3 RESULTS 
3.3.1 DESCRIPTION OF GAMMOPATHY IN GD PATIENTS 
Based on the analysis of 75 patients with GD, 10 (13.3%) were identified as having a 
blood paraprotein and their demographics are described in Table 3-2 (Patients 1-10). 
Patient 8 died from sepsis in 2001 just prior to commencing chemotherapy for multiple 
myeloma with a paraprotein of 56g/l. 
 
As of the 1/2//2009, the average age of those with a paraprotein was 59.6 years (range 
27-87; n=9). The mean paraprotein level was 8.4g/l with 9/10 being IgG in isotype and 
6/10 being kappa light chain expressing. Patient 5 had bi-clonal low level IgG 
paraproteins of differing light chain class. Patients 4 and 10 had undergone splenectomy 
prior to developing a paraprotein. Interestingly, patients 2 and 3 were male siblings of 
similar age. Patients 2 and 10 had persistently elevated IgA immunoglobulins 
(polyclonal), despite ERT, whereas all other treated patients with a paraprotein had 
normal serum levels within their unaffected immunoglobulin classes. All patients had 
radiological evidence of skeletal disease. Patient 2 developed a paraprotein whilst on 
ERT but it is unclear whether patient 10 had a paraprotein prior to commencing disease-
modifying therapy. All other patients had a documented paraprotein before starting ERT.   
 
Five patients with a paraprotein had undergone bone marrow examination:- 
 
(A) Patient 3. Bone marrow examination (November 2007) revealed an infiltrate of 25% 
Gaucher cells and approximately 5% plasma cells.  His skeletal disease was attributed to 
GD rather than myeloma-related end organ tissue impairment (ROTI) and he was 
classified as having MGUS.  
 
(B) Patient 4 underwent bone marrow examination in June 2008 when his paraprotein 
level was 15g/l. The trephine revealed an infiltrate of 50% Gaucher cells without 
elevation in plasma cell numbers. Skeletal manifestations were attributed to GD and he 




Table 3-2. Characteristics of 10 Gaucher disease patients with a blood paraprotein.  
Bone Marrow Burden (BMB) score is calculated on T1 image intensity on MRI, T2 image intensity 
and the distribution of bone marrow anomaly (maximum score 8).  ASM (asymptomatic myeloma), 
MM (multiple myeloma) and MGUS (monoclonal gammopathy of undetermined significance).  
 
(C) Patient 5 underwent a bone marrow trephine in August 2006 revealing numerous 
Gaucher cells and an infiltrate of plasma cells, which in part clustered into organised 
sheets. He was classified as having asymptomatic myeloma, as dictated by International 
Myeloma Working Group (IMWG) criteria, and the bony disease was reported as being 
consistent with GD.  
 
(D) Patient 8 had a bone marrow examination in 2001, the same year as his death, 
revealing only a low-grade plasma cell infiltrate together with the presence of numerous 
Gaucher cells. Initially he was classified as having asymptomatic myeloma with his 
skeletal disease attributable to GD. However his paraprotein subsequently peaked at 
56g/l. This gentleman had decreased peripheral blood counts and impaired performance 
status. He was suspected to have multiple myeloma but died of septicaemia prior to 
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9 46 1 MGUS IgG-λ N370s 
L444P 
2664 Wild No Yes 
moderate 




(E) Patient 10 underwent bone marrow examination in 2004 and 2008 for low blood 
counts. Gaucher cells were evident but an increase in plasma cell numbers was not 
reported. His skeletal disease was attributed to GD  
 
3.3.1.1 GLUCOCEREBROSIDASE ACTIVITY – GAMMOPATHY 
Initially it was hypothesised that baseline glucocerebrosidase activity would be 
predictive for the development of gammopathy (polyclonal or monoclonal). Patients 
with type III disease have more severe disease and generally lower residual enzyme 
activity. Baseline glucocerebrosidase activity was considered a marker of disease 
severity for this comparison. This data was available for 32 patients, which included 6 
individuals with a paraprotein. GD patients without gammopathy (0.1±0.1; 
Activity/Mid-reference range; mean±SD) had identical enzyme activity to those with 
gammopathy (0.1±0.1; p=0.98; Mann Whitney test). Baseline glucocerebrosidase 








Figure 3-2. Enzyme activity of GD patients/mid-range value of the reference range in those with (A) 
gammopathy and (b) paraproteinaemia.  














































3.3.1.2 INCIDENCE OF POLYCLONAL GAMMOPATHY 
The absolute levels of IgG, IgM and IgA were analysed in treatment-naive individuals, 
excluding immunoglobulins with an associated paraprotein (Figure 3-3). In total, 59% 
(37/75) had polyclonal gammopathy with IgM being the commonest affected 
immunoglobulin. Elevated IgM, IgA and IgG levels were seen in 38%, 20% and 22% of 
patients respectively. Gammopathy affecting two immunoglobulin classes were present 
in 9/75 individuals with a further 3/75 patients having increases in all 3 isotypes (IgA, 
















Figure 3-3. Graph representing the absolute levels of immunoglobulins in untreated GD individuals. 
The number of patients with elevated values is reported above each immunoglobulin isotype. The 
broken line indicates the upper limit of normal range.  
 
In treated individuals (>12 months), polyclonal increases in IgM, IgA and IgG were seen 
in 9%, 12.5% and 9.4% respectively. In comparison to ERT-naïve individuals, 























3.3.1.3 POLYCLONAL GAMMOPATHY – DISEASE MODIFYING THERAPY 
ERT led to a highly significant reduction in the absolute immunoglobulin levels of IgM 
(n=55 p<0.0001; paired data; Wilcoxon Signed Rank Test), IgA (n=54; p<0.0001) and 
IgG (n=51; p<0.0001) isotypes in individuals who had received treatment for a 























































































Figure 3-4. Absolute immunoglobulin levels pre and post a minimum of 12 months therapy.  
(A) IgM, (B) IgA and (C) IgG isotypes (Wilcoxon Signed Rank Test). Horizontal line represents 
mean, broken line indicates upper limit of normal. (D) Graph represents the percentage of patients 




The treated cohort had received therapy for a median of 9 years and the percentage of 
individuals with elevated IgM or IgG levels reduced with treatment. Therefore, ERT is 
effective in attenuating polyclonal gammopathy. 
 
3.3.1.4 MONOCLONAL GAMMOPATHY - DISEASE MODIFYING THERAPY 
The paraprotein levels in patients on ERT, with quantified paraproteins over several 
years, are plotted below. Interestingly, the patient with multiple myeloma (patient 8), 
experienced a large fall in his paraprotein post splenectomy (Figure 3-5). However, this 
was transient, despite concomitant treatment with ERT. Although the other 6 patients 


























Figure 3-5. Trend of paraprotein over time for GD patients with a longstanding M-band on ERT. 



































































3.3.1.5 GAMMOPATHY AND CHITOTRIOSIDASE ACTIVITY (ERT NAÏVE) 
Peak chitotriosidase activity is reported below in treatment-naïve individuals and for 
patients with a paraprotein or polyclonal gammopathy. Patients with gammopathy, 
monoclonal or polyclonal, had significantly elevated chitotriosidase activity compared to 
those with normal immunoglobulin analysis (p<0.05; Figure 3-6). Patients with a 
paraprotein had a similar chitotriosidase activity (8134±5743 nmol/hr/ml; n=29; 
mean±SD) compared to GD individuals with normal immunoglobulins (5436±4120; 
n=10; p=0.14). These comparisons assume an equal distribution of null chitotriosidase 
gene mutations between analysed groups. Sub-analysis of patients with functional 
chitotriosidase genes (wild type), demonstrated higher chitotriosidase enzyme activity in 













Figure 3-6. Graph showing chitotriosidase activity (nmol/hr/ml) in patients, with and without 
gammopathy, prior to the instigation of disease modifying therapy.  
(A) an unselect GD population or (B) in those known to have functional chitotriosidase genes. 

















































































Chitotriosidase activity did not correlate with the absolute levels of IgM (r=-0.02, 
p=0.86), IgA (r=0.21, p=0.08) or IgG (r=0.33, p<0.01). This comparison holds true 
when comparing those with functional chitotriosidase genes.  
 
3.3.1.6 GAMMOPATHY AND CHITOTRIOSIDASE ACTIVITY (ERT ERA) 
Patients with gammopathy had increased chitotriosidase activity (2759±2665 
nmol/ml/hr; mean±SD) compared to those without gammopathy (1288±1796; p<0.01). 
This observation holds true for those with functional chitotriosidase genes (p<0.01; 
gammopathy 2881±2139 versus normal immunoglobulins 847±742; Figure 3-7). In 
patients receiving ERT, chitotriosidase activity was not significantly elevated in 
individuals without a paraprotein (1503±1957 nmol/ml/hr; n=64) when compared with 



















Figure 3-7. Chitotriosidase activity of GD patients with gammopathy or normal immunoglobulins in 
the ERT era.  
































































3.3.1.7 ACID PHOSPHATASE, SERUM ACE AND FERRITIN IN PATIENTS 
WITH GAMMOPATHY (ERT NAÏVE) 
Additional biomarkers, of GD severity (acid phosphatase, ferritin and S-ACE), were 
analysed in those with normal immunoglobulins, polyclonal gammopathy and 
individuals with a paraprotein. Available data, in ERT naïve patients, shows serum acid 
phosphatase and S-ACE to be elevated in those with gammopathy compared to those 
with normal immunoglobulins. Ferritin levels were not discriminatory between GD 
patients with and without gammopathy (Table 3-3).  
 
 No gammopathy Gammopathy p-value 
Acid Phosphatase (ng/ml) 
Normal:- 2.6-6.2 
9.2±3.2 (n=30) 11.6±5.1 (n=41) <0.05 
S-ACE (U/ml) 
Normal:- 8-55 
99.9±75.3 (n=31) 143.7±103.7 (n=43) <0.05 
Ferritin (ng/ml) 
Normal:- 30-340 
441±372 (n=30) 515±263 (n=43) 0.4 
 
Table 3-3. Serum levels of acid phosphatase, S-ACE and ferritin in GD individuals with 
gammopathy (monoclonal or polyclonal) or normal immunoglobulins. 
 
Patients with a paraprotein had a higher serum acid phosphatase level than those without 
(p<0.05; Table 3-4) but had equivalent levels of S-ACE and ferritin. 
 
 No Paraprotein Paraprotein p-value 
Acid Phosphatase (ng/ml) 
Normal:- 2.6-6.2 
10.1±3.6 (n=62) 13.3±8.1 (n=9) p<0.05 
S-ACE (U/ml) 
Normal:- 8-55 
117.8±86.4 (n=65) 179.7±136.4 (n=9) p=0.07 
Ferritin (ng/ml) 
Normal:- 30-340 
466.9±373.9 (n=65) 591.8±281.8 (n=9) p=0.15 
 
Table 3-4. Serum levels of acid phosphatase, S-ACE and ferritin in GD individuals with and without 
a paraprotein.  
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3.3.1.8 ZIMRAN SEVERITY INDEX – GAMMOPATHY (ERT NAÏVE) 
The Zimran severity score (ZSS) was able to be calculated in 56 ERT naïve patients, 10 
of who had a paraprotein. Patients with polyclonal gammopathy had an identical ZSS 
(8.1±3.2; mean±SD) to those without gammopathy (9.6±5.1; p=0.2; Figure 3-8). 
However, patients with a paraprotein had a ZSS (12.2±5.3) (p<0.05) higher than 
individuals with polyclonal gammopathy (8.9±4.2).  
 
GD patients with a paraprotein did not have a higher ZSS than GD patients (normal 
immunoglobulins plus polyclonal gammopathy) without a paraprotein (p=0.06).  
 
























Figure 3-8. Zimran score in patients with normal immunoglobulins, polyclonal gammopathy and 






























3.3.1.9  PLATELET COUNT – GAMMOPATHY 
Thrombocytopenia in individuals with GD is most often due to visceral sequestration, 
particularly in the spleen. In addition, infiltration of the bone marrow, by lipid-laden 
macrophages, may compound this. Therefore, a low platelet count may be a surrogate 
marker for disease severity. Prior to ERT, GD patients with gammopathy had a 
significantly lower platelet count (102±65x109/L; mean±SD) than those with normal 
immunoglobulins (166±138x109/L; p=0.02; Figure 3-9). The platelet count did not differ 
in patients with or without a paraprotein (p=0.19). However 9/10 individuals with an M-




















Figure 3-9. Platelet counts in patients with GD that are ERT naïve.  
(A) No gammopathy versus gammopathy. (B) No paraprotein versus paraprotein. Horizontal line 
indicates mean, broken lines signifies normal range.  
 
In those on ERT for a minimum of 12 months, the platelet count was identical in those 
with gammopathy (210±110x109/L; n=35; mean±SD) and those without gammopathy 
(187±89x109/L; p=0.26). 
 
3.3.1.10 SPLENECTOMY  
Historically, splenectomy was performed in treatment naïve individuals for refractory 
























































be an indicator of disease severity. The incidence of splenectomy was determined in 75 
treatment-naïve individuals and was found to be equivalent between GD patients with 
gammopathy (asplenic 9/44 patients) and with normal immunoglobulins (9/31; p=0.6). 
In individuals with a paraprotein, only 2/10 patients had undergone splenectomy.  
 
3.3.1.11 GBA1 MUTATIONS - GAMMOPATHY 
GBA1 genotype was available in 72 patients (Table 3-5) of which 22 alleles were 
unidentified. The most common genotype in those with a paraprotein was 
N370S/L444P, whereas N370S/N370S was more prevalent in those with normal 
immunoglobulins. There was no statistical link between any allele or genotype, 
including N370s homozygosity and the presence of gammopathy (monoclonal or 
polyclonal). 
 








N370S/N370S 7 7 2 
N370S/L444P 5 6 4 
N370S/? 6 10 1 
L444P/? 2 1 0 
L444P/R463C 3 0 0 
N370S/D409H 1 3 0 
N370S/84GG 1 4 0 
RecNcil/? 0 0 1 
R463C/? 0 0 1 
N370S/C1263del55 1 0 0 
N370S/IVS2+1 1 0 1 
N370S/V349L 1 0 0 
R463C/R463C 0 0 0 
N370S/RecNcil 0 1 0 
N370S/R120Q 1 1 0 
 
Table 3-5. GBA1 genotype in individuals with normal immunoglobulins, polyclonal gammopathy or 
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3.3.2 CHITOTRIOSIDASE ACTIVITY – PLASMA CELL 
DISORDERS 
Chitotriosidase activity was determined in healthy controls, patients with GD and non-
Jewish individuals with either MGUS or multiple myeloma. In addition, chitotriosidase 
enzyme activity was determined in Jewish patients with a paraprotein, including those 



































Figure 3-10. Chitotriosidase activity in non-GD patients with gammopathy and GD patients. 
(A) Chitotriosidase activity (nmol/ml/h) plotted against age in samples derived from healthy 
controls. (B) Chitotriosidase activity (log scale) in individual groups. Boxed population indicates a 
small cohort of outliers within the group derived from non-Jewish myeloma patients. Dashed line 
indicates the upper limit of normal range. Group means indicated by horizontal line.  































































Chitotriosidase activity has been reported to increase with age89 and higher enzyme 
activities were recorded in healthy controls of advancing age (Figure 3-10). Therefore, 
all analysed groups were aged-matched to within a decade. The mean age and 
chitotriosidase activity in the analysed groups are reported in Table 3-6.  
 
 
Table 3-6. Mean age and chitotriosidase activity (nmol/ml/hr plasma) within individual analysed 
groups.  
 
Patients with GD had a significantly higher enzyme activity than healthy controls 
(p<0.0001). Chitotriosidase activity was identical in healthy controls, Jewish patients 
with a paraprotein and non-Jewish patients with either multiple myeloma or MGUS.  
 
Boxed individuals in the non-Jewish-derived myeloma group (n=5, with low or near 
absent chitotriosidase activity), may represent a population with null chitotriosidase 
genes. In addition, these patients were all on immunomodulatory drugs (thalidomide or 
lenalidomide), as either maintenance or treatment. Disease burden within the boxed 
group, varied significantly, from frank relapse to plateau post-autograft.  These patients 
had all received at least 1 prior course of chemotherapy. However, there were many 
patients, with a similar disease stage or treatment profile, that were part of the myeloma 
cohort, non-boxed, with unremarkable chitotriosidase activity. 
 
3.3.3 MONOCYTE GLUCOCEREBROSIDASE ACTIVITY  
A flow cytometric assay was used to determined glucocerebrosidase activity in 
monocytes derived from healthy controls (n=5), patients with GD (n=5) or non-Jewish 
patients with myeloma (n=5). In addition, the monocytes of three Jewish individuals 
Group Mean  age Chitotriosidase Activity 
Mean±SD 
Healthy Controls 67.7 63.0±47.4 
MGUS (Non-Jewish) 70.6 56.5±66.4 
Myeloma (Non-Jewish) 64.8 81.3±61.1 
Paraprotein (Jewish) 72.6 74.9±48.9 
Gaucher Disease 48.1 2244±2076 
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A B
with myeloma were analysed. Patients with GD had low enzyme activity compared to 
healthy controls (p=0.002). However, glucocerebrosidase activity was not lower in 














Figure 3-11. Monocyte Glucocerebrosidase activity in controls, non-GD individuals with myeloma 
and patients with GD.  
Monocyte glucocerebrosidase activity as determined by the MFI of liberated fluorochrome from the 
carrier substrate di-β-glucopyranoside. Enzyme activity reported as a ratio to a paired sample pre-














Figure 3-12. (A) Monocytes were identified based on forward and side scatter characteristics. (B) 
Representative histogram showing a reduction in liberated fluorescein from samples derived from 







































3.3.4 GBA1 SCREENING 
Initially, a small cohort of DNA samples was processed from healthy controls and 
patients with either multiple myeloma or MGUS, in order to assess the suitability of 
screening for GBA1 mutations using a manufactured strip-test (ViennaLabs, Vienna, 
Austria). The kit provides material for the isolation and in vitro amplification of DNA 
sequences for the commonest GBA1 mutations and recombinant alleles by reverse 
hybridisation. Amplified products are biotinylated and hybridised to a test strip with 
immobilised oligonucleotide sequences (wild and control sequences). Results were 
interpreted using a streptavidin-alkaline phosphatase reporter system. As expected, the 
strip-test did not identify any healthy controls of non-Jewish ethnicity, as having 
mutated GBA1 alleles. However, two individuals of Jewish descent were newly 
identified as having GBA1 mutations. Patient 1 had multiple myeloma and was found to 
be a compound heterozygote (N370S/R496H). Patient 2 was a heterozygote for N370S 
and had a longstanding low-level paraprotein (MGUS).  Based on these initial findings a 
combination of allele specific PCR and DNA sequencing was employed to maximise the 
detection frequency of GBA1 mutations. 
 
Figure 3-13. GBA1 analysis. Schematic diagram, normal strip test and compound heterozygote 







Table 3-7. Results of GBA1 mutation screening using a pre-manufactured strip-test.  
 
3.3.4.1 GBA1 SCREENING STUDY - DEMOGRAPHICS 
In total, 77 patients of Jewish ethnicity were recruited from 4 NHS hospital trusts. 48/65, 
7/65 and 10/65 of individuals reported had Ashkenazi, Sephardic or mixed/ unknown 
Jewish ancestry (data was not collected on 12 individuals). Paraproteinaemia was most 
commonly associated with MGUS or myeloma. A minority of patients had 
lymphoplasmacytic lymphoma (LPL), AL-amyloidosis, or chronic lymphocytic 




























Table 3-8. Patient demographics of identified Jewish patients with a paraprotein at 4 London based 
NHS Trusts.  
RFH (Royal Free Hospital NHS Trust Hampstead), NWLH (North West London Hospitals NHS 
Trust), BCF (Barnet and Chase Farm Hospitals NHS Trust) and BHR (Baking Havering Redbridge 
NHS Trust). LPL (lymphoplasmacytic lymphoma), CLL (Chronic lymphocytic leukaemia). 




Myeloma 25 3 5 1 (Jewish) 
MGUS 1 1 0 1 (Jewish) 
Healthy Controls 6 0 0 0 
 RFH NWLH BCF BHR 
Patients 
Identified from 
Database Search  




49/60 6/8 14/17 8/9 
Male:Female 21:28 3:3 7:7 4:4 
MGUS (n=) 20 4 9 7 
Myeloma (n=) 16 1 4 1 
Smouldering 
Myeloma (n=) 
3 0 0 0 








1 LPL 0 
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3.3.4.2 GBA1 MUTATION SCREENING – RESULTS 
Of the 77 patients, 7 were found to be heterozygous for a GBA1 mutation. In addition, 
one patient was found to be a compound heterozygote (N370S/R496H).  All mutations 
were confirmed based on two sequences. Approximately 10.4% of individuals (1:9.6) 
were found to have an abnormal GBA1 locus with a mutated allele frequency of 5.8% 
(9/154). N370S was the commonest allele in the 8 individuals with an abnormal GBA1 
gene.  
 
Table 3-9. Description of Jewish patients with a paraprotein harbouring GBA1 mutations. 
 
 
Compared to a reported 1:12 carrier rate in Ashkenazi Jews, an increased frequency of 
mutated GBA1 alleles was not observed in those with a paraprotein (Z test=0.67, normal 
distribution, p=0.5). Statistical analysis using an online calculator 
(http://www.swogstat.org), revealed the power of this study, based on the pre-study 
statistical criteria specified to be 57.2% (alpha error=0.05, RR=2, control 
population:sample population 32:1; one tailed test). In a two-tailed test, power decreased 
to 41% (Statistics performed by Richard Morris in the Department of Primary Care and 
Population Sciences, Royal Free Hospital). 
 cDNA Exon Protein Mutation Disease Status 
Patient A c.1226A>G 9 p.Asn409Ser N370S/Wild MGUS Carrier 
Patient B c.1226A>G 9 p.Asn409Ser N370S/Wild LPL Carrier 
Patient C Allele 
Specific  
PCR 
2 - 84GG/Wild Myeloma Carrier 






N370S/R496H Myeloma Gaucher 
disease 




Patient F c.1226A>G 9 p.Asn409Ser N370S/Wild Myeloma Carrier 
Patient G c.1226A>G 9 p.Asn409Ser N370S/Wild MGUS Carrier 












Patient C, a myeloma patient, was found to be a carrier for 84GG, a single base 
insertion, in exon 2. This is demonstrated on gel electrophoresis following allele-specific 













Figure 3-14. Gel electrophoresis (2% agarose) demonstrating patient C to be heterozygous for the 
84GG single nucleotide insertion.  






















Figure 3-15. Patient D. The illustrated mutation reflects heterozygotic expression of the exon 11 


























































































































Figure 3-16.  Figure 3.16. Patient H. The illustrated mutation reflects 






3.3.4.3 DESCRIPTION OF JEWISH PATIENTS WITH GBA1 MUTATION 
 
A brief description of the patients with GBA1 mutations is provided below:- 
 
(A) Patient A (N370S/Wild). This 79 year old lady originally presented in 2006 with an 
IgG paraprotein of 21g/l. Based on staging investigations MGUS was diagnosed with 
3% plasma cells on a bone marrow specimen. Currently her paraprotein remains stable. 
Co-morbidity includes idiopathic Parkinson’s disease. 
 
(B) Patient B (N370S/Wild). This 63 year old man was diagnosed with 
lymphoplasmacytic lymphoma in 2006 following investigation for a persistent 
lymphocytosis. Serum electrophoresis revealed two IgGκ paraproteins of 2g/l and 11g/l. 
Radiological staging revealed no lymphadenopathy or hepato-splenomegaly. Currently 
he remains stable and untreated.   
 
(C) Patient C (N370S/Wild). This 81 year old woman was diagnosed with MGUS in 
2007 with two low level paraproteins (2g/l and 4g/l) and 6-8% plasma cells on a bone 
marrow trephine. Currently she is well. 
  
(D) Patient D (N370S/R496H). This 72 years old woman was initially diagnosed with 
asymptomatic myeloma in 2004 with an IgGκ paraprotein of 25g/l. In 2006 her 
paraprotein progressively rose and this was associated with a 20% infiltrate of plasma 
cells on a bone marrow trephine. She had a partial response (PR) to cyclophosphamide, 
dexamethasone and thalidomide. In 2008 bortezomib and dexamethasone were 
prescribed for progressive disease, leading to a good PR.  She has just commenced 
lenalidomide/dexamethasone for relapsed disease. Despite being found to be a 
compound heterozygote for GD, no Gaucher cells were noted on prior bone marrow 
examination.  
 
(E) Patient E (E326K/Wild). This 80 year old lady was diagnosed with multiple 
myeloma (20-30% infiltrate of plasma cells) complicated by amyloid affecting the oral 
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cavity, including lips. No paraprotein was present but she had a lambda light chain litre 
of 507mg/l. Echocardiography and serum amyloid A protein (SAP) scintigraphy 
demonstrated the absence of further deposition. Currently she remains well with stable 
disease after completing a course of melphalan, steroid and thalidomide.  
 
(F) Patient F (N370S/Wild). This 70 year old gentleman presented in 2008 with IgD 
myeloma complicated by a thoracic plasmacytoma. Staging investigations revealed a 
10% plasma cell infiltrate on bone marrow trephine, skeletal disease and a paraprotein of 
3g/l. He was treated with 6 cycles of cyclophosphamide, dexamethasone and 
thalidomide and received 20Gy radiotherapy to the plasmacytoma. .  
 
(G) Patient G (N370S/Wild). This 91 year old gentleman with MGUS has had a stable 
low level IgG paraprotein <10g/l for the past 7 years.  
 
(H) Patient H (N370S/Wild). This 84 year old gentleman has had a stable IgMκ 
paraprotein since 2008. MGUS was diagnosed post staging investigations including 
bone marrow examination. 
 144 
3.4 DISCUSSION 
The results presented in this chapter demonstrate a high incidence of monoclonal and 
polyclonal gammopathy in the local cohort of patients with GD. Data presented here, 
for the first time, supports the hypothesis that disease severity is a risk factor for 
gammopathy. ERT naïve patients with gammopathy had higher chitotriosidase 
activity, serum acid phosphatase (ACP) and serum-ACE together with lower platelet 
counts than those without gammopathy. In addition, serum acid phosphatase 
(p<0.05) and S-ACE (p=0.07) seemed higher in GD patients with a paraprotein 
compared to those without. Furthermore GD patients with a paraprotein had a higher 
ZSS than those with polyclonal gammopathy. ERT led to a reduction in all 
immunoglobulins (IgG, IgM and IgA) and stabilised the level of paraproteinaemia. 
Macrophage precursors (peripheral blood monocytes), derived from non-GD patients 
with a paraprotein, had normal glucocerebrosidase activity. Furthermore, non-GD 
patients with an establish paraprotein, had normal plasma chitotriosidase activity. 
This data, does not support the hypothesis that non-GD patients with an M-band 
acquire similar abnormalities within their monocytic-macrophage lineage to that seen 
in GD. Despite recruiting from 4 NHS trusts serving large numbers of Jewish 
patients, the number of Jewish patients identified with a paraprotein was low. 8/77 
Jewish patients with a paraprotein were found to have GBA1 mutations (7/77 
heterozygotes; 1/77 homozygote). The study was of insufficient power (57.2%) to 
reject the null hypothesis.  
 
In the RFH cohort, in ERT naïve individuals, 59% had polyclonal gammopathy, in 
keeping with the frequency reported by other investigators74;139;162. Furthermore, 
12/75 (16%) individuals had elevation in two or more immunoglobulin classes (IgM, 
IgA or IgG). Wine et al. (2007) reported polyclonal gammopathy in 21/23 (91%) 
untreated paediatric patients with type I GD, of which 11/21 children (52%) had 
increased levels of more than one immunoglobulin234. The higher incidence of 
polyclonal gammopathy reported in this small cohort is likely to reflect a group of 
patients with severe disease as the mean age at presentation was 3.9 years. These 
findings support the chapter hypothesis that gammopathy is more prevalent in those 
with severe disease. In the RFH cohort many individuals presented in adulthood or 
remain untreated. IgM was the commonest elevated immunoglobulin (38%) in 
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keeping with the report by Khalifa et al. 2010235 describing gammopathy within a 
juvenile population of GD patients. The majority of published cohorts in GD patients 
have reported IgG to be the predominantly elevated isotype43;74;138;139. However, a 
small increase in the reference range for IgM, would have led to many more 
individuals within the RFH cohort to having normal levels.  
 
A few comments should be made regarding the staging of monoclonal gammopathies 
in GD. Firstly, it is difficult to distinguish between myelomatous bone disease and 
pathology secondary to their storage disorder as compression fractures, lytic disease 
and osteoporosis are common to both377. Therefore, GD patients with progressive 
skeletal pain, with biochemical evidence of a clonal disorder (Bence Jones 
proteinuria, elevated serum light chains or paraproteinaemia), should be considered 
for a CT guided bone biopsy to exclude bony plasmacytoma, given the high reported 
incidence of plasma cell neoplasms. In addition, anaemia, a feature of symptomatic 
myeloma, is also a hallmark of GD. Based on agreed international diagnostic criteria 
(International Myeloma Working Group; IMWG) clonal plasma cell populations 
greater than 10% on bone marrow examination cannot be classified as MGUS378. The 
percentage of plasma cells on bone marrow sampling may be underestimated in GD 
due to dilution by accumulated Gaucher cells. This may lead to the incorrect 
staging/classification of the plasma cell disorder. Non-GD patients with 
asymptomatic myeloma (plasma cell infiltrate >10%) have a higher rate of 
progression to symptomatic myeloma than those with MGUS (plasma cell 
infiltrate<10%)203;227 and therefore require more frequent follow-up and appropriate 
counselling.  
 
Data from a Minnesota based population study of more than 20,000 participants 
reported paraproteinaemia in 3.2%, 5.3% and 7.5% of individuals older than 50, 70 
and 85 years in age respectively201. From the cohort of 75 RFH patients with GD, 
13.3% (n=10) were found to have a blood paraprotein. As of 1/2/2009, the mean age 
of GD patients with a paraprotein was 59.6 years (n=9; excluding patient 8, 
deceased). The incidence of monoclonal gammopathy varies with race and is more 
common in blacks than caucasians (Aged>70, 8.4% versus 3.8%; p<0.001)204. Data 




The high incidence of paraproteinaemia in the RFH cohort of GD patients was in 
keeping with prior reports74;81;138;139.However, Brautbar et al. (2004), in an Israeli 
based study of GD patients, reported a low incidence of paraproteinaemia (1%)43. 
Speculatively, the number of patients with GD identified as having a clonal plasma 
cell disorder, in their study, may have been increased by screening for a urinary M-
band or an abnormal serum light chain ratio. Whether GD patients have a higher 
incidence of light chain or non-secretary myeloma is unknown. In a cohort of 13 GD 
patients (German/Dutch) with monoclonal gammopathy only one individual was 
reported to have light chain myeloma81, in keeping with the low number of 
individual case reports136. An abnormal free light chain ratio is a strong predictor for 
progression from MGUS to multiple myeloma, in non-GD patients379.  Interestingly, 
de Fost et al. (2008) reported an abnormal free light chain ratio in all three of their 
GD patients that had or subsequently progressed to malignant disease81. In contrast, 
only 1/9 of their patients with MGUS had an abnormal kappa/lambda ratio.  
 
M-band size, IgA isotype, the percentage of bone marrow plasma cells and an 
abnormal free light chain ratio are risk factors predictive of progression to multiple 
myeloma from MGUS380. An American based study showed that approximately 1% 
of MGUS patients per year develop multiple myeloma203. It is unknown at present 
whether these risk factors or if specific cytogenetic abnormalities are able to predict 
for transformation to malignant disease in those with GD. Data capture should be 
encouraged via collaborative registries to detail disease characteristics and the 
natural history of those with plasma cell disorders.      
 
Kappa light chain expressing paraproteins are more common than lambda in non-GD 
populations200;201. In the RFH GD cohort there was a small predominance of kappa 
light chain containing paraproteins (6κ:5λ). Nine out of the ten Gaucher patients, 
reported above, had IgG paraproteins, which is the most frequent isotype in non-GD 
patients with either MGUS or multiple myeloma201. No patient with GD had an IgM 
paraprotein, although, this observation maybe limited due to the low number of 
individuals with a monoclonal band (n=10). An IgM paraprotein, in two population 
studies in non-GD patients, was reported to be the monotypic immunoglobulin in 17-
23.7% of individuals200;201. Combining the RFH patients with published cohorts of 
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GD patients with paraproteinaemia, an IgM band was found in 4/31 (12.9%) 
individuals74;81;138;139.  Patients with IgM MGUS are more likely to progress to Non-
Hodgkin Lymphoma (NHL), chronic lymphocytic leukaemia (CLL), 
lymphoplasmacytic lymphoma or AL-amyloidosis, than myeloma211;380. 
Speculatively, if GD patients are more prone to non-IgM plasma cell clones, then the 
probability of progressing to multiple myeloma is higher. Multiple myeloma, in most 
cohorts, has been reported to be increased in GD78;129;130. However, whether GD 
leads to an increased incidence of NHL is debatable65;129;381.    
 
It was hypothesised that severity markers, including the ZSS, were predictive for 
gammopathy in GD. In support of this, ERT naïve patients with an M-band had a 
higher ZSS (12.2±5.3; mean±SD) than those with polyclonal gammopathy (8.9±4.2). 
In contrast, others have failed to demonstrate a higher ZSS in GD patients with 
monoclonal gammopathy81. However the ZSS was identical in GD patients with 
polyclonal gammopathy and normal immunoglobulins.  Criticisms of the Zimran 
score include its insensitivity to reflect disease reduction with disease modifying 
therapy. The Zimran score was published in 1989 and was intended to predict the 
clinical severity of GBA1 genotypes in the pre-ERT era104. Newer severity indexes, 
incorporating scoring domains for biomarkers and the incorporation of modern 
imaging modalities, may prove more sensitive in identifying individuals at risk of 
gammopathy (e.g. GauSSI-I score)106, including malignant disease. 
  
In an Israeli based study, measures of disease severity did not predict for the 
development of gammopathy43, although blood biomarkers were not included in their 
analysis. Based on the data reported above, biomarkers including chitotriosidase 
activity, ACP, S-ACE and platelet count were more deranged in ERT naïve 
individuals with gammopathy than those with normal immunoglobulins. 
Furthermore, chitotriosidase activity remained predictive for gammopathy 
(monoclonal plus polyclonal) in individuals that had received ERT for a median of 9 
years. These data, for the first time, suggest that gammopathy is more common in 
severely affected individuals, and are in support of the chapter hypotheses. In 
contrast, untreated individuals with a paraprotein (n=10), perhaps due to low patient 
numbers, did not have significantly higher chitotriosidase activity (mean±SD; 
paraprotein 8134±5743; normal immunoglobulins 5436±4120; p=0.14) than those 
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with normal immunoglobulins. S-ACE, chitotriosidase and acid phosphatase are 
secreted by macrophages in GD, secondary to lysosomal dysfunction24. The ability of 
GD derived macrophages/osteoclasts to support plasma cell growth and expansion is 
explored in chapter 4.  
 
Pratt et al. (1968) suggested that disease bulk (organomegaly) predicted for 
polyclonal gammopathy138. Although, their cohort of GD patients with hepato-
splenomegaly had, in addition, evidence of either aseptic necrosis or chronic 
infection. However, both infection and inflammation are known causes of polyclonal 
gammopathy, casting doubt on this conclusion328. Macrophages are known to be 
more prominent in the bone marrow of non-GD patients with multiple myeloma and 
have been demonstrated to support plasma cell survival in culture245. Bone marrow 
rather than extra-medullary macrophage burden, due to plasma cell co-localisation, 
maybe more important aetiologically. In keeping with this line of argument, in an 
American cohort, N370S homozygosity was associated with a high incidence of both 
skeletal disease and multiple myeloma52. In the RFH cohort, infiltrates of 
macrophages, of upto 50%, have been reported in the bone marrow of GD patients 
with paraproteinaemia.  
 
Serum ACP was found to be higher in the RFH cohort with gammopathy compared 
to individuals with normal immunoglobulins and in those with a paraprotein 
compared to patients without. Tartrate resistant acid phosphatase (TRAP), a specific 
acid phosphatase, is secreted by osteoclasts derived from the monocytic lineage and 
is a biomarker of disease severity in GD86. GD patients have clinical evidence of 
osteoclastic over-activity242 and osteoclasts have been shown to support plasma cell 
growth in vitro252. Osteoclasts are more prominent in the bone marrow of non-GD 
patients with myeloma262. It is currently unknown whether elevated serum TRAP is 
predictive for gammopathy in GD. Hypotheses pertaining to the superior ability of 
GD macrophages to undergo osteoclastic differentiation and to support plasma cell 
survival, are explored in chapter 4, using co-culture models.  
 
Ferritin, another biomarker of disease severity in GD24, was equivalent in those with 
and without gammopathy (monoclonal or polyclonal). Serum ferritin levels however 
are modified by other variables, including prior transfusion, gender, concomitant 
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inflammation, iron deficiency, infection and chronic disorders, such as 
rheumatological disease and renal failure382. 
 
Paired data, reported above, demonstrated a reduction in the absolute levels of IgM, 
IgA and IgG following a minimum of 12 months ERT (median treatment period, 9 
years), supporting the hypothesis that disease burden drives gammopathy. In 
addition, the number of individuals with elevated IgM or IgG levels decreased with 
ERT. These findings are in keeping with the results of others who reported a 
reduction in the incidence or level of gammopathy with ERT43;234;235. Macrophage 
derived biomarkers (S-ACE, ACP and chitotriosidase activity) were shown here to 
be elevated in treatment naïve individuals with gammopathy. IL-6 and IL-10, plasma 
cell supporting cytokines, are secreted by activated macrophages24. A study, reported 
by de Fost et al. (2008), demonstrated that the majority of GD patients with a 
monoclonal band had elevated IL-10 but normal IL-6 levels81. In contrast, other 
investigators have demonstrated higher plasma IL-6 levels in GD patients with 
monoclonal gammopathy74. Enzyme replacement has been shown, in a study by 
Allen et al. (2007), to reduce IL-10 levels, but not the plasma concentration of IL-
674.  
 
If polyclonal gammopathy pre-disposes to a plasma cell clone, due to chronic 
stimulation, then the development of a monoclonal band should be less common in 
the ERT-era. In the RFH cohort, only patient 2 developed a monoclonal band whilst 
receiving ERT. In a Dutch cohort, no patient with GD developed a paraprotein on 
treatment81. Accept for patient 8, in the RFH cohort, who already had a large 
monoclonal band >30g/l, the level of paraproteinaemia remained stable on ERT.  In 
the face of an aggressive plasma cell clone, the introduction of enzyme replacement 
may be insufficient to prevent progression. Malignant disease developed in 2/12 
Dutch patients whilst on ERT, although they were on treatment for only a short 
period of time81. The level of paraproteinaemia, in an Israeli based study, did not 
regress with ERT43, in keeping with our findings. This discussion raises important 
issues, including financial, regarding paraproteinaemia being an indication for ERT 
in GD.    
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It has been hypothesised that chronic inflammation/immune stimulation leads to the 
development of polyclonal gammopathy in patients with GD162. Several other 
inflammatory disorders including malignancy (haematological and non-
haematological), liver disease, chronic infection and rheumatological disease have 
been associated with a persistent elevation in serum immunoglobulins328. In fact, in 
the study performed by Dispenzieri et al. (2001), liver disease was the most frequent 
cause of polyclonal gammopathy. Due to insufficient clinical data, liver volume (or 
spleen volume) was not correlated with the presence of gammopathy in the RFH 
cohort. Furthermore, it is unclear if chronic immune stimulation and polyclonal 
expansion pre-disposes to clonal plasma cell expansion. In a cohort of non-GD 
patients with polyclonal gammopathy, no individual developed a paraprotein (n=148) 
after a median follow-up of approximately 6½ years328. Data capture was, however, 
incomplete as 37% of participants were lost to follow-up.  
 
Rheumatoid arthritis (RA), a chronic inflammatory disorder, characterised by joint 
destruction and enhanced autoimmunity, has been suggested to confer an elevated 
risk of multiple myeloma in a retrospective study383. Bi-clonal paraproteins have 
been reported in 9.5% (n=21)329and 23% (n=13)81 of patients with rheumatoid 
arthritis and type I GD, respectively. In comparison, in the general population, bi-
clonal bands have been reported to occur in about 3% of individuals with a 
paraprotein201. In the RFH cohort of GD patients, only one individual had bi-clonal 
gammopathy (10%; 1/10). In two patients with an established IgG paraprotein, a 
polyclonal increase in IgA was also present prior to the introduction of ERT. The fact 
that patients with GD and RA are prone to gammopathy, monoclonal or polyclonal, 
in more than one immunoglobulin class, supports hypotheses relating to the 
emergence of plasma cell clones secondary to polyclonal stimulation.  
 
It was hypothesised that residual glucocerebrosidase activity may be able to predict 
which individuals develop gammopathy. Baseline glucocerebrosidase activity, in the 
RFH cohort of GD patients, did not correlate with the development of gammopathy 
(monoclonal or polyclonal). However, residual enzyme activity and genotype are not 
reliable predictors of clinical severity in GD28;384.  In neuronopathic patients with GD 
(L444P/L444P), clinical phenotype varied considerably, in addition to fibroblast 
glucocerebrosidase activity (1-13.3% of control)56. Many individuals with 
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homozygous N370S disease remain clinically silent, in contrast to others who present 
with rampant disease52. Overall N370S/L444P is considered a more severe genotype 
than N370S/N370S. Despite this, in one small study, residual enzyme activity was 
found to be lower in those with N370S/N370S (n=4) than individuals with 
N370S/L444P (n=4)385.  Furthermore, glucocerebrosidase activity may not predict 
for storage load as other variables may have a modifying affect. For example, natural 
variations in the activity of catabolic pathways involved in the breakdown of either 
globoside or GM1-ganglioside24 would reduce glucosylceramide accumulation. In 
addition, decreased ceramide glucosyltransferase activity or increased 
glucosylceramide deacylase activity would alleviate glucosylceramide deposition.  
 
Specific genotypes did not predict for the development of gammopathy, monoclonal 
or polyclonal, in the RFH cohort. N370S homozygosity is the commonest genotype 
reported in the Gaucher registry28. However, there were more individuals with 
N370S/L444P than N370S/N370S in the paraprotein group, reported above. The 
converse was true in those without monoclonal bands with N370S/N370S being 
more common. This observation is limited by the fact that two of the patients with a 
paraprotein were brothers with the same genotype (N370S/L444P). The co-
inheritance of other cancer genes, pre-disposing to gammopathy, in these siblings, 
could not be excluded.  
 
Splenectomy, secondary to traumatic aetiology, in non-GD individuals, does not 
confer an elevated risk of malignancy386. The incidence of splenectomy within a 
combined German/Dutch cohort of GD patients, was found to be equivalent between 
those with cancer (n=14), including haematological, and those without (n=117)78. 
Prior splenectomy was not a risk factor for the development of gammopathy, 
monoclonal or polyclonal, in the RFH cohort. In keeping with the report of de Fost et 
al. (2008)387, the number of asplenic individuals was similar in those with and 
without a blood paraprotein. In an early report from the pre-ERT era, splenectomy 
was suggested to be less common in those with gammopathy (splenectomy rate; 4/6 
individuals with normal immunoglobulins, 1/10 with gammopathy)138. Compared to 
other GBA1 genotypes, multiple myeloma has been shown to be increased in those 
with homozygous N370S disease52. Interestingly in this report, 88.3% of individuals 
with N370S/N370S had an intact spleen, compared to 61.5% of those with other 
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genotypes (p<0.0001). Skeletal disease rather than visceral bulk, has been reported to 
be the predominant clinical phenotype in individuals with homozygous N370S 
disease52. These findings add credibility to hypotheses regarding abnormalities 
within the bone marrow microenvironment being critical to the development of 
plasma cell neoplasms in GD.    
 
It has been reported that splenectomy leads to decreased IgM levels in patients with 
type I GD162 . In fact, in patient 8, reported here, splenectomy was associated with an 
impressive decrease in the level of paraproteinaemia, 55g/l to 34g/l. Splenomegaly is 
a common clinical finding in patients with GD28. The spleen is a major lymphoid 
organ and exposes circulating blood cells continuously to processed antigen, foreign 
or self, by antigen presenting cells in organised follicles. In GD, the spleen is 
infiltrated by both Gaucher cells and inflammatory immune cells24. Accumulated 
glucosylceramide has been reported to contribute to less than 2% of the excess 
weight in splenectomised organs from those with GD24. It is currently unclear 
whether deposition of extra-cellular sphingolipid is responsible for the development 
of a polyclonal plasmacytosis in GD. However, glucosylceramide deposition, in a 
L444P mouse model, was not demonstrated, despite the development of 
gammopathy330. Shoenfeld et al. (1982) showed that lymphocytes from patients with 
GD, using a migration inhibition factor test, were able to be stimulated by either 
glucosylceramide or by splenic homogenates from those with GD162. They 
hypothesised that chronic immune stimulation was responsible for the elevated 
incidence of gammopathy in GD. Glucosylceramide has been shown to stimulate 
macrophages in culture388. This is in keeping with the findings reported in this 
chapter correlating disease severity to the presence of gammopathy.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
 
In addition, splenectomy leads to the removal of a mass of stimulated immune cells, 
conferring an immediate reduction in antigen presenting cells and the capacity to 
produce pro-inflammatory cytokines. B-cell proliferating cytokines, such as IL-6 and 
IL-10, have been reported inconsistently by investigators to be elevated in the blood 
of those with GD74;81. Gaucher cells, however, have been suggested to manufacture 
little IL-6 or IL-1058. Plasma IL-6 and IL-10 levels have been reported to be identical 
in asplenic GD patients and those with an intact spleen74, although in this study 11/22 
individuals were receiving ERT. Plasma cells are rarely seen in the peripheral blood, 
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but may occur in the presence of immune stimulation, infection or plasma cells 
neoplasms59.  Alternatively, in patient 8, it could be hypothesised, that clonal plasma 
cells, due to splenic sequestration, were de-bulked at splenectomy. MacDonald et al. 
(1975)389 reported the case of a 48 year old GD patient with bi-clonal gammopathy 
(IgG and IgA) and low blood counts secondary to hypersplenism. A fortnight post 
splenectomy, her IgA band had reduced by 50% but the IgG paraprotein remained 
stable. Further analysis revealed a large population of IgA-restricted plasma cells in 
the spleen, with a minor infiltrate of IgG-restricted plasma cells. The converse was 
found on bone marrow examination, with IgG-restricted plasma cells pre-
dominating. The focal development of a plasma cell clone in the spleen does not 
necessarily support the concept of chronic antigenic stimulation, as extra-medullary 
haematopoiesis is known to occur in GD390.  
 
It was hypothesised that patients with Multiple Myeloma and GD may share similar 
disturbances in cellular biology, including macrophage pathology. As described 
above here, individuals with GD have infiltrates of foamy macrophages on bone 
marrow examination. Previously, an elevated number of bone marrow macrophages 
have been reported in non-GD patients with myeloma245. Boven et al. (2004), based 
on splenic histocytochemistry, suggested Gaucher cells to have the cytokine profile 
of alternatively activated macrophages. They demonstrated that Gaucher cells have 
weak expression of both pro-inflammatory and B-cell proliferating cytokines, 
including IL-6 and IL-1058. It could be argued, however, that Gaucher cells, despite 
weak expression of B-cell proliferating factors, due to their accumulated mass, lead 
to a net increase in the secretion of these cytokines. This is unclear based on 
conflicting data from several studies measuring plasma levels81, but focal increases 
within the bone marrow micro-environment cannot be excluded and have not be 
studied in GD. It is unknown from the literature whether Gaucher cells within the 
bone marrow have a similar Th2 expressing cytokine profile to those in the spleen. 
As described above, individuals with GD and gammopathy have a higher mean 
chitotriosidase activity than those with normal immunoglobulin analysis. This 
finding is suggestive of macrophage bulk being a risk factor for the development of 
gammopathy. Alternatively, it could be argued, that elevated chitotriosidase activity, 
reflecting disease severity83, correlates with increased glucosylceramide deposition, 
inflammation or other immune defects, capable of facilitating plasma cell expansion.    
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Based on plasma chitotriosidase activity, non GD-patients, with plasma cell 
disorders, including multiple myeloma and MGUS, do not share the same spectrum 
of macrophage pathology as those with GD. In fact non-GD patients with multiple 
myeloma have similar plasma activity to an aged-matched population. As reported 
above, compared to healthy controls, macrophages accumulate in the bone marrow of 
non-GD patients with myeloma and may represent up to 10% of all cells245. Data 
reported above, however, did not control for null chitotriosidase genes. Assuming 
that all non-GD patients were heterozygotic for a null mutation, chitotriosidase 
activity would have only been marginally raised above the normal range for elderly 
individuals89. Chitotriosidase activity was found to increase with age, in keeping with 
the findings of other investigators89. Approximately one third of individuals are 
heterozygotic for a null chitotriosidase mutation with an additional 6% of the general 
population being homozygous for inactivating mutations357. A further criticism of the 
results reported here is that plasma chitotriosidase activity was not determined at 
baseline in all non-GD patients with multiple myeloma and therefore may not 
represent peak enzyme activity. Myeloma chemotherapy may be toxic to 
macrophages and could be postulated to have lead to a reduction in macrophage 
activity in vivo of treated patients. In addition, due to the decreased turnover of dead 
cells as chemotherapy progresses, the macrophages of treated individuals may have 
less apoptotic cells to digest and less saturated glucocerebrosidase activity. However, 
chitotriosidase activity was not elevated in individuals at presentation, relapse or 
with refractory disease in this cohort.    
 
Gaucher cells, based on electron microscopic examination, have been shown to have 
a different ultra-structure to the foamy macrophages present in the bone marrow of 
patients with haematological cancer (Pseudo-Gaucher cells)358. Monocytes, 
macrophage precursors, based on flow cytometric assay, had equivalent 
glucocerebrosidase activity in healthy controls compared to non-GD patients with 
plasma cell dyscrasias (malignant or benign). Thus, non-GD patients with plasma 
cell disorders do not acquire a secondary deficiency in glucocerebrosidase activity. 
However, these results do not exclude the development of secondary enzyme 
deficiency in tissue macrophages that have a longer life span391. In-situ hybridisation 
of bone marrow trephines for glucocerebrosidase mRNA would provide further 
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information to investigate this hypothesis. Tissue macrophages have significant 
phagocytic activity and have been shown to polarise towards a phenotype associated 
with alternatively activated macrophages by glioma cancer stem cells392. Therefore, 
peripheral monocytes or macrophages, extrinsic to the primary tumour, may not 
develop the same biochemical abnormalities or cytokine profile as those abutting 
malignant growths.   
 
Jewish patients without GD but with a plasma cell disorder, compared to healthy 
controls or non-Jewish individuals with MGUS or multiple myeloma, had identical 
plasma chitotriosidase activity and monocyte glucocerebrosidase activity. Therefore, 
being of Jewish ancestry seems not to be a risk factor per se for developing 
biochemical abnormalities in the monocytic lineage consistent with GD. Jewish 
patients included in these results were confirmed to be negative for GBA1 mutations. 
Due to the founder effect, there is an increased incidence of specific mutations in 
BRCA1/BRCA2148, conferring an elevated risk of breast and gynaecological cancer, 
in Ashkenazi Jews. In addition, certain mutations in MSH2 and APC393, imparting an 
elevated risk of colorectal cancer, are reported in the Ashkenazi Jewish population. It 
is unclear, at present, whether GBA1 is an additional cancer gene within this 
population. In addition, although individuals with GD have an elevated incidence of 
myeloma130;287, it is unknown whether these individuals co-inherit additional cancer 
genes conferring an elevated risk of multiple myeloma. Speculatively, homozygosity 
for GBA1 mutations alone may be insufficient to confer an elevated risk of 
malignancy, including clonal plasma cell disorders, in those with GD. GBA1 is 
located to the long arm of chromosome 1 and abnormalities of chromosome 1q are 
not uncommon in individuals with multiple myeloma394. One study demonstrated a 
gain of chromosomal material to 1q in approximately 50% of patients with multiple 
myeloma, raising speculation of a tumour promoter gene394. It could be hypothesised 
that due to gene linkage the GBA1 locus is co-inherited with additional tumour 
promoter genes or oncogenes that confers the observed elevated risk of malignancy 
in GD. If GBA1 heterozygosity was associated with an elevated risk of monoclonal 
gammopathy, then this hypothesis would warrant further investigation.      
 
Although, the ViennaLabs® strip test is an economical and time efficient method for 
GBA1 mutation screening, there have been reports within the literature of false 
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positive results with Gaucher diagnostic kits utilising impregnated oligonucleotide 
probes395. In addition, there are more than 300 reported mutations within the GBA1 
gene and this kit detects only 1027. Using this strip-test, based on 635 individuals 
with non-neuronopathic disease from the International Collaborative Group Gaucher 
Registry, approximately 9% of mutant alleles would go undetected33. Moreover, in 
the first 4 Jewish patients screened for GBA1 mutations using the striptest, one 
heterozygote and one compound heterozygote was identified. For these reasons, it 
was justifiable to employ an alternative screening strategy. In order to increase the 
detection of GBA1 mutant alleles, a combination of DNA sequencing (exons 5-11) 
and allele specific PCR (IVS2+1 plus 84GG, exon2) were employed. Despite 
recruiting from 4 NHS trusts serving large populations of Jewish patients, only 163 
individuals were identified from electronic hospital databases based on recorded 
demographics (religion/ethnicity).  In total, 92 patients gave informed consent of 
which 77 had successful GBA1 analysis. The concurrent treatment of a subset of 
individuals with chemotherapy may have contributed to the inability to isolate DNA 
of sufficient quality for analysis. The number of expected patients with a paraprotein, 
per London borough, assuming a 3% incidence of MGUS in those >50 years, is 
shown in Table 3-10. Census data in 2001 reported 41% of the Jewish population in 
London to be >50 years in age (Piggott and Lewis 2006). 
 
London Borough Jewish Number 
(2001 Census) 
Number >50 
years in age 
Expected number 
with a paraprotein 
(>50 years)  
Camden 11,153 4,572 137 
Redbridge 14,796 6,066 182 
Harrow 13,112 5,376 161 
Barnet 16,686 6,841 205 
Brent 6,464 2,650 80 
Enfield 5,336 2,188 66 
 
Table 3-10. Expected number of Jewish patients >50 years with a paraprotein per London 
Borough. 
 
The four participating NHS trusts, in this study, would have served the majority of 
Jewish patients in the London Boroughs listed in Table 3-10. In total 831 Jewish 
individuals with a paraprotein, aged >50 years, are estimated to be present within 
these boroughs. In total, assuming these parameters, we identified 20% (161/831) of 
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those with a monoclonal band. This may not be surprising as the majority of the 
population with an M-band are well and speculatively remain clinically silent. In 
addition, ethnicity and religion are often poorly recorded in both patient notes and 
electronic demographic databases. Individuals with a paraprotein, in the hospital 
setting, are likely to be skewed towards those with malignant disease or are identified 
inadvertently post investigation of an alternative co-morbidity.  
 
The fact that only 161 individuals were identified may reflect that GBA1 
heterozygotes are not at an elevated risk of monoclonal gammopathy. Mutated GBA1 
alleles were not increased in 77 Jewish individuals with a paraprotein. However, this 
study had insufficient statistical power, as described above in section 3.3.4.2, to 
reject the null hypothesis. In comparison, an association of GBA1 carrier status and 
idiopathic Parkinson’s disease, has required cohorts of at least 300 people to 
demonstrate an association396;397. Using the observed GBA1 mutation frequency 
reported here (8/77), compared to a 1:12 carrier rate, would require the screening of 
1347 Jewish patients (http://www.swogstat.org) with a monoclonal band to reject the 
null hypothesis (Statistics performed by Richard Morris in the Department of 
Primary Care and Population Sciences, Royal Free Hospital).  
 
Interestingly, patient A in the screening study reported here had Parkinson’s disease 
and MGUS. As discussed above, GBA1 heterozygosity is associated with an 
increased risk of idiopathic Parkinson’s disease352.  
 
Patient B, diagnosed with myeloma, was found to be a compound heterozygote for 
N370S/R496H. However, she was in her 7th decade, had no visceral disease and 
Gaucher cells were absent on staging bone marrow examination. As described above, 
clinical penetrance is variable and many individuals, like patient B, will remain 
clinically silent unless investigated for an alternative co-morbidity. However, given 
the frequency of GBA1 mutations in Ashkenazi Jews, all patients presenting with a 
paraprotein should be assessed for the possibility of GD. Currently, it is unclear 
whether GD patients with a paraprotein, who fail to meet traditional treatment 
criteria, should receive ERT66. However, as demonstrated in the RFH cohort of GD 
patients, with the exception of patient 8, ERT seems to prevent elevation in the 
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paraprotein level. This is keeping with the findings of Brautbar et al. (2004)43. 
Patient B remains untreated, for GD. 
 
Patient 6, a N370S heterozygote, warrants further discussion, as he had IgD multiple 
myeloma and presented with a thoracic plasmacytoma. IgD is an infrequently 
expressed isotype in multiple myeloma with few case reports in the literature398 and 
has been suggested to occur with a frequency of <0.5%399. IgD myeloma is 
associated with a poor prognosis and frequently presents with renal failure and 
amyloidosis400.  This gentleman, however, remains in plateau since treatment in 
2008. Whether the incidence of rare myeloma phenotypes, including IgD, IgE and 
non-secretory neoplasms, are increased in those with GD is unknown. Prior reports, 
including non-secretory IgD myeloma156 and multiple hepato-splenic 
plasmacytomas163 complicating GD, are present in the literature. However, rare 
presentations of plasma cells disorders, in GD, are more likely to be reported than 
those with more conventional presentations.  
 
Patient 8 with AL-amyloidosis was found to be a carrier of an E326K mutation. It 
has been debated whether this GBA1 allele is a polymorphism or a disease-causing 
mutation401.  GBA1 mutation analysis demonstrated the presence of E326K in 4 
patients with GD (Type I, II and III; n=155)401 but only in combination with an 
additional disease causing mutation in the same allele. E326K containing alleles in 
GD patients have been found to have an equivalent incidence as that found in a non-
GD control population. A baculovirus expression system, using insect derived Sf9 
cells, showed that the E326K allele led to an approximately 60% reduction in 
glucocerebrosidase activity compared to wild type402.  Chabas et al. (2005) reported 
the frequency of E326K in a Spanish population of GD patients. They reported 
E326K to be present in approximately 40% of individuals with type II disease as part 
of a complex allele containing an additional mutation and speculated that it was a 
genetic modifier conferring increased disease severity. In the same expression 
system, the L444P/E326K allele led to lower enzyme activity than Sf9 cells 
expressing L444P alone402. Carriage of an E326K allele was not uncommon in a 
study screening for GBA1 mutations in a predominately non-Jewish population of 
Parkinson’s disease patients375. It has been hypothesised by Velayati et al. (2010) 
that mutant GBA1 alleles, in the heterozygotic state, can lead to proteasomal 
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dysfunction secondary to ER stress352.  It is unknown whether the E326K allele could 
lead to similar organelle dysfunction.  
 
All Jewish patients with a paraprotein, that were identified to have GBA1 mutations, 
were currently in at least their 7th decade of life. Therefore GBA1 mutations seemed 
not to pre-dispose to monoclonal gammopathy at an earlier age. In contrast 4/10 GD 
patients in the RFH cohort developed a paraprotein prior to their 5th decade. Most 
individuals identified with a GBA1 mutation had MGUS  
 
In conclusion, this study continues to recruit, but currently lacks sufficient statistical 
power to refute the null hypothesis that carriage of a GBA1 mutation pre-disposes to 
monoclonal gammopathy. Biomarkers of disease severity including chitotriosidase 
activity and serum ACE are higher in GD patients with gammopathy than those with 
normal immunoglobulins. These are macrophage-derived biomarkers and the 
hypothesis that lipid laden Gaucher cells support plasma cell growth and survival 
using cell culture-based models is further explored in chapter 4. Non-GD patients 
with plasma cell dyscrasias do not exhibit the same pattern of macrophage activation 
as that seen in GD. Alternatively, as disease severity predicts for gammopathy, other 
disturbances in innate or adaptive immunity, outside of the monocytic lineage, may 
confer an increased susceptibility to myeloma. This hypothesis is investigated in 
chapter 5. Currently, the International Gaucher Registry has inadequate data capture 
to record clinical information on GD patients with plasma cell disorders. By 
promoting the central collection of data pertaining to GD patients with myeloma or 
MGUS, several outstanding questions may be answered. These include:- 
 
1. Should all GD patients with a paraprotein be treated with ERT?  
2. Should all GD patients with myeloma be treated with ERT?  
3. Do GD patients with myeloma respond to chemotherapy as well as those 
without GD? 
4. Do patients with GD tolerate chemotherapy as well as those without GD?  
5. Do GD patients on ERT with myeloma respond better to chemotherapy? 
6. Is there a role for intensification of disease modifying therapy, including 
combined ERT/SRT treatment, in GD patients with multiple myeloma? 
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Although, there are several case reports speculating the answers to these questions, 
firm consensus and evidence is lacking.  
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4 IN VITRO MYELOMA CELL CO-CULTURE 
EXPERIMENTS 
4.1 INTRODUCTION 
The understanding of tumour biology in multiple myeloma has expanded over the 
past two decades, with a body of research focusing on the bi-directional relationship 
between plasma cells and the local bone marrow microenvironment. In vitro models 
have demonstrated a growth and survival advantage of primary or immortalised 
myeloma cells co-cultured on stromal or osteoclast monolayers252;259. Both 
macrophage and osteoclast cultures have been shown to protect chemotherapy 
treated myeloma cells from apoptosis245;303. Experimental models have also 
demonstrated an increase in osteoclastogenesis following co-culture with myeloma 
cells302.   
 
Skeletal disease, including osteopenia and lytic lesions, are common clinical findings 
in both GD and myeloma, suggestive of osteoclastic over-activity28;403. As 
demonstrated in chapter 3 and previously in the literature158, patients with GD have 
large infiltrates of foamy macrophages abutting plasma cells on bone marrow 
examination. Macrophages have also been shown to be more prominent in the bone 
marrow trephines of non-GD patients with myeloma compared to those with MGUS, 
implicating a role for these monocytic-derived cells in the development of plasma 
cell dyscrasias245. The pathological mechanisms underlying the development of 
gammopathy in GD are unknown and likely to be multi-factorial. Abnormalities 
within the bone marrow environment, including macrophage accumulation, 
deposition of extracellular glucosylceramide, chronic immune stimulation, elevated 
B-cell proliferating cytokines and impaired tumour surveillance are all speculated to 
play a role66;74;81;133;138;234;335. The hypothesis explored in this chapter is that the GD 
bone marrow microenvironment is more permissive to plasma cell growth and 
survival compared to those without GD. 
 
Chemoresistance is a challenge in the treatment of multiple myeloma. Currently it is 
not possible to predict which patients will respond to a particular chemotherapy 
regimen. Inter-individual differences in drug kinetics and acquisition of protective 
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mechanisms within the malignant cells themselves (drug efflux pumps, p53 
mutations) alter the sensitivity of malignant cells to chemotherapy404. Cytogenetic 
abnormalities including t(4;14), 17p-, t(14;16) and t(14;20) predict for an inferior 
treatment outcome to traditional chemotherapeutic agents. Translocations involving 
chromosome 14 couple the IgH enhancer gene with the fibroblast growth factor 
receptor 3 [FGFR3; t(4;14)], multiple myeloma SET domain gene [MMSET; 
t(4;14)], MAF oncogene [t(14;16)] and MAFB gene [t(14;20)]405. Mechanistically, 
these cytogenetic aberrations enhance plasma cell proliferation and survival. The loss 
of chromosomal material on 17p- is associated with down-regulated p53 activity (a 
tumor suppressor protein). Novel agents, including bortezomib and lenalidomide, 
have been suggested to overcome some of these poor prognostic variables including 
t(4;14)405.  
 
Additionally, the local bone marrow environment modulates chemoresistance, thus 
promoting research into the effects of anti-myeloma therapies on the non-tumour 
component. Thalidomide, lenalidomide and bortezomib have all been shown to 
inhibit osteoclastogensis307-309.  The bisphosphonate zoledronate, an inhibitor of 
osteoclastogenesis, has been shown to alter survival in newly diagnosed patients with 
multiple myeloma (Morgan et al, European Haematology Association abstract book, 
Barcelona, 2010).  In vitro studies have shown that zoledronate retards plasma cell 
growth and induces the apoptosis of both myeloma cell lines and IL-6 producing 
human stromal cells406.  
 
4.1.1 APOPTOTIC PATHWAY 
Primary myeloma cells have a low proliferation rate and their accumulation over 
time may be secondary to a biological phenotype consistent with survival. Apoptosis 
is associated with a distinct pattern of morphological features, including nuclear 
condensation, membrane blebbing, chromatin clumping and the presence of an 
apoptotic body407. Apoptosis may be activated via either the intrinsic or extrinsic 
death pathways. Binding of TNFα, TRAIL or FAS ligand to their respective 
transmembrane death receptors activates the extrinsic pathway, resulting in the 
cleavage of caspase-8 (Figure 4-1). Bid, a pro-apoptotic protein, is cleaved by 
caspase-8 to a truncated form that then activates the intrinsic pathway408.  
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Irradiation or chemotherapy leads to cell death mainly through the intrinsic 
pathway409. The intrinsic pathway, or mitochondrial-mediated pathway, is composed 
of a rheostat of regulatory proteins. The Bcl-2 family of related proteins includes 
both pro-apoptotic (Bid, Bik, Bim, Bax, Bak) and anti-apoptotic proteins (Bcl-2, Bcl-
xL, Bcl-w and Mcl-1)408. These play a pivotal role in regulating the release of 
mitochondrial derived cytochrome c. Once a cell is committed to death, pro-
apoptotic factors such as cytochrome c are released from mitochondria resulting in 
the activation of a cascade of caspases. Activation of effector caspases leads to the 
proteolytic cleavage of several proteins, including poly (ADP ribose) polymerase 
(PARP), DNA-dependent protein kinase and protein kinase C-delta in the terminal 
stages of cell death407;408;410;411. PARP is an 116kDa intra-cellular protein and is 
involved in DNA repair, which is heavily dependent on the consumption of ATP. In 
dying cells, where DNA damage is extensive, PARP is inactivated by proteolytic 
cleavage in order to preserve energy for adjacent cells that are either viable or 
salvageable from death.    
 
Bcl-2, the first anti-apoptotic protein to be described, is over-expressed in follicular 
lymphoma due to the t(14;18) chromosomal translocation. Other lymphoid tumours, 
including multiple myeloma and diffuse large B-cell lymphoma (DLBCL) have been 
shown to over-express Bcl-2 in the absence of chromosomal rearrangements412. 
DLBCL has an inferior prognosis in the face of Bcl-2 over-expression413. Bcl-2 anti-
sense therapy maybe of benefit in the treatment of patients with myeloma, chronic 
lymphocytic leukaemia and non-Hodgkin lymphoma414. The over-expression of Bcl-
2 in multiple myeloma has been correlated with disease stage and may be a risk 
factor for extra-medullary disease415;416. Mcl-1, an anti-apoptotic protein, has been 
shown to be upregulated in malignant plasma cells, as demonstrated by flow 
cytometry, and is associated with an inferior event-free survival417. Levels of Bcl-xL 
did not correlate with clinical outcome in one study418. However, Bcl-xL expression, 
as assessed on trephine biopsy, predicted for an inferior response to induction 
chemotherapy and was more prevalent at relpase419.  Linden et al. (2004) developed 
a transgenic mouse model that over-expressed Bcl-xL in the B-cell lineage, under the 
regulation of the kappa light chain enhancer. These mice had elevated serum 
immunoglobulin levels, foci of plasma cells within their bone marrow together with 
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hyaline casts in the kidneys420. Pro-apoptotic proteins such as Bim, PUMA, tBid, 
Bad and Noxa regulate the activity of many of the anti-apoptotic proteins involved in 
the mitochondrial death pathway, including Bcl-2, Bcl-xL and Mcl-1421. 
Phosphorylation of ERK via activation of transmembrane receptor tyrosine kinases 
leads to the down-regulation of Bim expression422. p53 is a tumour suppressor 
protein and is encoded by a gene on the short arm of chromosome 17. It has a well 
established role in preventing malignancy and in addition, is a key regulator of 
apoptosis, DNA repair and cell cycling423. Chemotherapy can cause apoptosis of 
cancer cells by inducing the expression of p53.411 TP53 mutations in cancers, 
including myeloma, confer a poorer prognosis424. p53 interacts with pro-apoptotic 




Figure 4-1. Pathways of apoptosis. Simplified schematic illustrating the intrinsic/mitochondrial 
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4.1.2 HYPOTHESES 
The following hypotheses are explored in this chapter:- 
 
Hypothesis 1:- GD compared to non-GD derived monocytic cells preferentially 
support plasma cell expansion and survival.  
Rationale:- Co-culture experiments in non-GD patients have demonstrated that 
osteoclasts and macrophages promote plasma cell survival. Osteoclast cultures have 
been shown to expand plasma cells. 
Methods:-  Plasma cell co-culture experiments utilising adherent monolayers 
derived from controls and GD patients. 
 
Hypothesis 2:- GD compared to non-GD derived macrophages/osteoclasts 
protect myeloma cells from chemotherapy induced apoptosis. 
Rationale:- Co-culture experiments of non-GD patients have shown that 
macrophages and osteoclasts reduce the sensitivity of plasma cells to 
chemotherapeutic drugs. Furthermore, there are anecdotal reports of poor responses 
to chemotherapy in GD patients with myeloma. 
Methods:- Plasma cell co-culture experiments utilising adherent monolayers derived 
from controls and GD patients. 
 
Hypothesis 3:- GD macrophages precursors are primed for osteoclastic 
differentiation.  
Rationale:- Plasma cell co-culture promotes osteoclast formation in macrophage 
cultures derived from non-GD patients. Osteoclasts and plasma cells co-localise in 
the bone marrow specimens of non-GD patients and have been suggested to 
reciprocally facilitate the growth and survival of each other. 
Methods:- Plasma cell co-culture experiments utilising adherent monolayers derived 
from controls and GD patients.  
 
Hypothesis 4:- Compared to control cultures, GD derived 
macrophages/osteoclasts are more efficient at preventing apoptosis in myeloma 
cells pre-treated with chemotherapy. 
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Rationale:- Co-culture experiments in non-GD patients have shown that 
macrophages and osteoclasts rescue plasma cells pre-treated with chemotherapy.  
Methods:- Plasma cell co-culture experiments utilising adherent monolayers derived 
from controls and GD patients.
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4.2 METHODS 
These methods are supplementary to those described in chapter 2. 
 
4.2.1 D14-21 CO-CULTURE EXPERIMENTS 
PBMCs, derived from both healthy controls and patients with GD, were isolated and 
plated (0.25x106 total) in 24-well plates as described in chapter 2. Each experimental 
well contained 3 glass inserts that were subsequently stained for TRAP following 
recovery on D21 (osteoclast enumeration). Cells were cultured in 1ml of osteoclast 
(OC) medium (R10, 25ng/ml M-CSF and 30ng/ml RANK-L) for the first 2 weeks 
with twice weekly changes in growth medium. On D14, 3x104 NCI-H929 or 7.5x104 
U266 cells (minimum viability 90%) were added to co-culture wells or grown alone 
for a further 7 days in 3mls of OC medium. Three half medium exchanges (1.5mls) 
were performed during the final week of culture, including on D20. Plasma cells 
were recovered from duplicate experimental wells on D21 by re-suspending the non-
adherent fraction by gentle agitation and washing twice in R10.  
 
4.2.1.1 CONTACT DEPRIVED CO-CULTURE 
Trans-well inserts were used in some experiments to deprive co-cultured plasma cells 
from contact with the underlying osteoclast monolayer. 0.4µm pore polyethylene 
terephthalate coated transwell inserts (Millicell; Millipore, Dundee, UK) were placed 
in 24-well plates. Myeloma cell lines were grown in the upper chamber. Co-cultured 
plasma cells were recovered by gentle re-suspension and washing three times with 
1ml of R10. Bi-polar microscopy confirmed the absence of residual myeloma cells.  
 
4.2.1.2 CO-CULTURE WITH ERT 
Imiglucerase (CerezymeTM, Genzyme Inc., Cambridge, MA), enzyme replacement 
therapy (ERT), was added to Gaucher-derived osteoclast cultures on D1, at a 
concentration of 1unit/ml. Co-culture experiments were otherwise performed 
identically to that described above. Paired wells were cultured in the absence or 
presence of ERT until termination on D21. Aliquots of concentrated imiglucerase 
were stored at -80°C until required.  
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4.2.1.3 CO-CULTURE (D14-21) OUTCOME ASSAYS 
Using the methodology described in chapter 2, plasma cells harvested from co-
culture wells were subjected to GIEMSA staining, trypan blue staining, annexinV/PI 
immuno-staining (0.25-0.5x106 cells) and BrdU/PI analysis (0.5x106 cells). In 
addition, plasma cells were re-suspended at 0.22x106cells/ml and 90µl of cell 
suspension was plated in triplicate in 96-well plates.  Cells were exposed to doubling 
dilutions of doxorubicin or melphalan for 24 hours before undergoing a 4-hour MTT 
dye reduction assay. Glass inserts, harbouring the adherent monolayer, were removed 
carefully with forceps and stained for TRAP as described in chapter 2. 
 
4.2.2 RESCUE OF DOXORUBICIN TREATED U266 MYELOMA 
CELLS 
Osteoclast cultures, GD or control-derived, were grown in 1ml of OC medium with 
two changes of medium per week until D18. U266 cells (0.5x106/ml) were pre-
treated with 0µM, 0.5µM, 1µM, 2µM or 4µM doxorubicin for 6 hours, washed twice 
in PBS and re-suspended in 1ml of OC medium. Drug treated cells were plated on 
monolayers of osteoclasts that had been grown for 18 days or plated alone in 2mls of 
OC medium. U266 cells were then cultured alone or with osteoclasts between D18-
21. All experimental conditions were performed in duplicate. Following this, non-
adherent cells were harvested and counted, analysed by cytospin, stained with 
annexinV/PI (0.25-0.5x106 cells) or plated in a 4 hour MTT dye reduction assay 
(1x104 cells in triplicate).  
 
4.2.3 PLASMA CELL PURITY DETERMINED BY GIEMSA 
STAINING 
Cytospins were prepared from recovered cells by spinning 2.2x104 cells at 400rpm 
for 3 minutes. After drying for 2 hours, slides were fixed in methanol and stained for 
30 minutes in 1:20 GIEMSA solution (Chapter 2). Cultured plasma cells were readily 
identifiable from primary mononuclear cells on D21. Myeloma cells (U266 or NCI-
H929 cell line) have eccentrically placed nuclei, clumped chromatin, densely 
basophilic cytoplasm and a prominent peri-nuclear Golgi zone. Multi-nucleate 
plasma cells were often seen. In comparison, cultured macrophages were larger in 
size and had dusky grey cytoplasm with evident vacuoles. Macrophages also had an 
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eccentrically placed nucleus but the chromatin was less clumped in comparison to 





Figure 4-2. Plasma cell purity was determined morphologically from cytospins of harvested 
cells. Scale bar 100µm. 
 
 
4.2.4 MACROPHAGE CYTOTOXICITY ASSAYS 
4x104 peripheral blood monocytes (CD14+ve/64+ve) were plated in triplicate in 96-
well plates and grown in OC medium. Growth medium was changed twice in week 1 
and on alternative days between D8-18. On day 18, doubling dilutions of 
doxorubicin (0-16µM) and melphalan (0-200µM) were added for 48 hours prior to 
undergoing a 1 hour MTS dye reduction assay as described in chapter 2. 
 
4.2.5 LYSATES FOR WESTERN BLOTTING 
NCI-H929 myeloma cells (4x104 cells) were co-cultured on GD or control derived 
monolayers between D14-21 as previously described. Cells recovered from co-
culture were incubated for 2 hours on tissue culture plastic in order to adhere out 
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contaminating monolayer cells.  Plasma cell purity was determined by Giemsa 
staining. Protein lysates were made from duplicate co-culture wells derived from GD 
patients or healthy controls containing untreated NCI-H929 cells. In addition, lysates 
were made from plasma cells re-suspended in R10 and exposed to 50µM melphalan 
for 24 hours.   
 
4.2.6 HARVESTING ADHERENT MONOLAYER CELLS 
Adherent cells were washed in PBS for 15 minutes at 37°C. Aspirated PBS was 
replaced with a 1ml mixture of lidocaine and EDTA (100mls 0.02M EDTA solution, 
Sigma Aldrich: 10mls 2% lidocaine, Hameln pharmaceuticals) and returned to the 
cell incubator for a further 15 minutes. Cells were then recovered by gentle pipetting. 
Bi-polar microscopy confirmed the complete harvesting of the adherent cell fraction. 
Recovered cells were centrifuged at 300g for 10 minutes and re-suspended in R10. 
Cytospins were prepared. Cell suspension was stained with To-PRO-3 iodide and the 






4.3.1 VALIDATION OF EXPERIMENTAL TECHNIQUES 
Initially described in section 4.3.1 is data validating experimental techniques 
including:- 
o The culture of macrophages/osteoclasts from GD patients and healthy 
controls (culture alone) 
o Experiments validating and optimising the plasma cell/osteoclast co-culture 
model 
o Assays employed assessing myeloma cell line purity, growth, survival and 
chemo-sensitivity in culture alone or post osteoclast/macrophage co-culture 
o Confirmation of the glucocerebrosidase activity of monocytes derived from 
healthy controls and GD patients  
 
4.3.1.1 OSTEOCLAST CULTURE 
Monocytes derived from the peripheral blood of healthy controls and GD patients 
(0.25x106) were grown in osteoclast medium for 3 weeks. Adherent monocytes were 
initially small and spherical but by day 7 had become larger in size and developed 
spindle shaped morphology with polar cytoplasmic projections (Figure 4-3). After 21 
days in culture, there was a mixture of spindle shaped cells and larger multi-nucleate 
forms with abundant cytoplasm. Many multi-nucleate cells exhibited ruffled edges 
and morphologically had the appearance of either mature macrophages or 
osteoclasts. GD cultures demonstrated a larger number of multi-nucleate cells at day 
21 compared to controls. Osteoclasts were distinguished from multi-nucleate 
macrophages by demonstrating TRAP positivity on histo-chemical staining in both 
control and GD cultures. Both control and GD-derived monolayers were successfully 
grown until D21 without noticeable decreases in density or signs of toxicity, 
including cytoplasmic vacuolation, cell fragmentation and floating debris. 
 
In conclusion, it was demonstrated, that peripheral blood monocytes were able to be 























Figure 4-3. Microscopic appearance of cultured macrophages by bi-polar microscopy.  
Bi-polar microscopy demonstrating spindle shaped macrophages at day 7 (A) together with a 
mixture of larger cells with abundant cytoplasm post 21 day culture (B, C). Scale bar 40µm. 
 
 
4.3.1.2 OPTIMISATION AND VALIDATION OF THE CO-CULTURE 
MODEL 
As the co-culture model was developed de novo, many experimental modifications 
were required to address initial methodological problems. The following preliminary 
experiments were carried out in order to optimise the model:- 
 
Harvestable Plasma Cell number  
Approximately 3x106 harvestable myeloma cells were required following co-culture 
in order to complete all out-come measures (cell count, trypan blue, cytospin, 
annexin/PI, BrdU/PI cell cycle and MTT assay).  Prior to recovery, 0.1-1x105 
myeloma cells were plated for 7 days on osteoclast cultures between D14-21. 
Titration experiments demonstrated 3x104 NCI-H929 or 0.75x104 U266 plated cells 
respectively were required to yield the desired cell number from triplicate 
experiments following 7 days co-culture. No difference in recoverable cell number 
was observed between GD and control co-cultures.  
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Growth Medium Exhaustion  
Co-culture experiments (D14-21) using a 1ml working volume led to medium 
exhaustion by D21 for both myeloma cell lines. Further experiments established a 
3ml working volume with three 1.5ml medium changes between D14-21 as optimal. 
In addition, a residual volume buffer of >1ml during medium changes prevented the 
inadvertent aspiration of co-cultured myeloma cells (confirmed visually).   
 
Bi-polar Microscopy  
Myeloma cells were smaller in size and more spherical than the underlying adherent 
monolayer cells (Figure 4-4). Myeloma cells in the first few days of co-culture co-
localised with or formed clusters over the underlying mononuclear cell culture. 
Following 7 days of co-culture, myeloma cell numbers had vastly increased, forming 
sheets of cells. There was no morphological difference, by bi-polar microscopy, 
between control and GD-derived monolayers following 7 days of co-culture.  Cell 
densities over inserted glass coverslips were fairly uniform after 3 weeks incubation, 




Figure 4-4. Bi-polar microscopy of co-cultured U266 myeloma cells on D21.  
(A, B) In comparison to spindle shaped macrophages, U266 myeloma cells are small and form 
adherent clusters to the underlying monolayer. Scale bar 50µm. 
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4.3.1.3 PLASMA CELL PURITY AND CHEMOTHERAPY-INDUCED LOSS 
OF CD138 SURFACE EXPRESSION  
This section investigates the identification, morphologically and by flow cytometry, 
of myeloma cell lines harvested from osteoclast co-culture. It is important to 
establish whether the cell surface expression of plasma cell markers (e.g. CD138) 
remains intact post co-culture or diminishes with chemotherapeutic insult. If the 
expression of plasma cell markers remains intact, then this can be employed to gate 
on the population in flow cytometric assays. 
 
Both the U266 and NCI-H929 myeloma cell lines express CD138 (Sydecan-1) on 
their cell membranes. However, CD38, another common plasma cell marker, was 
absent on the cell surface of U266 cells (see section 2). Preliminary co-culture 
experiments were performed to assess CD138 expression as a surrogate marker of 
plasma cell purity. U266 cells were exposed to various concentrations of doxorubicin 
(0-4µM) for 6 hours, washed and plated either alone or in co-culture (D18-21) for 3 
days. Plasma cells were identified based on low side scatter.  In comparison, 
macrophages have a significantly higher side scatter profile.  
 
Drug treatment led to loss of CD138 expression in plasma cells cultured either alone 
or in co-culture. Cells harvested from osteoclast wells at all drug concentrations had 
a higher percentage of CD138+ve cells compared to non-co-culture wells (Figure 
4-5; Figure 4-6). Two-way ANOVA demonstrated both drug concentration (p<0.001) 
and co-culture (p<0.01) to have a significant effect on CD138 expression. The 
combination of a low percentage of CD138-ve U266 plasma cells in stock solution 
and the loss of expression with chemotherapeutic insult adds error in using this 
marker to assess for low levels of contaminating primary adherent mononuclear 
cells.  
 
Therefore morphological determination of plasma cell purity following Giemsa 
staining was used as the preferred method. Additionally, plasma cell purity could be 
enriched by the 2 hour incubation of harvested cells on tissue culture plastic in order 


















Figure 4-5. CD138 quantification of doxorubicin treated myeloma cells 72 hours post-treatment 
at stated concentrations.  
Following drug exposure, plasma cells were incubated alone or on D18 osteoclast cultures. 







Figure 4-6. Representative flow cytometry plots of gated plasma cells harvested after 72 hour 
exposure to doxorubicin (Dox). Plasma cells were cultured alone or co-cultured with D18 
osteoclast layers.  
Arrows represent cell debris/necrotic cells. FSC (forward scatter), SSC (side scatter). 




























4.3.1.4 FLOW CYTOMETRY AND MORPHOLOGICAL 
CHARACTERISTICS OF CO-CULTURED U266 CELLS 
As described above, U266 plasma cells were pre-treated with doxorubicin and 
cultured alone or in co-culture (D18-21) for 3 days. More cell debris and necrotic 
cells (Figure 4-6; arrowed) were evident at lower forward scatter in doxorubicin 
treated U266 only wells compared to co-culture wells at the corresponding 
doxorubicin concentration. Co-cultured plasma cells had a lower and more uniform 































Figure 4-7. Representative cytospins of recovered U266 cells, untreated or pre-treated with 
doxorubicin (Dox), following 72 hour co-culture or culture alone. Scale bar 50µm.
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These observations were confirmed morphologically by GIEMSA staining (Figure 
4-7). Cytospins of doxorubicin treated U266 cells cultured alone showed 
significantly more apoptotic bodies compared to co-culture wells at all doxorubicin 
concentrations.  In comparison to co-culture wells, doxorubicin treated U266 cells 
recovered from non co-culture wells were less healthy and contained cells with 
irregular cytoplasm, nuclear fragments, reduced basophilic staining and left-shifted 
plasmablastic morphology (visible nucleoli and non-clumped chromatin). These 
findings suggest that co-culture leads to a healthier recoverable plasma cell 







4.3.1.5 MYELOMA CELL LINE DRUG SENSITIVITIES  
To establish drug sensitivities of myeloma cell lines for future co-culture 
experiments, U266 and NCI-H929 cells were treated for 72 hours with doubling 
dilutions of doxorubicin, melphalan, dexamethasone or bortezomib. Both myeloma 
cell lines were sensitive to melphalan, doxorubicin and bortezomib (Table 4-1; 
Figure 4-8). The U266 myeloma cell line was resistant to tested dexamethasone 
concentrations (61nm to 4mM). Therefore, dexamethasone was not used as a 
potential drug for future co-culture experiments. The therapeutic window for 
bortezomib, especially for the NCI-H929 myeloma cell line, was narrow, as 
demonstrated by the large decrease in absorbance with doubling drug concentration 
(Figure 4-8). Therefore melphalan and doxorubicin were selected as the drugs of 





Table 4-1. IC50 for doxorubicin, melphalan and bortezomib in the U266 and NCI-H929 cell lines. 

























Figure 4-8. Drug sensitivity of the U266 and NCI-H929 myeloma cell lines to melphalan (A) and 
Doxorubicin (B).  
Mean and SD plotted in (A) and (B). (C) Bortezomib, two drug cytotoxicity curves plotted for 
each cell line. The U266 cell line was resistant to dexamethasone at tested concentrations (D).
 IC50 U266 (n=3) IC50 NCI (n=2) 
Doxorubicin µM 1.41±0.13 0.47±0.26 
Melphalan µM 48.23±11.62 22.97±9.09 
Bortezomib nM 8.04±6.75 16.24±13.55 















































































































4.3.1.6 CALIBRATION OF ANNEXINV/PI ASSAY 
U266 cells (0.5million/ml) were treated for 6 hours with doubling concentrations of 
doxorubicin and incubated for 72 hours prior to analysis. Healthy (annexin–ve, PI-
ve), early apoptotic (annexinV+ve, PI-ve) and dead cells (annexinV+ve/PI+ve) were 
enumerated by flow cytometry. Increasing concentrations of doxorubicin led to a 
lower proportion of healthy cells and a higher proportion of apoptotic cells (Figure 
4-9). A concentration-dependent increase in annexinV/PI+ve U266 cells was seen 
with increasing irradiation dose at 72 hours (data not shown). In conclusion, 
annexinV/PI quantification is a sensitive assay for assessing plasma cell viability 
following co-culture. In addition, doxorubicin concentrations greater than 1µM led to 
a significant increase (>20%) in the proportion of annexinV/PI positive cells. 
Therefore, doxorubicin concentrations greater than 1µm were used in subsequent co-
culture experiments comparing the ability of the monolayer to rescue pre-treated 































Figure 4-9. Annexin/PI quantification of doxorubicin treated U266 cells following 72 hour 
exposure.  
(A) 0µM doxorubicin (B) 4µM doxorubicin. (C) Percentage annexinV/PI positive cells post 




























































4.3.1.7 CALIBRATION OF BRDU/PI FLOW CYTOMETRIC ASSAY 
BrdU is a thymidine analogue and is incorporated into the DNA of dividing cells 
during S-phase of the cell cycle, whereas PI is a nucleic acid stain. Primary plasma 
cells have a low proliferation fraction in contrast to immortalised cell lines that 
divide rapidly. Titration experiments were conducted to optimise the incubating 
concentration (10-40µM) and exposure time to BrdU (2-4 hours) for both the U266 
and NCI-H929 cell lines. Both myeloma cell lines had greater than 30% of cells 
identifiable in S-phase following incubation for 4 hours with 20µM BrdU (optimised 
protocol), which was similar to the experimental protocol of others425. U266 cells 
(0.25x106) were treated with various concentrations of doxorubicin or irradiation for 
6 hours and placed in a cell incubator for 72 hours. Increasing concentrations of 
doxorubicin and doses of irradiation led to a reduction in the proportion of cells in S-
phase (Figure 4-10). It was concluded that this assay allowed sufficient sensitivity to 




























Figure 4-10. U266 cells exposed to (D) doxorubicin (n=1) or (E) irradiation (n=1) led to a 
concentration-dependent reduction in the number of U266 cells in S-Phase at 72 hours.  
Cell cycle plots demonstrate the number of cells in S-phase following 72 hour exposure to (A) 
0µM doxorubicin, (B) 0.1µM doxorubicin and (C) 0.25µM doxorubicin.
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4.3.1.8 CONFIRMATION OF CONTROL AND GAUCHER MONOCYTE 
GLUCOCEREBROSIDASE ACTIVITY 
It was hypothesised that cultured monocytes, with abnormal sphingolipid 
metabolism, may preferentially support plasma cell survival and growth. Gated 
peripheral monocytes from GD patients had lower lysosomal glucocerebrosidase 
activity (Figure 4-11) than monocytes from healthy controls, as assessed by flow 
cytometry (see chapter 3). Monocyte glucocerebrosidase activity was determined by 
the MFI of liberated fluorochrome from the carrier substrate FDGlu and was 
expressed as a ratio of the sample MFI to that obtained from a paired specimen 
treated with the lysosomal glucocerebrosidase inhibitor CBE. GD derived PBMCs, 
based on morphological examination, were able to generate healthy monolayers after 


















































Figure 4-11. Monocyte glucocerebrosidase activity was determined by the MFI of liberated 
fluorochrome from the carrier substrate fluorescein di-β-D-glucopyranoside.  
Activity reported as a ratio of MFI Sample/MFI CBE Sample. Mean+SD plotted.  
**p<0.01 
 
4.3.1.9 CONFIRMATION OF LYSOSOMAL DYSFUNCTION IN GD 
MONOCYTES 
Immunofluorescent staining was used to assess the distribution of BODIPY 
lactosylceramide (visualised green) within the cell and the endo-lysosomal 
compartment was visualised red (Lysotracker). In monocytes derived from healthy 
controls, lactosylceramide was concentrated in the cellular membrane (Figure 4-12). 
GD monocytes accumulated lactosylceramide in their lysosomal compartment, as 
demonstrated by the co-localisation of BODIPY (visualised yellow). Therefore 




Figure 4-12. Representative examples of GD and control monocytes stained for lactosylceramide 
(green) and the lysosomal compartment (lysotracker; red).  
GD monocytes due to lysosomal dysfunction accumulated lactosylceramide in the lysosomal 
compartment. The signals in control monocytes remain mostly separated.  
 
 
4.3.2 OSTEOCLAST GENERATION FROM NON CO-CULTURE 
It was demonstrated above that GD monocytes have low glucocerebrosidase activity 
and abnormal lipid trafficking. This section explores the ability of GD monocytes to 
undergo osteoclastic differentiation. Osteoclasts are known to support plasma cell 
growth in vitro. 
 
After 21 days of culture, the number of TRAP+ve cells derived from controls or GD 
patients was enumerated (average of 2 coverslips). Cultures with sub-optimal density 
or morphological evidence of cell toxicity at day 21 were discarded. TRAP+ve cells 
with 3 or more nuclei were counted as osteoclasts. Cells that were TRAP+ve and 
contained less than 3 nuclei were labelled as pre-osteoclasts. Controls harboured a 
lower number of osteoclasts (8.1±6.8; Mean±SD) compared to GD patients 
(54.2±48.07; Figure 4-13) at day 21. Osteoclasts derived from GD patients were 
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generally larger in size than those seen in control culture with many being greater 
than 400µm in length. There were areas of both dense osteoclastogenesis and sparse 
osteoclast generation on recovered glass inserts from GD cultures (Figure 4-14). 
TRAP+ve cells generated from GD patients were generally of a higher ploidy than 
those seen in control cultures. Although not formally enumerated, the number of 
























Figure 4-13. Number of osteoclasts generated following 21 day culture of adherent mononuclear 
cells from Gaucher patients compared to controls.  
Mean=plotted line. 
 
There was significant heterogeneity in the number of osteoclasts generated between 
Gaucher patients. In contrast, the number of osteoclasts generated from controls was 
uniformly low. This is a repeat observation of previous work from our laboratory 
pending publication (Mathew Reed, Dr Derralynn Hughes). In addition, our group 
has correlated the number of TRAP+ve cells with positive staining for the osteoclast 
vitronectin receptor and enhanced bone resorption. Gaucher disease leads to lytic 
bony lesions and osteoporosis, both indicative of osteoclast over-activity.  This 
model has been optimised, both in culture duration and cytokine supplementation 
(RANK-L/M-CSF), to exploit theoretical differences in osteoclast generation 
between the GD and control bone marrow microenvironment. This model was used 































Figure 4-14. TRAP stain following 21 day culture of adherent mononuclear cells from controls 
and GD patients. 
Sparse osteoclastogenesis is typical in controls (A). GD patients generate significantly more 
TRAP+ve osteoclasts and pre-osteoclasts in culture (B). Scale bar 100µm. 
 
4.3.3 PLASMA CELL CO-CULTURE EXPERIMENTS (D14-21) 
PROLIFERATION/SURVIVAL 
It has been demonstrated so far, that GD monocytes, have evidence of lysosomal 
dysfunction and more readily undergo osteoclastic differentiation than control 
monocytes. Experiments, from here in, explore whether these abnormalities, confer a 
proliferative or survival advantage on co-cultured myeloma cell lines.  
 
Plasma cells proliferate when co-cultured with osteoclasts or macrophages. NCI-
H929 cells (3x104) or U266 (7.5x104) cells were co-cultured with control or GD 
monolayers (D14-21). Plasma cells were co-cultured in contact with the underling 
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monolayer (CT) or trans-well inserts (TW) for 7 days. Harvested cells were counted 
and cell cycle analysis and viability testing were performed.    
4.3.3.1 PLASMA CELL PURITY 
Mean plasma cell purity, as determined morphologically by Giemsa staining, was 
greater than 94% for NCI-H929 or U266 cells co-cultured in contact. There was no 
statistical difference in mean plasma cell purity between controls and GD co-cultures 
(Table 4-2). 
 
   
 
 
Table 4-2. Plasma cell purity of co-cultured plasma cells in a contact-dependent system. 
Mean±SD. 
 
4.3.3.2 NCI-H929 PLASMA CELL NUMBERS 
Contact-dependent cell culture, irrespective of monolayer origin, led to an increase in 


























Figure 4-15. Number of NCI-H929 plasma cells harvested from contact co-culture (CT) or 
contact-independent co-culture (TW) compared to plasma cell only wells.  
Mean plotted. *p<0.05 **p<0.01. 
 
 Control Gaucher 
NCI-H929 95.5±2.2 (n=16) 95.7±3.1 (n=18) 












































There was no difference in the number of plasma cells harvested following contact 
co-culture between control (1.3x106±0.5; Mean±SD; n=16) and GD monolayers (1.3 
x106±0.3; n=18). Although contact co-culture did lead to a statistical increase in 
NCI-H929 cell number, this was less than a 50% difference from the mean of plasma 
cell alone wells. In addition, there was significant heterogeneity in cell number 
between individual cultures. However, paired experiments, using trans-well inserts, 
confirmed the contact-dependent increase in NCI-H929 myeloma cell number (Table 
4-3).   
 NCI Contact NCI Trans-well P Value 
Control 1.8±0.4(n=6) 0.87±0.3 (n=6) p<0.05 
Gaucher 1.3±0.4(n=9) 0.9±0.1 (n=9) p<0.05 
 
Table 4-3. NCI-H929 plasma cell number (x106) from paired co-culture experiments.  
Mean±SD. Wilcoxon Signed Rank Test.  
 
Interruption of cell contact with the underlying monolayer led to a reduction in NCI-
H929 plasma cell number to values seen post culture of NCI-H929 cells alone. There 
was no statistical difference between the number of NCI-H929 plasma cells 
recovered from contact deprived co-cultures of controls (0.8x106±0.26; Mean±SD; 
n=16) compared to contact deprived GD co-culture (0.9 x106±0.1; n=18) in this 
additional series of experiments.  
4.3.3.3 U266 PLASMA CELL NUMBER 
There was no significant difference between the number of U266 cells harvested 
from culture alone (0.83x106±0.18; Mean±SD; n=10) and contact co-culture with 
either GD (0.77x106±0.2; n=9) or control monolayers (0.97x106±0.14; n=8). Based 
on the increase in NCI-H929 plasma cell number in contact culture, reported here, 
and prior literature documenting the increase in U266 cells with osteoclast co-
culture, this was an unexpected result. Giemsa staining of glass inserts from co-
culture wells revealed large numbers of un-recovered plasma cells adhering to the 
underlying monolayer; this was despite two washes in R10 medium and gentle 
pipetting. More vigorous pipetting, however, led to a drop in plasma cell purity due 
to admixed monolayer cells. Co-culture wells with <90% purity were discarded from 
analysis. GD monolayers did not lead to a proliferative advantage over control 
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Figure 4-16. Giemsa stain of a recovered glass inserts from U266 control co-culture.  
A cluster of small plasma cells are seen co-localised with adherent GD or control monolayer 
cells. Scale bar 200µm. 
 
4.3.3.4 CELL CYCLE ANALYSIS 
Based on recoverable cell number, GD monolayers did not promote a proliferative 
advantage over control co-culture.  However, U266 cells were unable to be fully 
harvested from co-culture wells due to adherence to the underlying monolayer 
(Figure 4-15). This is in contrast to NCI-H929 cells that were easily recoverable. 
Based on cell number alone, a proliferative advantage may have been masked if GD 
monolayers were more adhesive to U266 plasma cells then control monolayers. As 
an additional measure of cell proliferation, independent of cell adhesion, cell cycle 
analysis was performed on harvestable U266 or NCI-H929 cells grown alone for 7 
days or following co-culture (D14-21). BrdU/PI analysis was used to calculate the 
percentage of harvested plasma cells in S, G0/G1 and G2/M phases of the cell cycle 
(Figure 4.17; Figure 4.18). Co-culture compared to culture alone did not lead to an 
increase in the number of plasma cells in S-phase for either the U266 or NCI-H929 
cell lines. GD-derived co-culture compared to control co-culture did not lead to a 
higher percentage of U266 or NCI-H929 plasma cells in S-phase. There was an 
increase in the percentage of NCI-H929 cells in G0/G1 phase (p<0.05) from GD co-
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culture compared to culture alone. Otherwise, cell cycle analysis for the different 




















Figure 4-17. BrdU/PI cell cycle analysis of harvested U266 or NCI plasma cells following 7 day 
























Figure 4-18. Representative BrdU/PI analysis of the % of cells in S-phase from plasma cell alone 






























































60 Plasma cell alone   n=8






























































Plasma cell alone   n=8





4.3.3.5 PLASMA CELL SURVIVAL/VIABILITY 
The viability of NCI-H929 or U266 cells following 7 days of co-culture or culture 
alone was assessed by trypan blue exclusion or annexinV/PI quantification (D14-21). 
Plasma cells were cultured in contact (CT) or physically separated from the 
underlying adherent monolayer by trans-well inserts (TW). All datasets represent a 
minimum of n=8, apart from contact-independent co-cultures derived from controls 






























Figure 4-19. Viability of NCI-H929 and U266 cells lines determined by trypan blue exclusion 
(A,B) and AnnexinV/PI assay (C,D) following culture alone or co-culture.  
Mean±SD plotted. Cell survival demonstrated by dual positivity for annexinV/PI or trypan blue 
exclusion. Box and whiskers plots in (C) and (D) represent median, inter-quartile range and 







































































































































































































Co-cultured plasma cells, in a contact-dependent model, were more viable than those 
cultured alone based on both trypan blue exclusion and dual positivity for 
annexinV/PI (Figure 4-19; Figure 4-20). GD monolayers did not convey an additional 
survival advantage over non-GD derived co-cultures.  
 
Contact-independent co-cultures using trans-well inserts led to a fall in plasma cell 
viability compared to contact co-culture for both the U266 and NCI-H929 myeloma 
cell lines. GD monolayers also did not confer a survival advantage over osteoclast 
cultures derived from controls, in transwell experiments. Compared to U266 plasma 
cell alone wells, non-contact GD co-culture led to a statistically lower percentage of 





Figure 4-20. Representative flow cytometry plots of annexinV/PI immuno-staining of NCI-H929 
or U266 plasma cells grown alone or in contact co-culture.  


































4.3.4 DRUG SENSITIVITY OF CO-CULTURED PLASMA CELLS  
4.3.4.1 MTT DRUG SENSITIVITY 
Plasma cells were cultured alone or with control or GD-derived monolayers (D14-
21) before being plated, in triplicate, in 96 well plates (2x104/well). Cells were 
exposed to doubling dilutions of melphalan and doxorubicin for 24 hours before 
performing a MTT dye reduction assay. Any chemo-protective advantage imparted 
on recovered plasma cells from co-culture is likely to diminish over time and 
therefore the drug IC50 was established at 24 hours rather than at a later time point. 
Both the U266 and NCI-H929 cell lines demonstrated a higher IC50 to either drug 
than that stated in the validation experiments above (section 4.2.1.5). This is 
explained by the fact that the MTT assay was performed at 72 hours in validation 
experiments rather than at 24 hours post co-culture. Additionally, drug sensitivities in 
section 4.2.1.5 were established in R10 medium whereas plasma cells were grown 
for 7 days in OC medium (RANK-L/M-CSF) in the experiments described here.  
 
Control co-culture did not lead to an increase in the melphalan IC50 for either the 
NCI-H929 (NCI alone 44.9±14.8; Control/NCI CT 41.6±6.6µM; Mean±SD) or U266 
cell lines (U266 alone 82.9±39.2 µM; Control/U266 CT 78.2±21.2 µM) compared to 
plasma cell culture alone (Figure 4-21). Gaucher co-culture, however, led to a 
significant increase in the melphalan IC50 of both the NCI-H929 (Gaucher NCI/CT 
54.7±13.9 µM; p<0.01) and the U266 (Gaucher U266/CT 110.9±36.6µM; p<0.01) 
cell lines compared to control co-culture. 
 
The doxorubicin IC50 for both myeloma cell lines in co-culture was not increased 
compared to non co-culture (Table 4-4).  
 
 






U266 2.3±0.9 (n=10) 2.3±0.9 (n=8) 3.3±1.4 (n=9) * 
NCI-H929 1.9±0.9 (n=9) 1.9±1.1(n=14) 1.7±0.6 (n=18) 
 
Table 4-4. Drug sensitivity to doxorubicin (µM), at 24 hours, of harvested (A) NCI or (B) U266 
cells cultured alone or in co-culture (D14-21) for 7 days.  
Mean±SD reported. *p=0.08 
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From these initial observations, GD monolayers seem to prime myeloma cell lines 
for survival against melphalan but not doxorubicin. A trans-well system was used to 
investigate whether the increase in melphalan IC50 was due to protection conferred by 
contact or due to secretion of a survival factor from the underlying GD adherent 
monolayer. Contact deprivation led to a decrease in the melphalan IC50 of NCI-H929 
cells in paired GD co-cultures (contact IC50 48.2µM; transwell IC50 34.9 µM; paired 
t-test p<0.01;Figure 4-22).  In addition, IC50 of melphalan in U266 cells was lower in 
cells harvested from trans-well inserts than co-culture in 3 out of 4 paired 








Figure 4-21. Drug sensitivity to melphalan of harvested (A) NCI-H929 or (B) U266 cells cultured 
alone or in co-culture for 7 days.  
Contact co-culture (CT).  Mean indicated by line. *p<0.05 **p<0.01 
 
In contrast to GD cultures, NCI-H929 cells recovered from contact or contact-
independent control co-cultures demonstrated identical chemosensitivity to 
melphalan at 24 hours. Disruption of cell contact did not lead to a difference in the 
doxorubicin IC50 of co-cultured NCI-H929 plasma cells harvested from either control 
or GD osteoclast cultures. Plasma cell purity remained high (mean >94%) with no 
difference in purity between plasma cells harvested from either GD or control co-
culture. However, the increase in melphalan IC50 observed in GD co-culture could be 
secondary to a small contaminating population of monolayer cells that are more 
resistant to melphalan or metabolically active than the equivalent number of admixed 











































































reading. Although, it could be argued that a small contaminating population of 
adherent cells did not lead to a higher doxorubicin IC50  in the contact co-culture of  
NCI-H929 cells with either control or GD derived monolayers. However, drug assays 


















Figure 4-22.  (A) Melphalan or (B) Doxorubicin IC50 of co-cultured NCI plasma cells (D14-21) in 
paired experiments utilising trans-well inserts.  


















Figure 4-23. Melphalan IC50 of GD co-cultured U266 plasma cells (D14-21) in paired 
experiments utilising trans-well inserts.  






















































































































4.3.4.2 DRUG SENSITIVITY OF MACROPHAGE CULTURES 
Control or GD monocytes (4x104 cells) were plated, in triplicate, in 96-well plates 
and grown in OC medium for 18 days. Adherent cells were exposed to doubling 
concentrations of melphalan and doxorubicin for 48 hours before being performing a 
MTS dye reduction assay (Figure 4-24).  Drug sensitivity of Gaucher and control 




























Figure 4-24. Drug sensitivity of day 20 osteoclast cultures following 48 hour exposure to (A) 
melphalan or (B) doxorubicin as determined by MTS dye reduction assay.  














































































































































































There was no difference in melphalan sensitivity of cultured Gaucher monocytes 
compared to control monocytes. GD derived monolayer cells were statistically more 
sensitive to doxorubicin at several concentrations (1µM, 8 µM and 16 µM) compared 
to control monolayers (Figure 4-24). Therefore it can be concluded that the small 
contaminating population of GD monolayer cells is not the explanation for the 
elevation in melphalan IC50 of harvested NCI-H929 plasma cells. Despite an equal 
number of contaminating control monolayer cells in co-culture, elevation in the 
melphalan IC50 was not demonstrated for either the U266 or NCI-H929 cell lines.  
 
4.3.4.3 PARP-CLEAVAGE 
The MTT dye reduction assay was used to calculate the IC50 of chemotherapeutic 
drugs in plasma cells harvested from co-culture, as detailed above. The principle of 
this test is the mitochondrial reduction of MTT reagent to a purple foramen which is 
detectable by colorimetric assay. This assay is commonly used as a measure of cell 
proliferation, drug toxicity or both. However, limitations of the MTT dye reduction 
test include large variations in absorbance due to alterations in metabolic activity.  
 
PARP is an 116kDa intra-cellular protein that is cleaved into an 85kDa fragment 
during the terminal stages of apoptosis. In order to confirm that GD monolayers 
protected plasma cells from apoptosis, western blotting for PARP cleavage of co-
cultured (D14-21) NCI-H929 plasma cells harvested from GD or control monolayers 
was performed. Harvested NCI-H929 cells were re-suspended in culture medium and 
incubated for 2 hours on tissue culture plastic to increase plasma purity by adhering 
out contaminating macrophages. Plasma cell purity remained high from both control 
(99±0.5%; n=6) and GD co-culture (97±1.4%; n=5). Harvested NCI-H929 plasma 
cells were then exposed to 50µM melphalan for 24 hours before cell lysates were 
made. Optical densitometry was used to determine band intensity and the ratio of 
cleaved PARP:total PARP was calculated (Figure 4-25). PARP cleavage was 
significantly higher in controls compared to GD patients (p<0.01) implying a 
protective effect of GD monolayers secondary to decreased activity of intracellular 







Figure 4-25. (A) PARP cleavage as determined by optical density. (B) Western blot of melphalan 
treated NCI-H929 cells following co-culture (C=Control, G=Gaucher) compared to untreated 
stock NCI-H929 cells (S). 
 
 
4.3.4.4 PLASMA CELL PRIMING  
GD monolayers prime plasma cells for survival against melphalan as demonstrated 
by an elevation in drug IC50 and decreased PARP cleavage. It was, therefore, 
hypothesised that this survival advantage was due to the ability of GD monolayers to 
alter the basal levels of pro and anti-apoptotic proteins in co-cultured plasma cells. 
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4.3.4.5 TP53 EXPRESSION  
p53 is a tumour suppressor protein and many different cellular stressors, including 
chemotherapy, can induce expression. Induction of p53 has several different affects, 
including the up-regulation of DNA repair mechanisms, cell-cycle arrest and 
initiation of apoptosis in unsalvageable cells. Western blotting for p53 content was 
performed in lysates of stock NCI-H929 cells either untreated or following 24 hours 
exposure to 25µM and 50µM melphalan (Figure 4-26). Lysates of drug naive or 
chlorambucil treated primary chronic lymphocytic leukaemia cells (CLL) were used 
in control lanes. NCI-H929 plasma cells had constitutionally high expression of p53 
and this was not increased further by melphalan. The p53 pathway in NCI-H929 cells 
is thus dysfunctional, as in many other immortalised cell lines.  Expression of p53 in 





Figure 4-26. p53 expression in NCI-H929 cells as determined by western blotting (30µg 
protein/lane).  
Lanes (A) untreated NCI (B) 25µM melphalan NCI (C) 50µM melphalan NCI (D) untreated 
CLL cells (E) 20µM chlorambucil CLL cells (F) 50µM chlorambucil CLL cells.  
 
4.3.4.6 INTRINSIC APOPTOSIS PATHWAY - PROTEINS 
Lysates were made from untreated NCI-H929 cells following co-culture (D14-21) 
with control (n=6) or GD monolayers (n=6). Mean plasma cell purity, determined by 
Giemsa staining, remained greater than 97%, irrespective of monolayer origin. The 
basal levels of regulatory proteins within the intrinsic death pathway were 
investigated. This included two pro-apoptotic proteins (Bim and PUMA) and three 
anti-apoptotic proteins (Bcl-2, Bcl-xL and Mcl-1), see Figure 4-27. In this set of 
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experiments, stock lysates (S) were made from NCI cells grown in R10 medium 
















Figure 4-27. Western blotting for pro and anti-apoptotic proteins from untreated co-cultured 
NCI-H929 plasma cells (D14-21) compared to stock NCI-H929 plasma cells.  
Gaucher ([G], n=6), control ([C], n=6) and stock cells ([S], n=4).  
 
The optical density of proteins was quantified by scanning densitometry. Compared 
to GD co-culture, NCI-H929 cells harvested from control co-culture demonstrated 
increased basal levels of the pro-apoptotic protein Bim (p<0.05) and the anti-
apoptotic protein Bcl-xL (p<0.05) (Figure 4-28). In addition PUMA was up-
regulated in the majority of control co-cultures although, based on optical density, 
statistical significance was not reached (p=0.09). Mcl-1 was present at equivalent 
levels irrespective of the monolayer origin. Bcl-xL, Bim and PUMA were expressed 
in equivalent amounts in NCI cells harvested from GD co-cultures compared to stock 
NCI cells (n=4). Bcl-2 was not expressed in the NCI-H929 cell line. Integrity of the 





























Figure 4-28. Optical density of Bim, PUMA and Bcl-xL of NCI-H929 cells harvested from co-
culture (D14-21) compared to lysates of stock NCI cells.  Mean represented by plotted line. 
 
The intrinsic, mitochondrial apoptotic pathway is complex and involves a rheostat of 
regulatory proteins. Activation of cell surface tyrosine kinases including the 
epidermal growth factor receptor, leads to the phosphorylation of ERK, and the 
subsequent down-regulation of Bim expression. NCI-H929 cells harvested from 
either control or GD monolayers had equivalent levels of both ERK and 
phosphorylated ERK. Therefore BIM is up-regulated in NCI-H929 cells harvested 








Figure 4-29. ERK and p-ERK expression of harvested NCI cells from GD (G) or control (C) co-









































































4.3.5 EFFECT OF CO-CULTURE ON OSTEOCLAST NUMBER  
The results reported above have demonstrated that GD patients generate more D21 
TRAP+ve cells in culture than controls when monolayers are grown alone in OC 
medium. U266 (7.5x104) and NCI-H929 (3 x104) plasma cells were co-cultured with 
D14 osteoclast cultures from GD patients or controls before termination on D21. 
Coverslips were fixed, stained for TRAP and the number of osteoclasts was 
determined (average of 2 coverslips) for comparison to that generated in paired 
osteoclast only wells. All co-culture wells exhibited a decrease in adherent 
monolayer cell density on recovered cover-slips in comparison to non co-culture 
wells. Additionally, co-culture with the U266 cell line led to aggregation and areas of 
clearing on recovered glass coverslips (Figure 4-16). Despite this, Gaucher co-
culture led to an increase in the number of osteoclasts generated for both the U266 
(p<0.05; Wilcoxon signed rank test) and the NCI-H929 (p<0.05) myeloma cell lines. 
In comparison, control co-culture did not lead to an increase in osteoclastogenesis 
and the number of osteoclasts generated remained low (Figure 4-30; Figure 4-31). 
GD co-culture led not only to an increase in osteoclast numbers but, subjectively, to 
larger multi-nucleate TRAP+ve cells compared to either culture alone or co-culture. 
Many TRAP+ve cells extended cytoplasmic processes to neighbouring osteoclasts or 








Figure 4-30. Number of TRAP+ve cells generated in contact co-culture (D14-D21) for the (A) 





































































































Figure 4-31. Number of TRAP+ve cells post plasma cell co-culture.   
TRAP staining in (A) GD osteoclast culture (B) Gaucher NCI-H929 contact co-culture and (C) 
Gaucher U266 co-culture. (D) Representative image of solitary osteoclast from D21 control 
culture. Scale bar 100µm. 
 
Co-culture experiments using trans-well inserts were performed to ascertain whether 
the increase in osteoclastogenesis was contact mediated or secondary to a soluble 
factor. Paired GD co-culture experiments supported the later as the mean number of 





















Figure 4-32. Number of osteoclasts generated in contact or trans-well co-cultures compared to 
sole culture.  


























































4.3.6 EFFECT OF ENZYME REPLACEMENT THERAPY ON 
MELPHALAN IC50 AND OSTEOCLASTOGENESIS 
MTT dye reduction assay was used to confirm that 1unit/ml of imiglucerase (ERT) 
was not toxic to PBMCs in culture (data not shown). Imiglucerase 1unit/ml is 
equivalent to peak blood concentrations achieved in patients post administration and 
is the standard concentration employed by other investigators in our laboratory.   
 
Paired GD cultures were grown for 21 days +/- the addition of 1ul/ml of 
imiglucerase. NCI-H929 cells (4x104) were added on D14 and co-cultured for 1 
week (D14-21) as described above (n=4). Plasma cell purity remained high with a 
minimum purity of 98%. ERT did not lead to a decrease in NCI-H929 cell number in 
3 out of 4 experiments and only a reduction of <15% in the other (Figure 4-33). Cell 
viability (trypan blue exclusion) and the percentage of healthy annexinV-ve/PI-ve 
NCI-H929 cells were similar between ERT-treated and ERT-naïve wells in 3 out of 4 





Figure 4-33. GD derived co-culture experiments supplemented with ERT.   
(A) Cell enumeration, (B) AnnexinV-ve/PI-ve quantification of NCI-H929 myeloma cells 
harvested from D21 Gaucher monolayers from 4 different experiments +/- ERT (Patients 1-4).  
 
In addition, ERT-treated wells did not lead to a reduction in the IC50 of melphalan as 
determined by MTT assay 24 hours post-harvest in 3 out of 4 experiments.   










































































Figure 4-34. Melphalan IC50 of co-cultured NCI-H929 harvested from GD co-culture wells (+/- 
ERT).  
 
However, the number of osteoclasts generated on D21 was reduced in paired ERT-
treated wells compared to numbers reported above in control co-cultures. Densities 
were reduced in all co-culture wells on glass inserts compared to cultures performed 
in non co-culture. However, ERT seemed to lead to a more pronounced reduction in 
the monolayer density than ERT-naïve wells, probably due to a lack of large multi-
nucleate TRAP+ve cells. Cumulative toxicity of ERT following 3 weeks of culture 
could not be excluded. Although the number of osteoclasts generated in ERT wells 





Figure 4-35. D21 TRAP staining of recovered glass inserts following co-culture of NCI-H929 
(D14-21) cells in the (A) absence and (B) presence of ERT. Scale bar 100µm.
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4.3.7 RESCUE OF DOXORUBICIN-TREATED U266 CELLS 
Previously published data have shown that both osteoclast and macrophage cultures 
derived from peripheral blood are capable of rescuing drug treated plasma cells245;252. 
In addition, the underlying adherent monolayer has been postulated to reduce the 
proportion of apoptotic tumour cells by phagocytosis. Using our co-culture system, 
U266 cells were pre-treated with several different concentrations of doxorubicin for 
6 hours before being plated alone or on D18 adherent monolayers (control or GD 
derived) for 72 hours. Cells were harvested on D21 by gentle pipetting, counted and 
used in annexinV/PI and MTT assays.  
 
Earlier, it was demonstrated that exposure of U266 cells to doxorubicin 
concentrations ≥1µM for 72 hours resulted in ≥20% annexinV/PI positivity. The 72 
hour IC50 of doxorubicin in U266 cells was 1.41µM ±0.13 (n=3). Therefore 
concentrations higher and lower than the IC50 were used to establish whether 
Gaucher monolayers could rescue doxorubicin-treated plasma cells from apoptosis 
more efficiently than those derived from controls. As described above doxorubicin 
concentrations of 0.5µM or above led to a near absence of proliferating cells at 72 
hours.  
 
4.3.7.1 PLASMA CELL NUMBER 
Plasma cell purity was determined morphologically following Giemsa staining. 
Mean plasma cell purity remained greater than 90% from all co-culture wells 
irrespective of the origin of the monolayer (GD or control). 
 
Significantly higher numbers of plasma cells were harvested from U266-alone wells 
compared to control culture following 72 hour exposure to 0µM (p<0.01; Wilcoxon 
signed rank test), 0.5µM (p=0.06), 1µM (p<0.05), 2µM (p<0.01) or 4µM (p<0.01) of 
doxorubicin. There was no difference in the number of plasma cells harvested from 












Figure 4-36. Enumeration of doxorubicin pre-treated U266 cells recovered from culture.  
Recovered U266 cells were counted and compared to the number obtained from the untreated 
U266-alone well. All datasets represent mean values of greater than n=8, accept for U266 cells 
pre-treated with 0.5µM of doxorubicin where n≥3 is represented (Figure 4-36). Data represents 
Mean+SD. 
 
4.3.7.2 ANNEXIN V/PI QUANTIFICATION  
Control co-culture wells had a lower number of annexinV+ve/PI+ve cells at all 
doxorubicin concentrations compared to U266-alone wells. GD co-culture did not 
lead to a statistically lower number of late apoptotic cells compared to control co-
culture. In fact, after exposure to 4µM doxorubicin there was a higher number of 
annexinV+ve/PI-ve plasma cells in GD co-culture (p<0.05) but no difference in the 















Figure 4-37. Percentage of AnnexinV+ve/PI+ve U266 plasma cells following 72 hours culture 







































































Additionally, the percentage of early apoptotic cells (annexinV+ve/PI-ve) was 
statistically higher in U266 alone wells than co-culture wells at all concentrations 


































Figure 4-38. Percentage of AnnexinV+ve/PI-ve U266 plasma cells following 72 hours culture 
alone or co-culture. *p<0.05 ***p<0.001 
 
4.3.7.3 MTT DATA – CELL RESCUE 
Doxorubicin treated U266 cells were recovered at 72 hours and a MTT dye reduction 
assay was performed.  U266 cells recovered from either co-culture or culture alone 
had identical mean values for absorbance in doxorubicin-naïve wells. Surprisingly, 
mean absorbance increased in plasma cells following exposure to 1µM doxorubicin 
irrespective of co-culture or origin of the adherent monolayer, possibly reflecting 
increased metabolic activity of chemotherapy-exposed cells. Control co-culture led 
to a statistically higher absorbance reading compared to U266-alone wells following 
exposure to 2µM (p<0.01) and 4µM (p<0.01) doxorubicin (Figure 4-39). Gaucher 
co-culture compared to control co-culture led to a lower MTT absorbance value at 
4µM doxorubicin (p<0.05). This is in keeping with the annexinV/PI flow cytometry 
data in which control co-culture led to a lower number of early apoptotic cells 






















Figure 4-39.  Absorbance post MTT assay of U266 cells pre-treated with doxorubicin followed 
by 72 hours co-culture or culture alone.  
Control (Con). Each subgroup consisted of a minimum of n=5. Mean±SD plotted. *p<0.05 
**p<0.01 
 
4.3.7.4 HAEMOPHAGOCYTOSIS VERSUS CELL ADHESION 
Based on cell number, there were statistically fewer U266 plasma cells harvested 
from GD or control co-culture wells at all doxorubicin concentrations compared to 
non co-culture wells. Macrophages are large vacuolated cells that have phagocytic 
capacity. They ingest pathogens, recycle iron by digesting old red blood cells and 
destroy apoptosing cells within phagosomes. Macrophages as well as osteoclasts 
exhibit a cocktail of adhesive proteins.  
 
Co-culture wells were aspirated and washed once gently in PBS prior to removing 
inserted coverslips and staining with Giemsa. Microscopic examination revealed a 
significant number of residual clumped plasma cells centred on macrophages from 
the 0µm and 1µm doxorubicin co-culture wells. In wells exposed to 2µm and 4µm 
doxorubicin, the number of remaining plasma cells was less. Haemophagocytosis 
was noted in all co-culture wells but was only seen in the minority of monocytic-























































Figure 4-40. Giemsa staining of glass inserts from co-cultured plasma cells following 72 hours 
culture of myeloma cells treated with (A) 0µM and (B) 4µM of doxorubicin.  






Figure 4-41. Giemsa staining illustrating haemophagocytosis of U266 cells in a co-culture well 
derived from a Gaucher patient following pre-treated with 4µM doxorubicin. Scale bar 50µm.  
 
 
A mixture of EDTA/lidocaine was used to remove residual adherent cells from co-
culture wells and the number of plasma cells was enumerated by flow cytometry 
based on side scatter characteristics (Figure 4-42).  As demonstrated below, the 
Phagocytosis 
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forward scatter/side scatter characteristics of plasma cells are different to 
macrophages. The number of plasma cells harvested decreased with doxorubicin 




Figure 4-42. Plasma cells are adherent to the underlying monolayer.  
Side scatter characteristics from cultures of (A) plasma cells (B) macrophages. Identification of 
plasma cells based on low side scatter (C) from co-culture wells and (D) the percentage of 
plasma cells harvested from co-culture wells at the stated doxorubicin concentration (Control, 
Con; Gaucher, GD). 
 
The number of harvested cells, following exposure to lidocaine/EDTA, was counted 
using a haemocytometer and the number of adherent myeloma cells was calculated 
by multiplying by the percentage of plasma cells determined by flow cytometry 
(Figure 4-43). Based on these data, plasma cell adhesion does not explain the 
numerical deficit between plasma cells aspirated following co-culture compared to 
culture alone. For all co-culture wells (GD or control), the number of cells harvested 
compared to culture-alone was at least 2x105 lower. A combination of 













































Figure 4-43. Absolute number of plasma cells identified from harvested co-culture wells based 
on total cell number and plasma cell % as determined by flow cytometry from two experiments.  
 
It was then hypothesised that adherent plasma cells were less healthy than the non-
adherent fraction. To-Pro-3-iodide was used to identify the apoptotic component 
(low side scatter) for both the non-adherent and adherent plasma cells fraction. At all 
doxorubicin concentrations, the apoptotic concentration was higher for the adherent 
fraction (Figure 4-44). The percentage of annexinV+/PI+ve cells remained constant 
in the non-adherent fraction irrespective of doxorubicin concentration (1-4µM). In 
contrast, the percentage of TO-PRO+ve apoptotic cells in the non-adherent fraction 


















































Figure 4-44. Comparison of the viability of co-culture U266 plasma cells pre-treated with 
doxorubicin (adherent versus non-adherent).   
Plasma cells identified on side scatter (A) were subjected to staining with To-Pro; (D) 
enumeration of the percentage of apoptotic cells from the non-adherent (ASP) and adherent 
plasma cell populations (HARV), n=1. Illustrated is the number of apoptotic plasma cells from 














































Figure 4-45. Graph showing the percentage of adherent TO-PRO+ve plasma cells (derived from 
combined Gaucher/Control data) recovered from the co-culture of doxorubicin treated U266 
cells (n=4). Mean represented by plotted line.
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4.4  DISCUSSION 
These results, demonstrate, for the first time potential differences in the bone marrow 
microenvironment that may render malignant plasma cell in GD patients more 
resistant to chemotherapy. However, neither a proliferative nor a survival advantage 
of a GD monolayer on co-cultured myeloma cell lines was demonstrated when 
compared to a control monolayer. Peripheral blood monocytes from GD patients 
generated more osteoclasts than control monocytes at D21 when cultured alone or in 
the presence of plasma cells.  
 
Flow cytometry confirmed monocytes from GD patients to have less 
glucocerebrosidase activity than those derived from controls (Chapter 3). Kinetic 
studies have shown that monocytes, relatively young haematopoietic cells, have a 
short half life in peripheral blood (measurable in hours)426, before migration and 
differentiation into tissue macrophages. Organ macrophages, on the other hand, may 
have a life span measurable in years391. Therefore, our 21 day culture experiments, 
may be of insufficient time to allow GD monocytes to either accumulate significant 
quantities of glucosylceramide or to develop pathological levels of lysosomal 
dysfunction. Experiments using CBE, an inhibitor of lysosomal glucocerebrosidase, 
have demonstrated the accumulation of glucosylceramide at 72 hours in the THP1 
cell line and by D15 in fibroblast cultures, as determined by thin layer 
chromatography427. In contrast, glucosylceramide accumulation was only seen in the 
liver of the L444P mouse model after 7 months by electron microscopy, but not 
before330. However, gammopathy, follicular hyperplasia and plasmacytosis were 
noted in 2 month old L444P mice, despite an absence in accumulation of 
glucosylceramide (thin layer chromatography) in the liver, spleen and brain, although 
the bone marrow was not examined. Therefore glucosylceramide accumulation is not 
a necessity for gammopathy. In addition, as reported here, abnormalities of lipid 
trafficking and lysosomal dysfunction are evident in the monocytes of GD patients.  
 
GD derived mononuclear cell cultures generated more TRAP+ve cells compared to 
controls at D21 in the presence of RANK-L and M-CSF. This is a repeat observation 
of prior work from our laboratory, awaiting publication. There was significant 
heterogeneity in the number of D21 osteoclasts generated between individual GD 
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patients. Speculatively, this maybe due to differences in disease severity, treatment 
status (ERT or SRT), the timing of blood sampling relative to ERT administration, 
the concomitant use of bis-phosphonates or differences within baseline 
glucocerebrosidase activity. GD osteoclasts were larger with higher ploidy than those 
generated in control cultures. However, individual GD patients tended to produce a 
similar number of osteoclasts at D21 each time their PBMCs were cultured, 
suggestive of intrinsic differences between patients in their response to RANK-L/M-
CSF. Previously it has been shown that cultured macrophages (D12), generated from 
the PBMCs of healthy controls, have both a larger cell diameter and higher 
cytoplasmic:nuclear ratio when incubated with the lysosomal glucocerebrosidase 
inhibitor CBE428. Further work is required to establish inter-individual differences in 
cytokine receptor density and their ability, on ligand binding, to stimulate intra-
cellular pathways of osteoclastogenesis. It has been suggested that homozygous 
N370S disease is a risk factor for skeletal pathology52. Future studies are required to 
see whether in vitro osteoclast production mirrors the severity of bony disease in 
vivo. Currently the literature is sparse regarding osteoclast biology in GD.  
 
Osteoclast cultures derived from controls typically generated fewer TRAP+ve cells 
compared to GD patients following 3 weeks of culture. In contrast to other groups, 
who have reported a large number of TRAP+ve osteoclasts by D14, lower 
concentrations of RANK-L and M-CSF were used in the experiments reported here. 
This was optimised to create a mixed macrophage/osteoclast model that exploits both 
the inherent differences in osteoclast generation between controls and GD patients, 
whilst still reflecting the macrophage-predominant pathology of this disorder. 
Strategies used to increase osteoclastogenesis by other investigators include, the 
addition of dexamethasone259;429, the use of dentine discs (personnel communication, 
Professor Tim Arnett, University College London), dose escalation of M-CSF or 
RANK-L252 and the priming of adherent cells by the non-adherent lymphoid fraction 
in the first few days of culture430.         
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
Here, an in vitro co-culture system was developed to investigate the effect of 
peripherally derived mononuclear cells (macrophages/osteoclasts) from GD patients 
on plasma cell proliferation and survival. This model simplifies the in vivo bone 
marrow microenvironment, which is more complex and includes other components 
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such as osteoblasts, stromal cells, lymphoid cells, vasculature, extracellular matrix 
and bone. Plasma cell isolates of high purity (>90%) were recovered from co-culture 
experiments, which was ascertained morphologically. Other investigators have used 
CD138 cell surface immuno-staining as a marker of plasma cell purity431. However, 
the data reported here show that CD138 (Sydecan-1) is lost from the cell surface of 
U266 cells within 72 hours of exposure to doxorubicin and so cannot be used as a 
marker of purity for cells recovered from co-culture wells. Co-culture experiments 
using myeloma cell lines have demonstrated a lower proliferation index, a reduction 
in cell signalling kinase activity, an increased Bcl6:Blimp1 ratio and up-regulation of 
the STAT3/ERK pathway in the CD138-ve fraction, conferring a phenotype 
associated with chemo-resistance425. Experimental data, including that by 
Schmidmaier et al. (2004), reporting the induction of chemoresistance on co-cultured 
CD138+ve plasma cells by a stromal layer, neglects the CD138-ve fraction where the 
more resistance cancer cells may reside431. Others have shown a significant loss of 
CD138 expression from untreated co-cultured myeloma cells lines in the first week 
of culture 425;432. The long term co-culture of primary plasma cells (6 weeks) leads to 
plasmablastic morphology, the loss of mature plasma cell markers such as 
CD38/CD138 and to the weak expression of more immature markers including CD19 
and CD45303. Based on the findings of the experiments reported here and previously 
published data, it was felt that CD138 was not a valid marker of plasma cell purity 
and could be misleading, therefore plasma cell purity was determined 
morphologically by Giemsa staining.    
    
In keeping with previous reports, co-culture (D14-21) led to a higher number of NCI-
H929 cells (GD or control) compared to myeloma cells grown alone252, but GD 
monolayers did not confer an additional numerical advantage. GD patients have been 
reported to have elevated plasma levels of the B-cell proliferating cytokines, IL-6, 
IL-8 and IL-1072;74;78, compared to a healthy control population, although this has not 
been reported by all investigators. IL-6 is the major growth and survival factor for 
plasma cells and has been found to be elevated in the blood of non-GD patients with 
myeloma433. Plasma concentrations of IL-6 in GD patients with an M-band have 
been found to be identical to those without a paraprotein81. IL-10 was found to be 
elevated in nearly all GD patients with a monoclonal band in comparison to only 
50% of those without an identifiable M-band81. Limitations of these observations 
 215 
include the fact that normal plasma levels do not necessarily reflect or exclude local 
elevations within the bone marrow microenvironment. The ability of Gaucher cells to 
secrete cytokines supportive of plasma cell expansion has been questioned. Boven et 
al. (2004) analysed splenectomy specimens by immunocytochemistry from GD 
patients and demonstrated that Gaucher cells have the phenotype of alternatively 
activated macrophages with only weak staining for cytoplasmic IL10 and membrane 
bound IL-658. These findings suggest that Gaucher cells are unable to produce 
significant amounts of B-cell stimulating cytokines, however, the ability of 
neighbouring lymphoid cells within the spleen pulp to secrete these interleukins has 
not been investigated. Future analysis of culture supernatants within our 
experimental model may help to document important differences in cytokine profiles 
between GD and control adherent monolayers.   
 
The number of U266 cells recovered was identical irrespective of co-culture (D14-
21). Giemsa staining of recovered inserts demonstrated large numbers of un-
recovered U266 cells that had adhered to the underlying monolayer, thus potentially 
masking a real increase in cell number from co-culture wells. Similar to the U266 
cell line, the 5TGM1 myeloma cell line is non-adherent in stock culture, but this cell 
line was also unable to be fully recovered from co-culture with a stromal layer 
despite several washes with PBS 434.  Yaccoby et al. (2004) showed a lower number 
of primary myeloma cells recovered from co-culture, possibly due to adherence, 
although in the face of increased BrdUrd staining and [3H] thymidine 
incorporation259. High purity osteoclast monolayers have been suggested to confer a 
proliferative advantage over bone marrow stroma in promoting the expansion of 
myeloma cell lines252. However, D21 cultures in our model contained large numbers 
of macrophages and at present the literature is devoid in documenting their ability to 
proliferate or adhere to co-cultured plasma cells. In keeping with our findings, Zlei et 
al. (2007) co-cultured U266 cells on bone marrow stroma from healthy controls, the 
M2-10B4 stromal cell line or PBMC osteoclast cultures, and reported no increase in 
the number of harvestable cells compared to culture alone432. However, others have 
clearly shown an expansion of U266 cells on primary stromal layers, but to varying 
degrees252. Osteoclast monolayers have been shown to lead to the increased 
incorporation of BrdU in co-cultured U266 cells302. Differences in experimental 
methodology, including growth medium (the majority of investigators used αMEM), 
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the timing of initiation or duration of co-culture, cytokine supplementation, 
composition of the adherent monolayers (stromal cell line, macrophage, osteoclast or 
primary bone marrow cells) or variation in the proliferating capacity of individual 
batches of foetal calf serum may add to the uncertainty when comparing results 
between individual investigators. The same batch of foetal calf serum was used for 
each experimental protocol reported above.  
 
Both in vitro and in vivo data support the concept of cell fusion between myeloma 
cells and osteoclasts, based on cytogenetic analysis, including FISH311;435. Co-culture 
experiments identifying the male-derived U266 cell line by either sex chromosome 
or BrdU labelling have supported the concept of an osteoclast-myeloma hybrid 
cell311. The authors did not include in their analysis osteoclasts with detectable 
myeloma cell nuclei based on remnant CD138 immuno-staining (i.e. cells 
undergoing phagocytosis) but failed to acknowledge that detectable plasma cell 
nuclei may be pending degradation in the face of an unidentifiable CD138+ve cell 
membrane. The prolonged culture of U266 plasma cells has been shown to lead to 
osteoclastic differentiation demonstrated by adherence, TRAP positivity, expression 
of bone metalloproteinases, RANK-L induced bone destruction and re-arrangement 
of the actin cytoskeleton310. Phagocytosis, adherence or the generation of such hybrid 
cells would reduce the number of U266 cells harvestable from our co-culture system.  
 
Neither the NCI-H929 nor U266 plasma cells require cytokine supplementation, 
including IL-6, to facilitate growth or survival in culture. Speculatively, the use of 
primary plasma cells259 or the INA-6 or OPC myeloma cell lines252;436, all heavily 
reliant on IL-6 for their growth and survival, may have demonstrated a numerical 
difference between culture alone, control co-culture or GD co-culture. Additionally, 
reducing the amount of FCS in the OC medium may have made our system more 
sensitive to any potential differences in cytokine profile secreted by GD or control 
monolayers. Differences in cytokine production by GD or control monolayers may 
be of insufficient magnitude to alter the growth cycle of these immortalised cell lines 
grown in OC medium supplemented with 10% FCS.  Abe et al. (2004) showed a 
large difference in OPC cell numbers following 14 days of osteoclast culture 
compared to culture alone, in medium devoid of IL-6 supplementation; however the 
expansion of co-cultured U266 cells (IL-6 independent) was dramatically less 
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impressive252.  Based on BrdU incorporation, stromal layers have been shown to lead 
to a vast increase in the percentage of S-phase cells in the IL-6 dependent cell lines, 
UM-2 and UM-3437. Osteoclast monolayers generated from myeloma patients or 
healthy controls have been suggested, by some investigators, to be equally supportive 
of primary plasma cell growth259.  Although others have demonstrated a growth 
advantage for both IL-6 dependent and independent myeloma cell lines on stromal 
layers derived from myeloma patients438.  Bone marrow stromal layers from multiple 
myeloma patients compared to healthy controls have been shown to up-regulate 
vascular cell adhesion molecule VCAM-1 expression via a NF-κB-dependent 
pathway and to secrete more IL-6, secondary to increased signalling via p38 
MAPK438.   
 
Experimental data, reported here, using trans-well inserts, supports a contact 
dependent increase in NCI-H929 cell number, irrespective of the origin of the 
monolayer. Co-culture experiments using adhesion assays and neutralising antibodies 
have shown that very late antigen VLA-4 expressing plasma cells can interact with 
stromal cells expressing VCAM-1304. It has been further demonstrated that the 
contact co-culture of plasma cells with primary osteoclast monolayers leads to 
substantially higher levels of IL-6 in the culture medium252. Trans-well experiments 
demonstrated lower IL-6 concentrations than contact co-culture, but were still 
significantly higher than levels found in the supernatant of osteoclast only 
cultures252. In the experiments presented here, the number of harvested NCI-H929 
cells was identical between Gaucher trans-wells and control trans-wells. In summary, 
based on cell number it has not been possible to show a proliferative advantage of a 
GD monolayer compared to that derived from healthy controls in contact co-culture 
for either myeloma cell line or for NCI-H929 plasma cells in a contact-deprived 
model. Paired experiments led to an identical number of NCI-H929 plasma cells 
harvested from GD co-culture, irrespective of the addition of ERT. It should be noted 
that the activity of stored ERT was not confirmed on thawing, adding uncertainty to 
this conclusion.    
 
Cell cycle analysis demonstrated an equivalent number of U266 and NCI-H929 cells 
in S-phase on D21, irrespective of whether they were cultured alone or co-cultured 
with GD or control monolayers. This was somewhat surprising given the higher 
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mean number of NCI-H929 cells following co-culture. Although there was a mean 
increase in NCI-H929 plasma cell numbers harvested from co-culture compared to 
culture alone, many individual experiments did not led to an increase in plasma cell 
numbers. In addition, by D21 the growth medium from co-culture wells is likely to 
be relatively more depleted of nutrients, with higher concentrations of toxic by-
products of cellular respiration, secondary to the presence of highly metabolic 
macrophages/osteoclasts. RPMI 1640 contains phenol red and co-culture wells 
demonstrated a slight change to a darker red colour, indicating lower pH, compared 
to non co-culture wells by D21, although not dramatically so. Speculatively, cell 
cycle analysis during the early stages of co-culture, reducing the impact of medium 
exhaustion and toxin accumulation, may have demonstrated a difference in the 
percentage of plasma cells in S-phase compared to non co-culture. In summary, GD 
co-cultures did not confer a proliferative advantage on either cell line compared to 
control co-culture. 
 
Contact co-culture (D14-21), GD or control, led to a more viable plasma cell 
population compared to contact-independent co-culture or 1 week culture alone, for 
both the U266 and NCI-H929 myeloma cell lines, in keeping with prior 
data252;259;432;437. GD co-culture (D14-21), irrespective of contact, did not convey a 
survival advantage over control monolayers. Cell viability was similar between 
plasma cell-only wells and those recovered from trans-well inserts, suggesting that 
soluble factors alone are not sufficient to promote survival. Macrophages are able to 
digest apoptotic cells and can recognise externalised phosphatidylserine on the cell 
membrane of damaged cells264. There is some evidence that osteoclasts have 
haemophagocytic activity, based on their ability to digest chondrocytes within the 
epiphyseal growth plate of rat and mice long bones439;440. As discussed above, there 
are publications supporting the concept of an osteoclast-myeloma fusion cell311. 
Yaccoby et al. (2004) reported that cultured osteoclasts have haemophagocytic 
capacity based on the ingestion of apoptotic plasma cells (trypan blue staining) 
following exposure to lethal doses of dexamethasone259. Although they demonstrated 
that 95% of their cultures were TRAP+ve osteoclasts, they failed to acknowledge 
that the remaining 5% of undifferentiated cells were TRAP-ve macrophages with 
potentially high phagocytic activity. A spectrum of differentiation is likely to exist 
within the monocytic lineage ranging between non osteolytic TRAP-ve macrophages 
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and TRAP+ve bone osteoclasts. In support of this concept, histological analysis of 
peri-prosthetic material, harvested at the time of operative invention, showed that a 
subset of TRAP+ve/vitronectin receptor+ve cells had both the morphology and 
CD68 immuno-reactivity of tissue macrophages441. A large number of cells within 
the culture system used in this chapter, were TRAP-ve and thus likely to have 
significant phagocytic activity.  
 
In these experiments, U266 plasma cells, pre-treated with doxorubicin, demonstrated 
a concentration-dependent increase in the percentage of TO-PRO+ve cells adhered to 
the underlying monolayer. In keeping with this finding, Zheng et al. (2009), by using 
antibodies to ICAM-1 to prevent the adhesion of melphalan-treated plasma cells to 
the underlying adherent monolayer, demonstrated an increase in the percentage of 
recoverable annexinV positive cells to levels seen in non co-culture wells245. The 
authors concluded that the contact co-culture of macrophages, protected plasma cells 
from chemotherapy based on annexinV analysis despite their own data suggesting 
that the apoptotic plasma cell population was adherent and thus not harvestable. The 
interaction of ICAM-1 with CD11b/18 on alveolar macrophages has been shown, by 
other investigators, to enhance the phagocytosis of FITC-labelled microspheres442. 
Despite these caveats, it can be concluded that the co-culture of untreated myeloma 
cell lines (D14-21) with GD or control monolayers leads to a more viable plasma cell 
population compared to culture alone. Assuming equivalence in phagocytic activity 
and the ability to adhere apoptotic cells between monolayers, GD co-cultures did not 
confer an additional survival advantage over control cultures.  
 
Co-cultured NCI-H929 or U266 plasma cells (D14-21) harvested from GD osteoclast 
cultures, in a contact-dependent manner, led to an increase in the melphalan IC50 for 
both cell lines. This was not seen in plasma cells recovered from control cultures. In 
addition, NCI-H929 cells harvested from GD co-culture and incubated for 24 hours 
with 50µM melphalan demonstrated reduced PARP cleavage, compared to those 
recovered from control co-culture. NCI-H929 cells, primed by GD monolayers, had a 
statistically higher number of plasma cells in GO/G1 phase of the cell cycle 
compared to non co-culture cells. Malignant cells arrested in G0/G1 have been 
shown to be more resistant to chemotherapy443;444. Cycling plasma cells in S-phase 
have lower expression of the anti-apoptotic protein Bcl-2445, conferring an increased 
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susceptibility to chemotherapy. The experiments reported here, were designed to 
establish whether GD monolayers primed plasma cells for survival. In comparison, 
other investigators, have added drug to the co-culture system, in order to replicate 
more accurately the in vivo model, or studied the rescue of plasma cells pre-treated 
with chemotherapy245;252;446.   
 
Bone marrow stromal cells, patient-derived or cell line, have been shown to be 
sensitive to both melphalan and doxorubicin, two drugs historically used in the 
treatment of multiple myeloma447. D18 osteoclasts/macrophages derived from GD 
patients were more sensitive at several different concentrations to doxorubicin 
compared to controls, whereas the MTS ratio following melphalan treatment was 
equivalent at all tested concentrations. Plasma cell purity was equivalent between 
wells harvested from control or GD patients following 7 days co-culture (mean 
purity ≥94%; minimum 90%). These findings exclude a small contaminating 
population of chemoresistant GD monolayer cells being the explanation for the 
observed increased in melphalan IC50. Potentially, up to 10% of harvested cells were 
admixed osteoclasts or macrophages. As GD monolayer cells were comparatively 
more sensitive to doxorubicin, this may have masked a true increase in the IC50 of 
recovered cells following culture (D14-21). Compared to control co-culture, 
significance was not reached in doxorubicin treated U266 cells recovered from GD 
co-culture (p=0.08). Additionally, it could be argued that post harvest, during the 24 
hour MTT cytotoxicity assay, the plasma cells were still in co-culture, with 
potentially a plasma cell/monolayer cell ratio of 10:1. Abe et al. (2004) added 
doxorubicin to co-culture wells using a ratio of 20:1 (plasma cells:osteoclast) and 
reported a protective effect based on cell number only252. Yaccoby (2005) claimed 
that a 1000:1 ratio (plasma cell:osteoclast) was sufficient to prevent dexamethasone-
induced apoptosis, based on annexinV analysis only303.  However, the author did not 
provide data on recoverable plasma cell number or cell proliferation and, in addition, 
failed to exclude the adherence or phagocytosis of apoptotic cells to the underlying 
osteoclast monolayer, thus casting doubt to this observation.  
 
Based on 24 hour MTT drug assay, using doubling concentrations of doxorubicin or 
melphalan, induction of chemoresistance was not demonstrated in myeloma cell lines 
primed by control co-cultures (D14-21) compared to culture alone. Prior literature 
 221 
has reported252;259 the induction of chemoresistance by bone marrow stroma and 
osteoclast layers in co-cultured plasma cells, which were in contact. Publications are 
lacking regarding the effect of macrophages on the chemosensitivity of plasma cells 
and the report by Zheng et al. has several limitations, as discussed above245.  In 
contrast, the system used here compares the ability of GD and control monolayers to 
prime plasma cells for survival. Unlike GD co-culture, control adherent monolayers 
demonstrated very few TRAP+ve osteoclasts by D21 and consisted almost entirely of 
macrophages. Whether the difference in osteoclast generation is the explanation for 
the observed difference in melphalan IC50 is speculative. As osteoclasts support 
myeloma growth and survival, investigators in recent years have studied the impact 
of novel agents including thalidomide309, bisphosphonates252, lenalidomide308 and 
bortezomib307;448 on their ability to impair osteoclastogenesis.     
 
Immortalised myeloma cell lines have an array of pro and anti-apoptotic proteins, 
which are constitutionally expressed (e.g. Bim, Bcl-xL, Mcl-1 and Bcl-2) and 
inducible by either cell contact or exposure to chemotherapy245;449-451. RPMI-8266 
plasma cells, co-cultured on a fibronectin-coated surface, down-regulated Bim 
expression (pro-apoptotic) and acquired chemoresistance to melphalan451. The 
addition of IL-6, a bone marrow derived cytokine, to cultures of the MDN myeloma 
cell line led to induction of the anti-apoptotic proteins Bcl-xL and Mcl-1252;450;452.  In 
addition, the transfection of U266 cells with a Mcl-1 over-expressing construct has 
been shown to prevent interferon-induced cell death453. Therefore, apoptotic 
regulatory proteins are inducible and can alter the chemosensitivity of myeloma cell 
lines. It was hypothesised that GD monolayers by altering the levels of these proteins 
in co-cultured plasma cells, confer melphalan chemoresistance. 
 
In the co-culture system used here, untreated NCI-H929 cells harvested from D21 
control monolayers, had increased levels of the pro-apoptotic protein Bim compared 
to those from GD co-culture, where expression was low and similar to that found in 
stock cells grown in R10 without RANK-L/M-CSF supplementation. In the NCI-
H929 myeloma cell line, Bcl-2 was not expressed. Curiously, Bcl-xL was also 
expressed at high levels in untreated NCI-H929 cells primed by control monolayers 
(D14-21) compared to GD osteoclast cultures. In keeping with these findings, 
macrophage monolayers matured with the conditioned growth medium of myeloma 
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cells have been shown to lead to the induction of Bcl-xL expression in co-cultured 
ARP-1 cells245. Bim, in comparison to other pro-apoptotic proteins, has been found 
to be potent killers of fibroblasts in an in vitro cytotoxicity assay454. Bim is known to 
down-regulate the activity of several anti-apoptotic proteins including Bcl-2, Mcl-1, 
A1, Bcl-xL and Bcl-w408. There is a rheostat of inducible pro and anti-apoptotic 
proteins and in these experiments only a targeted minority have been assessed. It can 
therefore be speculated that the net induction of pro-apoptotic proteins outweighs the 
up-regulation of any anti-apoptotic proteins in NCI-H929 cells primed by control 
monolayers compared to GD co-cultures. 
   
The increase in melphalan IC50 for both myeloma cell lines harvested from GD 
monolayers, compared to control co-culture, was in the order of only 30%. Contact 
deprivation from the underlying monolayer following harvest, may lead to a rapid 
loss in plasma cell priming and the subsequent re-balancing of pro and anti-apoptotic 
proteins. This may have contributed to the failure to demonstrate a protective effect 
following control co-culture, the inability to induce chemoresistance in harvested 
cells that were then exposed to doxorubicin and the relatively small increase in 
melphalan IC50 following GD co-culture. Western blot analysis has demonstrated the 
ability of pro and anti-apoptotic proteins to be induced followed by rapid decline 
within a few hours of therapeutic challenge453;455.      
 
In this co-culture system, immortalised cell lines were used due to their constant 
availability and ability to proliferate to yield high enough cell numbers to perform all 
outcome measures. It was demonstrated that peripheral lymphocyte subsets of GD 
patients, including CD19+ve B-cells, have low glucocerebrosidase activity as 
determined by flow cytometry (see chapters 3 and 5). During the course of this study, 
no GD patient with a plasma cell disorder underwent bone marrow examination. 
Clonal plasma cells derived from GD patients, due to low enzyme activity and 
abnormal sphingolipid metabolism, may have intrinsic differences in their cellular 
biology, which alter chemosensitivity. Therefore, they may be primed differently to 
immortalised plasma cells lines generated from individuals without GD. A further 
criticism of these experiments is that the myeloma cell lines used have intact 
glucocerebrosidase activity instead of glucocerebrosidase-deficient plasma cells that 
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may have differences in their cellular biology (discussed below). This should be 
addressed in future experiments.  
 
Morjani et al. (2001) demonstrated a link between multi-drug resistance (MDR) and 
sub-cellular glucosylceramide accumulation in a breast cell cancer line456. 
Additionally MCF7-resistant breast cancer cells, pre-treated with CBE for 24 hours, 
demonstrated further increased resistance to doxorubicin. Treatment with 
glucosylceramide synthase inhibitors had been linked to the increased 
chemosensitivity of primary and immortalised CLL cells, although the authors failed 
to demonstrate a reduction in the P-glycoprotein (P-gp) multidrug efflux pump in 
patient derived samples, suggesting an alternative mechanism457. Additionally, their 
data were based on an MTT assay, which reflects cell proliferation and viability, 
rather than more specific markers of apoptosis, such as caspase activity or PARP 
cleavage. Intracellular ceramide has a role in the regulation of cell cycling and the 
mediation of chemoresistance. Chemosensitivity is linked to the accumulation of 
ceramide458. In contrast, depleted intracellular levels are found in primary tumours, 
refractory cancers and immortalised malignant cell lines. Ceramide analogues have 
been shown to induce apoptosis in breast cancer cell lines458. GD patients, due to 
enzyme deficiency, are unable to hydrolyze glucosylceramide to ceramide. 
Translating this into a clinical setting, there is insufficient literature at present to 
conclude whether GD patients respond less well to chemotherapy than non-GD 
patients as both favourable and un-favourable responses have been reported81;136;161. 
There is no consensus on whether myeloma, complicating GD, is an indication for 
disease modifying therapy66;161.  As discussed in chapter 2, no patient with an 
established M-band had escalation in their paraprotein level whilst on ERT. 
Therefore, it can be argued, as MGUS can progress to myeloma, all patients with 
evidence of a clonal plasma cells disorder should receive ERT.  In this co-culture 
system, the addition of ERT did not lead to a reduction in the melphalan IC50 of co-
cultured NCI-H929 plasma cells.  However, it should be noted, that ERT was 
obtained and stored frozen from the remnants of patient vials. A major limitation to 
the data presented above is that the activity of stored ERT was not confirmed on 
thawing. This should be addressed in future experiments in order to validate this 
assay and the reported findings.  
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Autophagy is a lysosomal dependent process involved in the catabolism of cellular 
organelles and waste products. It has been speculated to play an important role in the 
modulation of chemosensitivity459. In a mouse model of neuronopathic GD, impaired 
autophagy has been demonstrated in neurons and astrocytes460.  It has been shown 
that mice haplo-deficient in beclin-1, a regulator of autophagy, are more susceptible 
to developing cancer and several human cancers have been associated with the loss 
of beclin-1 expression459. Speculatively, glycolipid loaded plasma cells in GD 
patients, due to the impaired function of autophagosomes, maybe less sensitive to 
chemotherapy. 
 
GD osteoclast cultures generated more TRAP+ve osteoclasts at D21 than control 
osteoclast cultures and this was enhanced further by the co-culture (D14-21) of either 
NCI-H929 or U266 plasma cells. In this experimental system, the number of 
osteoclasts generated from controls remained low and did not increase post co-
culture, suggesting that PBMCs cultured from GD patients are primed for 
osteoclastic differentiation. The co-culture of 5TGM1 or ARH-77 myeloma cells, 
which are reported to support osteoclastogenesis more vividly than the U266 cell 
line, may have led to enhanced osteoclast formation in control monolayers434. In the 
clinical setting, bony pathology, including lytic lesions, are often seen in patients 
with GD or myeloma242;403. Serum TRAP activity, a biomarker of osteoclast 
function, has been reported to be elevated in patients with GD86. Patients with GD or 
multiple myeloma have been shown to have raised serum levels of the osteoclast 
stimulating cytokines, MIP1α and MIP1β79;247.  In particular, MIP1β has been 
associated with the severity of skeletal disease in GD79. Bone marrow cells, derived 
from myeloma patients, generated more osteoclasts in culture, compared to healthy 
controls, when supplemented with the conditioned growth medium of myeloma cell 
lines. In addition, the authors demonstrated a correlation between myeloma disease 
severity and the number of osteoclasts generated in vitro305. Cancer patients with 
bone involvement generate more osteoclasts in culture from PBMCs compared to 
healthy controls290 . The number of osteoclasts generated in vitro has been shown to 
be predictive of skeletal metastasis in lung cancer patients461.  Therefore, immature 
precursors from myeloma or cancer patients, like GD patients, are also primed for 
osteoclastic differentiation. In the data reported here, the addition of ERT prevented 
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osteoclastogenesis in GD contact co-cultures wells, with the number of osteoclasts 
similar to that generated in control co-cultures.  
 
Unlike other investigators, these experiments were unable to demonstrate a contact-
dependent increase in the number of osteoclasts generated from co-culture in non-
GD patients252;259;302;304.  This may be due to differences in methodology. In 
comparison, Yaccoby et al. (2004) used PBMCs mostly derived from myeloma 
patients and co-cultured them with primary plasma cells. Additionally, they used 
higher concentrations of RANK-L, supplemented their culture medium with 
dexamethasone during the first few days of culture and performed co-culture with a 
20:1 plasma cell/osteoclast ratio259. Abe et al. (2004) used rabbit derived bone 
marrow stroma, higher concentrations of RANK-L, used a 1:2.5 plasma 
cell/osteoclast ratio and counted the number of resorption pits, in order to quantify 
osteoclastogenesis252. Hecht et al. 2008 used low concentrations of RANK-L 
(25ng/ml), co-cultured with a 1:4 to 1:1 plasma cell/osteoclast ratio and quantified 
osteoclastogenesis based on the detection of TRAP5b within the culture 
supernatant302. Unlike these investigators, the experiments reported in this chapter 
used RPMI 1640 rather than αMEM as the culture medium. Co-culture was initiated 
at a similar period to other investigators using PBMCs259;302 but in comparison only 
3x104 NCI-H929 cells or 7.5x104 U266 cells were added to D14 OC cultures (a total 
of 0.25x106 plated on D0). Therefore, it may be that there were insufficient plasma 
cells in contact with the control adherent monolayer to enhance osteoclastogenesis 
during the initial and perhaps critical phases of co-culture. This assumption is 
supported by the following pieces of evidence:- (1) The supplementation of 
conditioned medium from myeloma cell lines has been demonstrated to prevent the 
apoptosis of rabbit osteoclasts in culture298 (2) In situ hybridization and RT-PCR has 
demonstrated the expression of RANK-L, a potent stimulator of osteoclastogenesis, 
by both the NCI-H929 and U266 plasma cells lines462, although this has been 
contested by other investigators463 (3) Conditioned medium, NCI-H929 or U266 cell 
line derived, has been shown to enhance osteoclastogenesis in mouse derived bone 
marrow cell cultures462.  
 
The phagocytosis of plasma cells was noted in the majority of co-culture wells. GD 
monocytes cultured with heat denatured erythrocytes have been shown to 
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demonstrate tubular structures resembling glucosylceramide within the endo-
lysosomal compartment, on electron microscopic examination464. Speculatively, the 
phagocytosis of plasma cells by GD monocytes could impair lysosomal function 
further and potentate their inherent ability to undergo osteoclastic differentiation. GD 
co-culture experiments demonstrated a similar increase in the number of D21 
TRAP+ve osteoclasts, irrespective of contact, compared to GD non co-culture for 
either myeloma cell line, suggesting a soluble factor. This is in keeping with data 
cited above, where conditioned medium (CM) derived from NCI-H929 or U266 cells 
supported osteoclastogenesis462.  Candidate cytokines supporting osteoclast 
generation in the culture supernatant include MIP-1α, MIP1β, IL-3, hepatocyte 
growth factor (HGF) and RANK-L300. Neutralizing antibodies to osteoclastogenic 
cytokines (IL-1α, IL-1β, IL-6, TNF-α, TNF-β and PTH-rp) failed to prevent bone 
lysis by the CM of 5TGM-1 myeloma cells in a foetal rat bone assay434.  The 
inhibition of M1P-1α or RANK-L has led to decreased osteoclast production in a co-
culture based model259;305. In contrast, to the results reported in this chapter, other 
investigators have reported a contact-dependent increase in osteoclastogenesis 
mediated by the VLA-4/VCAM-1 axis between plasma cells and the adherent 
monolayer304;434. Data suggest that MIP-1α and MIP1β, via an autocrine/paracrine 
mediated process, can facilitate the VLA-4 dependent adhesion of myeloma cells to 
VCAM-1 expressing stromal cells304.  
 
In conclusion osteoclastogenesis, based on the number of TRAP+ve cells, is 
enhanced in GD co-culture, irrespective of contact and is prevented by the addition 
of ERT. Further experiments are required, including immunofluorescence for the 
vitronectin receptor and functional assays of bone resorption, to confirm these initial 
observations. The various intracellular signalling pathways of osteoclastogenesis 
mediated by RANK-L and M-CSF binding should be explored to document more 
fully differences between GD patients and healthy controls. 
 
Here, U266 cells were pre-treated with doxorubicin for 6 hours prior to plating alone 
or in contact co-culture (D18-21) for 3 days with GD or control-derived monolayers. 
Macrophage, stromal or OC monolayers have been suggested to protect primary 
plasma cells or myeloma cells lines from chemotherapy-induced death245;252;303;446.  
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Compared to U266 culture alone, co-culture led to a lower number of recoverable 
plasma cells, although there were no difference between GD and control-derived 
monolayers at all doxorubicin concentrations. Giemsa staining of recovered plasma 
cells cultured alone revealed a large number of apoptotic bodies and a higher 
proportion of left shifted plasma cells with disrupted morphology compared to co-
culture wells. In keeping with other investigators, the cultured monolayer was 
adherent to a more apoptotic population of non-harvestable plasma cells, compared 
to a relatively more healthy population in suspension245.  The numerical deficit of 
harvested U266 cells from the co-culture experiments reported here was not 
explained by adherence alone and haemophagocytosis was demonstrated in the 
adherent monolayer. Zheng et al. (2009), the only published report on the co-culture 
of chemotherapy-treated plasma cells with macrophage monolayers, suggested 
protection against cell death in the absence of phagocytosis, based on the inhibition 
of endocytosis by cytochalasin B245. However, they did not conclusively demonstrate 
that cytochalasin B entirely inhibited phagocytic activity, as this analysis was only on 
the non-adherent fraction. In addition, it might be speculated that the morphological 
analysis of the adherent monolayer would have confirmed the engulfment of plasma 
cells. In the experiments reported in this chapter, despite a similar number of non-
adherent annexinV/PI+ve cells for all doxorubicin treated wells (1-4µM), the 
percentage of TO-PRO+ve adherent cells increased dramatically with escalating drug 
concentration. This raises serious doubts about the conclusions of several 
investigators demonstrating a protective effect by osteoclasts, macrophages or bone 
marrow stroma based on the annexinV assay only303;446.         
 
GD monolayers, based on annexinV/PI data and 4 hour MTT dye reduction assay, 
led to a more apoptotic U266 plasma cell population compared to control co-culture 
(D18-21) in wells exposed to 4µM doxorubicin only, but not at lower concentrations. 
This suggests that GD osteoclast cultures do not provide an advantage in the rescue 
of doxorubicin treated U266 cells. This observation is only valid if GD adherent 
monolayers have equal phagocytic capacity and adhesive properties to apoptotic 
plasma cells at all tested concentrations of doxorubicin.  
 
In conclusion, here, for the first time, several novel findings are reported of GD 
derived monolayers on plasma cell growth, survival and chemosensitivity. Co-
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cultures derived from patients with GD primed plasma cells for survival against 
melphalan. Osteoclast cultures derived from GD patients did not convey a 
proliferative advantage over adherent monolayers generated from controls. GD 
macrophages were primed for osteoclastic differentiation and this was enhanced 
further by the co-culture of plasma cells. Further experiments are required with 
primary plasma cells or enzyme-deficient cell lines to replicate the in vivo 
microenvironment more accurately. More formal collaboration is required between 
individual treatment centres to collate patient data regarding the outcome of GD 
patients with plasma cell disorders. Currently it is unclear whether GD patients with 
myeloma have a worse prognosis or are more resistant to chemotherapy. Future work 
should build on the novel data presented above. 
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5 LYMPHOID ABNORMALITIES IN GAUCHER 
DISEASE 
5.1 INTRODUCTION 
Chapter 4 looked at whether the GD stromal environment promoted plasma cell growth, 
survival or harboured chemo-resistance. Locally, in the bone marrow, stromal cells and 
immune cells interact. GD is predominantly regarded as a macrophage disorder and the 
literature is relatively devoid of reports investigating the immunological 
microenvironment. There are only a handful of reports detailing lymphocyte 
abnormalities in GD4;139;255;347;348;465. Skewing of the immune profile in GD may 
facilitate plasma cell expansion, due to either impaired tumour surveillance or from the 
secretion of B-cell proliferating factors.   
 
In this chapter it was hypothesised that patients with GD have abnormalities within their 
lymphocyte subsets, either numerical or functional, that impair tumour surveillance. 
Findings are compared to those described in non-GD patients with malignancies. 
 
5.2 TUMOUR SURVEILLANCE 
Tumour surveillance describes the hosts’ ability to prevent, recognise and eradicate 
cancer cells. Impaired “tumour surveillance” may be as important mechanistically in the 
development of cancer as intrinsic changes within the cells themselves that confer 
malignant transformation. Observational data from patients with various cancers have 
demonstrated inferior outcomes or progressive disease in those with a low absolute 
lymphocyte counts466;467, NK-cells468, iNK-T cells469 or elevated regulatory T-cells470. 
Additionally, an abnormal CD4/CD8 ratio has been shown to be a predictor of poor 
outcome in those with cancer468. Patients with human immunodeficiency virus (HIV) 
infection have an elevated risk of malignancy471. The stimulation of NK and iNK-T cells 
in mouse models of carcinogenesis has been shown to lead to tumour regression and 
prolonged survival472. Furthermore patients with common variable immunodeficiency, a 
condition characterised by both T- and B-cell defects, have an increased risk of 
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developing gastric and haematological cancers473. Dhodapkar et al. (2003) assessed the 
ability of plasma cell antigen presentation by dendritic cells (DCs) to stimulate 
autologous T-cells derived from patients with MGUS and myeloma. They showed that 
patients with myeloma had impaired effector T-cell responses, based on ELISPOT IFN-γ 
production, when compared to patients with MGUS474. These studies demonstrate the 
importance of lymphocytic cells in the immunological control of cancer.  
   
Both the innate and adaptive immune system partakes in the immunological attack of 
cancer cells. Tumour-derived antigens are presented by cell surface MHC class I 
molecules to the T-cell receptor of cytotoxic T-cells (CTLs). Recognition of non-self 
leads to the lysis of cancer cells, secondary to the release of perforin, FasL, IFN-γ, 
granzymes and granulysin336.  
 
Stimulated iNK-T cells can kill cancer cells via the activation of CTLs and NK- cells338. 
NK-cell activity is modulated by inhibitory and activating cell surface receptors475. NK-
cells can induce tumour cell death directly by the exocytosis of cytotoxic granules, the 
engagement of tumour cell death receptors (Fas/TRAIL) and indirectly by maturing 
dendritic cells, all of which are crucial in facilitating a potent CTL response337. Plasma 
cells are an important component of the adaptive immune system and generate a diverse 
array of antibodies recognising non-self. The production of tumour-specific 
immunoglobulins leads to cancer cell death secondary to direct opsonisation, 
complement-dependent cytotoxicity or antibody-dependent cytotoxicity, via the 
activation of NK-cells or macrophages336. Macrophage effector function has been 
suggested to be compromised in patients with GD, with defects in free radical 
production, phagocytosis and the killing of staphylococcus aureus being reported476. 
Lytic granules, including perforin, are stored within lysosomal-like compartments and 
their release maybe impaired in GD477.   
 
5.2.1 NK-CELLS 
NK-cells play a major role in innate immunity and kill tumour cells via the release of 
cytotoxic granules or from the engagement of trans-membrane death receptors, including 
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Fas and TRAIL. NK-cells are typically CD3-ve, CD56+ve and CD16+ve and constitute 
approximately 15% of peripheral blood lymphocytes475. Two distinct populations can be 
identified based on their intensity of CD56 expression. The CD56 dim population 
predominates in peripheral blood (~90%) and confers high cytotoxicity. In contrast, the 
CD56 bright population is less common, secretes high quantities of cytokine following 
activation but confers little direct cytotoxicity337.  NK cells, like T-cells, have an array of 
inhibitory and activating receptors including killer immunoglobulin-like receptors 
(KIRs), lectin receptors, leukocyte immunoglobulin-like receptors, lectin receptors, Fc 
receptors and MHC class I molecules475. Tumour cells can evade elimination by CTLs 
by the down-regulation of MHC class I molecules. However the loss of MHC class I 
expression in cancer cells induces killing by NK-cells due to loss of inhibitory receptor 
signalling337;475.  Low NK-cell activity has been correlated with an elevated risk of 
cancer development and the subsequent progression to metastatic disease342;343.  
 
5.2.2 INVARIANT NK-T CELLS 
Although iNK-T cells constitute 0.01-1% of all peripheral blood T-cells478, they play a 
key role in innate and adaptive immunity. Animal models have demonstrated their 
immunological importance in regulating cancer surveillance, allergic reactions, 
inflammatory conditions, auto-immune disease, microbial defence and organ 
rejection338. In peripheral blood, their numbers have been found to be depleted in 
untreated patients with either melanoma or prostate cancer479;480. Similarly to 
conventional T-cells, they have a T-cell receptor but in contrast, they uniformly express 
the same alpha chain (Vα24Jα18 humans; Vα14Jα18 mice)481 with preferentially 
pairing to Vβ11. Antigen presenting cells, including macrophages and DCs, present 
processed glycolipid on their surface by CD1d tetramers. iNK-T cells are activated by 
the engagement of their T-cell receptor by CD1d presented antigens332. CD1d molecules 
are related to MHC class I molecules and are complexed with β2 microglobulin. 
Elevated surface CD1d expression has been demonstrated on the monocytes of patients 
with GD4.  
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Glycolipids have important T-cell immunomodulatory effects21. The administration of 
beta-glycolipids (β-glucosylceramide being an example) has been shown to beneficially 
effect the T-cell profile in various animal models of disease including hepatitis482, 
colitis483, hepatocellular carcinoma21 and acute/chronic GvHD484. Alpha glycolipids, 
such as alpha-galactosylceramide, also alter T-cell subsets, ameliorate disease and alter 
cytokine profiles485. Zigmond et al. (2007) administered glucosylceramide to mouse 
models of hepatocellular carcinoma (HCC) and autoimmune colitis.  Increased IFN-γ 
production was associated with tumour regression in the HCC mouse model whereas 
depressed IFN-γ levels were documented in mice with auto-immune colitis483. 
Therefore, iNK-T cells have remarkable plasticity, expressing either a Th1 (IFN-γ) or 
Th2 (IL-4) cytokine profile depending on the net contribution of individual stimuli. 
Although glucosylceramide, a naturally occurring sphingolipid, has been shown to have 
an anti-inflammatory and anti-tumour effect in mouse models, it is currently unknown 
whether β-glycolipids are effectively loaded onto CD1d molecules or out-compete more 
potent immuno-modulatory ligands in GD. 
  
5.2.3 HYPOTHESIS 
The following hypotheses are explored in this chapter:-  
 
Hypothesis 1:- GD lymphocytes have low glucocerebrosidase activity, accumulate 
substrate and have abnormalities within their lymphoid repertoire that contribute to a 
microenvironment favourable to carcinogenesis.   
Rationale:- Non-GD patients with abnormalities in their lymphocyte count or subsets, 
including NK-cells, have an increased incidence of malignancy.   
Methods:- Local patient data, immunophenotyping and electron microscopy.   
 
 
Hypothesis 2:- Patients with GD, due to disturbances in sphingolipid metabolism and 
glycolipid presentation, have abnormalities in iNK-T cell expansion. This contributes to 
a microenvironment conducive to malignancy.  
Rationale:- Numerical low numbers of invariant NK-T cells are seen in individuals with 
malignancy.  
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Methods:- Sphingolipid stimulation assays, cell culture.   
 
Hypothesis 3:- Patients with GD, due to impaired NK-function, have impaired tumour 
surveillance.   
Rationale:- Decreased peripheral NK-cell lytic activity is associated with impaired 
tumour surveillance in non-GD individuals. 
Methods:- NK killing assays.  
 
 
Hypothesis 4:- Patients with GD have numerical and function abnormalities within their 
peripheral blood cells that lead to impaired tumour surveillance.  
Rationale:- Non-GD patients with impaired peripheral blood killing assays have an 
elevated risk of malignancy.  
Methods:- Peripheral blood killing assays.
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5.3 METHODS 
The methods described here are supplementary to those described in chapter 2. 
 
5.3.1 FLOW CYTOMETRY – LYMPHOCYTE SUBSETS 
Flow cytometry was performed, as described in section 2.5, in order to establish the 
percentage of CD3+ve, CD3-ve/CD56+ve, CD3+ve/CD56+ve, CD3+ve/6B11+ve, 
CD3+ve/CD4+ve and CD3+ve/CD8+ve lymphocytes in healthy controls and patients 
with GD. Lymphocytes were identified based on their forward and side-scatter 
characteristics with a minimum of 10,000 gated events acquired.  
 
5.3.2 ANALYSIS OF B-CELL SUBSETS 
Peripheral blood B-cell subsets were analysed by staff in the Department of 
Immunology at the Royal Free Hospital (London, UK) according to a standard operating 
procedure. Briefly, 1ml of sample blood (EDTA tubes) was added to 14mls PBSA (5l 
PBS, 10g azide, 10g bovine serum albumin). Cells were centrifuged at 1500rpm for 15 
minutes and re-suspended in a 1:10 dilution of Hoffmans buffer (8.3g NH4Cl, 1g HC03, 
37mg disodium EDTA, pH7.4). Following incubation at room temperature for 10 
minutes, cells were centrifuged for 5 minutes at 1500rpm. Cells were washed and re-
suspended in 1ml PBSA. 100µl of cell suspension was added to two tubes containing the 
following antibody cocktails:- 
 
Tube A:- CD27-FITC (Beckham Coulter) 1/5, CD19-PC7 (BD Biosciences) 1/4, IgD-PE 
(Oxford Biotechnology) 1/200 and IgM-Cy5 (Jackson Immuno Research) 1/400. 
Tube B:- CD38-FITC (BD Biosciences) 1/4,  CD21-PE (BD Biosciences) 1/4, CD19-
PC7 1/4 and IgM-Cy5 1/100. 
 
Each tube was made up to a total volume of 20µl with PBSA. Samples tubes were mixed 
thoroughly and incubated in the dark for 15 minutes. 20µl of 1% paraformaldehyde was 
added to each tube prior to acquisition on a FACSCalibur (Becton Dickinson).  
















Quad Events % Gated X Mean Y Mean
UL 3306 65.13 4.44 903.35
UR 940 18.52 54.64 671.68
LL 162 3.19 7.06 10.26
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Figure 5-1.  B-cell subsets determined using two panels of antibodies. 
 
5.3.3 CONDURITOL-B EPOXIDE ASSAYS  
PBMCs were separated from peripheral blood as described in section 2.4.1. Ce1ls 
(1x106/ml) were plated, in duplicate. Growth medium medium was supplemented with 
IL-2 (200iu/ml) and several different concentrations of CBE (0-500µM). A half change 
in growth medium was performed on D4. PBMCs were recovered on D8 and 
glucocerebrosidase activity was determined using a fluorometric-based assay (chapter 
2.8.5). CBE was stored in concentrated aliquots (100µL; 50mM; -20°C) until required. 
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IL-2 was reconstituted in 50mM acetic acid (filtered) and divided into aliquots of 
10,000U (stored at -20°C until use).  
 
The cytotoxicity of CBE was determined by plating 2x105 PBMCs, in triplicate, in 96- 
well plates. Growth medium was supplemented with IL-2 (200iu/ml) and several 
different concentrations of CBE (0-500µM). Distilled water (300µL) was placed into 
empty wells to prevent sample evaporation. Culture wells underwent a half change in 
growth medium on D4 (100µL) and an MTS dye reduction assay was performed on D7 
as described in section 2.8.3.    
 
5.3.3.1 PBMC LIPID STIMULATION CULTURES 
PBMCs from healthy controls and patients with GD were separated from peripheral 
blood using 3% dextran and Ficoll-Paque™ plus, as described in section 2.4.1. The 
percentage of 6B11+ve lymphocytes in a CD3 gate was quantified to establish the 
percentage of iNK-T cells. The 6B11 monoclonal antibody identifies the CDR3 epitope 
on the TCR α-chain formed by recombination of Vα24 and Jα18. As described in 
chapter 2.5, cultured cells were incubated for 30 minutes on ice with antibodies against 
6B11 (FITC) and CD3 (APC).  
 
2mls of PBMCs were plated (1x106/ml) in 24-well plates and cultured in R10 with 
200iu/ml IL-2 alone or supplemented, in addition, with either 100ng/ml of alpha-
galactosylceramide (αGalCer; Enzo Life Sciences; distributed Axxora, Nottingham, 
UK) or 100ng/ml of isoglobotrihexosylceramide (iGB3; Enzo Life Sciences). Both 
glycolipids were soluble in pyridine and stored concentrated at 5µg/ml at -20°C until 
use. PBMCs were cultured for 14 days with twice weekly half changes in growth 
medium (1ml).  Glycolipid was added to wells at 100ng/ml for the first two medium 
changes only. The percentage of iNK-T cells (CD3+ve/6B11+ve) was quantified on 
D14. Recovered cells were identified based on the expression of the pan T-cell marker, 
CD3, within a live gate.  The majority of cultured cells were T-cells and many IL-2 
stimulated cells were apoptotic as indicated by the dense population of cells with low 










additional criteria of detecting at least 100 cells with CD3/6B11 positivity. 6B11+ve 




























Figure 5-2. Flow cytometry for invariant NK-T cells.  
6B11+ve invariant NK-T cells were identified post 14 day culture (αGalCer supplemented) within a 
live gate and reported as a % of the total number of CD3+ve cells (A, B, D).  (C) Type I NK cells co-
expressed CD3. 
 
5.3.3.2 PBMC αGALCER - CBE CULTURES 
PBMCs from healthy controls were cultured as described above (see section 5.4.3.1), but 
in contrast cultures were terminated on D10. Experiments were performed in duplicate 
and cells were grown in IL-2 alone (200iu/ml), IL-2 plus αGalCer (100ng/ml) or with 
IL2, αGalCer and CBE (50µM or 100µM). The percentage of iNK-T cells was 









5.3.4 LYMPHOCYTE GLUCOCEREBROSIDASE ACTIVITY  
Flow cytometry was used to determine enzymatic activity in control and GD- derived 
lymphocytes as described in chapter 2.5.4 (FDGlu assay).  Within the lymphocyte gate, 
a minimum of 10,000 events were analysed with at least 2,500 events in lymphoid sub-
populations. The assay was made specific for lysosomal glucocerebrosidase by dividing 
the MFI of the sample, reflecting liberated fluorescein from the carrier substrate di-ß-D-





























Figure 5-3. (A, B)  Flow cytometry plots demonstrating the gating of CD19+ve lymphocytes. (C) 
Representative histograms demonstrating liberated fluorescein from control CD19+ve lymphocytes 
(green line) compared to a paired sample pre-treated with CBE (red line).
 239 
5.3.5 NK-CELL AND PBMC KILLING ASSAYS  
NK-cell killing assays were performed as described in detail in section 2.11. Briefly, NK 
cells were separated from the peripheral blood of healthy controls and patients with GD 
using MACs technology, as described in section 2.11.1. Isolated CD56+ve NK cells 
were cultured alone or stimulated with IL-2 (200 iu/ml) overnight. Killing assays were 
performed using a 5:1 effector:target ratio. Target cells (NCI-H929, JJN3 and K562 cell 
lines) were pre-labelled with the fluorescent dye PKH26. K562 is a monocytic 
leukaemia-derived cell line and is particularly sensitive to effector cell killing342;343;486. 
The percentage of apoptotic PKH26 target cells was determined by uptake of the nucleic 
acid dye TO-PRO®-3-iodide (see chapter 2.5.5) on completion of the 4 hour killing 
assay.  
 
All PBMC killing assays were stimulated overnight with IL-2 (200iu/ml) and performed 
at effector:target ratios of 40:1, 20:1 and 10:1. The percentage of TO-PRO+ve target 
cells (NCI-H929, JJN3 or K562) was determined 4 hours post co-culture.  
 
Paired healthy controls were within 10 years of age to those with GD and performed in 
parallel at the same time. 
 
5.3.6 ELECTRON MICROSCOPY    
PBMCs were isolated from peripheral blood and prepared for electron microscopy as 
described in chapter 2.4.2.  Prepared samples were viewed using a Phillips CM120 
transmission electron microscope.  
 
5.3.7 IMMUNOFLUORESCENT STAINING 
Cytospins were prepared using PBMCs isolated from healthy controls and patients with 
GD (0.22x106/ml; 400rpm; 5 minutes). Cytospins were dried in air for 2 hours and slides 
were stained with lysotracker and BODIPY-tagged lactosylceramide, as described in 




5.4.1 LYMPHOCYTE COUNT 
It has been suggested that patients with GD may develop gammopathy on a background 
of chronic antigenic stimulation. This may be reflected by an increased peripheral 
lymphocyte count, perhaps representing polyclonal stimulation. The mean ALC was 
similar between demographically matched healthy controls (1.6±0.4x109/l; mean±SD; 
n=22), untreated patients with GD (n=45; 1.7±1.2x109/l) and from the same patients 
(n=45) after receiving a minimum of 12 months ERT (1.9±0.9x109/l). Within the ERT 
cohort, 6/8 patients with the highest lymphocyte count had undergone splenectomy 
(Boxed group; Figure 5.4) and this difference was statistically significant when 
compared to the number of asplenic individuals outside of the boxed group (Fisher’s 
exact test, p<0.01). The development of polyclonal lymphocytosis is not uncommon in 
patients without GD following splenectomy and therefore this is an important 
confounding factor.  
 
The mean lymphocyte/WCC ratio was identical between individual groups, although, in 
the ERT cohort the spread of results was clearly greater. Paired analysis failed to 
demonstrated a reduction in the lymphocyte count following a minimum of 12 months 
ERT (Pre ERT, 1.8±1.3x109/l; ERT 1.9±0.9x109/l; n=31; mean±SD). This is in contrast 
to absolute immunoglobulin levels, which decreased with therapy (see Chapter 3). In 
addition, the mean ALC was similar in untreated individuals with gammopathy 
(1.7±1.0x109/l; n=25), polyclonal or monoclonal, and those with normal 
































Figure 5-4. (A) Absolute lymphocyte count and (B) lymphocyte/white cell count ratio in healthy 
controls, untreated GD patients and those on ERT.  
Mean indicated by horizontal line. Boxed populations in (A) represent outliers and individuals who 
have had a splenectomy are represented in red.   
 
5.4.2 FUNCTIONAL AND STRUCTIONAL ABNORMALITIES IN 
GD LYMPHOCYTES 
Peripheral lymphocytes are young haematopoietic cells with a short half-life in blood. 
Therefore, they may not develop the same functional abnormalities or ultra-structural 
characteristics as lipid-laden macrophages. Experiments in this section investigate 
glucocerebrosidase activity, glucosylceramide deposition and lipid trafficking within 
individual lymphocyte subsets.   
 
5.4.2.1 LYMPHOCYTE GLUCOCEREBROSIDASE ACTIVITY 
Peripheral blood monocytes and lymphocytes were gated on their forward and side 
scatter characteristics.  Glucocerebrosidase activity was determined by the MFI of 
liberated fluorochrome from the carrier substrate, FDGlu, and was expressed as a ratio 
of the sample MFI to that obtained from a paired sample from the same individual 
treated with the lysosomal glucocerebrosidase inhibitor CBE. Lymphocytes, compared 




















































lymphocytes from patients with GD demonstrated a significantly lower enzyme activity 




















Figure 5-5. Glucocerebrosidase activity as determined by flow cytometry of monocytes and 




















Figure 5-6. Glucocerebrosidase activity as determined by flow cytometry of lymphocyte subsets 


























































































































































































































Figure 5-7. Lymphocyte glucocerebrosidase activity (Control versus Gaucher).  
(a) Glucocerebrosidase activity in lymphocyte subsets was determined by gating on individual 
populations using fluorochromes detectable in FL2/FL3. (B, C) Histogram plot of FDGlu activity in 
FL1 of B and NK cells from healthy controls. (D) Histogram demonstrating absent activity in NK 








Individual lymphocyte subsets were identified by immunostaining and the enzyme 
activity within each subset was quantified. CD19+ve B-cells, compared to CD3+ve T-
cells, had significantly higher glucocerebrosidase activity in healthy controls (p<0.01; 
MW test). Enzyme activity was significantly lower in all lymphoid subsets derived from 
patients with GD. (Figure 5-6; Figure 5-7). 
 
 
5.4.2.2 ABNORMAL MEMBRANE TRAFFICKING IN GD LYMPHOCYTES 
It has previously been shown that glucocerebrosidase-deficient cells have impaired re-
cycling of membrane lactosylceramide within the endo-lysosomal compartment 487. 
Lactosylceramide is normally concentrated in membrane structures with a small amount 
being recycled in the endocytic pathway. Previously, our laboratory has demonstrated 
the abnormal accumulation of lactosylceramide in lysosomes of cultured macrophages 
from patients with GD (Personnel communication; Dr Derralynn Hughes and Matthew 
Reed). 
 
Immunofluorescent staining was used to assess the distribution of BODIPY 
lactosylceramide (visualised green) within the cell, including the endo-lysosomal 
compartment (Lysotracker; visualised red). In both monocytes and lymphocytes derived 
from healthy controls, lactosylceramide was concentrated in the Golgi and endosomal 
membranes (Figure 5-8). Compared to control lymphocytes, control monocytes had 
significantly more lysosomes, as demonstrated by the number of lysotracker stained 
organelles.  Both GD monocytes and lymphocytes accumulated lactosylceramide in the 
lysosomal compartment, as demonstrated by the co-localisation of BODIPY (visualised 
yellow). Thus, it can be concluded that lymphocytes from patients have a pattern of lipid 

























































Figure 5-8. Representative immunofluorescent images of PBMCs from patients with GD and 
healthy controls.  
Patients with GD concentrated BODIPY-lactosylceramide (green) to the lysosomal compartment 
(red) as visualised yellow (combined signal). In contrast, cells from healthy controls rarely co-
localised signals. Purple arrows indicate lymphocytes, white arrows represent monocytes.    
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5.4.2.3 ELECTRON MICROSCOPY OF LYMPHOCYTES 
It has been demonstrated above that lymphocytes from patients with GD have low 
glucocerebrosidase activity and dysfunctional lysosomes. Using transmission electron 
microscopy (TEM), the lymphocytes of 3 patients with GD, including one untreated, 
were assessed for evidence of glucosylceramide accumulation. Accumulated 
glucosylceramide adopts a tubular structure when deposited in the lysosomes of enzyme- 
deficient macrophages264.  
 
Lymphocytes were identified on TEM based on size, shape and a small rim of peri-
nuclear cytoplasm. In contrast, monocytes were larger, had a lower nuclear:cytoplasmic 
ratio, contained more organelles and had an indented nucleus. Several mitochondria 
were seen in the cytoplasm of lymphocytes, but the presence of other identifiable 
organelles was rare. There was no difference in the morphology of lymphocytes derived 
from healthy controls or patients with GD. Distended structures, consistent with 
engorged lysosomes, were not detected in lymphocytes from any of the three GD 
patients, despite scanning many slices. In addition, accumulation of tubular structures 
within the organelles of GD monocytes was not demonstrated (data not shown). The 
ultra-structural appearances of monocytes derived from GD patients were identical to 
those seen in healthy controls.  
 
5.4.3 B-CELL SUBSETS 
Building upon the theory of chronic antigenic stimulation, it was hypothesised that 
patients with GD, due to their elevated incidence of gammopathy, may have a relatively 
higher percentage of differentiated B-cells in peripheral blood compared to healthy 
controls. The control population was a historical cohort consisting of 25 healthy 
volunteers. The cohort of GD patients (n=10) described below were of mixed clinical 







































































Figure 5-9.  Transmission electron microscopy of lymphocytes derived from controls (A, B) and an 
untreated patient with GD (C-F).
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Number - 25 10 - 
CD19 CD19+ve 12.0±4.9 9.3±3.2 0.13 
Naïve B-cells CD19+ve IgD+ve CD27-ve 64.9±12.8 63.9±14.4 0.84 
IgM Memory CD19+ve IgD+ve CD27+ve 12.0±6.9 12.7±5.6 0.65 
Class Switched CD19+ve IgD-ve CD27+ve 13.2±5.0 11.7±8.0 0.48 
CD21 low B-cells CD19+ve CD21-ve CD38-ve 7.4±2.5 8.7±3.5 0.52 
Transitional  
B-cells 
CD19+ve CD21int CD38+ve IgM+ve 5.3±2.4 7.0±3.5 0.25 
Plasmablasts CD19+ve CD21 –ve CD38+ve IgM-ve 2.2±2.1 0.8±0.7 <0.05 
 
Table 5-1. Percentage of B-cell subsets in the peripheral blood of controls and Gaucher patients. Int 
= intermediate.  
 
Patients with GD had a normal percentage of CD19+ve B-cells in the peripheral blood. 
Surprisingly, the number of plasmablasts was lower in patients with GD (p<0.05), 
including two individuals with a long-standing paraprotein. These results demonstrate 
that patients with GD do not have skewing of the B-cell population towards a more 
















Figure 5-10. Percentage of peripheral plasmablasts in the blood of healthy controls and GD patients. 
















































5.4.4 T-CELL SUBSETS 
GD has been linked to a higher incidence of several malignancies and abnormalities 
within T-cell subsets (as discussed in section 5.2), including the depletion of NK-cell 
numbers, may contribute to impaired tumour surveillance. Healthy control populations 
were age matched (described in Table 5.2) in preference to gender and race. There was a 
maximum of 3 patients who were not receiving ERT within any of the analysed groups. 
Patients with GD were mainly composed of middle-aged men who represent the 















Table 5-2. Demographic data on GD patients and healthy controls for each comparison analysed 
below.  
5.4.4.1 CD3 POPULATION 
















Figure 5-11. (A) Percentage of CD3+ve lymphocytes in controls and GD patients. Mean indicated by 





























CD3 42.3 46.9 24 21 1.7 3.3 
CD3/CD4 41.7 46.7 37 31 1.5 1.8 
CD3/CD8 38.8 45.0 32 28 1.9 2.1 
CD1d 
Monocytes 
42.4 44.6 17 19 1.1 2.1 




5.4.4.2 CD3/4 AND CD3/8 POSITIVE POPULATIONS 
The percentage of CD3+ve/CD4+ve and CD3+ve/CD8+ve cells was determined within 
















Figure 5-12. Representative flow cytometry plots of (A) CD3/4 and (B) CD3/8 lymphocyte 
populations. 
 
Compared to the control group, GD patients had a significantly lower percentage of 
CD3+ve/CD4+ve lymphocytes (p<0.05). There were a decreased percentage of 
CD3+ve/CD4+ve cells (p=0.01) in splenectomised GD patients compared to the 
“unselect” GD population (Figure 5-13). Controls had a lower percentage of 
CD3+ve/CD8+ve cells (p=0.05) than GD patients with gammopathy. Compared to non-
GD patients, the mean percentage of CD8+ve T-cells in the “unselect” GD population 
was not elevated. Patients with gammopathy, monoclonal or polyclonal, demonstrated a 
similar spread in values for both lymphoid populations compared to the “unselect” GD 
cohort.  
 
The CD4/CD8 ratio was significantly higher (p<0.001) in healthy controls (1.8±0.7; 
mean±SD) compared to that found in GD patients (1.0±0.7). Excluding patients with 
undetectable chitotriosidase, as this is likely to represent those with homozygous null 
mutations and thus not representative of disease activity, and those with unavailable 
data, there was no correlation between current chitotriosidase activity and the percentage 
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of CD3+/CD4+ve or CD3+ve/CD8+ve cells (Figure 5-13). Limitations of this analysis 
include the low number of patients, absent documentation of the chitotriosidase 
genotype (null mutations) and the fact that the majority of patients were on ERT with 
plasma chitotriosidase activities less than 2000nmol/hr/ml. Pre-ERT chitotriosidase 
activity did not correlate with the current percentage of CD3+ve/CD4+cells (r2=0.004, 


























Figure 5-13. Quantification of CD4+ve and CD8+ve peripheral T-cells in control and GD patients.  
Percentage of (A)CD3+ve/CD4+ve and (B)CD3+ve/CD8+ve cells. GD patients with a paraprotein 
are represented in red within the GD gammopathy cohort. Mean indicated by the horizontal line. 
Log chitotriosidase activity compared to the % of (C) CD3+ve/CD4+ve and (D) CD3+ve/CD8+ve 










































































































5.4.4.3 NATURAL KILLER CELL POPULATIONS 


















Figure 5-14. Representative flow cytometry plot of lymphocytes using CD3/56 immunostaining. 
 
In comparison to CD3+ve NK-cells, CD3-ve NK-cells expressed CD56 more intensely. 
The peripheral blood of GD patients contained a higher percentage of CD3+ve NK-cells, 
but a lower percentage of CD3-ve NK-cells (Table 5-3).  
 
Cells Control Gaucher Disease 
CD3+ve/CD56+ve % 5.1±3.1 9.5±7.6** 
NK CD3-ve/CD56+ve % 12.9±7.7 9.0±4.7* 
CD56+ve % 18.1±7.7 19±8.8 
 
Table 5-3. NK subsets in control and GD patients. Mean±SD. *p<0.05 **p<0.01 
 
Compared to the unselected GD population, patients with gammopathy, including those 
with an M-band, had a similar mean and spread of results for both NK populations. 
Asplenic patients had an identical distribution of results to GD patients with 
gammopathy and the unselected GD cohort. In patients with GD, current chitotriosidase 
activity did not correlate with the percentage of CD3+ve/CD56+ve (r2=0.1, p=0.13) or 
CD3-ve/CD56+ve cells (r2=0.1, p=0.14). Pre-ERT chitotriosidase activity did not 
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correlate with the current percentage of CD3-ve/CD56+cells (r2=0.008, p=0.95) or 



























































Figure 5-15.  Percentage of (A) CD3+ve/CD56+ve and (B) CD3-ve/CD56+ve cells. GD patients with 
a paraprotein are represented in red within the GD gammopathy cohort.  
Horizontal line indicates the mean. 
5.4.4.4 INVARIANT NK-T CELLS 
Invariant NK-T cells (CD3+ve/6B11+ve) are known to expand when presented with 
sphingolipid on CD1d tetramers. As sphingolipid metabolism is abnormal in GD, it was 
hypothesised that the number of iNK-T cells may be different to that observed in healthy 
controls. The number of 6B11+ve iNK-T cells reported below is a ratio to the total 
number of CD3+ve T-cells. Compared to healthy controls, GD patients had a 
significantly lower percentage of iNK-T cells (0.14%±0.09 versus 0.07%±0.07; 
mean±SD; p=0.001; Figure 5-16). Despite low patient numbers in the GD gammopathy 
group, there was still a highly significant decrease in the percentage of iNK-T (p<0.01) 
compared to controls. Chitotriosidase activity, pre-ERT (r2=0.008, p=0.95) or current 























































































Figure 5-16. (A) Percentage of CD3/6B11+ve invariant NK cells in healthy controls and GD patients. 
Line represents median. GD patients with a paraprotein are represented in red in the GD 
gammopathy cohort. Flow cytometry plots from two controls (B, C) and a GD patient (D). 
Percentage of iNK-T cells is reported in the right upper quadrant. 
 
 
5.4.4.5 CD1D EXPRESSION 
CD1d molecules are expressed on antigen presenting cells, including peripheral blood 
monocytes. The MFI of CD1d was statistically higher on GD monocytes compared to 



































































Figure 5-17. (A) Median fluorescent intensity of CD1d molecules on monocytes derived from 
healthy controls and GD patients.  
Mean represented by horizontal line. GD patients with a paraprotein are represented in red. (B) 
CD1d histogram representing two patients with GD (red) and two healthy controls (Blue). 
 
The GD patient with the highest MFI was a newly diagnosed patient who was treatment- 
naïve (CD1d MFI = 129). Excluding patients with absent chitotriosidase activity, there 
was no correlation between CD1d expression and plasma activity (r2=0.04, p=0.5). 
Furthermore, pre-ERT chitotriosidase activity did not correlate with the MFI of CD1d 
(r2=0.14, p=0.13).   
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5.4.5 LIPID STIMULATION EXPERIMENTS  
Results reported above that patients with GD have a lower percentage of iNK-T cells 
and elevated expression of CD1d on peripheral blood monocytes. As discussed in 
section 5.2.2, iGB3 and αGalCer are examples of glycolipids that can stimulate and 
expand iNK-T cells when presented by APCs on CD1d tetramers. As the percentage of 
peripheral iNK-T cells is low in GD, it was hypothesised that these cells may have a 
blunted response to glycolipid stimulation. PBMCs were cultured for 14 days in the 
presence of IL-2 (200iu/ml) alone, IL-2 plus iGB3 (100ng/ml) or IL2 plus αGalCer 
(100ng/ml). On D1 and D14 the percentage of iNK-T cells was determined. This assay 
was used to determine the ability of GD monocytes to present glycolipid and expand 
iNK-T cell numbers.  
5.4.5.1 MONOCYTE QUANTIFICATION:- PRE-CULTURE 
Patients with GD had an identical percentage of peripheral blood monocytes 
(CD14+ve/CD64+ve) compared to healthy controls (Controls 14.4%±5.1 versus GD 

















Figure 5-18. Percentage of CD14/64 monocytes in healthy controls and GD patients. Mean indicated 
by horizontal line.  
 
Therefore, it was assumed in the subsequent lipid stimulation experiments that GD and 
controls had an equal number of monocytes capable of CD1d presentation in culture. It 
was shown above that GD monocytes have a higher surface expression of CD1d than 























5.4.5.2 LIPID STIMULATION EXPERIMENTS – ABSOLUTE INVARIANT NK-
T PERCENTAGE 
The percentage of CD3+ve/6B11+ve cells, pre-culture, was higher in the PBMCs of 
healthy controls (0.08±0.04; mean±SD; n=12) compared to those with GD (0.06±0.03; 
n=9; p<0.05). Bi-polar microscopy at D7 revealed a vast increase in cell number and the 
formation of lymphocyte proliferation centres. Two week culture led to an increase in 
the percentage of CD3+ve/6B11+ve cells from both GD patients (p<0.01) and controls 
(p<0.01). Following 14 days of culture in αGalCer supplemented wells, there was a 
higher percentage of iNK-T cells in experiments derived from controls compared to 
those from GD patients (p<0.05). There was no difference in the percentage of iNK-T 
cells harvested from GD or control wells supplemented with IL-2 alone (p=0.43) or IL-2 
plus iGB3 (p=0.27). Paired experiments derived from controls, supplemented with 
αGalCer, had a higher number of iNK-cells compared to IL-2 culture alone (p=0.001; 
Figure 5-19). The addition of glycolipid did not lead to an increase in iNK-T cells in 



















Figure 5-19.  Absolute percentage of invariant NK-T cells following 14 day culture (control or GD 
derived), in IL2 alone, iGB3 or αGalCer. Horizontal line indicates group median. Statistical 































































































Figure 5-20. Representative flow cytometry plots of invariant NK-T cells on D14 (control or GD 
derived), in IL2 alone, iGB3 or αGalCer.  
The epitope 6B11 is specific for the CDR3 region on the invariant α-chain.  
 
5.4.5.3 INVARIANT NK-T EXPANSION – POPULATION DOUBLING 
Population doubling (PopD) was calculated as PopD = log(D14/D0)/log2 where D14 
and D0 represent the percentage of CD3+ve/6B11+ve cells. Paired PBMC cultures, 
derived from healthy controls, led to a significantly shorter population doubling time in 
the presence αGalCer (p=0.001). Analysis between all other groups, either control or 



































































Figure 5-21. Population doubling of iNK-T cells on D14 (control or GD derived) in IL2 alone, iGB3 
or αGalCer.  
Mean indicated by horizontal line. Statistical analysis between groups was performed using a 
Wilcoxon signed rank test. 
 
  
5.4.5.4 INVARIANT NK-T EXPANSION – CBE TREATMENT 
As demonstrated in the section above, αGalCer was unable to expand iNK-T cells in 
GD-derived cultures. It was hypothesised that the percentage of iNK-T cells in culture 
could be attenuated in αGalCer stimulated wells by the addition of CBE, an inhibitor of 
lysosomal glucocerebrosidase. PBMCs were incubated, in duplicate (1x106/mls), in the 
presence of IL-2 and several different concentrations of CBE for 8 days. On D8, 
glucocerebrosidase activity was determined and expressed as a ratio of the total protein 
content. Nearly all CBE concentrations tested led to a 50% reduction in 
glucocerebrosidase activity (Figure 5-22).  In addition, control PBMCs were cultured in 
a 96-well plate (in triplicate) and exposed to several different concentrations of CBE for 
7 days before undergoing MTS dye reduction assay (2 hour).  CBE was not toxic to 
PBMCs (n=3). Based on these results, 50µM and 100µM CBE was used in subsequent 
experiments. These results are consistent with those reported by other investigators in 
which primary cells were cultured with CBE concentrations between 50-500 µM427;488. 
 260 
 









































Figure 5-22. (A) Glucocerebrosidase activity of D8 PBMC cultures (controls) grown from D1 in 
several different concentrations of CBE (derived from duplicate cultures). (B) MTS toxicity assay 
on D7 PBMC cultures (control) subjected to CBE (n=3).  
Mean and standard deviation plotted.   
 
 
PBMCs from two healthy controls (previously noted to expand their iNK-T cell 
population following stimulation with αGalCer) were grown in αGalCer, αGalCer plus 
50µM CBE or αGalCer plus 100µM CBE for 10 days. CBE at both concentrations led to 













































































































































































































































































































Figure 5-23. Invariant NK-T lipid stimulation assays in the presence of CBE.   
(A) Results of two individual experiments following 10 day culture with αGalCer alone or, in 
addition, CBE (50µM, 100µM). Results reported as a ratio to the percentage of iNK-T cells 
harvested from the paired D10 αGalCer well. Mean+SD plotted (n=2). (B) Flow cytometry plots 
represent the results acquired from experiment A. Number of iNK-T cells represented in the upper 
right quadrant.  
 
5.4.6 NK-CELL AND PBMC KILLING ASSAYS 
The results reported here demonstrate both numerical abnormalities within individual T-
cell subsets and the inability of αGalCer to expand GD iNK-T cells. Immune cells 
derived from GD patients (effector cells) maybe less able to kill tumour cells (target 
cells) due to impaired lysosomal function. Killing assays were performed on three 
different immortalised cell lines (NCI-H929, K562 and JJN3) with unstimulated NK-
cells and IL-2 primed cells (NK or PBMCs). NK-cells were isolated from the buffy coat 
of peripheral blood based on CD56 expression using MACs column technology. 
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5.4.6.1 VALIDATION OF MODEL; IL-2 ENHANCES NK-CELL KILLING 
Control-derived NK-cells (n=4) were cultured overnight, in paired experiments, in the 
presence or absence of IL-2 (200iu/ml). Killing assays were performed the following 
day with a NK (effector cell) to target ratio of 5:1. Target cells were pre-labelled with 
the intracellular dye PKH26 and the percentage of TO-PRO+ve cells (apoptotic) was 
determined 4 hours post co-culture. NK-cells, stimulated with IL-2, demonstrated an 












Figure 5-24. IL-2 enhanced the killing of cell lines by NK-cells derived from healthy controls (n=4). 
Mean+SD plotted.   
 
 
5.4.6.2 VALIDATION OF MODEL:- NK CELLS MEDIATE THE MAJORITY OF 
PBMC CYTOTOXICITY 
 
Killing assays were performed on control CD56+ve and CD56-ve cells, as described 
above, with an effector:target ratio of 5:1 (n=4). The CD56-ve fraction contains 
cytotoxic T-cells, helper T-cells, B-cells and monocytes. Figure 5.25 shows that CD56-


























































Figure 5-25. The CD56-ve fraction compared to the CD56+ve fraction harbours comparatively little 
cytotoxic activity (n=4). Percentage of TO-PRO+ve cells reported.  
This comparison holds true for both IL-2 stimulated and IL-2 naïve cells. Mean+SD 
plotted.*p<0.05  
5.4.6.3 CONTROL VERSUS GAUCHER NK KILLING ASSAYS 
Paired experiments were performed comparing aged-matched healthy controls and GD 
patients with an effector:target ratio of 5:1. The results are shown in Table 5-4. 
 Gaucher:Control TO-PRO+ve 
(Mean±SD) 
K562 IL2 (n=4) 1.1±0.12 
K562 (n=4) 1.2±0.2 
NCI-H929 IL2 (n=4) 1.0±0.2 
NCI-H929 (n=4) 1.3±0.6 
JJN3 IL2 (n=4) 1.0±0.15 
JJN3 (n=4) 1.2±0.5 
 
Table 5-4. Killing assay reported as a ratio of killed target cells in GD assays divided by the 
percentage in control assays. Mean±SD reported (n=4).  
 
Greater cell kill was observed in K562 cells, irrespective of IL-2 supplementation, 
compared to the NCI-H929 and JJN3 cells lines. NK-cells derived from patients with 
GD, compared with NK-cells derived from healthy controls, were equally effective in 



























































































Figure 5.27). IL2-naïve NK-cells derived from patients with GD led to an equivalent 
number of apoptotic cells in the 3 target cell lines. In fact, un-stimulated CD56+ve cells 
from controls demonstrated an inferior ability to induce cell death in the K562 cell line 
in 3 out of 4 paired experiments. The GD patient reported in experiment A exhibited the 
highest level of killing from IL2-naïve NK cells in all three cell lines.  The overnight 
stimulation of NK-cells with IL-2 led to a higher percentage of apoptotic cells in GD 
experiments, but statistical significance was only reached for the NCI-H929 cell line 
(p<0.05; MW). This may be due to insufficient patient numbers. None of the patients 
with GD in the tested cohort had an M-band. It was therefore concluded that GD-derived 


































Figure 5-26. NK-killing assay comparing age matched control and GD patients (n=4; A-D).


















































































































































































































































Figure 5-27. NK Killing 
assay. Representative 
flow cytometry plots. 
K562 cells were pre-
labelled with PKH26 
and the percentage of 
TO-PRO+ve cells post 
killing assay is 
represented in 




5.4.6.4 CONTROL VERSUS GAUCHER CD56-VE KILLING ASSAY 
Compared to healthy controls, IL2-naïve CD56-ve cells from GD patients were able to 
induce more cell death in NCI-H929 cells compared to cells from healthy controls 
(p<0.05). IL-2 stimulation of the CD56-ve fraction derived from control cultures led to 
an increase in the percentage of apoptotic cells in both the K562 (p<0.05) and NCI-H929 
(p=0.057) cell lines, confirming the cytotoxic capacity of this fraction. This was similar 
to that seen in GD killing assays where the addition of IL-2 led to a higher percentage of 
apoptotic cells in the K562 cell line (p<0.01), but this failed to reach significance in the 
NCI-H929 cell line (p=0.09). Therefore, it was not possible to demonstrate inferior 


























Figure 5-28. Percentage of TO-PRO+ve cells post 4 hour killing assay with the CD56-ve fraction 













































































5.4.6.5 CONTROL VERSUS GAUCHER PBMC KILLING ASSAYS 
As demonstrated above, GD patients have decreased CD4, iNK-T and CD3-ve NK-cell 
numbers, in addition to an increased percentage of CD3+ve NK cells. Therefore, PBMC 
killing assays were performed to replicate not only these numerical differences but to 
exploit any functional abnormalities that may exist in the interactions of GD blood cells. 
PBMC killing assays, pre-stimulated with IL-2 overnight, were performed with K562, 
JJN3 and NCI-H929 cells at effector:target ratios of 40:1, 20:1 and 10:1.   
 
Compared to healthy controls, cultures from patients with GD demonstrated an impaired 
ability to kill K562 cells at all effector:target ratio (Table 5-5; Figure 5-29; Figure 5-30).   
The mean percentage of kill in K562 killing assays decreased in parallel with the 
reduction in effector:target ratio.  
 





K562 40:1 56.3±12.1 45.1±15.2 <0.01 
K562 20:1 48.9±16.6 36.1±13.2 <0.05 
K562 10:1 37.3±18.2 26.2±11.9 <0.05 
NCI 40:1 9.4±8.3 12.5±8.8 NS 
NCI 20:1 9.7±6.8 10.4±8.1 NS 
NCI 10:1 18.9±6.9 7.6±6.2 <0.0001 
JJN3 40:1 16.9±10.5 18.11±9.4 NS 
JJN3 20:1 14.9±9.9 13.6±8.4 NS 
JJN3 10:1 9.1±6 9.2±6.7 NS 
 
Table 5-5. Percentage of apoptotic To-Pro+ cells in killing assays performed in K562, NCI-H929 and 
JJN3 cells cultured with PBMCs-derived from controls or GD patients.  NS = non-significant.  
 
The mean percentage of apoptotic cells above background cell death was less than 20% 
at all concentrations for both myeloma cell lines. Curiously, control PBMCs were more 
effective at killing NCI-H929 cells at a ratio of 10:1 than 20:1 (p<0.01; paired t-test). 
 268 
K562 40:1 Paired T-test p<0.01





















K562 20:1 Paired T-test p<0.05






















K562 10:1 Paired T-Test p<0.05




















NCI 10:1 Paired T-test p<0.0001






















The percentage of TO-PRO+ve NCI-H929 cells was higher in control killing assays 



































Figure 5-29. Graphical representation of paired killing assays (n=12) documenting the numerical 
difference in TO-PRO+ve cells between controls and GD patients.  




































































































































































































































































































Figure 5-30. Representative flow cytometry plots of PBMC cytotoxicity assays comparing control 
and GD patients. The percentages refer to cells in the right upper quadrant (apoptotic). 
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5.5  DISCUSSION  
The novel results reported in this chapter demonstrate abnormalities within the lymphoid 
fraction of GD patients that could confer impaired tumour surveillance. Compared to 
healthy controls, patients with GD had a higher percentage of CD3+ve NK-cells, a 
decreased CD4:CD8 ratio and a reduction in the percentage of CD3-ve NK, iNK-T and 
CD4+ve T-cells. The results also show that GD lymphocyte subsets have depleted 
glucocerebrosidase activity. Lysosomal dysfunction was confirmed in GD lymphocytes 
on the basis of abnormal intra-cellular trafficking of lactosylceramide. Compared to 
healthy controls, GD patients demonstrated an inability to expand iNK-T cells in culture 
with αGalCer supplementation. GD monocytes had abnormally high cell surface CD1d 
expression. PBMCs, generated from patients with GD, displayed an inferior ability to 
kill co-cultured immortalised cell lines. However, no difference was demonstrated in the 
ability of NK-cells, derived from healthy controls and those with GD, to kill K562, NCI-
H929 or NCI-H929 cells.  
 
The following evidence supports the immunological importance of lymphocytes in 
tumour control. A low ALC predicts for an inferior outcome in several haematological 
malignancies, including follicular lymphoma, DLBCL and Hodgkin lymphoma467. In 
addition, patients with myeloma who have a low ALC have an inferior response to 
treatment with bortezomib and dexamethasone489. Thus, more aggressive tumours may 
give rise to a cytokine profile that suppresses lymphocyte production. Successful tumour 
control has been correlated with an early recovery in the ALC following stem cell 
transplantation (autograft or allograft)467. Marti et al. (1988) suggested a high normal 
ALC in treatment-naïve patients with GD. However, these findings are questionable 
given the size of the cohort (n=8) and the fact that 4/8 patients had been 
splenectomised139. Splenectomised individuals, irrespective of aetiology, commonly 
develop a lymphocytosis, which is partly due to an increase in large granular 
lymphocytes490.  
 
Numerical differences were not demonstrated in the absolute number or percentage of 
lymphocytes derived from healthy controls and patients with GD. In addition, the ALC 
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was identical in GD patients, irrespective of treatment status or the presence of 
gammopathy (monoclonal or polyclonal). These finding do not support the hypothesis 
that chronic immune stimulation leads to the development of polyclonal lymphocytosis 
in GD patients. Inflammatory cytokines, including IL-1β and TNF-α, have been reported 
to be elevated in the peripheral blood of patients with GD, although these findings have 
been inconsistent between investigators73;76;77;81. Immunocytochemistry on splenectomy 
specimens failed to demonstrate the expression of a Th1 pro-inflammatory profile in 
lipid laden macrophages, including the expression of IL-1β and TNF-α58. Interestingly, 
the percentage of peripheral lymphocytes has been shown to be elevated in a cohort of 
male patients with Fabry disease (11/22 on ERT), irrespective of treatment status350.  
Although the ALC was preserved in GD, abnormalities of the lymphoid profile, that may 
confer an increased risk of cancer, were investigated next.      
 
In PBMCs from healthy controls, lymphocytes had relatively low glucocerebrosidase 
activity compared to monocytes, as demonstrated by flow cytometry. Compared to 
healthy controls, GD lymphocytes had statistically lower enzyme activity, in keeping 
with results reported by other investigators53;346;491. Additionally, these results show a 
reduction in glucocerebrosidase activity in individual lymphocyte subsets, including 
CD3-ve NK cells, CD3+ve NK-cells, CD3+ve cells and CD19+ve cells. Reduced 
lymphocyte activity compared to that measured in monocytes maybe due to differences 
in lysosomal number and/or cell size. Studies comparing the activity of beta-
galactosidase to glucocerebrosidase could be employed to ascertain whether there are 
differences in lysosomal glucocerebrosidase activity (controlling for lysosomal number) 
between different cell types including lymphocyte subsets. The majority of GD patients 
analysed were receiving ERT, suggesting the inability of treatment to significantly affect 
residual enzyme activity. Lymphocytes, due to their low residual glucocerebrosidase 
activity, may be particularly sensitive to enzyme depletion if exposed to sufficient 
substrate.  B-cells, derived from control assays, had statistically higher enzyme activity 
than T-cells and therefore may be more compromised in deficient states. Whether this 
contributes to the high incidence of B-cell disorders in GD rather than an increased risk 
of T-cell disorders is speculative. Glucocerebrosidase-deficient CD34+ve cells in culture 
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have an impaired ability to form erythroid burst forming units, granulocyte colony 
forming units (CFUs) and monocyte CFUs, but the ability of these cells to proliferative 
and differentiate lymphocytes was not explored53.    
 
Ultrastructural examination failed to demonstrate features consistent with 
glucosylceramide accumulation, including distended lysosomes, vacuole formation, 
membrane-bound inclusions and tubular arrays, in GD lymphocytes. This contrasts with 
the findings of others who have reported abnormalities, using electron microscopy, in 
both peripheral lymphocytes and EBV transformed B-cells from patients with GD345;346. 
Although often quoted in the literature, it is unclear whether Brűck et al. (1991), based 
on their published report, actually identified ultrastructural abnormalities in GD 
lymphocytes465. In keeping with our findings, others have failed to demonstrate 
inclusions within GD-derived lymphocytes from skin biopsies492. Lymphocytes are 
relatively young blood cells and lysosomal storage is likely to be related to both the age 
of the cell and the severity of the enzyme deficiency. The fact that two of our patients 
were on disease modifying therapy and the other untreated individual had recently 
presented in middle age with mild disease may have reduced the chance of observing 
ultra-structural abnormalities. The use of immuno-conjugates raised against 
glucosylceramide may have improved detection sensitivity. Lymphocyte inclusion 
bodies have been readily identified in other LSDs, including neuronal ceroid-
lipofuscinoses (NCL), Mucopolysaccharidosis (MPS), GM gangliosidosis, mucolipidosis 
(ML), metachromatic leukodystrophy, glycogenosis and Niemann Pick disease465;493;494. 
These disorders have a poorer prognosis than GD and, therefore, sphingolipid deposition 
may be more prominent. Ultrastructural abnormalities have also been demonstrated in 
CD4, CD8 and CD56 lymphocyte subsets from patients with MPS, ML and NCL494. 
Macrophages have a comparatively longer life-span than peripheral blood lymphocytes 
and thus are more likely to accumulate glucosylceramide over time495. In addition, as 
macrophages have significantly higher glucocerebrosidase activity, they may be more 
susceptible to the deposition of glucosylceramide in deficient states.   
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Although structural abnormalities within GD lymphocytes were not demonstrated, they 
were functionally abnormal on the basis of lipid trafficking. Compared to lymphocytes 
from healthy controls, BODIPY-tagged lactosylceramide accumulated abnormally in the 
lysosomes of lymphocytes derived from patients with GD rather than being concentrated 
in the Golgi apparatus and endosomal compartment. This is in keeping with prior reports 
of enzyme-deficient macrophages and fibroblasts in GD487.  Physiological sphingolipid 
metabolism has been shown to be important in controlling cell apoptosis and 
proliferation19-21. Abnormal sphingolipid haemostasis may confer a proliferative 
advantage on differentiating B-cells or lead to the apoptotic depletion of specific subsets 
involved in tumour surveillance.   
 
Using a panel of antibodies (CD19, IgD, CD27, CD21, CD38 and IgM)  the percentage 
of naïve B-cells, IgM memory, class switched, CD21 low expressing B-cells, transitional 
B-cells and plasmablasts in the peripheral blood of healthy controls and patients with 
GD was compared. This has previously been described in non-GD individuals496;497. 
Patients with GD had a significantly lower percentage of plasmablasts, but otherwise 
individual populations were identical to that seen in healthy controls. This was 
somewhat surprising as it was expected that patients with GD would have a higher 
percentage of CD19+ve/CD38+ve plasmablasts given the elevated incidence of 
gammopathy. Additionally, two patients had an established M band. The majority of the 
GD cohort were, however, receiving ERT and had only modest elevations in their 
chitotriosidase activity (<2000nmol/hr/ml plasma). These findings, therefore, may not be 
representative of an untreated cohort with severe disease.  
 
Marti et al. (1988) reported a three times higher increase in the mean percentage of 
CD20+ve lymphocytes in an untreated cohort of patients with GD in comparison to a 
control population139. However, within our cohort (n=10) there was an identical 
percentage of CD19+ve peripheral B-cells in healthy controls and patients with GD. 
CD19 was used as a pan B-cell marker which, unlike CD20, additionally identifies more 
primitive cells, including pre-B and pro-B cells. The fact that our GD cohort was 
composed of individuals mostly on disease modifying therapy is a more plausible 
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explanation for these conflicting observations. In addition, by documenting only the 
percentage of peripheral B-lymphocytes, an increase in the absolute number of 
CD19+ve cells could have been missed. The literature is relatively sparse in detailing 
peripheral B-cell populations either pre or post ERT. Khalifa et al. (2010) reported a 
decrease in the percentage of peripheral blood CD19+ve cells in 12/16 paediatric 
patients, 6 of whom were ERT-naïve (European Haematology Association, Abstract 
Book, 2010)235. This report, however, lacked information detailing the control 
population and whether a pre-existing reference range was used. Although the 
percentage of peripheral CD19+ve B-cells has been demonstrated to be elevated in both 
treated and ERT-naïve Fabry patients, there have been no reports describing an 
increased incidence of gammopathy350.  
 
Decreased peripheral T-cells have been reported to impair tumour surveillance486;498.  
In patients with CLL, a higher T-cell/leukaemic monoclonal B-cell ratio has been 
reported to predict for early stage disease and mutated IgH genes, both associated with a 
better prognosis499. However, neither of these variables was associated with the absolute 
number of CD3+ve T-cells. In the results reported here, a similar percentage of CD3 
cells were found in healthy controls and individuals with GD. This contrasts with the 
results of other investigators who have demonstrated a decrease in CD3+ve T-cells in a 
paediatric population, approximately a third of whom were on ERT235.  In comparison, 
the majority of GD patients reported here were receiving ERT and speculatively the 
analysis of untreated individuals may have yielded a different result. Prior data have 
suggested that ERT leads to the correction of some, but not all, immune defects in GD. 
Balreira et al. (2005) showed disturbances within CD1d expression, MHC class II 
expression and the percentage of CD4 plus CD8 lymphocytes in ERT treated 
individuals. The intensity of MHC class II expression was suggested to fall with 
treatment. In a cohort of patients with Fabry disease, the mean percentage of CD3+ve T-
cells was identical to a control population, irrespective of disease modifying therapy. 
However, these patients had a mild disease phenotype without evidence of renal failure, 
cerebrovascular disease or heart failure350.  
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The results reported here show that patients with GD have a lower percentage of 
peripheral CD4+ve T-cells, in addition to a vastly reduced CD4:CD8 ratio when 
compared to healthy controls. The percentage of CD8+ve cells did not differ between 
controls and GD patients. However, there was borderline significance towards a higher 
percentage of CD8+cells in GD patients with gammopathy compared to controls 
(p=0.05). Other investigators have demonstrated a similar decease in the percentage of 
CD4+ve T-cells, irrespective of treatment, in addition to an increase in the proportion of 
CD8+ve lymphoid cells in GD patients on ERT only4. In keeping with our results, the 
CD4/CD8 ratio was inverted in 10/16 paediatric patients of whom 10/16 were receiving 
ERT235. Published reports in ERT-naïve individuals have been inconsistent with studies 
reporting both increases and decreases in the number of CD4 and CD8 +ve T-cells139;347. 
The percentage of CD8+ve T-cells has been shown to be reduced in a cohort of 
untreated Fabry patients, although the percentage of peripheral CD4+ve cells was 
identical to that of healthy controls350. Fabry disease is caused by a deficiency in α-
galactosidase A which results in the accumulation of globotriaosylceramide and 
diagalactosylceramide plus secondary substrates such as globoside15. In comparison to 
GD, Fabry disease may lead to attenuated glucosylceramide accumulation due to 
impaired globoside metabolism and the generation of ceramide for glycosylation 
(glucosylceramide synthase). Therefore, differences in the lipid profile between 
individual sphingolipidosis may confer a tendency towards certain lymphoid profiles.  
    
With regards to malignancy, anomalies of peripheral blood lymphocytes have been 
correlated with tumour risk, stage and prognosis. In patients presenting with colorectal 
cancer, survival was adversely affected by a lower CD4/CD8 ratio468. A study from 
Brazil showed a lower CD4/8 ratio in 15 individuals from families with a high incidence 
of cancer per se compared to a control population486. The same group demonstrated a 
lower helper/suppressor T-cell ratio in patients presenting with primary brain tumours498. 
Based on these results, GD patients with an abnormal CD4/CD8 profile may be more 
susceptible to malignancy.   
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Our GD cohort, despite being mostly treated, had a 50% reduction in the number of 
CD3-ve/CD56+ve NK-cells, which is in keeping with previously reported results in 
ERT-naïve individuals348. Prior publications reporting decreased NK-cell numbers in 
GD patients have been based on the expression of CD56 alone, which also identifies a 
population of large granular lymphocytes in addition to a smaller population of iNK-T 
cells139;235. CD3-ve NK-cells have a fundamental role in the lysis of cancer cells339 and 
reduced numbers may predispose to a micro-environment more favourable to 
tumourigenesis. Convincing data supporting the benefit of NK-cells in the control of 
haematological cancers comes from clinical trials detailing improved survival and 
disease control in leukaemic patients who received an infusion of alloreactive NK-cells 
post bone marrow transplantation337. Patients with liver metastasis, secondary to 
gastrointestinal malignancy, have been shown to have a lower percentage of intra-
hepatic CD3-ve NK cells compared to those without metastasis500.  Infiltration of 
metastatic organs with NK-cells correlates with a better prognosis in bowel501, gastric502 
and squamous cell lung cancers503.  A reduction in peripheral blood NK-cell number or 
activity has been shown to correlate inversely with tumour burden in multiple myeloma 
and, in addition, predicts for a poorer outcome in those with DLBCL254;504. It has been 
suggested that NK-cells enhance tumour killing in DLBCL, secondary to their ability to 
induce death in rituximab-opsonised B-cells504. In a group of patient with CLL, a higher 
NK-cell/leukaemic monoclonal B-cell ratio was found in those with early stage disease 
or mutated IgH genes and predicted a longer treatment free interval499.  Results from 
section 5.4.4.3 above show that patients with GD had a higher number of NK-T like 
cells (CD3+ve/CD56+ve) in the peripheral blood, although the absolute number of 
CD56 lymphoid cells was identical. Akagi et al. (2008) suggested that elevated blood 
NK-T like cells (%) conferred a worse prognosis in patients with advanced gastric 
cancer505.  
 
Several malignancies, including multiple myeloma and hepatocellular cancer, have been 
suggested to occur with increased frequency in patients with GD 78;130. Prospective 
observational studies are required to delineate whether depleted NK numbers in GD 
patients are able to predict for the subsequent development of cancer or a lymphoid 
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clone. Due to limited patient numbers, it has not been possible to demonstrate here 
whether GD patients with gammopathy have a lower percentage of CD3-ve NK cells, 
than GD patients with normal immunoglobulins. As the GD cohort consisted almost 
entirely of ERT treated patients, it is unclear whether treatment-naïve individuals would 
share the same disturbances in immune profile. However, the number of CD56+ve 
lymphocytes was found to be identical in a group of patients with Fabry disease when 
compared to a control group, although this would have also included the detection of 
some large granular lymphocytes350. In our centre only 1 patient developed a paraprotein 
whilst on disease modifying therapy. Here, NK-cells in peripheral blood have been 
studied, but histo-pathological studies are required to demonstrate whether these 
findings are representative of the lymphoid infiltrate in body organs, including lymph 
nodes and bone marrow, of GD patients. The possibility exists that NK-cells re-
distribute from the peripheral blood to body organs in GD, conferring normal immunity.  
 
iNK-T cells, or type I NK-cells, are a unique subset which recognise glycolipid ligands 
presented on CD1d molecules via the T-cell receptor, which consists of a specific Vα24-
Jα18 chain with preferential pairing to a Vβ11 chain338;506. The depletion of iNK-T cell 
numbers has been demonstrated in patients with cancer, including those with prostate 
cancer and melanoma479;480. Additionally, in patients with haematopoietic cancer, the 
percentage of Vα24+ve NK cells has been shown to be reduced in those with chronic 
myeloid leukaemia, lymphoma, acute myeloid leukaemia and the myelodysplastic 
syndrome469. A normal percentage of iNK-T cells was reported in one study of patients 
with gastrointestinal cancer 507, although the percentage reported, including in the 
control population, was higher than previously reported reference ranges478;508. The 
ability of expanded iNK-T populations to regress cancer has been demonstrated by 
several investigators in mouse models and early phase human trials, including those with 
advanced non-small cell lung cancer481;509.  Both lenalidomide and thalidomide, 
immuno-modulatory drugs used in the treatment of multiple myeloma, have been 
suggested to exert their beneficial effects by increasing the number of IFN-γ secreting 
iNK-T cells510. As described above, patients with GD had an approximately 50% 
reduction in the mean number of peripheral iNK-T cells, based on CD3/6B11 dual 
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positivity. This contrasts with the findings of a Portuguese group, who reported an 
increase in the percentage of Vα24+ve/CD4 iNK-T cells in ERT-treated GD patients, 
but not in the treatment-naïve patients4.  However, they used an antibody to Vα24, 
which is less specific for iNK-T cells than the 6B11 monoclonal antibody, reacting with 
the CDR3 epitope formed by the germ-line selection of the Vα24 and Jα18 TCRα loci. 
iNK-T cells only constitute 0.01-1% of all peripheral blood T-cells478. Therefore, these 
results, when compared to ours, would have been more susceptible to skewing by non-
invariant NK-T Vα24+ve lymphoid populations. The identification of iNK-T cells by 
Vα24 positivity alone is recognised to over-estimate the population478. This is further 
highlighted by the fact that the percentage of CD4+ve type I NK-cells reported by this 
group (mean 0.83%) is far higher than that reported by others employing more robust 
flow cytometric detection protocols, including the enumeration of Vα24+ve/Vβ11+ve, 
6B11+ve/Vβ11+ve or CD1d/ αGalCer binding cells478;510;511. The mean percentage of 
iNK-T cells within our control population was 0.12, which is in keeping with that 
reported by other investigators508;511;512. A reduction in IFN-γ producing iNK-T cells in 
individual patients with GD would compromise tumour surveillance. Again, these 
experiments need to be repeated in untreated individuals to ensure that these findings are 
not secondary to ERT. The majority of treated patients, however, had high 
chitotriosidase activity, skeletal disease or cytopenias, consistent with active disease.  
 
As detailed in prior reports by Balreira et al. (2005), the results shown above confirm 
that GD monocytes have increased cell surface expression of CD1d compared to that 
seen in healthy controls4;255. Pre-treatment with the lysosomal glucocerebrosidase 
inhibitor, CBE, has been shown to up-regulate the cell surface expression of CD1d in 
healthy monocytes4.  Balreira et al. (2010) reported an up-regulation of CD1d on 
cultured THP1 cells (monocytic leukaemia cell line) following exposure to CBE for 3 
days255. This was statistically questionable based on low sample numbers (n=6), the 
inappropriate use of a parametric based t-test and the fact that in only 2/6 experiments 
using CBE treated THP1 cells was there evidence of increased CD1d expression. 
Glycolipids are known to regulate type I NK cell expansion and mouse models of 
several LSDs (Sandoff, Niemann Pick type I, Fabry disease, Tay-Sachs and GM1 
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gangliosidosis) have shown depleted iNK-T cell numbers in the liver, spleen and thymus 
of sacrificed animals335. These results are in keeping with our findings in patients with 
GD, despite being reported in a predominantly ERT-treated cohort. In contrast to Fabry 
mouse models, the number of CD4+ve and CD8+ve iNK-T cells have been found to be 
normal in treated and ERT-naive Fabry patients350. The generation of GD mouse models 
has been historically difficult, as enzyme deficient mice died prematurely due to 
epidermal water loss513. However, viable animal models have been established in recent 
years and their full immunological characterisation is awaited514.  
 
Lysosomal dysfunction has been hypothesised to lead to the defective expression or 
loading of MHC class I, MHC class II and CD1d molecules477. Epitope loading on 
MHC-I molecules was previously thought to occur only in the cytosol, although a 
lysosomal-dependent process has now been suggested477. MHC-I molecules are 
responsible for the presentation of tumour antigens to cytotoxic T-cells, which induce 
killing via the release of FasL, perforin, granzyme and nitric oxide338. Additionally, 
CD1d tetramers present endogenous glycolipid, including tumour-derived antigens, to 
iNK-T cells. Monocytes derived from GD patients have been shown to have elevated 
levels of cell surface CD1d and MHC-II, although no difference in the membrane 
expression of MHC-I molecules was identified4. ERT was suggested by the authors to 
decrease cell surface MHC-II levels, but to have no affect on CD1d expression. This is 
keeping with the results reported here where CD1d expression was significantly higher 
on GD monocytes.  
 
Tumour cells can avoid immune detection by the down-regulation of MHC expression. 
Spanoudakis et al. (2009) demonstrated a reduction in both the cell surface expression 
and transcription of CD1d on plasma cells in individuals with relapsed myeloma when 
compared to those with newly diagnosed disease or MGUS515. The ligation of cell 
surface CD1d molecules has been shown to lead to the lysis of tumour cells515. Reduced 
CD1d expression is speculated to impair tumour surveillance, secondary to the inability 
to present antigen to IFN-γ secreting Th1 type I NK cells336. Gadola et al. (2006) 
demonstrated abnormal CD1d expression on the cell surface of thymocytes and 
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peripheral B-cells in mouse models of Niemann Pick disease, but not in the other LSD 
mouse models335. Based on RT-PCR, CD1d expression was equivalent in healthy 
controls (n=2), treated GD patients (n=4) and an untreated patient (n=1)4. However, as 
this analysis was performed macroscopically, based on perceived gel band intensity, and 
not by either optical densitometry or copy number, further studies with greater 
sensitivity are required to validate this result. In contrast, CD1d expression has been 
shown to be decreased on the cell surface of monocytes from Fabry patients, irrespective 
of treatment status350. This contrasts with the findings in the Fabry mouse model335, but 
further re-enforces the differences in CD1d expression compared to that seen in GD 
patients. It may be that the loading of CD1d tetramers rather than the level of cell 
surface expression is important.  
 
Saposins, sphingolipid activator proteins, are speculated to play an essential role in the 
loading of self-derived or non-self glycolipids onto CD1d molecules in the lysosomal 
compartment332. There are several potential mechanisms, hypothesised by Gadola et al. 
(2006)335, by which the impaired loading of endogenous glycolipid onto CD1d tetramers 
may impair iNK-T expansion in LSDs. Firstly, endogenous lipids, such as iGB3, may be 
pathologically accumulated and trapped in dysfunctional lysosomes. This is in keeping 
with the results reported above, which demonstrated the mis-trafficking and 
accumulation of organelle (Golgi and endosomal) lactosylceramide to the lysosomal 
compartment of GD monocytes. A similar fate could be speculated to occur with 
glycolipid complexed CD1d molecules. Additionally, it could be hypothesised that 
accumulated substrate, for example glucosylceramide in GD, out-competes natural 
sphingolipid ligands, including iGB3, and abnormally saturates CD1d molecules in the 
endo-lysosomal compartment. Although these mechanisms could be postulated to lead to 
a decrease in type I NK cell numbers, others have argued that the chronic presentation of 
sphingolipid, which accumulates abnormally in GD, may lead to progressive depletion, 
secondary to their constant activation and subsequent exhaustion255.   
 
PBMCs, derived from healthy controls or GD patients, were cultured (D1-14) in the 
presence of IL-2 alone, IL-2 plus αGalCer or IL-2 plus iGB3. In PBMCs, CD1d was 
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expressed almost entirely on monocytes and was almost absent from the cell surface of 
lymphocytes (data not shown). Based on CD14/64 dual positivity, GD patients and 
healthy controls had an identical number of CD1d expressing monocytes. This is in 
keeping with previous reports331. In contrast to GD derived cultures, αGalCer led to a 
significant increase in the percentage and expansion of iNK-cells by D14 in experiments 
generated from healthy controls. In 8/11 control derived cultures, αGalCer led to a lower 
doubling time than any of the values recorded in the paired IL-2-only wells. Prior data 
have suggested that the response of individuals to expand iNK-T cells in response to 
αGalCer challenge is conserved over time and donors can be divided into strong or weak 
responders508. Compared to young adults (25-35yrs), healthy elderly volunteers (70-
88yrs) have been demonstrated to have inferior responses in their iNK-T doubling time 
to αGalCer511. The average age of our control cohort was 37.3±7.0 years (mean±SD) 
compared to 39±12.4 years in the GD cohort. Compared to IL-2 wells, the addition of 
iGB3 did not lead to an increase in the percentage of CD3+ve/6B11+ve cells in paired 
cultures from control or GD patients. These findings are in keeping with those reported 
by Balreira et al. (2010) who demonstrated the proliferation of iNK-T cells in response 
to αGalCer but not to iGB3. In their experiments, glycolipid was presented by THP1 
cells either unadulterated or matured with retinoic acid into macrophages255. αGalCer is 
a non-endogenous lipid and is known to be a more potent activator of iNK-T cells than 
iGB3, therefore, it is more likely to drive these cells into cell division. The injection of 
αGalCer into mouse models of LSDs, including Sandoff disease, Niemann Pick C and 
Fabry disease, has been shown to lead to impaired cytokine production (Th1 or Th2) 
when compared to normal mice335. In conclusion, GD patients have low peripheral iNK-
T cell numbers, impaired responses to αGalCer stimulation and abnormal CD1d 
expression. Therefore it is conceivable that these abnormalities confer an elevated risk of 
malignancy in GD due to impaired responses to physiological sphingolipid or the 
inability to present tumour antigens on CD1d molecules.   
 
PBMC experiments generated from healthy controls were supplemented with αGalCer, 
with or without the addition of the addition of CBE (50µM and 100µM). Treatment with 
CBE led to a decrease in the number of iNK-T cells on D10. CBE was not toxic to 
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PBMCs at any of the concentrations used (0-500µM), although selective toxicity of the 
iNK-T cell population could not be excluded. Further studies, using proliferation assays, 
such as CFSE, (carboxyfluorescein diacetate succinimidyl ester) are required to 
conclusively demonstrate differences in iNK-T expansion. CFSE assays have been used 
to confirm type I NK expansion to glycolipids in PBMC assays, in order to dismiss 
superior survival as a cause of increased iNK-T numbers post culture255;508. These results 
contradict the report by Ilan et al. (2009) who argued, at length, regarding the benefits of 
glucosylceramide in GD patients, and suggested an evolutionary advantage20. They 
described the beneficial effects of glucosylceramide administration in animal models of 
colitis, hepatitis, hepato-cellular carcinoma, melanoma and GvHD, secondary to the 
proliferation of iNK-T cells. Their argument assumes that glucosylceramide can be 
loaded physiologically onto CD1d tetramers and that iNK-T cells themselves are normal 
in GD. In addition, a rheostat of other sphingolipids are accumulated and depleted in 
GD, due to enzyme deficiency. However, the results reported above show that patients 
with GD have a deceased percentage of peripheral iNK-T cells that are unable to expand 
when challenged with αGalCer. In addition, CBE-induced enzyme inhibition blunted the 
expansion of these cells. This maybe due to abnormal CD1d activity4 or intrinsic 
disturbances within the lymphocytes themselves, including sphingolipid accumulation. It 
is also currently unknown whether T-cells from patients with GD have a physiological 
T-cell receptor with an intact intracellular signalling cascade.  
 
Therefore, in opposition to Ilan et al. (2009), it could be hypothesised that GD patients 
have an elevated risk of cancer secondary to numerical and functional defects in the 
iNK-T population. In support of this concept, patients with gastrointestinal or uterine 
cancer were unable to expand iNK-T cells in culture to the same magnitude as healthy 
controls in the presence of αGalCer507. This may be due to decreased iNK-T cells being 
a risk factor for the development of cancer or that the tumour itself suppresses this 
lymphocyte population. Either way, cancer surveillance is compromised. iNK-T cells 
have been shown to be important in enhancing tumour regression via the stimulation of 
NK cells472.  
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NK cells were isolated from peripheral blood by immuno-magnetic separation based on 
CD56 positivity. Using a NK killing assay, it was demonstrated that NK-cells derived 
from patients with GD were not inferior in their ability to induce cell death in K562, 
NCI-H929 or JJN3 target cells (n=4), irrespective of augmentation with IL-2. This was 
despite a comparatively higher percentage of CD3-ve NK cells in healthy controls. In 
comparison to the CD56+ve (NK) fraction, little cytotoxicity was imparted by CD8+ve 
cytotoxic T-cells within the CD56-ve fraction. The killing capacity of CD56-ve cells 
derived from patients with GD was not inferior. The cytotoxicity of cultured PBMCs has 
been shown to be decreased in individuals with a family history of breast cancer516 or 
cancer per se517. PBMC-induced cytotoxicity has been shown to predict for disease stage 
in myeloma518 and breast cancer343. An 11 year follow-up study demonstrated an 
increased risk of malignancy in individuals whose PBMCs showed impaired cytotoxicity 
in killing assays342.  GD patients were aged matched to within 10 years of healthy 
controls, as peripheral blood cytotoxicity has been reported to decrease with age519. 
Killing in PBMC assays is reflective of NK-cell activity and is modulated by the 
presence of CD56-ve lymphoid subsets and monocytes. PBMC-derived cytotoxicity 
assays, in addition, exploit both numerical and functional differences within individual 
constituents. PBMCs from GD patients were inferior in their ability to kill K562 cells at 
3 different effector:target ratios. In addition, assays from GD patients displayed impaired 
killing of the relatively more robust NCI-H929 cell line at a ratio of 10:1. Further studies 
are required to explore this observation, including the possibility of an inhibitory factor 
being secreted by a cellular component of GD blood cells. Speculatively, individuals 
with an impaired PBMC cytotoxicity assay may be at an elevated risk of developing 
malignancy or gammopathy. Comparisons between GD patients and controls are 
required in order to document the number of regulatory T-cells or γδ T-cells, both being 
reported to have a role in tumour surveillance336.     
 
Although lysosomal pathology is universal amongst those with various storage 
disorders, GD has been the only LSD associated with an elevated risk of 
malignancy78;130;132. Many LSDs, especially those with neuronopathic involvement, lead 
to premature death before an age normally associated with cancer development. GD is 
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the most prevalent storage disorder, with large numbers of enlisted patients in data 
registries, supporting the capture of cancer episodes28;130. Prior to the introduction of 
ERT, males with Fabry disease typically survived to middle age. In contrast, many 
females with Fabry disease, due to X-linked inheritance and random lyonization, have 
survived for longer. Despite this, there are only isolated case reports of cancer episodes, 
including the development of leukaemia and bilateral renal cancer, in patients with 
Fabry disease152;154.  
 
In conclusion, GD should not only be considered a disorder of macrophages, but also of 
lymphocytes. GD patients, based on the data presented here, have an abnormal 
CD4:CD8 ratio, NK-cell subsets, peripheral blood cytotoxicity and a functionally 
impaired CD1d-iNK-T cell axis. Perhaps the polyclonal expansion of plasma cells in 
GD, secondary to chronic immune simulation, pre-disposes plasma cells to clonal 
expansion and these clones persist due to impaired tumour surveillance. However, it is 
currently unclear why this would confer a preferentially elevated risk of plasma cell 
neoplasms rather than non-haematological malignancies, suggesting modifying factors 
within the bone marrow microenvironment of GD patients. Co-culture experiments are 
required to assess the affect of GD lymphocytes on plasma cell expansion and other 
cellular components of the bone marrow, including osteoclasts. In the era of ERT, only 
collaborative studies can generate significant power to answer important biological 




The work presented here demonstrates novel data regarding biological disturbances 
in GD that may confer an increased risk of plasma cell dyscrasias including 
abnormalities within the monocytic and lymphoid lineages. Several clinical reports 
have established a high incidence of polyclonal and monoclonal gammopathy in GD, 
but biological models exploring these clinical observations are sparse. Abnormalities 
in the local microenvironment and immune profile have been described in non-GD 
individuals with active malignancy and in those that subsequently develop cancer. It 
was therefore appropriate to investigate whether similar patho-physiological 
disturbances occur in GD. The aim of this thesis was to explore different hypotheses 
and risk factors relating to the development of plasma cell dyscrasias in GD.  
 
Firstly, in chapter 3, it was established that the RFH population of GD patients 
(n=9/74; 12%; mean age 59.6 years; ERT era) had a high rate of paraproteinaemia 
and polyclonal gammopathy. In untreated individuals macrophage-derived 
biomarkers, including chitotriosidase activity (p<0.05), S-ACE (p<0.05) and acid 
phosphatase (p<0.05), were significantly elevated in GD patients with gammopathy 
when compared with those with normal immunoglobulins. Furthermore, the Zimran 
severity score (ZSS) was significantly higher (p<0.01) in individuals with an 
established paraprotein than in those with polyclonal gammopathy. No difference in 
the ZSS was identified between those with polyclonal gammopathy and normal 
immunoglobulins, possibly due to limitations in the sensitivity of this scoring index.  
ERT led to a reduction in the absolute levels of all immunoglobulin classes (IgM 
[p<0.001], IgG [p<0.001] and IgA [p<0.001]) and stabilised the level of 
paraproteinaemia in all but one patient who had a paraprotein of >50g/l.  
 
The results reported above support disease severity as being a risk factor or co-factor 
for gammopathy and refute the conclusions of other investigators who failed to 
demonstrate an association in adults43. These findings are in keeping with Wine et al. 
(2007) who suggested disease severity was a risk factor for polyclonal gammopathy 
in a paediatric population234. Children with early onset type I disease have been 
found to have high rates of polyclonal gammopathy234, but the development of 
paraproteinaemia has not been reported. In the RFH cohort of GD patients, 8/9 alive 
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patients with a paraprotein, are currently in their 5th decade or older (4 patients 44-54 
years, 4 patients 68-83 years and 1 patient aged 27 years). Unfortunately, serum 
electrophoresis was not routinely performed throughout their clinical care and 
therefore the age at which they developed a paraprotein for most is unknown. Only 1 
GD patient under 30 years old currently has an M-band. GD patients may be more 
likely to develop clonal plasma cell disorders when exposed to disease related 
pathology for a long duration of time. Monoclonal gammopathy is more common in 
non-GD populations with advancing age203. Speculatively, GD related pathology, in 
combination with additional biological factors that are non-GD related, predisposes 
to early onset paraproteinaemia.  
 
Shoenfeld et al. 1982 hypothesised that chronic immune stimulation in GD leads to 
polyclonal gammopathy and pre-disposes activated plasma cells to clonal 
expansion162. This hypothesis is supported by data presented in chapter 3, which 
correlates macrophage burden (biomarker data) with the presence of gammopathy. In 
a GD mouse model, excised lymph nodes with lymphadenitis were shown to have 
plasma cell infiltrates330. In addition, the authors reported elevated TNF-α levels, a 
pro-inflammatory cytokine, in the liver of sacrificed animals. In GD, it has been 
hypothesised that disease severity leads to enhanced antigenic stimulation, secondary 
to the non-physiological presentation of sphingolipids or antigen formation resulting 
from tissue damage. Antigen presentation has been suggested to be impaired in GD 
with abnormalities in CD1d molecules, MHC class II molecules and the number of 
dendritic cells being described4;331.  
 
In the cohort of patients reported here, only one individual developed a paraprotein 
whilst receiving ERT. In keeping with the findings of others, ERT has been 
suggested, to stabilise the level of paraproteinaemia but not to reduce it43.  ERT, in 
some case reports, failed to prevent progression to malignant disease81. As 
individuals with GD have an increased risk of polyclonal gammopathy, MGUS and 
multiple myeloma, this may reflect a continuum of disease, which may be retarded 
by the introduction of ERT. These findings raise several issues, including financial, 
regarding the use of ERT in individuals with multiple myeloma or benign 
paraproteinaemia who do not meet traditional treatment criteria. Speculatively, 
polyclonal plasmacytosis may predispose to clonal expansion and may be prevented 
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by the early introduction of ERT. Data capture via the Gaucher registry for example 
is required to establish whether GD patients have a higher rate of progression from 
MGUS to multiple myeloma. Additionally, collaborative data is required to answer 
whether traditional risk factors for malignant progression, such as abnormal serum 
light chain analysis, the percentage of bone marrow plasma cells or the level of 
paraproteinaemia, hold true in GD. Whether ERT retards the rate of malignant 
transformation is still not known. However, some authors endorse ERT in 
combination with chemotherapy for the treatment of GD patients with myeloma161, 
despite the lack of supporting data.  
 
Residual glucocerebrosidase activity, genotype or prior splenectomy did not predict 
for the subsequent development of gammopathy. Local clinical datasets detailing 
spleen and liver volumes were insufficient to correlate visceral bulk with the 
development of immunoglobulin abnormalities. However, thrombocytopenia, a 
surrogate marker of sequestration, was significantly lower in untreated individuals 
with gammopathy (p<0.01). In chapter 3, we described the case of an individual who 
experienced a dramatic fall in the level of paraproteinaemia post-splenectomy, in 
keeping with a prior case report520. Collaborative data, including that derived from 
the Gaucher registry, are required to establish whether hepato-splenomegaly is a 
clinical risk factor for gammopathy. Glucocerebrosidase activity and genotype are 
considered to correlate only loosely with clinical phenotype, perhaps due to 
individual differences in the enzymatic activity of catabolic and anabolic 
sphingolipid pathways that modulate glucosylceramide load. 
 
In vitro and in vivo data, in non-GD patients, have suggested that macrophages are a 
vital component of the myeloma bone marrow environment, support plasma cell 
survival and induce chemoresistance245. Macrophages have been shown to make up 
approximately 10% of cells in the trephine samples of myeloma patients245. Gaucher 
cell infiltrates of upto 50% were seen in the trephine sections of RFH patients with 
paraproteinaemia. Homozygous N370S individuals have been suggested to be at an 
increased risk of multiple myeloma compared to other genotypes and to have a high 
incidence of skeletal disease52. Non-GD individuals with haematological 
malignancy, including NHL, myeloma, CML, MGUS and MDS, have been reported 
to have elevated numbers of pseudo-Gaucher cells on bone marrow examination. 
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Published data has established that osteoclasts, differentiated macrophages, are 
supportive of plasma cell growth and survival252;259. These findings formed the 
experimental rationale for chapter 4 where biological models were used to establish 
whether GD-derived macrophages/osteoclasts generate a bone marrow 
microenvironment favourable to plasma cell expansion.  
 
Pseudo-Gaucher cells have an identical appearance to Gaucher cells by light 
microscopy. Several investigators have postulated their appearance to be acquired 
secondary to sphingolipid accumulation from saturated glucocerebrosidase activity. 
The presence of these cells within the bone marrow of patients with haematological 
cancer leads to speculation regarding the role of pseudo-Gaucher cells and Gaucher 
cells in rendering the microenvironment favourable to clonal expansion. Prior data 
have established the infiltration and pro-cancerous role of M2 polarised macrophages 
in tumours. Boven et al. (2004) demonstrated than Gaucher cells have a phenotype of 
M2 macrophages58, which are speculated to confer increased susceptibility to 
carcinogenesis.  
 
Data presented in chapter 3 demonstrated normal plasma chitotriosidase activity in 
non-GD individuals with MGUS and multiple myeloma. Additionally, monocytic 
precursors from non-GD individuals with benign or malignant gammopathy were 
shown to have normal glucocerebrosidase activity. Therefore, non-GD individuals 
with paraproteinaemia fail to demonstrate the same biochemical abnormalities within 
the monocytic-macrophage lineage as those found in GD.  Furthermore, pseudo-
Gaucher cells have been shown to have a different ultrastructure and phenotype to 
Gaucher cells.  
 
In chapter 4, macrophage/osteoclast cultures derived from GD patients and healthy 
controls were compared with respect to their ability to support plasma cell growth, 
survival and to induce chemo-resistance. Firstly, GD-derived peripheral monocytic 
cells were confirmed to have low glucocerebrosidase activity (p<0.01) and lysosomal 
dysfunction based on abnormal membrane lipid trafficking. Secondly, it was 
confirmed that co-culture, irrespective of monolayer origin, led to the contact-
dependent proliferation and survival of NCI-H929 myeloma cells, in keeping with 
previous reports in non-GD patients252. Data presented here demonstrated that GD 
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monolayers did not convey either a growth or survival advantage over control 
monolayers to myeloma cells, based on the co-culture of NCI-H929 or U266 
myeloma cell lines. These conclusions are limited by the fact that GD patients have 
large macrophage infiltrates in vivo and numerical rather than functional differences 
may be responsible for the elevated risk of gammopathy. This may be the key patho-
physiological difference conferring plasma cell expansion in GD. Further co-culture 
experiments using myeloma cell lines, whose growth and survival are reliant on 
macrophage-derived cytokines (e.g. IL-6), are required in order to confirm the non-
proliferative advantage of GD monolayers. Furthermore, co-culture experiments 
using primary cells, whose survival in culture is dependent on IL-6 supplementation, 
should be explored. Enzyme-linked immunosorbent assay (ELISA) quantification of 
the cytokine profile of culture supernatant might be useful in demonstrating potential 
differences in the levels of B-cell proliferating cytokines between GD and control-
derived macrophage cultures. In addition, this hypothesis could be tested by 
supplementing plasma cell cultures with GD or control-derived culture supernatant. 
As reviewed above, published data have been contradictory, as to whether the serum 
levels of B-cell proliferating cytokines are elevated in GD. In addition, Gaucher cells 
have been shown to have weak IL-6 expression58 but due to their accumulated bulk, a 
proliferative advantage on plasma cells may still be conferred in vivo.  
 
Moreover, monocytes are relatively young haematopoietic cells and are unlikely to 
have accumulated substantial amounts of glucosylceramide during the 3 week culture 
period. Future experiments should be performed, using either thin layer 
chromatography or oil-red O staining, to clarify substrate accumulation. 
Speculatively, relatively young macrophages with low levels of glucosylceramide 
deposition may be biologically different to those with more pronounced lipid 
accumulation. 
 
In chapter 4 original data are presented demonstrating that GD-derived monolayers 
compared to control cultures induced melphalan chemo-resistance in plasma cells 
lines (NCI-H929 and U226) and this was contact dependent. Melphalan exposed 
NCI-H929 cells derived from control monolayers exhibited higher PARP cleavage 
than cells harvested from GD monolayers. Furthermore, untreated NCI-H929 cells 
harvested from control monolayers had higher levels of the pro-apoptotic protein 
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Bim and higher levels of the anti-apoptotic protein Bcl-xL than that seen in cells 
derived from GD cultures. PUMA, another pro-apoptotic protein, was also elevated 
in most myeloma cell harvests derived from control experiments, compared to GD 
co-culture. It seems that the net disturbance in pro and anti-apoptotic proteins primes 
myeloma cells derived from GD culture for survival against the alkylating agent 
melphalan. These findings need to be confirmed in other myeloma cell lines and 
experiments using primary myeloma cells. Experimental limitations in this co-culture 
model include the use of myeloma cells with undisturbed sphingolipid metabolism. 
Co-culture experiments should be performed in the future with myeloma cells that 
have lysosomal dysfunction and substrate accumulation secondary to 
glucocerebrosidase deficiency. It is currently unknown whether plasma cells with 
dysregulated sphingolipid metabolism, perhaps due to disturbed autophagy, are more 
resistant to chemotherapy. Little data is available to support this hypothesis but 
investigators have shown that chronic lymphocytic leukaemia cells become more 
sensitive to chemotherapy in the presence of drugs that are known to reduce 
lysosomal glucosylceramide load (glucosylceramide synthase inhibitors)457.   
 
Speculatively, these in vitro data suggest that GD patients with myeloma should 
receive ERT in order to reduce the potentially detrimental effects of accumulated 
Gaucher macrophages on myeloma cell chemosensitivity. However, the addition of 
ERT to our co-culture system did not increase the chemosensitivity of NCI-H929 
cells to melphalan in paired GD-derived experiments. This may be due to the short 
duration of culture experiments where the duration of exposure to ERT is insufficient 
to reverse lysosomal dysfunction. Further weight to this argument would be provided 
by the induction of chemo-resistance by GD co-culture to other chemotherapeutic 
agents and more novel agents, such as immunomodulatory drugs or proteasome 
inhibitors. Curiously, co-culture did not lead to an elevated doxorubicin IC50 in 
Gaucher-derived experiments. This may be due to differences in the mechanism of 
action of melphalan and doxorubicin. Due to the narrow therapeutic range of 
bortezomib in toxicity assays, this drug was not used in co-culture experiments. In 
another set of experiments, U266 cells pre-treated with doxorubicin were not rescued 
more effectively by GD monolayers than cultures derived from controls. Future 
experiments could involve the addition of chemotherapy to co-culture in order to 
replicate a more physiological model.   
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It has been previously established in co-culture experiments that plasma cells 
enhance osteoclastogenesis from cultured peripheral blood mononuclear cells252. In 
chapter 4 it was shown that GD macrophages, compared to control macrophages, 
underwent osteoclastic differentiation more readily in the presence of M-CSF and 
RANK-L. Results reported here demonstrate that myeloma cell line co-culture 
enhanced osteoclastogenesis in GD-derived cultures in a contact-independent 
manner, suggesting the presence of a soluble factor. In comparison, control cultures 
continued to generate a low number of small osteoclasts in co-culture experiments. 
Osteoclasts were defined as TRAP+ve cells with 3 or more nuclei. To confirm these 
findings, functional assays detailing bone resorption should be performed. The use of 
immunofluorescence demonstrating the presence of F-actin ring formation and the 
vitronectin receptor would also confirm osteoclastic differentiation. GD osteoclast 
precursors seem primed for osteoclastic differentiation and these findings should be 
consolidated in the future by demonstrating increased flux through intracellular 
pathways mediating osteoclastogenesis, including molecules upregulated by M-CSF 
and RANK receptor signalling by Western blotting (non co-culture and plasma cell 
co-culture experiments).  
 
Future experiments should also be performed to correlate the number of osteoclasts 
formed in vitro with the induction of melphalan resistance in co-cultured myeloma 
cells. It is plausible that the reduction in chemosensitivity is mediated by increased 
osteoclast numbers rather than GD-derived macrophages. It would also be of interest 
to know whether in vitro osteoclast generation is different in GD patients with 
polyclonal gammopathy, MGUS or multiple myeloma. Prior data, in non-GD 
patients, have suggested that osteoclast numbers on bone marrow trephine 
examination are higher in those with myeloma than MGUS262. Furthermore, the same 
study demonstrated that patients with MGUS had more osteoclasts than healthy 
controls.  
 
Recently, osteoblast-osteoclast coupling has been shown be an important modulator 
of plasma cell growth and survival in the bone marrow microenvironment. GD 
mouse models generated from the conditional deletion of GBA1 in haematopoietic 
and mesenchymal tissue have recently been reported325. Mistry et al. (2010) showed 
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normal osteoclastic activity but disturbed osteoblastic activity based on the histo-
morphometric analysis of bones in this mouse model. Early osteoblast differentiation 
and precursor proliferation were found to be impaired. These findings challenge the 
notion that osteoclastic over-activity is responsible for lytic lesions and osteoporosis 
in GD. The co-culture data presented in chapter 4 also conflicts with their 
conclusions regarding physiological osteoclastogenesis. Future co-culture 
experiments are required to examine the effect of GD osteoblasts on myeloma cell 
growth and survival.    
 
There is already a wealth of knowledge regarding abnormalities in the lymphocyte 
profile, impaired tumour surveillance and cancer risk in non-GD patients. GD 
traditionally is classified as a disorder of macrophages with rare reports focusing on 
lymphocyte abnormalities. Based on the results reported in chapter 5, which includes 
original data, abnormalities demonstrated within the lymphoid fraction in GD 
patients may contribute to a microenvironment polarised towards clonal expansion.  
 
Initially, GD lymphocytes were found to have low glucocerebrosidase activity with 
evidence of lysosomal dysfunction, based on the mis-trafficking of membrane lipids. 
Control or GD-derived lymphocytes were shown to have comparatively low enzyme 
activity compared to monocytes, questioning the importance of intact sphingolipid 
metabolism within this lineage. However, B-cells compared to T-cells from healthy 
controls had significantly higher glucocerebrosidase activity and therefore may be 
more reliant on intact enzyme activity. Whether this leads to terminally differentiated 
B-cells i.e. plasma cells, becoming more sensitive to proliferating stimuli in GD is 
speculative. Electron microscopic analysis failed to demonstrate substrate 
accumulation within the lymphocytes of 3 GD patients, including an untreated 
individual, despite the results of some authors demonstrating glucosylceramide 
deposition. EM analysis using immuno-conjugates to glucosylceramide or lipid 
analysis by thin layer chromatography of the lymphoid fraction may clarify this 
issue. 
 
As reviewed in chapter 5, non-GD patients with malignancy have been shown to 
acquire lymphoid abnormalities in the peripheral blood or within the cancerous organ 
that, speculatively, contribute to a microenvironment favourable to tumour cell 
 293 
survival. These include abnormalities in the absolute lymphocyte number, CD4/CD8 
ratio, NK cell fraction (numerical and lytic activity) plus numbers of invariant NK-T 
and regulatory T-cells. The data presented here demonstrates that patients with GD 
have a lower percentage of CD3 positive/CD4 positive cells, a depressed CD4/CD8 
ratio, a higher percentage of CD3 positive/CD8 positive cells in GD patients with 
gammopathy, increased NK-T like cells, a low percentage of CD3 negative NK cells 
and a depleted pool of invariant NK-T cells. Limitations to this analysis include the 
fact that comparisons were based on percentage rather than absolute lymphocyte 
numbers. However, GD patients had an identical absolute lymphocyte count in 
peripheral blood when compared to controls. Further criticisms include that the 
majority of patients (85%) were on ERT and the effect of disease modifying therapy 
on lymphocyte subset composition is currently unknown. Collaborative analysis is 
required of ERT naïve patients, including those presenting with severe disease, to 
answer this question. Paired analysis should be performed looking at the effect of 
ERT on T-cell subsets from individual patients over a period of time, including pre-
treatment. Balreira et al. (2005) reported decreased CD4 positive T-cells and 
increased CD8 positive T-cells in the peripheral blood of patients on ERT, but not in 
untreated individuals compared to controls4. It could be hypothesised, that treated 
patients compared to ERT naïve individuals, due to higher peak disease burden, are 
more likely to develop abnormalities in their lymphoid profile. Due to the low 
number of untreated patients, in the analysed RFH cohort, the effect of ERT, if any, 
on lymphocyte subsets, could not be established.     
 
Invariant NK-T (iNK-T) cells show remarkably plasticity and can be polarised to 
mediate either a Th1 or Th2 immune response. Abnormalities of iNK-T cells have 
been described in animal and human subjects with cancer. They normally comprise 
0.01-1% of all peripheral lymphocytes and are stimulated by antigen presenting cells 
(APCs) harbouring glycolipid on CD1d tetramers. In the experiments described in 
chapter 5, GD patients had low iNK-T cell numbers that failed to expand in culture 
in response to αGalCer. Curiously, cultures supplemented with iGB3, an endogenous 
sphingolipid, failed to expand iNK-T cells derived from both controls and GD 
patients. This may be because αGalCer is a more potent stimulator of iNK-T cells. 
Preliminary experiments showed that the addition of conduritol-B-epoxide, a 
lysosomal inhibitor of glucocerebrosidase, blunted the expansion of control iNK-T 
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cells in response to αGalCer supplementation. Therefore it can be concluded that GD 
patients have disturbed iNK-T cell numbers and an impaired response to glycolipid 
stimulation that may contribute to a microenvironment conferring impaired tumour 
surveillance. Further experiments, using different glycolipid stimuli, are required to 
confirm these findings.  
 
In addition, it was demonstrated that CD1d tetramers are expressed at a higher 
intensity on the cell surface of monocytic cells from patients with GD. It is unclear 
whether APCs from GD patients are able to recycle membrane CD1d tetramers or if 
they are capable of the physiological complexing of sphingolipid in the disturbed 
lysosomal compartment. Alternatively, naturally occurring sphingolipids may be out-
competed by the preferential complexing of glucosylceramide in GD leading to a low 
number of iNK-T cells in vivo and an inability to load exogenous sphingolipid in 
culture experiments. Further work is required to explore these hypotheses. 
Supplementary experiments include the fluorescent labelling of CD1d molecules and 
time-phase studies detailing CD1d re-cycling in control and GD APCs. Additionally, 
although GD patients have higher expression of CD1d on the monocyte cell surface, 
it is unclear whether GD cells contain higher amounts of CD1d or if this represents 
non-physiologically re-distribution to the cell membrane. Western blotting is 
required to clarify the cellular content of CD1d.  
 
NK-T cells derived from GD patients were shown to have significantly lower 
glucocerebrosidase activity than those derived from controls. Despite this, CD56 
sorted NK-T cells from GD patients and controls demonstrated equivalence in killing 
assays, irrespective of pre-activation with IL-2. Furthermore the CD56-ve fraction, 
derived from peripheral blood of GD patients, was not inferior in the killing of 
immortalised cell lines. However, in paired PBMC killing assays, matched for age, 
GD patients compared to healthy controls demonstrated inferior killing of the K562 
myeloid cell line at 3 different effector:target ratios. Criticisms of the NK cell killing 
assay include that the lower numbers of CD3 negative NK-cells  in GD patients were 
not reflected in this assay but are represented in experiments utilising PBMCs. 
Individuals with poor prognosis breast cancer have been shown to have impaired 
PBMC killing activity compared to those with more favourable disease or healthy 
controls343. Therefore, it is concluded that numerical and functional abnormalities in 
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the peripheral blood of GD patients confer impaired tumour surveillance. Further 
studies are required to establish whether these findings are representative of those 
found in individual organ systems in GD patients, including the bone marrow.     
 
Chapters 4 and 5 address abnormalities within the bone marrow microenvironment 
and lymphoid fraction respectively and provide initial insight into some of the 
biological mechanisms that may confer an elevated risk of myeloma in GD. GBA1 
heterozygotes have an elevated incidence of Parkinson’s disease351 but the patho-
physiology behind this remains unclear. Enzyme misfolding leading to ER stress and 
proteasomal dysfunction has been suggested to cause cellular pathology in GBA1 
heterozygotes. However, it is unclear at present whether carrier status confers an 
elevated risk of paraproteinaemia, perhaps due to a similar mechanism as that present 
in GBA1 heterozygotes with PD. Gaucher gene mutations are found most commonly 
in the Ashkenazi Jewish population (1:12-1:14 individuals) but are less common in 
the Sephardic Jewish population. In chapter 3, the GBA1 analysis of 77 Jewish 
patients (mixed ancestry, mostly Ashkenazi [87%]) with a paraprotein, recruited 
from 4 different NHS trusts, was reported. In total, 8/77 (1:9.6) individuals had 
mutated GBA1 alleles (Mutation [patient number]; N370s/wild type [5], 84GG/wild 
type [1], N370s/R496H [1] and E326K/wild type [1]). Seven patients were found to 
be heterozygotes with one previously unknown GD patient being identified. The data 
reported here does not support an increased carrier frequency of mutated GBA1 
alleles in Jewish patients with a paraprotein.  
 
Pre-recruitment statistical monitoring calculated that 118 Jewish people with a 
paraprotein were required to reject the null hypothesis (power 80%, p<0.05, carrier 
frequency in Ashkenazi Jewish population 1:12). In the 4 recruiting NHS trusts we 
recruited 77 out of 161 (48%) individuals identified with a paraprotein. It was 
projected that 831 Jewish individuals greater than 50 years old, from the London 
boroughs served by these trusts, would harbour paraproteins. Speculatively, the 
majority of individuals with a paraprotein may remain clinically silent. Furthermore, 
GBA1 carrier status may not confer an elevated risk of monoclonal gammopathy. 
Potentially, rare mutations within exons 2-4 may have been missed as sequencing 
was performed in exons 5-11 only. However, based on the report of Hruska et al. 
(2008), 41/261 known GBA1 mutations are found in exon block 2-4. Allele specific 
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PCR and enzyme digests were used to identify the two common mutations, 84GG 
and IVS2+1, harboured in this region. Further criticisms of this study include that 
recruited individuals were of mixed Jewish descent. However, in the 55 individuals 
whose Jewish ancestry was known, 87% (48/55) were of Ashkenazi origin (2% 
unknown, 11% Sephardic Jewish). The carrier rate in Sephardic Jews of GBA1 
mutations is poorly defined but is not of the same magnitude as that found in 
Ashkenazi Jews. Recruitment continues in order to meet statistical targets. The 
acquisition of the relevant local approvals, the recruitment of patients and the time 
required to perform GBA1 gene analysis is best approached in collaboration due to 
logistical, financial and manpower limitations. If GBA1 carrier status leads to an 
elevated risk of paraproteinaemia then gene-linkage studies are required to exclude 
co-inheritance of a closely positioned cancer gene.  
 
In conclusion, these studies have employed several different experimental 
approaches to understand why patients with GD have a higher incidence of 
gammopathy. Hypotheses formed were based on biological abnormalities found in 
non-GD patients with malignancy.  This thesis reports novel data regarding clinical 
risk factors for the development of gammopathy in GD, the in vitro affects of GD 
macrophages/osteoclasts on plasma cells and lymphoid abnormalities that may 
confer impaired tumour surveillance (Figure 6.1). It was demonstrated that GD 
patients have a decreased CD4:CD8 ratio plus a low percentage of CD3-ve NK-cells 
and iNK-T cells. iNK-T cells derived from GD patients were unable to expand in 
culture to αGalCer stimulation. Furthermore PBMC killing assays derived from GD 
patients displayed inferior cytotoxicity to those derived from healthy controls. These 
abnormalities have been linked to an elevated risk of malignancy in non-GD patients. 
It can therefore be hypothesised that GD patients due to impaired tumour 
surveillance are more tolerant to clonal plasma cell expansion. Serum biomarkers of 
macrophage burden were predictive of gammopathy. PBMC cultures derived from 
GD patients were primed for osteoclastogenic differentiation when cultured alone or 
in co-culture with plasma cells. Osteoclasts and macrophages have been shown to 
support plasma cell survival in vitro. Speculatively, the GD bone marrow 
microenvironment, is favourable to polyclonal expansion, which favours the 
development of a clonal disorder on the background of chronic immune stimulation, 
as postulated by Shoenfeld et al. (1982). Although, GD cultures did not convey a 
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proliferative advantage, this was based on a numerical identical number of 
macrophages/osteoclasts in culture. In vivo, GD bone marrows, compared to non-GD 
patients, have large macrophage infiltrates.  Furthermore GD cultures, compared to 
control cultures, protected plasma cells from melphalan induced apoptosis. As to 
whether GBA1 heterozygosity confers an elevated risk of paraproteinaemia remains 
unanswered. Future work should build on the data and experimental models 


































Figure 6-1. Summary of findings speculated to modulate the risk of developing plasma cell 
disorders in Gaucher disease. 





↓ Glucocerebrosidase activity  - lymphocytes 
Abnormal membrane lipid trafficking  - lymphocytes 
↓ CD4:CD8 ratio 
↑ CD3+ve/CD8+ve T - cells 
↓ CD3+ve/CD4+ve T - cells 
↓ CD3 - ve NK cells 
↓ iNK - T cells;  ↑ CD1d  
Impaired iNK - T expansion 
Impaired PBMC killing assays 
Normal NK - killing assays 
GBA1 carriers 
? 
8/77 individuals with  
mutated GBA1 alleles  
(1:9.6) 
Gaucher cell  
accumulation 
No proliferative advantage 
No survival advantage 
Induction of melphalan chemo - resistance 
(MTT, PARP cleavage) 
Abnormal plasma cell priming 




↑ Osteoclast formation 







↑ Macrophage Biomarkers  






7   APPENDIX 1
  299 
Patient Information Sheet  
(Myeloma or AL-Amyloidosis Patients) 
 
Investigation of the Linkage between Gaucher Disease and B-
Cell Disorders including Multiple Myeloma 
 
 
You are being invited to take part in a research study. Before you decide it is 
important for you to understand why the research is being done and what it 
will involve. Please take time to read the following information carefully. Talk 
to others about the study if you wish. 
 
Background 
Myeloma is a bone marrow cancer affecting the white blood cells of the 
immune system.  White blood cells are responsible for attacking and 
destroying infection and viruses when they enter the body.  
 
Despite 4,000 new cases every year, myeloma remains a relatively unknown 
cancer. The cause is unknown; exposure to certain chemicals, radiation, 
viruses and a weakened immune system are thought to be potential causal 
or trigger factors. Inexplicably, there is a higher than normal incidence in 
certain ethnic groups, particularly Afro-Caribbean people, suggesting that 
genetic factors may play a role.  
 
AL-Amyloidosis is a condition concerning the same type of abnormal 
haematological cell as that seen in myeloma (plasma cell) but is its own 
clinical entity.  Again, the cause is unknown. There are some overlapping 
disease similarities with those that suffer from myeloma but there are also 
many differences.    
 
Gaucher disease is a rare inherited disorder in which patients lack an 
enzyme needed to break down certain fatty substances. This deficiency 
leads to the excessive storage of fatty material within the cells and tissues of 
the body. The most common form of Gaucher disease (type 1) affects 
approximately 1 in 50,000 of the general population. However, approximately 
1 in 850 of the Ashkenazi Jewish population is affected and the estimated 
carrier status within the Ashkenazi Jewish population is 1 in 14. 
 
For unknown reasons, patients with Gaucher disease have an increased risk 
of developing myeloma (estimated as 6 times more common). Approximately 
1 in 10 Gaucher patients have a specific blood protein, called a paraprotein, 
which is found in both malignant and non-malignant conditions, including 
myeloma and AL-Amyloidosis.  
 
Gaucher disease is a condition of disordered lipid/fat metabolism that leads 
to a particular set of observed clinical complications. Sometimes the 
presentation of the disorder can be extremely mild and is not picked up in 
extremely well patients without obvious symptoms or signs. Normal human 
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cells have two sets of identical chromosomes excluding sex chromosomes.  
Gaucher disease requires an abnormal copy of the affected gene on each 
chromosome. One normal copy coupled with one abnormal Gaucher gene on 
the other chromosome confers a ‘carrier’ status. 
 
We know that patients with Gaucher disease have an increased incidence of 
Multiple Myeloma but we are unsure if this link is true for those who are a 
carrier (i.e. one abnormal gene). We are also unsure if there is an increased 
risk of AL-Amyloidosis in those with a Gaucher gene mutation. 
 
As a patient with multiple myeloma or AL-Amyloidosis we would be interested 
in both testing your Gaucher gene status and looking at how your cells 
behave in comparison to normal and Gaucher patients. 
 
What is the Purpose of the Study? 
We would like to observe whether having Gaucher disease, carrier status or 
being mutation free affects the natural history, clinical presentation or 
response to treatment of multiple myeloma or AL-amyloidosis.  
 
Why have I been Chosen? 
As a myeloma or AL-Amyloidosis patient, you are suitable for inclusion in this 
study. Depending on your ethnic background, you may have an increased 
incidence of Gaucher disease.  
 
Do I have to take part? 
No. It is your decision if you want to take part or not. If you do, you will be 
given this information sheet to keep and be asked to sign a consent form. 
You are free to withdraw your consent at any time during the study, and you 
do not have to give a reason for this. A decision to withdraw at any time, or a 
decision not to take part, will not affect the standard of care you receive. 
 
What will I have to do? 
You will be required to fully read the information leaflet (disseminated by post 
or at clinical appointment) with a contemplation period of greater than 24 
hours elapsing before providing signed consent. Informed consent will 
include demonstration of your understanding and us answering any 
questions that you may have in relation to the study. A consent form will then 
be signed in the presence of one of the clinical investigators (Dr Mehta, Dr 
Hughes or Dr Ayto). 
 
We would like to collect data about your disease over a prolonged period of 
time (no set time length to the study). Any information required about your 
clinical status will be obtained from your hospital records.  
 
 
Additionally we will take a few extra blood samples at either your routine 
clinical appointment or at an alternative time convenient to you. If you agree 
we could provide this either in a hospital setting or within your home. If you 
undergo a bone marrow examination as part of routine clinical care, we 
would like to take an extra bone marrow aspirate sample for testing.  
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If you have had a bone marrow procedure in the past, we would like your 
permission to perform additional tests on any stored samples in the 
pathology department.  
 
If you have any questions about the questionnaire, please contact Dr Mehta, 
Dr Hughes or Dr Ayto (contact details listed below). 
 
What are the possible disadvantages and risks of taking part? 
We will collect research blood samples either at the time of routine blood 
testing or at a pre-arranged another time convenient to you. The volume of 
additional blood taken is relatively small and not likely to cause any side-
effects. We may take the sample of blood either in a hospital setting or at 
your home, depending on preference.  
 
We would like to take up-to 30mls (6 teaspoons) of blood which is a small 
volume that will not expose you to any additional risk. We may take a few 
experimental samples over time (anticipated as not more than 3 samples in 3 
years) looking at different aspects of the above associations. 
 
It is highly unlikely that you will experience any additional discomfort or 
inconvenience as blood will be taken by a trained professional and for 
existing patients mostly at the same time as your routine blood tests through 
the same needle.  
 
A bone marrow research sample will only be collected if you are having this 
test as part of your clinical management and you have indicated this on your 
consent form. This specimen is small and requires no additional needle or 
invasive procedure. If you are undergoing a bone marrow examination then 
an extra 20mls (4 teaspoons) will be aspirated which again is a small volume 
not associated with any additional risk. 
 
You may be diagnosed to have or to be a carrier for Gaucher disease. This is 
a much less serious condition than myeloma. If you are a carrier you will 
require no treatment but may have implications with regards to family testing. 
In the unlikely event you are identified as having Gaucher disease, then you 
will be reviewed locally at the Royal Free Hospital, one of the few national 
centres, in order to be counselled and to be treated. Gaucher disease is 




What are the possible benefits of taking part? 
There will be no direct personal benefit and there is no financial incentive or 
reward. A greater understanding of the natural history of Gaucher disease 
and the mechanisms behind multiple myeloma or AL-Amyloid will be 
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What happens when the research study stops? 
Our plans are to accumulate data over a long period of time and only by this 
can we achieve the goals of the study. Termination of the study at any point 
will lead to us stop collecting your data. We would like your permission to 
store any collected research samples in order to perform further experimental 
tests in the future. Consent would be re-sought if any proposed tests were 
not in the remit of this research study submitted and approved by our Local 
Ethics Committee.  
 
Will my taking part in the study be kept confidential? 
Yes. All the information about your participation in this study will be kept 
confidential. 
 
Involvement of the General Practitioner/Family doctor (GP) 
We will inform your GP that you are participating in this study but only if you 
agree and indicate this on your consent form. 
 
 
Will any genetic tests be done? 
Yes. Diagnosis for Gaucher disease is made by measuring enzyme activity to 
determine if there is a deficiency of the specific enzyme, beta-
glucocerebrosidase. It is also necessary to analyse the DNA to identify the 
mutational changes which cause the disorders. A further genetic test we also 
be performed looking for common mutations in a gene that gives rise to a 
secretary product of Gaucher cells (pathological hallmark of Gaucher 
Disease) called chitotriosidase.  
 
What will happen if I get a positive diagnosis of Gaucher Disease? 
You will be referred to the National Centre at the Royal Free Hospital for 
assessment. The specialists there are also specialists in Myeloma and AL-
Amyloidosis. If you a found to have a Gaucher gene mutation then you will 
receive the appropriate counselling. Gaucher disease is easily treatable with 
currently available drugs.  
 
Do I have the right to object to being informed of such a diagnosis? 
Yes. We consider it to be in your best interest to be informed so that you may 
receive the best possible treatment. 
 
 
Will I be referred for re-testing outside the study? 
No. 
 
What will happen to the results of the research study? 
The results of the study may be presented in scientific journals and 
publications and in conference presentations. They may also be shared with 
other participants and relevant community groups. Results of this research 
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Who is funding the research? 
Funding has been given by Myeloma UK and distributed by the special 




Who has reviewed the study? 
The study was given a favourable ethical opinion for conduct in the NHS by 
The Royal Free Hampstead REC. 
 
The study was assessed independently by a Myeloma expert, and given 
favourable professional opinion for conduct by Dr Panos Kottaridis, 
Consultant Haematologist at the Royal Free Hospital.  
 
Contact Details 
If you have any questions regarding this study, please ask the doctor or 
nurse looking after you or contact – 
 
Dr Mehta    Dr Hughes 
Consultant Haematologist  Senior Lecturer in Haematology 
Royal Free Hospital   Royal Free Hospital 
Pond Street    Pond Street  
London    London 
NW3 2QG    NW3 2QG 
 
Tel:     Tel: 
0207 794 0500 ext. 33264  0207 794 0500 ext. 33476 




Dr Ayto     
Clinical Research Fellow   
Royal Free Hospital    
Pond Street     
London     
NW3 2QG     
 
Tel:      
0207 794 0500 ext. 33324  
Email:    
r.ayto@medsch.ucl.ac.uk 
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Study Number:  ____________ 
Patient Identification Number for this trial: ___________  
 
CONSENT FORM  
(Myeloma Patient or AL-Amyloidosis Patient) 
 
Title of Project: Investigation of the Linkage between Gaucher Disease and B-Cell 
Disorders including Multiple Myeloma 
 
 
                    Please initial box 
        
1. I confirm that I have read and understood the information sheet for the 
above study. I have had the opportunity to consider the information, ask 
questions and have had these answered satisfactorily. 
 
 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care 
or legal rights being affected. 
 
 
3. I understand that relevant sections of any of my medical notes and data 
collected during the study may be looked at by responsible individuals 
from regulatory authorities or from the NHS Trust, where it is relevant to 
me taking part in this research. I give permission for these individuals to 




4. I agree blood samples to be taken for experimental studies including a 





5. I agree to an additional bone marrow aspirate sample to be taken for   
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7. I agree to being told my Gaucher gene mutational status and receive the 





8. I agree for research specimens to be stored and understand that no 
additional tests will be performed outside the remit of this study unless 
written consent is re-sought.  
 
 






   Please initial box        
  
____________________ ___________ __________________ 




________________________ _____________ _____________________ 
Doctor    Date   Signature 
 
When completed, 1 copy for patient, 1 copy for researcher site file and 1 copy 
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